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PREFACE 
The recent viral pandemic in humans has made it clear to millions of people how crucial rapid 
diagnostics and applied biosecurity are in infectious disease control. Worldwide, cattle 
farmers and their veterinarians almost continuously face a similar challenge in their animals 
related to different and often simultaneous respiratory tract infections. Among these 
infections, Mycoplasma bovis is absolute priority. M. bovis is highly contagious and a leading 
indication for antimicrobial mass medication. Treatment is difficult as they are inherently 
resistant against many antimicrobials and can evade the immune response of the body 
facilitating chronic, persistent infections.  
Today, M. bovis control is still problematic. Effective biosecurity is hampered by incomplete 
epidemiological knowledge on M. bovis, especially concerning the existence of different 
strains and their spread between the dairy, beef and veal sector. Currently, using routine 
culturing, it takes more than a week to get a test result for M. bovis and susceptibility testing 
is not available. Alternative techniques like qPCR and antibody ELISA are often too 
expensive, lack sensitivity or show interpretative difficulties. Both for therapeutic outbreak 
management and more effective biosecurity, having rapid, accurate, and reasonably prized 
diagnostic tests available is crucial.  
 
Thriving on the technological evolution in the field of diagnostics, this doctoral thesis 
explores the possibilities of MALDI-TOF MS and nanopore sequencing to make M. bovis 
diagnosis more fast and reliable. Epidemiological results obtained by these new protocols 
were also incorporated, since prevention of spread is at least as essential as treatment to 
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1.1 INTRODUCTION ON MYCOPLASMA BOVIS 
Characteristics of Mycoplasma species   
Mycoplasma bovis, previously known as Mycoplasma agalactiae var. bovis or M. 
bovimastitidis (Askaa and Erno, 1976), is one of the many known Mollicutes species (Razin, 
1978). The class of the Mollicutes received its name due to the loss of their cell wall during 
evolution (molli: soft; cutis: skin) (Razin and Hayflick, 2010). More than 190 Mycoplasma 
species are currently documented (Rottem, 2003). These prokaryotes are among the smallest 
self-replicating organisms in the world (200-300 nm in diameter) (Razin, 1996), containing a 
genome length of 0.6-1 Mbp, with a low guanine-cytosine (GC) content of approximately  25-
30% (Thompson et al., 2011;  Kumar et al., 2020). The genome length is very small, in 
comparison to other bacteria, such as Escherichia coli, of which the bacterial genome size is 
4.6 Mbp (Travisano, 2001). The limited genomic information of Mycoplasma species restricts 
its metabolic activities, resulting in the requirement of highly species-specific environments 
for growth. The necessary supplements, like amino acids, lipids, and energy sources such as 
pyruvate, arginine or urea, are usually withdrawn from the host (Rosenbusch, 1994; 
Masukagami et al., 2017). However, even under optimal circumstances, the growth rate of 
Mycoplasma species in vitro is very low (Miles, 1992; Rosenbusch, 1994; Razin and 
Hayflick, 2010).   
 
Mycoplasma species are mostly host specific, although they are occasionally able to colonize 
other hosts (Rottem, 2003). M. bovis is mostly a pathogen of cattle, causing many different 
clinical diseases, such as bovine respiratory disease (BRD), arthritis and otitis in calves 
(Maunsell and Donovan, 2009) and mastitis and arthritis in adult cattle (Maunsell et al., 
2011). However, next to affecting cattle, M. bovis has also been responsible for clinical signs 
in other ruminants, such as bisons (Janardhan et al., 2010), white-tailed deer (Dyer et al., 
2004), mule deer (Register et al., 2019), pronghorn (Malmberg et al., 2020), sheep (Kumar et 
al., 2012), and goats (Rodríguez et al., 2000). Other possible carriers are rabbits (Boucher et 
al., 2001), poultry (Ongor et al., 2008), and in exceptional cases possibly even humans 
(Madoff et al., 1979). Many other Mycoplasma species can be isolated from cattle, such as the 
extremely pathogenic Mycoplasma mycoides subsp. mycoides causing contagious bovine 
pleuropneumonia (Nicholas and Ayling, 2008). This pathogen is eradicated in Europe, but 
still a huge problem in Africa (Dudek et al., 2021). For several other Mycoplasma species 
(e.g. M. bovirhinis, M. dispar, M. canis, ..) the degree of pathogenity in cattle is not always 
clear.  
General introduction  Chapter 1 
10 
 
Economic impact of M. bovis infections in cattle 
The economic impact of M. bovis infections in cattle is very difficult to determine and only 
few studies have tried to estimate the cost. Before the 21st century, production losses due to 
M. bovis diseases were already counting for 32 and 108 million dollar per year in the 
American beef and dairy industry, respectively (Rosengarten and Citti, 1999). Production 
losses that are associated with M. bovis are for example a reduction in carcass quality, average 
milk production, and average daily gain (Rosengarten and Citti, 1999; Pardon et al., 2013; 
Francoz et al., 2015). The additional costs of losses to antimicrobial therapy, extra labor, 
mortality, culling, diagnostic tests and control measures were not included in this study. 
Another cost that can be included and is mostly forgotten, is the additional housing and 
feedings costs, due to lower average daily gain and extra time required to reach expected 
slaughter weight, due to the chronic nature of M. bovis infections (Maunsell et al., 2011; 
Calcutt et al., 2018). In Europe, it was estimated that 576 million euros per year were lost due 
to BRD of which at least 25% was attributable to M. bovis (Nicholas et al., 2000). These 
numbers are already quite outdated, but new estimates have not been published recently. 
Nevertheless, since the prevalence of M. bovis has probably increased the last few decades, 
and taking inflation into account, current costs due to M. bovis infections are probably greatly 
surpassing earlier estimations.  
 
Prevalence 
After the first isolation of M. bovis in the United States in 1961 from milk (Hale et al., 1962), 
this pathogen was rapidly observed in Europe and other continents as well (Nicholas et al., 
2008) with currently a higher prevalence in central and Southern Europe compared to the 
Scandinavian countries (Gille, 2018). Finland was the last European country to get infected in 
2012 by purchase of imported cattle (Haapala et al., 2018). Next to Finland, New-Zealand 
was able to stay M. bovis free for a very long time, but also got infected in 2017 by a currently 
unresolved infection route. There seems to be an increased prevalence of M. bovis in the last 
years (Kusiluka, 2000; Passchyn et al., 2012; Gille et al., 2018a). However, at world scale it is 
difficult to interpret and compare the role of M. bovis, because of the variety of samples and 
diagnostic methods used in prevalence studies. Very diverse prevalence numbers have been 
reported in Europe (0-100%), depending on the diagnostic methods and study population used 
(Gille, 2018). In Belgium for example, over the last few years the prevalence of M. bovis was 
32% in dairy cattle by combined diagnostics of antibody enzyme-linked immunosorbent 
assays (ELISA) and polymerase chain reaction (PCR) on bulk tank milk (Gille et al., 2018a), 
General introduction  Chapter 1 
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while a previous study showed only 1.5% prevalence by culture on bulk tank milk (Passchyn 
et al., 2012). Another Belgian study showed 33% of the herds to be positive by PCR on 
bronchoalveolar lavages (BAL) obtained in acute respiratory outbreaks on conventional beef 
and dairy farms (Pardon et al., 2020). In contrast, 100% of the veal herds endure exposure to 
M. bovis as reflected in their specific M. bovis antibody titers (Pardon et al., 2011). These 
prevalence numbers in the veal sector are in line with studies in other countries, such as Italy 
and France (Arcangioli et al., 2008; Radaelli et al., 2008) and nurture the fear that the veal 
sector, currently combining high antimicrobial use and facing high M. bovis prevalence, are a 
reservoir for multi-resistant M. bovis isolates (Jarrige et al., 2017; Bokma et al., 2019a).   
 
Pathogenesis 
Various virulence factors of M. bovis have been described (reviewed by Perez-Casal, 2020), 
but the most important ones are probably the variable surface lipoproteins (Vsps). These 
lipoproteins are used to adhere to mucosal surfaces (Lysnyansky et al., 1999; Sachse et al., 
2000). M. bovis is mostly adhering to the mucosal surfaces of the upper respiratory tract 
(nasal cavity until tracheal bifurcation) and colonizing the tonsils (Miles, 1992; Maunsell and 
Donovan, 2009; Maunsell et al., 2011). However, it can also colonize the mucosal surfaces of 
the urogenital tract and the conjunctiva (Pfützner and Sachse, 1996; Levisohn et al., 2004). 
Another commonly colonized organ is the udder (Bennett and Jasper, 1980; Pfützner and 
Sachse, 1996). After colonization, multiplications at the site of infection will take place, and 
hematological spread of the pathogen to other organs is possible (Figure 1) (Bennett and 
Jasper, 1980; Maunsell and Donovan, 2009). Shedding of M. bovis mostly occurs from the 
upper respiratory tract and the udder (Bennett and Jasper, 1980; Soehnlen et al., 2012), but 
can for example also occur in semen (Haapala et al., 2018).  
 
Once M. bovis adheres to the mucosal surfaces, an immune response is initiated (Rottem, 
2003). However, M. bovis can evade both the innate and adaptive response (Kauf et al., 2007; 
Buchenau et al., 2010; Jimbo et al., 2017). Expression of the Vsps can be changed 
spontaneously by M. bovis and may allow to avoid the immune response (Lysnyansky et al., 
1999; Buchenau et al., 2010). Next to this, M. bovis is able to persist intracellularly (e.g. 
lymphocytes, embryonic turbinate cells, and erythrocytes) (Van Der Merwe et al., 2010; 
Bürki et al., 2015; Nunoya et al., 2020). 




Figure 1. Adherence and colonization sites of M. bovis marked by an asterisk: nares, eyes, brain, bulla 
tympanica, pharyngeal tonsillae, lung, heart, joints, abdomen, udder and urogenital tract. Also, 
hematological spread is possible (not shown).  
 
Intracellularly, M. bovis is able to evade the humoral immune response and antimicrobial 
agents that are not able to penetrate host cells (Razin and Hayflick, 2010). Next to this, M. 
bovis is also able to evade the cellular immunity by impairing the viability of neutrophils, 
lymphocytes and macrophages (Vanden Bush and Rosenbusch, 2002; Suleman et al., 2016; 
Jimbo et al., 2017; Zhao et al., 2021). Variation in neutrophil phagocytizing and killing of M. 
bovis by different strains of M. bovis has been described (Wiggins et al., 2011; Alabdullah et 
al., 2015, 2018). Finally, M. bovis is also able to produce biofilms depending on the 
expression of Vsps, making it more resistant against environmental stress (McAuliffe et al., 
2006). No influence of biofilm formation on the susceptibility of M. bovis to some 
antimicrobials was observed in the study of McAuliffe et al. (2006). Although in biofilm 
producing Mycoplasma hyopneumoniae isolates, an increase in minimum inhibitory 
concentration (MIC) values against different antimicrobials was observed (Tassew et al., 
2017). The capacity of circumventing the immune response together with the ability to 
produce biofilms, can contribute to the chronic and persistent nature of M. bovis infections 
(Buchenau et al. 2010; Razin and Hayflick, 2010). 
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M. bovis associated diseases   
Besides M. bovis, other Mycoplasma species (e.g. arginini, M. alkalescens, M. canadense, M. 
californicum, M. canis, M. bovirhinis, M. bovigenitalium and M. dispar) can be  isolated from 
cattle (Thomas et al., 2002; Gioia et al., 2021). However, literature is mostly conflicting about 
the pathogenicity of these mycoplasmas. Therefore it is very important to identify and 
distinguish M. bovis from other less or nonpathogenic Mycoplasma species. In addition, 
mixed infections with different Mycoplasma species or with other bacterial (e.g. Mannheimia 
haemolytica, Pasteurella multocida, Histophilus somni or viral (e.g. bovine viral diarrhea 
virus (BVDv), bovine respiratory syncytial virus, bovine parainfluenza type 3) pathogens, are 
frequently reported (Thomas et al., 2002; Szacawa et al., 2015; Animal and Plant Health 
Agency, 2016; Pardon et al., 2020). Nevertheless, the main focus in this thesis will be on M. 
bovis as it is widely accepted as a primary pathogen, causing pneumonia, arthritis, otitis, 
mastitis, and other less occurring manifestations of disease (Maunsell and Donovan, 2009; 




Pneumonia by M. bovis is seen in all cattle sectors and all ages of animals (Maunsell and 
Donovan, 2009; Maunsell et al., 2011). Nevertheless, the contribution of M. bovis to acute 
and chronic BRD is higher in production systems relying on animal purchase like the veal calf 
or feedlot industry (Boothby et al., 1983; Caswell et al., 2010; Pardon et al., 2011). M. bovis is 
also involved in BRD outbreaks in dairy and beef calves in winter time (Pardon et al., 2020). 
Clinical signs are not specific, but can include coughing, nasal and ocular discharge, 
tachypnea, dyspnea, adventitious lung sounds, lethargy and (mild) fever (Pfützner and Sachse, 
1996; Stipkovits et al., 2000; Caswell et al., 2010; Dudek et al., 2019). Chronic infections can 
result in decreased weight gain (Pfützner and Sachse, 1996; Stipkovits et al., 2000; Tschopp et 
al., 2001), and in severe cases, M. bovis can result in 5-10% mortality (Nicholas et al., 2008). 
Co-infection of M. bovis and BVDv may result in more chronic, unresponsive disease in veal 
calves and feedlots, and can aggravate clinical signs of M. bovis (Shahriar et al., 2002; Pardon 
et al., 2012).  
Ultrasound can sometimes support the suspicion of a M. bovis infection, when consolidations 
and small abscesses are present (Fig. 2a). The pathological findings are exudative 
bronchopneumonia with caseous, suppurative or fibrinonecrotizing lesions, dark red areas of 
consolidation and pleuritis (Fig. 2b) (Rodriguez et al., 1996; Maeda et al., 2003; Radaelli et 
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al., 2008; Dudek et al., 2019; Haapala et al., 2019). Neutrophils constitute the major 
phagocytic cell type found in tissues or secretions in systems infected with M. bovis (Gagea et 
al., 2006; Maunsell et al., 2012). 
 
  
Figure 2. Ultrasound of calf with pneumonia caused by M. bovis showing 
consolidations and abcedation of the lung (a). Multifocal to coalescing necrosuppurative 




Mastitis can either be present in a subclinical or clinical form in herds. When clinical signs are 
present, the non-responsiveness to treatment and the infection of several quarters with a milk 
drop and increased somatic cell counts are quite typical (González and Wilson, 2003; Al-
Farha et al., 2017). The udder is sometimes swollen and red (Fig. 3a), and abscesses can 
develop. Milk consistency varies from mildly abnormal to gritty or purulent (Figure 3b) 
(Gonzalez and Wilson, 2003; Bokma et al., 2019b). Mastitis caused by M. bovis mostly 
occurs in dairy cattle, but can also affect beef cattle (Bokma et al., 2019b).  
  
Figure 3. Clinical M. bovis mastitis in Belgian Blue beef cattle (a), and purulent 
milk obtained from this animal (b).  
ba
a b




Oral intake of M. bovis increases the risk of otitis in calves (Maunsell et al., 2012). Once M. 
bovis climbs into the middle ear via the Eustachian tube, it will easily multiply probably due 
to decreased reachability of the immune system (Maunsell et al., 2012). From the middle ear 
the infection can spread to the inner ear, and in severe cases even to the brain (Lamm et al., 
2004). M. bovis has also been identified in axons of the facial nerves, but it is unclear how 
these got infected (Maeda et al., 2003). Clinical signs of otitis include typical head tilt (Fig. 
4a), bilateral ear droop, purulent aural discharge (Fig. 4c) and neurological signs (Maeda et 





Figure 4. Typical head tilt in a calf with M. bovis otitis (a). Fibrinous omental bursitis and 
peritonitis caused by M. bovis (b). Skull of a calf with M. bovis otitis media and interna:   
purulent discharge in the tympanic bullae (c; arrow) (source: Bert De Jonge). Secondary 











Arthritis is commonly seen in both calves and cattle often together with pneumonia or mastitis 
(Stipkovits et al., 1993; Haines et al., 2001; Gagea et al., 2006; Wilson et al., 2007). Clinical 
signs are swelling of one or more joints, painful or warm joints, and lameness (Gagea et al., 
2006; Wilson et al., 2007).  
 
Less frequent manifestations of M. bovis 
Next to the common M. bovis associated diseases, also others can occur, such as endocarditis 
(Kanda et al., 2019), myocarditis (Haines et al., 2004), seromas (Gille et al., 2016), peritonitis 
and bursitis (Fig. 4b) (Bokma et al., 2019b), meningitis (Figure 4d) (Stipkovits et al., 1993), 
keratoconjunctivitis (Levisohn et al., 2004; Alberti et al., 2006), genital disorders and abortion 
(Pfützner and Sachse, 1996; Hermeyer et al., 2012).  
 
Epidemiology of M. bovis outbreaks 
Once a herd is infected, M. bovis can very rapidly spread. In a study in four Pennsylvanian 
veal calf herds by Soehnlen et al. (2012), the M. bovis prevalence in nasal swabs went from 
0% to approximately 85% within two months on farm. Also, in feedlot cattle and veal calves 
in other countries 51-100% of the animals seroconverted within a few weeks after exposure to 
M. bovis or became positive on culture and PCR (Stipkovits et al., 2001; Arcangioli et al., 
2008; Wawegama et al., 2016; Becker et al., 2020). In dairy herds, M. bovis was shown to be 
highly contagious as well. Punyapornwithaya et al. (2011) showed that the presence of one M. 
bovis mastitis cow in the hospital pen could result in spread to 66% of the cows (6/9) within 
12 days. The contagiousness of M. bovis was also supported by an experimental study in three 
cows that showed that inoculation with 108 colony forming units (CFU)/ml M. bovis in one 
quarter of the udder, resulted in a quick proliferation to 1010 CFU/ml in milk, and a spread to 
other quarters within 5 to 10 days. One cow was able to eliminate the infection, while the 
other two started shedding M. bovis again during the next lactation/after calving (Byrne et al., 
2005). Intermittent shedding by carrier animals was also shown by Caswell and Archambault 
(2007), and is probably the reason for outbreaks of M. bovis in dry cows (Bicknell et al., 
1983; Otter et al., 2015).  
In the dairy sector M. bovis is mostly known as pathogen causing mastitis in adult cattle. 
However a recent Finnish study showed the importance to also give attention to calves and 
young stock (Vähänikkilä et al., 2019). The study showed the infection dynamics of the 
introduction of M. bovis in naïve herds. In 89.5% (17/19) of the infected herds, a few cases of 
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clinical mastitis occurred, mostly within 8 weeks after the index case. In 26.3% of the farms, 
positive PCR results on bulk tank milk (BTM) were found, but only in the first month after 
the index case. In 88.2% of these herds, M. bovis could be isolated from nasopharyngeal 
swabs from calves, and half a year later in 57.8% of these herds, calves were still positive. 
One and 1.5 year after the index case, M. bovis was still present in the calves on 47.4% and 
31.6% of these herds, respectively (Vähänikkilä et al., 2019). However, whether this was an 
ongoing infection or a new introduction of M. bovis was not clear, as the M. bovis isolated at 
different time points were not compared by strain typing.  
 
1.2 PREVENTION AND CONTROL 
The contagious nature of M. bovis and the intermittent shedding by carrier animals emphasize 
the importance of prevention and control of this pathogen. Prevention signifies all measures 
taken to avoid a pathogen to enter a currently negative herd, whereas control stands for all 
measures taken to limit spread and consequences of an infection already present in a herd. It is 
important to understand risk factors for transmission and spread of M. bovis within and 
between herds to optimize both internal and external biosecurity. In the next chapters, risk 
factors for M. bovis entering into the herd and spreading within the herd will be outlined, as 
well as vaccination and treatment (both antimicrobial and anti-inflammatory drugs) 
possibilities. 
 
Risk factors for M. bovis introduction into the herd 
The most identified risk factors for introduction of M. bovis into the herd are purchase of 
animals from infected herds (Burnens et al., 1999; Bras et al., 2016; Pardon et al., 2020), and 
large herd size (Thomas et al., 1981; Fox et al., 2003; Murai and Higuchi, 2019). Herd size 
might also play a role in the clearance of clinical disease, as in Finland only small herds (< 70 
animals) seem to be able to eliminate M. bovis compared to larger herds (Vähänikkilä et al., 
2019). In contrast to previous studies, some authors did not find an association with herd size 
(Gonzalez et al., 1992; Gille et al., 2018a), which might at least partly depend on the cut-off 
used to define smaller and larger herd sizes and confounders, such as the presence of a 
breeding bull (Gille et al., 2018a). It is also likely that purchase and herd size are dependent 
factors, as purchase usually is necessary to expand the herd.  
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To give a better overview of current literature data, a meta-analysis was performed for 
purchase being a risk factor for M. bovis, showing that purchase was indeed associated with 
increased risk for a positive M. bovis herd, with a combined odds ratio of 5.91 (3.23-10.84) 
with a random effect model (Fig. 5). Heterogeneity is caused by random sampling error and 
true differences between studies (e.g. clinical diversity, methodological diversity). Here, 
heterogeneity might not be important as I2 was below 30% and Chi2 was not significant (P = 
0.21). An attempt was made to equalize data to perform a meta-analysis and create a forrest 
plot for herd size as well. However, this attempt was unsuccessful since too many articles 
were inconclusive on herd size per farm to set a matching cut-off value between small and 
large farms or used it as continuous value. A weak point in several of the risk factor analysis 
studies is that only significant results are shown, therefore potentially biasing the meta-
analysis. Also the diagnostic determination whether a herd is positive differed greatly between 
studies, as all kind of samples (nasal swabs, blood, bulk tank milk) and techniques were used 
(e.g. PCR, antibody ELISA, and combinations).    
 
 
Figure 5. Forrest plot showing the meta-analysis of 7 published studies on purchase as a risk factor in 
M. bovis infections in cattle and bison herds. In Aebi et al. (2015), purchase also included sporadic 
transportations, expositions, and animal trade. The forrest plot was created with Review Manager 5.3.   
 
Besides the above mentioned factors, other risk factors for introduction of M. bovis into the 
herd have been identified. One of the risk factors that is getting renewed attention is the 
transfer of M. bovis by semen, which has been demonstrated or suggested several times 
(Haapala et al., 2018; Yair et al., 2020). Also, herds with a breeding bull in the herd had 4.7 
higher odds to be M. bovis positive in BTM than those without a breeding bull (Gille et al., 
2018a). Exposure to a sale yard, animal movement, and using rental trailers or trailers from 
other farms can result in higher prevalence of M. bovis in cattle and bison farms (Aebi et al., 
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2015; Bras et al., 2016; Schibrowski et al., 2018). Last, but not least, the transfer of M. bovis 
by fomites or persons has been identified as potential risk factor (Gonzalez et al., 1992). Gille 
et al. (2016) showed the onset of postsurgical seromas by a single M. bovis strain on different 
closed herds, while the veterinarian was the only visitor.  
 
Risk factors for M. bovis spread within the herd  
Once M. bovis is introduced into the herd, spread between individual animals can be 
continued by other factors. One of the main routes of transmission, is probably the 
colonization of calves by drinking M. bovis infected milk (Butler et al., 2000; Foster et al., 
2009). The oral intake leads to colonization of the pharyngeal tonsils and an increased risk of 
pneumonia and otitis in calves (Maunsell et al., 2012). Nevertheless, Aebi et al. (2015) were 
not able to identify intake by milk as a risk factor. It was shown that colostrum can also 
contain M. bovis, although in low frequency. In Belgian colostrum samples of cattle from 17 
different farms with an M. bovis outbreak within the last month were tested. Out of the 17 
farms, only 4 were PCR positive for M. bovis (Gille et al., 2020). In another study however, 
colostrum fed by a tube was a risk factor in the univariable model, that was not withhold in 
the multivariable model (Gille et al., 2018a). Both observations are questioning the 
importance of M. bovis transmission by colostrum in comparison to the advantages for calves 
obtaining high quality colostrum. In Japan, the presence of an automatic calf feeder on farm 
was a risk factor for positive bulk tank milk samples (Murai and Higuchi, 2019).  
The importance of airborne transmission is well recognized for M. hyopneumoniae in pigs and 
Mycoplasma pneumoniae in humans, but insufficiently evidenced to play a major role for M. 
bovis so far (Sánchez-Vargas and Gómez-Duarte, 2008; Otake et al., 2010). Only Jasper et al. 
(1974) were able to culture M. bovis on agar directly from air, while Soehnlen et al. (2012) 
were not able to repeat this. Whether disinfection of the barn is an important protective factor 
against M. bovis infections is also not clear. No risk factors associated with disinfection of the 
barn, the parcel around the barn or use of disinfecting footbaths could be determined so far 
(Murai and Higuchi, 2019). The importance of persistence of M. bovis in the environment for 
novel or reinfection in a herd is unclear. Nevertheless, Piccinini et al. (2015) were able to 
isolate M. bovis from the cages and mangers, which may be a risk for indirect transmission of 
M. bovis to other animals. Next to this, M. bovis can survive in straw and sand at 20°C for 10 
days and 8 months, respectively (Pfützner, 1984; Justice-Allen et al., 2010). Another study 
showed survival for nearly 2 months in sponges and milk (4°C), and 2 weeks in water as well 
(Pfützner and Sachse, 1996). The latter might explain why that Schibrowski et al. (2018) 
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identified “shared water bucket” as risk factor for sero-increase between arrival and follow-up 
of Australian feeder cattle. 
Other risk factors associated with housing are the absence of an individual calving pen (Gille 
et al., 2018a), the absence of a hospital pen (Fox, 2012), grouping of different age classes in 
one space (Tschopp et al., 2001), housing recently purchased animals in the same airspace 
(Pardon et al., 2020), stressors due to overcrowding and high in-barn temperature (Aebi et al., 
2015). Also tie-stall in comparison to loose housing was a risk factor in the univariable model 
(Murai and Higuchi, 2019), although Burnens et al. (1999) were not able to find this 
association in a previous study. 
Next to the above mentioned risk factors, management factors may also be associated with M. 
bovis positive herds. For example, no identification of attention cows with colour marks or leg 
tags to distinguish diseased cows from healthy cows increased the odds of isolating 
Mycoplasma species (mostly M. bovis) from the bulk tank milk (Pinho et al., 2013). In 
addition, corporation-type farms have a higher risk for a M. bovis positive herd, than family 
run farms (Murai and Higuchi, 2019).  
 
A few important prevention measurements that can be implemented in the authors opinion 
and taking the above risk factors into account are: (1) identification of potentially infected or 
carrier animals when purchasing an animal and placing the animal in quarantine, (2) being 
aware of potential risk of breeding bull and artificial insemination, and (3) disinfection of 
barn, transport vehicles and fomites. For control, it is important to (1) terminate raw milk 
feeding, and (2) separate animals from different age groups, unknown health status and 
(chronically) infected animals. The role of vaccination and (metaphylactic) antimicrobial 
therapy in prevention and control will be outlined next.  
 
Vaccination 
In the last decades many attempts were made to develop vaccines against M. bovis (Perez-
Casal et al., 2017; Dudek et al., 2021). Unfortunately until now, no commercial vaccines are 
available on the European market and only few vaccines are available in the United States. 
However, the efficacy of these vaccines has been questioned (Maunsell and Donovan, 2009; 
Nicholas et al., 2009; Soehnlen et al., 2011). The available vaccines are designed for use in 
healthy cattle aged 45 days (Pulmo-Guard TM MpB), 60 days (Myco-B one dose) or even 
four months (Myco-BAC® B), which is contradictory since most clinical signs occur in 
animals of two to six weeks of age (Stipkovits et al., 2000; Maunsell and Donovan, 2009). So 
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far, there are no reliable data showing that any (commercial) vaccine is working well enough 
for the use in young calves to prevent colonization or disease caused by M. bovis (Maunsell 
and Donovan, 2009; Perez-Casal et al., 2017).  
 
There are many studies exploring the benefits of different vaccines in the prevention of M. 
bovis associated disease. However, all used a different challenge protocol (e.g. inoculation by 
aerosol, transthoracic or intravenously) and different concentrations and M. bovis strains 
(Chima et al., 1980; Nicolas et al., 2002). Published field studies often lack information 
concerning other pathogens causing BRD or control groups (Urbaneck et al., 2000; Dudek et 
al., 2016; Perez-Casal et al., 2017). Potential vaccine targets are for example the Vsps, 
conserved proteins, or membrane fractions of M. bovis. However, so far, attempts were not 
successful as the stimulated immune response did not result in protection against an 
experimental challenge (Nicholas et al., 2009; Mulongo et al., 2013; Prysliak et al., 2013; 
Prysliak and Perez-Casal, 2016). Another method that was explored, was the development of 
bacterins, which are mostly M. bovis strains inactivated by formalin or saponin treatment. 
This method was showing promising results, as the use of an autogenous vaccine containing 
formalin-inactivated strain of M. bovis and M. haemolytica resulted in the reduction of 
pneumonia in a feedlot (Urbaneck et al., 2000). The use of a vaccine that was inactivated with 
saponin resulted in less BRD lung lesions, lower rectal temperature compared to the 
unvaccinated group and less dissemination of M. bovis to other organs (Nicholas et al., 2002). 
Nevertheless, alternating results were obtained in cattle of different age, and in animals that 
were either infected before vaccination or not. Unfortunately, also aggravation of clinical 
BRD signs were observed in some vaccination studies (Rosenbusch, 1998; Bryson et al., 
1999; Maunsell et al., 2009). In a blinded, controlled field trial in veal calves with two 
commercial bactericin vaccines in the USA (Pulmo-GuardTM MpB, American Animal Health, 
Grand Priarie, Texas, USA and Mycomun® R, Biomune Co., Lenexa, Kansas, USA), a 
reduction in M. bovis lesions or colonization of the upper respiratory tract could not be 
attributed to vaccination (Soehnlen et al., 2011). In China, two M. bovis strains, attenuated by 
multiple passages (150 and 180), contributed to a significant reduction in lung lesions (Zhang 
et al., 2014). More recently three autogenous vaccines (inactivated with saponine) were 
administered to calves on three farms (two veal farms, one feedlot). After 6-9 months some 
differences were seen between vaccinated and unvaccinated calves in weight (higher, but not 
always significant in vaccinated calves), reduction of severe lung lesions and pleuritis (in 
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vaccinated calves), but there was no difference in the number of times that calves needed to 
be treated for BRD (Nicholas et al., 2019).  
 
There are still many gaps in the development of vaccines for M. bovis, such as an optimized 
challenge protocol, the type of immune response needed for best protection, identification of 
the optimal adjuvant(s), identification of conserved surface antigens for subunit vaccines, and 
the mutation of individual genes in attenuated strains (Maunsell and Donovan, 2009; Dudek et 
al., 2016, 2018; Perez-Casal et al., 2017; Calcutt et al., 2018). In addition, even when it would 
be possible to import vaccines from the United States, there is a great possibility that those 
vaccines are based on M. bovis strains that differ from those circulating in Europe or even 
within a specific country (Kumar et al., 2020). Therefore, control is currently mostly 
depending on antimicrobial treatment and the isolation or culling of chronically infected 
animals.  
 
1.3 ANTIMICROBIAL AND ANTI-INFLAMMATORY DRUG THERAPY  
Most of the antimicrobial use in calves worldwide is to prevent or treat BRD (Dedonder and 
Apley, 2015; Lava et al., 2016; Lhermie et al., 2020), while the main indications to treat adult 
cattle with antimicrobials are acute mastitis and dry-cow therapy (Thomson et al., 2008; 
Kuipers et al., 2016). However, M. bovis mastitis is non-responsive to antimicrobial therapy 
(Pfützner, 1990; Nicholas et al., 2016). Therefore focus will be here on the treatment of BRD. 
BRD is a syndrome and can be caused by bacteria (e.g. Pasteurellaceae, M. bovis), viruses 
(e.g. bovine respiratory syncytial virus, BVDv, bovine herpes virus type 1, parainfluenza type 
3 and bovine coronavirus), and environmental factors (e.g. housing, ventilation, ...), but most 
often a combination of those (Pardon and Buczinski, 2020). Diagnosis is necessary for 
targeted treatment, as clinical signs are often non-specific for any of the pathogens. 
Nevertheless, rapid treatment is often indicated and waiting for laboratory results can have 
disastrous consequences.   
 
Prophylactic and metaphylactic antimicrobial use in BRD outbreaks 
Mass medication or group treatment is widely used to prevent or treat BRD outbreaks, and 
has been shown to reduce BRD morbidity (Baptiste and Kyvsgaard, 2017). Treating healthy 
animals who are at risk with antimicrobials for the prevention of an outbreak is called 
‘prophylaxis’, while ‘metaphylaxis’ is the treatment of animals that are not showing clinical 
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signs, but are in some way in contact with animals that are diseased and are expected to be 
infected (ECDC, 2015). In some studies, there is an additional threshold for the number of 
clinical cases within a group (e.g. 10%) or even for a certain amount of time (e.g. 2-3 days in 
a row) before it is defined as ‘metaphylaxis’ (Lees and Shojaee Aliabadi, 2002; Edwards, 
2010). Although prophylactic use is forbidden in European countries (European Regulation 
2019/6), metaphylaxis is still frequently used in different production systems. The largest 
effect of group treatment on morbidity reduction of BRD is observed when morbidity is ≥10% 
compared to contact with diseased animals or animals with fever (Baptiste and Kyvsgaard, 
2017). Next to this, a meta-analysis on 58 publications showed that when the prevalence of 
BRD is low (< 25%), the ‘number needed to treat’ is high (7 calves) to prevent only one BRD 
case, which might not even be profitable in comparison to individual targeted treatment 
(Baptiste and Kyvsgaard, 2017). Only when morbidity is ≥50%, economic benefit is 
sometimes obtained (Baptiste and Kyvsgaard, 2017). However, to reduce antimicrobial use, 
the shift to individual treatment is necessary (Lava et al., 2016; Pardon, 2019). It was also 
shown that random clinical trials using parenteral antimicrobials alone resulted in lower 
morbidity than oral treatment alone (Baptiste and Kyvsgaard, 2017).  
Despite the different opinions on whether metaphylaxis is necessary or not, taking into 
account that M. bovis is a primary pathogen, rapidly spreading due to its contagious nature, 
resulting in high morbidity, high antimicrobial use, hampered animal welfare, and economic 
losses, metaphylaxis in an M. bovis outbreak is perhaps justified. Nevertheless, before any 
treatment is started, diagnosis is necessary, as using an ineffective antibiotic as first intention 
treatment will only lead to the use of more antimicrobials, therapy failure, and economic loss.  
 
Antimicrobial treatment of M. bovis 
M. bovis is a member of the Mollicutes and lacks a cell wall (Razin, 1978). Therefore 
antimicrobials of which the working mechanism is based on damaging the cell wall, like beta-
lactams (penicillines, cephalosporines) and polymyxins are not effective in the treatment of 
M. bovis associated diseases (Lysnyansky and Ayling, 2016). A second characteristic is the 
absence of folium acid production, with subsequent inherent resistance against trimethoprim 
and sulphonamides (Maunsell et al., 2011; Lysnyansky and Ayling, 2016). Intrinsic resistance 
against the 14-membered ring compound macrolide erythromycin is also described (Devriese 
and Haesebrouck, 1991; Francoz et al., 2005; Rosenbusch et al., 2005).   
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To treat M. bovis mainly florfenicol, tetracyclines, macrolides, and fluoroquinolones are used. 
Pleuromutilins are antibiotics which are not registered for the use in cattle, although they 
generally seem very efficient against Mycoplasma spp. in swine, and might be an option for 
use against M. bovis, as the use of critically important antibiotics (e.g. macrolides, 
fluoroquinolones) are discouraged by the World Health Organization (WHO) and the World 
Organization for Animal Health (OIE) (Aidara-Kane et al., 2018; OIE, 2019). In multiple 
European countries, including Belgium, the use of fluoroquinolones without a susceptibility 
test showing it to be the last resort therapy is even prohibited (KB 21 July 2016). 
 
Several authors have attempted to investigate antimicrobial treatment protocols in 
experimental studies or clinical field trials. Unfortunately, there are many pitfalls in the 
interpretation of effectiveness, such as influence of different study populations and co-
infections with other pathogens. Clinical field trials are also costly, time-consuming, and 
ethical reasons (e.g. inclusion of a negative control group) might prevent such studies from 
happening frequently. In addition, the used M. bovis strain might not always reflect the 
pathogenicity and antimicrobial susceptibility of other M. bovis strains. Next to different 
pathogenicity, there are no standard protocols for the determination of MIC values. Described 
MIC values of experimental strains should therefore be interpreted with caution. 
 
When using antimicrobials as prophylaxis for BRD, best relative risk reductions (‘the 
difference in event rates between two groups, expressed as a proportion of the event rate in 
the untreated group’, UWA, 2021) were shown when using broad-spectrum critically 
important antimicrobials (fluoroquinolones, macrolides) or combinations (tetracycline-
combinations). However, when using different antimicrobials as metaphylaxis instead of 
prophylaxis, no significant difference on morbidity outcome between antimicrobials was 
identified (Baptiste and Kyvsgaard, 2017). In the next paragraphs, a selection of clinical trials 
evaluating antimicrobial treatment protocols for M. bovis is briefly discussed.  
 
Florfenicol and tetracyclines 
In 2008 in a veal setting where M. bovis was the dominant pathogen, Catry et al. (2008) 
showed that the use of parenteral florfenicol was superior compared to the oral use of 
tilmicosin, doxycycline or saline. Less calves that were initially unaffected got sick, and an 
increase in body weight, and decrease in rectal temperature was observed (Catry et al., 2008). 
In addition, in a feedlot setting, Hendrick et al. (2013) showed that prophylactic treatment 
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with oxytetracycline compared to no treatment resulted in a reduced risk of BRD, but an 
increased risk for arthritis. However, no significant effect on BRD relapse, average daily gain 
or mortality was observed. In another study, in a natural outbreak of BRD including M. bovis, 
no significant differences were observed on the improvement of clinical signs, body weight 
gain or relapse within 60 days, when cattle were individually treated with either florfenicol or 
tulathromycin (Godinho et al., 2005b). In a recent natural outbreak of M. bovis pneumonia in 
beef young stock, treatment with florfenicol or oxytetracycline resulted in cure rates of 94.3% 
and 85.7% after 8 days, respectively, as evidenced by thoracic ultrasonography (De Cremer et 
al., 2019). These studies show that florfenicol and oxytetracycline can probably both be used 
as first intention parenteral treatment in BRD outbreaks. To what extent, acquired resistance 
to these molecules is frequent will be discussed later in this literature overview.  
 
Macrolides 
After prophylactic tilmicosin treatment in gnotobiotic calves the colonization of M. bovis was 
reduced, but not prevented (Gourlay et al., 1989). Also, treatment upon presence of clinical 
signs, reduced clinical scores and lung lesions. However, in both experimental and natural 
outbreaks, the superiority of tulathromycin compared to tildipirosin and tilmicosin as 
treatment for calves infected with M. bovis (MIC >64 µg/ml for tulathromycin) was shown by 
reduced depressed position, lower rectal temperatures, reduced lung lesions, reduced 
mortality, and a higher body weight (Godinho et al., 2005b; Bartram et al., 2016). In a 
controlled field trial where M. bovis (MIC > 16 µg/ml), M. haemolytica (0.5-2.0 µg/ml), and 
P. multocida (0.125-2.0 µg/ml) were involved in BRD, both the morbidity and the number of 
animals showing clinical signs in the first 14 days after treatment were significantly lower in 
the group treated with gamithromycin compared to saline (Baggott et al., 2011). Based on 
these studies, which were often executed or sponsored by the manufacturer of the product, 
tulathromycin and gamithromycin appear very efficient in the treatment of M. bovis. It is 
however concerning, that 14 days post-treatment M. bovis was still present in the lungs 
(Godinho et al., 2005a; Bartram et al., 2016). It would have been interesting in these studies to 
prolong the sampling time until slaughter, and to determine whether animals would have been 
able to cure themselves and eliminate M. bovis fully after a longer period or whether they 








Another antimicrobial showing to be potentially effective in the treatment of M. bovis in 8 
experimentally infected calves by intratracheal inoculation was spectinomycin (MIC 4.2 ± 2 
mg/L) (Poumarat et al., 2001). Lower concentrations of M. bovis were observed in the lung 
lobes after slaughter compared to those who were not treated. Unfortunately, M. bovis was 
still present in the lungs after treatment. The duration of the therapy in this trial (only 3 days) 
might have contributed to the fact that treatment did not result in clearance of the bacterium 
from the lungs, since it was recommended to treat animals for at least 10 days with 
antimicrobials, as otherwise relapse (30-70% of the animals) might occur (Currin, 2009).  
 
Valnemulin  
As mentioned before, pleuromutilins are not registered for antimicrobial therapy in cattle. 
Nevertheless there are studies showing promising results for valnemulin. A clinical field trial 
with M. bovis was executed with valnemulin in feed (21 days) compared to a placebo premix 
in a single farm. The results showed a decrease in M. bovis associated disease signs, reduced 
treatment incidence and mortality, and increased weight (Stipkovits et al., 2001). In addition, 
an experimental study was performed, where calves were treated with either enrofloxacin or 
valnemulin in the milk replacer (10 days) or they were not treated after infection (Stipkovits et 
al., 2005). Clinical score reduced significantly more rapid in the valnemulin group compared 
to the enrofloxacin and the group that was infected, but not treated. Rectal temperature did 
however reduce in both the valnemulin and enrofloxacin group without significant difference 
between these two. Isolation of M. bovis in different organs after slaughter showed 
significantly less isolation of M. bovis from animals treated with valnemulin than those with 
enrofloxacin (Stipkovits et al., 2005). Parenteral treatment of valnemulin and tiamulin, which 
are products available in swine, could therefore be further explored for the individual 
treatment of cattle infected with M. bovis.  
 
Combination of antimicrobial treatment and anti-inflammatory drugs 
More and more anti-inflammatory drugs (AIDs), especially non-steroidal anti-inflammatory 
drugs (NSAIDs), are used when animals are combatting an infectious disease for the 
reduction of fever, to relieve pain, and prevent the potential collateral damage caused by an 
overreaction of the immune system (Leslie and Petersson-Wolfe, 2012; Thiry et al., 2014). It 
is however not clear, whether this use of anti-inflammatory drugs, is recommended in M. 
bovis treatment.  
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A systematic review on evidence related use of anti-inflammatory drugs in BRD was 
performed by Francoz et al. (2012), showing at that time only 15 articles meeting the 
inclusion criteria. All differing greatly on study population, duration, and used (NS)AIDs. The 
only beneficial effect most of the randomized and blinded studies (n=6) were clear on was the 
rapid decrease in rectal temperature (Francoz et al., 2012). Additional potential NSAID 
benefit was the decrease in lung consolidations, although no improvement in clinical 
parameters was observed (Francoz et al., 2012). None of these six studies mentioned the 
presence of M. bovis.  
Since this systematic review, several studies were published including M. bovis as pathogen, 
and indeed rectal temperature, but also the depression score reduced significantly after six 
hours of administration of florfenicol-flunixin in comparison to florfenicol alone, when this 
was given to calves showing BRD signs. In this study, beside M. bovis, also other pathogens 
were present (Thiry et al., 2014). Next to rectal temperature, also respiratory signs reduced, 
although there was no significant difference between florfenicol alone or in combination with 
the NSAID. Limitation of such a study is that all BRD pathogens are observed together, and it 
is not clear whether M. bovis would respond different. In Dudek et al. (2019) the efficacy of 
either enrofloxacin treatment alone (SC, 3 days), or in combination with flunixin meglumine 
(NSAID, intravenously (IV), 3 days), when calves were experimentally inoculated with M. 
bovis (MIC enrofloxacin 0.25 µg/mL) was explored. A third treatment option was the 
combination of both enrofloxacin, flunixin meglumine, and the immunostimulator 
pegbovigrastim (day 1 and 7, SC). Also a negative control group was included. The best 
immune response, the least lung lesions and clinical signs were observed in the group treated 
with only enrofloxacin, while the combination of enrofloxacin with the NSAID or with the 
NSAID and immunomodulator showed more lesions.   
 
Another AIDs class are the corticosteroids. When 20 Jersey calves were experimentally 
infected with M. bovis in their milk, it was shown that the treatment with dexamethasone (IM, 
day 2) increased shedding of M. bovis in treated calves compared to those who were not 
treated. Next to this, the onset of shedding occurred faster and the duration of M. bovis 
shedding prolonged, suggesting that stress will also increase shedding (Alabdullah et al., 
2017). Another study suggested the potential synergistic influence of dexamethasone and M. 
bovis on reduced neutrophil functioning (Alabdullah et al., 2015), while same authors showed 
the impaired phagocytizing number of M. bovis by neutrophils exposed to dexamethasone 
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treatment (Alabdullah et al., 2018). Therefore, use of corticosteroids in M. bovis infections 
should be discouraged.  
 
Therapy evaluation and failure of treatment  
When facing an outbreak of BRD in calves, first one should make the decision whether an 
animal (or group of animals) needs to be treated (= antimicrobial decision making process). 
Often, this is based on the detection of clinical signs or pneumonia on ultrasound. Usually, 
samples for the detection of the pathogen are taken (nasal or lung swabs, bronchoalveolar 
lavage, transtracheal aspiration), and while pending laboratory results, empiric treatment, 
based on experience and available, local antimicrobial susceptibility information, is initiated. 
Depending on the turnaround time of the diagnostic tests and the severity of the disease, 
therapy success is clinically evaluated or identification of the pathogen and antimicrobial 
susceptibility testing will show whether an (in)appropriate antimicrobial treatment was started 
(Pardon, 2019). Inappropriate antimicrobial treatment is defined as: “The use of antibiotics 
with poor or no in vitro activity against the identified microorganisms causing infection at the 
tissue site of infection” (American Thoracic Society and Infectious Diseases Society of 
America, 2005). Whether in vitro includes translating in vitro results to in vivo results with 
clinical breakpoints is not clear, but these data should be included as well. In addition to 
‘appropriate treatment’, the treatment should also be ‘rational’, which is defined as: “patients 
receive medications appropriate to their clinical needs, in doses that meet their own individual 
requirements, for an adequate period of time, and at the lowest cost to them and their 
community” (WHO, 1985). The cost to their community, in terms of consequences, is 
especially important concerning the consequences of antimicrobial use, such as antimicrobial 
resistance. Therefore, the term ‘prudent use’ is also often applied: “Use which benefits the 
patient while at the same time minimizing the probability of adverse effects for the individual 
and the emergence or spread of antimicrobial resistance” (Pardon, 2019).   
 
Unfortunately, even when the laboratory results show that the appropriate antimicrobial 
treatment was initiated, therapy failure can still occur (or vice versa). Therefore, the 
‘definitive therapy’ should be decided while considering both clinical outcome and laboratory 
results. The pharmacokinetics and dynamics of certain antimicrobials are unpredictable in 
diseased animals. For example, florfenicol and marbofloxacin pharmacodynamics vary in 
diseased sheep and calves compared to healthy animals (Ismail and El-Kattan, 2007; Pérez et 
al., 2015; Booker and Lubbers, 2020). Next to this, medication errors (“any preventable event 
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that may cause or lead to inappropriate medication use or patient harm while the medication is 
in the control of the health care professional, patient, or consumer”, NCCMERP, 2021), such 
as with stocking temperatures, administration route, dose, and frequency of treatment, can 
result in treatment failure (Booker et al., 2020). For M. bovis, treating early in the disease 
course is of great importance as well (Currin, 2009), due to its immunomodulatory character, 
and formation of abscesses, giving it the ability to evade antimicrobials and the immune 
response. Delayed treatment even with the ‘appropriate’ antimicrobial treatment, can 
therefore result in therapy failure.     
 
In conclusion, the consequences of M. bovis outbreaks are extensive of which economic 
losses, high antimicrobial use, decreased defense mechanisms against other pathogens, and 
hampered animal welfare are only a few. Rapid identification of M. bovis and obtaining its 
susceptibility profile, is absolutely crucial for improved control and prevention. Next to rapid 
identification and susceptibility testing, strain typing can help to better understand possible 
introduction pathways and the epidemiological behavior of M. bovis. Both can help in the 
development of additional (inter)national guidelines for prevention and control of M. bovis.  
 
In the following chapters of this general introduction, the available diagnostic methods for 
identification, strain typing, and antimicrobial susceptibility testing will be discussed. 
Additionally, a brief overview of the available epidemiological data obtained by these 
methods will be given.    
 
1.4 IDENTIFICATION OF MYCOPLASMA BOVIS 
When facing a BRD outbreak, it is very important to know whether M. bovis is one of the 
involved agents, as first choice antimicrobial therapies for BRD often include antimicrobials 
that are not effective against M. bovis. For example, in the Netherlands (NL) and Belgium 
(BEL) the guidelines for antimicrobials use in BRD outbreaks include penicillin and 
potentiated sulphonamides, while for BRD including M. bovis, the first choice agents include 
florfenicol (NL, BEL), tetracyclines (NL) and macrolides (NL). In addition, as previously 
touched upon, metaphylactic treatment might be justified in the treatment of M. bovis. 
Therefore, to enable immediate rational use of an appropriate antimicrobial resulting in more 
therapy success and better control of further spread, early identification of  the presence of M. 
bovis is crucial.  
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Identification of M. bovis faces several challenges. Although many methods are available to 
identify M. bovis, none of them are perfect. Many can be improved, especially in terms of 
turnaround time, costs, and diagnostic accuracy. For instance, culture takes about 1-2 weeks 
to obtain definitive identification of M. bovis, costs of (multiplex) PCR can easily amount to 
125 euros per sample, and sensitivity of antibody ELISA is often disappointing. Most samples 
investigated for M. bovis are either from the respiratory tract, milk or blood for serology. 
Occasionally synovial samples, swabs from the middle ear, reproductive tract or other organs 
are presented. Conventional techniques for routine diagnostics/identification of M. bovis can 
be divided into two large categories: (1) detection of the bacterium (e.g. microbial culture, 
PCR) or (2) detection of antibodies (e.g. ELISA), showing a previous, but not necessarily 
present, infection with M. bovis. Detection of the bacterium can be subdivided into (a) 
culture-based methods resulting in an isolate, and (b) culture-independent methods (e.g. 
PCR), without obtaining an isolate from the sample (Parker et al., 2018).   
In the last decade, MALDI-TOF MS (Matrix-assisted laser desorption-ionization – time of 
flight mass spectrometry), has become a technique for faster diagnosis of bacteria following a 
cultivation step (Bizzini and Greub, 2010; Puchalski et al., 2016), including Mycoplasma 
species (Pereyre et al., 2013). Also efforts to make next-generation sequencing, a culture-
independent method, more accessible and affordable for diagnosis and strain typing have been 
made (Parker et al., 2018).  
 
Sampling methods in the standing animal  
In a BRD outbreak different sampling methods can be executed by the veterinarian. Most 
often a deep nasal swab (DNS; Fig 6A), a bronchoalveolar lavage (BAL; Fig 6B) or a trans-
tracheal aspirate/wash (TTA/TTW; Fig 6C) is performed. In short, before a DNS or BAL is 
performed the nostrils are disinfected with alcohol (70-90%). To perform the DNS, a swab is 
introduced via the nasal cavity until the nasopharynx where the swab is rotated, resulting in a 
sample of the nasopharyngeal mucosa (Van Driessche et al., 2017). In case of a BAL, a small 
sterilized catheter is introduced in the nasal cavity, carefully moved up passing the larynx and 
through the trachea until the bronchi are reached. Subsequently approximately 30 mL of 
saline is injected via the catheter, and immediately aspirated (Van Driessche et al., 2017). In 
this case an individual lung lobe is sampled (Pardon and Buczinski, 2020). For a TTA or 
TTW first the skin should be shaved, sterilized, and a local anesthetic should be applied at the 
lower part of the trachea. Subsequently, a human intravenous catheter or Large Animal Trans-
Tracheal Wash Kit (MILA international) is used to push through the skin into the trachea 
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where saline can be injected. The saline washes the tracheal bifurcation, and can be aspirated 
for further analysis (Timsit et al., 2013; Pardon and Buczinski, 2020).    
 
These techniques all have their advantages and disadvantages considering ease of use, cost, 
interpretation of test outcome, invasiveness and possible complications which are summarized 
in Table 1, and extensively described elsewhere (Pardon and Buczinski, 2020). Important for 
the interpretation of test results is the difference between isolating or identifying a pathogen 
from the upper respiratory tract (DNS) or the lower respiratory tract (the larger bronchial 
airways and alveoli) with a BAL (Chase and Kaushik, 2019). Some opportunistic pathogens 
(e.g. Pasteurellaceae), can be present on the nasopharyngeal mucosa as part of the common 
flora, not associated with pneumonia. However, when isolating them abundantly from the 
lung, they are most likely involved in pneumonia, and antimicrobial treatment is necessary. 
Opinions on the reflection of pathogens isolated from TTA/TTW are somewhat controversial, 
as some believe that only pathogens from the lung are transferred by cilia towards the 
bifurcation, while others comment on the possibility of aspirating mucus originating from the 
nasopharynx or indicating a bacterial tracheitis without the need of antimicrobial therapy 
(Pardon and Buczinski, 2020). In addition, DNS are resulting in more polymicrobial cultures 
(~80%) than those from BAL (~20%), which are more difficult to interpret (Van Driessche et 
al., 2017). However, it was shown by Doyle et al. (2017) that the agreement between DNS 
and BAL compared to TTW was good to very good for most pathogens involved in BRD, 
although the agreement for M. bovis was highest in BALf, and more M. bovis was isolated 




   
Figure 6. Methods to sample the respiratory tract of cattle: deep nasal swab (a), bronchoalveolar lavage 
(b), and trans-tracheal aspirate/wash (c). Source: Pardon and Buczinski, 2020.   
ca b
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Table 1. Sampling methods for the identification of M. bovis in cattle  






(Deep nasal) swab* ± + ± ± € 1m 
Trans trachael aspirate/wash ++ ± + + €€ 10m 
Bronchoalveolar lavage + ± + + €€ 1-10m 
Milk - + + + € 1m 
Body fluids** ± ± + + €€ 5-10m 
Blood (serology) ± + - ± € 1m 
* swabs can also be from the middle ear, eye or reproductive tract  
** e.g. joint, pleural, abdominal or cerebrospinal fluid 
*** sampling time in minutes (m), can vary between veterinarians depending on experience  
 
Other sampling methods, such as milk samples and body fluids, can be implemented in M. 
bovis mastitis or arthritis outbreaks, and problems with postsurgical seromas. Retrieving 
reliable milk samples rely on the correct sample technique (e.g. cleaning and disinfecting the 
teat, forestripping, handling the sterile sample tube, ..). Also, puncturing the skin to obtain 
body fluids, asks for a correct disinfection protocol to prevent contamination of the sample 
and introduction of an (new) infection in the body fluid.  
 
Culture-based methods for the identification of M. bovis 
First of all, sample storage is a key factor for the isolation of M. bovis from clinical samples. 
Not only because of potential overgrowth by other pathogens or contaminants, but also due to 
the fact that M. bovis does not survive very well in most samples. For example, M. bovis 
shows only short survival in milk at room temperature (23ºC) compared to storage of the 
samples in the fridge (5ºC) (Parker et al., 2016). It is recommended to store samples at 5ºC 
and culture them as soon as possible. After one day of storage, rapid reduction of viable M. 
bovis is observed (Boonyayatra et al., 2010). When delayed culturing is foreseen, samples can 
be frozen, as only a reduction of 1-2 log10 in viable M. bovis is observed in milk and 
colostrum samples (Biddle et al., 2004; Boonyayatra et al., 2010; Vyletělová, 2010; Gille et 
al., 2018b). Addition of glycerol (10-30%) can improve recovery from frozen milk samples 
(Boonyayatra et al., 2010).  
 
Conventional microbial culture 
Mycoplasmata require specific solid or liquid media to grow and interpretation needs a certain 
amount of expertise (Parker et al., 2018; Wisselink et al., 2019). The limit of detection of M. 
bovis culture is dependent on the exact method used, but has been estimated around 102 
CFU/mL in milk and in BALf (Sachse et al., 2010; Wisselink et al., 2019). Advantages of 
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culturing are simultaneous detection of other Mycoplasma species, low operating costs, the 
acquirement of an isolate, with possibility for additional molecular typing and antimicrobial 
susceptibility testing (AST), and a more straightforward clinical interpretation, as viable 
organisms are detected. Disadvantages are the long turnaround time before final identification 
is obtained (5-10 days), potential overgrowth by other pathogens or contaminants, and the 
need for correct sample preservation to safeguard the viability of the organisms. When 
cultured on solid media and inspected under the microscope, M. bovis shows a “fried egg” 
morphology, which is quite specific for the Mycoplasma genus, but not specific for M. bovis. 
Therefore, most culture-dependent systems require species confirmation using PCR or 16S 
rRNA sequencing, which is expensive and requires additional time. Confirmation after culture 
can also be obtained with a commercially available sandwich ELISA, which is applicable to 
tissue lysates and milk (Bio K 341, Bio X). It has also been described that Mycoplasma 
species can be distinguished with biochemical tests, such as film production and metabolic 
inhibition tests (Poveda and Nicholas, 1998). For example digitonin or nisin disc diffusion 
assays can be used to distinguish Mycoplasma from Acholeplasma species. To identify M. 
bovis, the presence of lipase activity can be tested with a selective-indicative agar containing 
Tween-80 (Devriese and Haesebrouck, 1991; Boonyayatra et al., 2012). Because such 
biochemical tests may not be very specific, it is unfortunate that diagnostic accuracy of these 
methods is poorly described until now. 
 
MALDI-TOF MS: novel culture-based method 
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF 
MS) is a technique which has become very popular in veterinary diagnostics over the last few 
years (Randall et al., 2015). Whereas the purchase of this device is a great investment, today 
many laboratories already have their own MALDI-TOF MS equipment. The easiness of the 
‘direct transfer method’, where colonies of bacteria from solid medium are deposited on target 
plates, covered with matrix, and are immediately ready for analysis, contributes to its 
popularity. Samples are vaporized and ionized without degradation due to the matrix by a 
laser, and the particles are subsequently accelerated in an electric field. Depending on their 
mass and charge, it takes a certain amount of time to arrive at the detector (large particles are 
slower) (Pavlovic et al., 2013; Bourassa and Butler-Wu, 2015), and the detection of the most 
abundant proteins, results in species-specific spectra. This spectrum can be compared to a 
commercial and/or in-house library (Sauer and Kliem, 2010; Pavlovic et al., 2013).  
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MALDI-TOF MS is mostly detecting proteins, which are usually unique per bacterial species 
(Clark et al., 2013; Dingle and Butler-Wu, 2013). Therefore, MALDI-TOF MS is even able to 
distinguish M. bovis from M. agalactiae better than 16S rRNA sequencing or species-specific 
qPCR (Pereyre et al., 2013; Cornelissen et al., 2017; Spergser et al., 2019). However, the 
proteome of microorganisms, and therefore the quality and reproducibility of spectra, can be 
influenced by different circumstances, such as growth medium and incubation time (Welker 
and Moore, 2011; Anderson et al., 2012; Martiny et al., 2013). Another influence on the 
results can be caused by the MALDI-TOF MS device that is used. Both Bruker Biotyper 
(Bruker Daltonics) and VITEK MSTM PLUS (bioMérieux) show a high level of agreement, 
although the commercial libraries are not completely the same (TeKippe and Burnham, 2014; 
Lévesque et al., 2015). It was shown that the VITEK MS result in more misidentifications 
when the bacteria of interest is not part of the library (Lévesque et al., 2015). Nevertheless, 
these libraries are frequently updated improving both devices.  
For Mycoplasma species, the ‘direct transfer method’ does not seem sufficiently reliable, due 
to the small colonies and often growth into the agar. Nevertheless, MALDI-TOF MS is able to 
perform identification of Mycoplasma species after an enrichment step and protein extraction 
from liquid culture (Pereyre et al., 2013; Spergser et al., 2019).  
MALDI-TOF MS is easy to use, rapid and compared to PCR, the consumable cost is much 
lower. Nevertheless, until now it remains unclear what the best growth conditions are 
allowing the fastest and most reliable identification of M. bovis for clinical applications.  
 
Culture-independent methods for the identification of M. bovis 
When isolation of M. bovis is not possible as a result of for example chronically infected 
organs or previous antimicrobial treatment, M. bovis can be visualized with the use of 
monoclonal antibodies (immunohistochemistry) or labeled DNA (in-situ hybridization) 
(Adegboye et al., 1995; Hermeyer et al., 2012). However, these methods are costly and 
require time and experienced staff (Dudek et al., 2020). In contrast, PCR has become the 
routine diagnostic method to identify M. bovis, as it is much faster, and will therefore be 
further outlined beneath.  
 
Conventional and real-time PCR 
PCR is a technique that detects specific parts of the DNA, and amplifies this part of the DNA 
until it can be visualized by fluorescent detection. One of the advantages of PCR is that 
storage conditions are less relevant than with culture-based methods, as DNA is the target and 
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no preceding culturing step is required (Parker et al., 2018). Both conventional (cPCR) and 
quantitative (real-time) PCR (qPCR) are frequently used in the detection of M. bovis. The 
advantage of qPCR compared to cPCR is a faster turnaround time. In addition, quantification 
of the sample content is possible with qPCR (Maurin, 2012). In general, for both cPCR and 
qPCR, a final identification can be reached more rapidly than with culture-dependent 
methods. The limit of detection is lowest in milk (102 CFU/ml) and BALf (10-103 CFU/ml), 
followed by semen (105 CFU/ml) and different kind of swabs (preputial, vaginal, eye and 
nasal) (106 CFU/ml). Besides the sample, the detection limit also depends on the targeted 
gene (respective sensitivity: uvrC > oppD > polC) (Parker et al., 2017; Wisselink et al., 2019), 
and the number of species in one sample (more species increases detection limit) (Parker et 
al., 2017). Many different methods for M. bovis qPCR are applied, not only using different 
target genes, such as the oppD, uvrC, fusA and polC, and 16S rRNA, but also different DNA 
extraction protocols and amplification platforms are used (Wisselink et al., 2019). 
Nevertheless, despite the multiplicity of cPCR and qPCR methods for M. bovis used in 
different laboratories, an interlaboratory evaluation showed comparable performance of all 
tested PCR methods (Wisselink et al., 2019). For one of these (triplex) real-time PCR tests 
sensitivity was 95.2% and specificity 73.9% for identification of M. bovis from BALf 
compared to PCR with denaturing gradient gel electrophoresis fingerprinting (PCR/DGGE) 
(Cornelissen et al., 2017). Another study showed comparable results for Pneumo4B multiplex 
qPCR kit on tracheal aspirates, as sensitivity and specificity were 96% and 71%, respectively 
(Pansri et al., 2020). Disadvantages are the same for cPCR as qPCR, such as higher costs 
compared to culture, other Mycoplasma species not being detected (except with multiplex 
tests, additional denaturing gradient gel electrophoresis (DGGE), or high resolution melting 
curve analysis (HRM)), possible cross-contamination of samples in the laboratory resulting in 
false positives, cross-reactivity with other Mycoplasma species (especially M. agalactiae), 
and a less straightforward clinical interpretation, because also non-viable organisms can be 
detected. In addition, no isolate will be obtained, and no strain database can be created. 
Therefore, the possibility for additional studies on antimicrobial susceptibility or strain typing 
are, although not completely non-existent (e.g. MLVA after PCR), very limited (Pinho et al., 
2012).  
 
Potential culture-independent M. bovis identification methods   
Lately, some other promising, but not routinely used methods were also published. For 
example the Procedure for Ultra Rapid Extraction and Loop-mediated isothermal 
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Amplification (PURE-LAMP) by Itoh et al. (2020). This method can identify M. bovis from 
milk within 2 hours and showed high sensitivity (85-97%) and specificity (100%) on 
individual milk samples (Itoh et al., 2020). Another point-of-care diagnostic method is the 
Rapid Polymerase Amplification Lateral Flow Dipstick (RPA-LFD), which shows the result 
within 30 minutes from different kind of samples (nasal swabs, joint, bulk tank milk, ..) with a 
sensitivity and specificity of 99.0% and 95.6%, respectively. There is no need for expensive 
equipment, and the interpretation is easy (Zhao et al., 2018). Finally, high resolution melting 
curve analysis (HRM), seems like a potential method for the identification of M. bovis (Ahani 
Azari et al., 2020). Nevertheless, more research is necessary to validate the above mentioned 
methods, before they can be implemented as reliable routine diagnostic methods. 
 
Next-generation sequencing: an upcoming culture-independent method 
Due to fast decreasing cost for whole genome sequencing (WGS) and decrease in turnaround 
time, it is becoming more attractive as an all-in-one diagnostic tool (e.g. identification, strain 
typing and AST). Sanger sequencing was the first-generation sequencing method, based on a 
single DNA fragment amplification at the time, resulting in short (800-1000 base pairs), but 
very accurate sequences. The second-generation sequencing is most commonly referred to by 
the Illumina short-read technology. Illumina technology is based on the sequencing-by-
synthesis approach resulting in even shorter reads (150-250 base pairs), but is in contrast to 
Sanger, able to sequence millions of DNA fragments at the same time (Goodwin et al., 2016). 
The many obtained short-reads can be a problem for Mycoplasma species due to their highly 
repetitive regions and extreme low GC content. Therefore, difficulties can occur during the 
reconstruction of a consensus genome, as with many small fragments it is hard to determine 
the exact location of the DNA fragment and how many repetitive regions are exactly present 
at a specific location (Sabat et al., 2013).  
However, third generation sequencing, such as technologies provided by Pacific Biosciences 
(PacBio) and Oxford Nanopore Technologies (ONT), enable the real-time sequencing of 
longer reads (20-200 kb), making the reconstruction of a consensus genome more easy in 
general and for Mycoplasma species in specific. 
 
PacBio’s Single Molecule Real-Time (SMRT) sequencing uses a SMRT flow cell with zero-
mode waveguides. When nucleotides are incorporated by a modified polymerase, the 
detection of phosphor-linked fluorophores allows to capture real-time incorporation of 
nucleotides (Slatko et al., 2018; https://www.youtube.com/watch?v=_lD8JyAbwEo&t=1s). A 
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big difference between nanopore sequencing and other platforms is the absence of an 
amplification step supported by polymerase with nanopore sequencing. Instead of detecting a 
secondary signal, nanopore sequencing directly detects ssDNA which can be bidirectional 
sequenced due to the addition of a hairpin (Goodwin et al., 2016). The DNA is passed along 
small channels (nanopores) (Fig. 7A), detecting k-mer-specific electrical currents (squiggles), 
which eventually allows interpretation of the k-mer sequence on the dsDNA strand (Fig. 7B) 
(Slatko et al., 2018; https://www.youtube.com/watch?v=GUb1TZvMWsw). A brief 
comparison between second and third generation sequencing methods is shown in Table 2.   
While high error rates have been observed upon the commercial release of nanopore 
sequencing technology in 2014-2015, immense research and development efforts in new 
pores, chemistry, basecalling algorithms and higher throughputs have enabled to increase the 
accuracy to a very high level. Single read accuracies of > 99.3% (Q20) will probably be 
reached in 2021 (ONT, 2021), therefore bringing the platform at the same accuracy levels 
next to Illumina and PacBio. When using Nanopore sequencing, obtained raw sequence data 
is further processed in a complete bioinformatics pipeline (including base calling, quality 









Figure 7. Schematic representation of ssDNA passing through the nanopore (A) resulting in an output 








One of ONTs devices, the MinION, is a portable sequencing platform, and has the potential to 
be applied directly in the field (Lamb et al., 2020). Until now, this has not been widely used in 
veterinary medicine, due to the remaining high cost, and as the raw read accuracy has been 
lower compared to Illumina (> 99%) (Rang et al., 2018). Therefore, the use of nanopore 
sequencing was limited to research and national surveillance settings, rather than applications 
in clinical diagnostics. However, MinION has already proven itself in the diagnosis of African 
Swine Fever, porcine viral enteric disease in piglets, and P. multocida in poultry (Costard et 
al., 2009; Theuns et al., 2018; Omaleki et al., 2020). In addition, McCabe et al. (2018) showed 
the rapid identification of viruses causing BRD using ONT from foetal lung cell cultures, and 
very recently (2021), nanopore sequencing was brought to the veterinary market as accessible 
tool for veterinarians for the identification of bacteria and viruses from BALf (PathoSense, 
Lier, Belgium). Unfortunately, standard protocols for the bioinformatics pipeline of nanopore 
sequencing are currently missing, and no information is available on the diagnostic accuracy 
of this method for the identification of Mycoplasma species from BALf.  
 
Detection of (previous) M. bovis infection: antibody ELISA  
Next to detecting the pathogen itself, antibodies can be detected in serum or milk. Robust 
detection of antibodies is possible with western blot analysis. Yet, this is a time consuming 
test. As a practical alternative, ELISA’s are preferred in routine diagnostics (Andersson et al., 
2019). Advantages of antibodies are that the animal does not need to be shedding the 
organism at the time of sampling and that longevity of antibody expression can last for 4-18 
months (Petersen et al., 2018a; Vähänikkilä et al., 2019). Disadvantages are the lag between 
infection and seroconversion (2-3 weeks later), uncertainty of possible cross-reactivity with 
other Mycoplasma species, influence of animal age on antibody detection, difficulties in 
interpretation given the substantial variation between different ELISA’s, and sometimes poor 
sensitivity (Parker et al., 2017; Petersen et al., 2018b; Parker et al., 2018). It is also concluded 
Table 2. Comparison of the most popular next-generation sequencing platforms  
 Second generation sequencing Third generation sequencing 
 Illumina PacBio Nanopore 
Sequencing method Sequencing-by-synthesis Single molecule Single molecule 
Polymerase Free floating Fixed to bottom Absent 
Read length Short-read (150-250bp) Long-read (~20kb) Long-read (up to 200kb) 
Real-time analysis  No Yes Yes 
Turnaround time 24-72h 4-20h 2-48h 
Raw read accuracy > 99.5% > 99.0% > 99.3% 
Initial cost €€€ €€€ € 
Portable model No No Yes 
General introduction  Chapter 1 
39 
 
that clinical disease in general is not correlated to the extent of the antibody response 
(Petersen et al., 2018a, Petersen et al., 2018b). The result is that most antibody ELISAs are 
not able to differentiate between healthy and diseased cows (Petersen et al., 2020). It is also 
possible that animals are shedding M. bovis, but antibodies cannot be detected in the bulk tank 
milk (Gille et al., 2018a). Whether this is a result of the lag time between infection and 
seroconversion, antibodies against other M. bovis associated diseases (e.g. pneumonia) 
without shedding of M. bovis in the milk, dilution of antibodies in the bulk tank milk by milk 
samples from M. bovis negative animals, or M. bovis binding to antibodies and interfering 
with the ELISA test is not clear.  
An import remark is that the diagnostic test accuracy of these tests differs tremendously. 
Differences are shown between both commercially available and in-house tests, but results 
also depend on the target population, such as calves or adult cows, and healthy or diseased 
animals (Petersen et al., 2018b; Andersson et al., 2019; Petersen et al., 2020). Therefore, it is 
necessary to think about the aim of sampling either specific animals or the herd in general. 
For example, due to the delayed seroconversion, antibody ELISA might not be very useful in 
the detection of an acute outbreak and strategizing antimicrobial use. However, antibody 
ELISA could be useful in the context of animal purchase, especially in combination with 
culture or PCR testing. In that case both prior exposure and current infection will be covered. 
Nevertheless, there is still a chance that carrier animals, which are not shedding M. bovis at 
the time of purchase and did not develop antibodies, will be missed. The clearest benefit of 
antibody ELISA use is to diagnose at herd level, determining M. bovis positive and negative 
herds.  
Recently, a point-of-care diagnostic method was developed, using a colloidal carbon test strip 
for the detection of M. bovis antibodies (Shi et al., 2020). Similar results were shown  
compared to antibody ELISA. Although cross-reactivity with more bovine Mycoplasma 
species should be investigated, this is a potentially interesting and rapid method for the 
identification of previous M. bovis contact.  
 
Limitations of identification diagnostics  
Even tough studies on individual samples show higher sensitivity of culture compared with 
qPCR assays (Castillo-Alcala et al., 2012; Parker et al., 2017; Wisselink et al., 2019), and 
different authors state that culture remains the ‘gold standard’ method for the detection of M. 
bovis (Parker et al., 2018; Calcutt et al., 2018), it seems not entirely correct to use this term   
‘gold standard’. As made clear above, all methods have their advantages and disadvantages, 
and none of them obtains both sensitivity and specificity of 100% (Table 3).  




Table. 3 Advantages and disadvantages of diagnostic methods identifying M. bovis from clinical samples (respiratory tract, milk, joint, body fluid, blood, ..)   
 Culture PCR Antibody ELISA 
Clinical sample All All Blood, milk 
Detection Viable bacteria DNA Antibodies 
TAT* 1-2 weeks 1-2 days 24 hours 
Costs €€ €€€ € 
Advantages • Evidence of live pathogen 
• Isolate available  
• Quantification possible 
• Detects multiple 
Mycoplasma species 
• No viable M. bovis necessary 
• Rapid results  
• Pooling of samples possible 
• Quantification possible (qPCR) 
 
• Shows previous challenge of M. bovis  
• Shedding of M. bovis not necessary 
 
Disadvantages • Viable M. bovis needed 
• Time consuming 
• Specific media needed 
• Unable to discriminate 
between Mollicutes without 
additional testing  
• Overgrowth of other bacteria 
possible 
• Shedding of M. bovis 
necessary 
• No isolate obtained 
• Shedding of M. bovis necessary 
• Clinical interpretation sometimes 
difficult (non-viable M. bovis) 
• No isolate obtained 
• Does not reflect present infection 
• Paired sera takes 3 weeks 
• Variable, but usually low sensitivity 
• Uncertainty of cross-reactivity with 
other Mycoplasma species 
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The most important feature that a diagnostic test for M. bovis should hold, namely being 
rapid, is lacking for culture and ELISA. Therefore, whenever the only aim is to rapidly 
identify M. bovis in an acute outbreak, to determine control and prevention strategies or when 
antimicrobial therapy has already been started, PCR may be the best option. When interested 
in the M. bovis status of a herd, antibody ELISA can be the diagnostic method of choice. 
However, in both cases no isolate will be obtained, and further testing possibilities are 
limited. Nevertheless, in research and also in practice, for directing prevention and control 
measures, there is need for information concerning antimicrobial susceptibility and 
epidemiology of M. bovis. To get this information, obtaining an isolate is of great importance, 
and therefore culture is currently still needed. Therefore, focus should be on developing rapid 
culture-based identification methods. The current possibilities to identify and directly obtain 




Figure 8. Current methods for the isolation of M. bovis with the advantage of the possibility to 
construct a databank of clinical isolates for additional antimicrobial susceptibility testing and  
epidemiologic studies, such as strain typing.  
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1.5 TYPING METHODS AND DIVERSITY OF MYCOPLASMA BOVIS 
At the moment, strain typing of bacteria is almost strictly used in research settings. In routine 
diagnostics, bacterial identification remains mostly limited to (sub)species level (e.g. 
Mycobacterium avium subsp. paratuberculosis) or sometimes serotyping (e.g. Salmonella 
Dublin). Nevertheless, in the recent years the attention towards strain typing has increased, 
because of its potential to provide important epidemiological information in outbreaks or in 
legal cases for example. Currently, strain typing in routine diagnostics is mostly used in 
human medicine for tracing an outbreak back to its source, for example in methicillin-
resistant Staphylococcus aureus (MRSA) and Salmonella outbreaks (Köser et al., 2012; 
Azarian et al., 2015; Hoffmann et al., 2016). Very recently, strain typing showed us the 
distribution of SARS-CoV-2 (COVID-19) over the world, and the importance of strain types 
with increased virulence or transmission capacities (Yang et al., 2020; WHO, 2020). 
Although the British variant of COVID-19 (SARS-CoV-2 VOC 2020 12/01) did not seem to 
show increased virulence at first, it immediate showed increased transmissibility (Public 
Health England, 2020; Davies et al., 2021). The fear for a more rapid spread and increased 
virulence, had great consequences on prevention measurements in many countries, such as the 
immediate closing of borders, and prolonged quarantine regulations.  
Strain typing can also help in understanding the epidemiology of bacterial pathogens, such as 
M. bovis, and subsequently improve control and prevention measurements. For example, 
previously in this thesis it was mentioned that the question was raised whether M. bovis 
specific strains persisted in the veal calf sector, and whether these were more resistant against 
antimicrobials. Strain typing can help to answer these questions. In addition, when strain 
typing is performed on M. bovis, the isolate could be traced back to its source, and how and 
where M. bovis was transmitted might be clarified. Identifying virulence genes and 
antimicrobial resistance features of specific M. bovis strains might hold important 
information, and can help in more targeted control and prevention.   
 
In the past, many molecular genetic tools for strain typing were explored to subtype M. bovis 
strains, but also phenotypical strain typing with MALDI-TOF MS has been studied (Becker et 
al., 2015). Also in strain typing diagnostics, whole genome based methods are gaining ground 
rapidly. When determining the strain typing method of use, it is important to keep the 
application in mind, but also whether cultivation is necessary to obtain high concentrations of 
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pure DNA or not. When including cultivation for M. bovis, significant increase in turnaround 
time and labor should be kept in mind.  
 
Molecular genetic tools for strain typing 
AFLP, RAPD, PFGE, and IS typing 
Some previously used molecular methods for M. bovis strain typing are amplification 
fragment length polymorphism (AFLP) and random amplification of polymorphic DNA 
(RAPD), which are PCR based methods. Arbitrarily primed PCR, which has also been used, 
is a derivative of RAPD (Butler et al., 2001). Another often used method requiring an isolate, 
is pulsed-field gel electrophoresis (PFGE), a method based on separating DNA fragments by 
macrorestriction resulting in different band patterns per strain type (Kusiluka et al., 2000; 
Butler et al., 2001; McAuliffe et al., 2004; M. K. Soehnlen et al., 2011; Castillo-Alcala et al., 
2012; Pinho et al., 2012). Previous methods were first compared by Kusiluka et al. (2000), 
who showed comparably robust and reproducible results of AFLP and PFGE on Danish M. 
bovis isolates. Later on, also McAuliffe et al. (2004) compared AFLP, RAPD, and PFGE on a 
subset of M. bovis isolates obtained in the United Kingdom. Although typing results of these 
methods are mostly in agreement, PFGE showed the least discriminatory power (McAuliffe et 
al., 2004). PFGE is also time consuming, more expensive, and results are difficult to compare 
between laboratories (Butler et al., 2001; McAuliffe et al., 2004; Castillo-Alcala et al., 2012; 
Menghwar et al., 2017). Even though good reproducibility of the RAPD results were shown 
by McAuliffe et al. (2004), this is usually a pitfall of the technique, and extra care should be 
taken in sample preparation (Butler et al., 2001; Sulyok et al., 2014). Differences in 
discriminatory power, reproducibility and ease of performance and interpretation of described 
methods are shown in Table 4.  
Another molecular method which is used to type M. bovis is insertion sequence (IS) typing. 
This is a PCR based method, focusing on mobile genetic elements in the DNA of M. bovis. 
Southern blots are used to visualize the IS profiles (Miles et al., 2005; Thomas et al., 2005; 
Aebi et al., 2012; Gille et al., 2016). Although typing results of this method show a 
correlation with RAPD and AFLP results, there was no correlation observed with PFGE 
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Multiple-locus variable-number tandem-repeat analysis (MLVA) 
The above mentioned methods all have their applications, however discriminatory ability 
remains limited. Therefore, later on multiple-locus variable-number tandem-repeat analysis 
(MLVA) became more popular to compare strains from several geographical areas within 
countries (Amram et al., 2013; Spergser et al., 2013; Sulyok et al., 2014; Becker et al., 2015). 
This method is based on PCR and determines the variability between loci of repetitive DNA 
(Van Belkum, 2007) with the advantage of adjusting the number of loci studied in function of 
evolutionary pace (van Belkum, 2007; Pinho et al., 2012; Spergser et al., 2013). Also the 
discriminatory power can be increased with the number of loci analyzed (Becker et al., 2015). 
Sulyok et al. (2014) showed that MLVA was better able to distinguish closely related strains 
in Hungary, than multi-locus sequence typing (MLST). Unfortunately, comparison of MLVA 
results between and within laboratories remains difficult (Pinho et al., 2012; Register et al., 
2015). Therefore, some authors have suggested that MLVA might best be used in 
combination with other techniques, such as MLST, RAPD or PFGE (Pinho et al., 2012; 
Sulyok et al., 2014). This would have its repercussions on costs, turnaround time and 
interpretation.  
 
Single-locus sequence typing 
When choosing for single-locus sequence typing, it is important to consider the locus of 
attention very carefully, as this will influence the discriminatory index enormously. In several 
countries, such as France and Spain, typing based on the PolC gene is frequently used 
(Becker et al., 2015; García-Galán et al., 2020), and appeared sufficiently discriminating to 
distinguish older and recent M. bovis strains from each other (Tardy et al., 2020). It was 
however not discriminatory enough to distinguish more recent Danish and French isolates 
(Becker et al., 2020; Tardy et al., 2020) and therefore probably not ideal for use of strain 
typing in diagnostics or for investigating recent outbreaks.  
 
Multi-locus sequence typing (MLST) 
Some of the above mentioned methods show either difficulties with both intra- and 
interlaboratory reproducibility and lack of discriminatory power (Table 4). A strain typing 
method that is characterized by both a good discriminatory power and high reproducibility is 
MLST. The principle of MLST is based on the DNA sequence of (parts of) seven 
housekeeping genes. A number is given to a specific allel sequence, and the combination of 
alleles are corresponding to one sequence type (ST) (Sabat et al., 2013). STs with similar 
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allelic profiles are grouped into clonal complexes (Rosales et al., 2015; Menghwar et al., 
2017). MLST is a robust, and reproducible method to strain type M. bovis, and a public 
database (pubMLST) where all results can be collected is available for (inter)national 
comparison (Register et al., 2015; Rosales et al., 2015). Unfortunately, even though 
housekeeping genes are known to be poorly variable and were therefore expected to be 
constant through evolution, it was recently shown that part of the M. bovis population missed 
the adh-1 locus, one of the genes that were used in the M. bovis MLST scheme. This 
observation led to the need for an adjusted MLST scheme, which was proposed by Register et 
al. (2020), and implemented immediately (PubMLST, M. bovis). 
 
Although MLST is a solid method to compare M. bovis isolates over countries, it is not ideal. 
The discriminatory power is sometimes insufficient (Sulyok et al., 2014; Becker et al., 2015), 
and the risk of losing another housekeeping gene by evolution in the future is imaginable. For 
better comparison between countries, discriminatory power, and reproducibility, WGS can be 
the solution (Tardy et al., 2020). 
 
Next-generation sequencing methods 
As mentioned in the previous chapter, next-generation sequencing (NGS) becomes more 
attractive as an all-in-one diagnostic tool. With the reduced cost, this also becomes more 
available for strain typing. Considering its high reproducibility and providing genetic 
information on the entire genome, NGS could be a great opportunity for surveillance and 
disease outbreaks. In addition, NGS may even be superior to the more classical methods, such 
as PFGE and MLST, as shown in human medicine (Leekitcharoenphon et al., 2014; Deng et 
al., 2016).  
 
When whole genomes of a pathogen are obtained and compared to each other, one can choose 
to approach the genome on different levels: (1) focusing on specific genes such as species-
specific MLST genes, (2) the core genome (cg) which is similar between genomes of the 
isolates from the same species or (3) the whole genome (wg), which is composed of the core 
genome and every strains accessory genome (Fig. 7). When multiple whole genomes of one 
species are assembled, this is called the pan genome. To illustrate this, when performing 
cgMLST, not only the alleles of seven house-keeping or MLST genes are included, but alleles 
of multiple genes located on the core genome are used. By performing wgMLST, also some 
accessory loci are included (Maiden et al., 2013). To compare genomes on the level of 
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nucleotides, instead of loci or genes, single nucleotide polymorphism (SNP) analysis can be 
performed. The same distinction can be made for SNPs present in the core genome (cgSNP) 
or whole genome (wgSNP). The common principles of cg and wg sequencing, are visualized 
in Fig 9.  
 
Figure 9. Visualization of the core and accessory genomes from different bacterial strains, and the 
possible strain typing methods (MLST, cgMLST, wgMLST, cgSNP, wgSNP) (source SNPs figure: 
dnabaser.com) 
 
Kinnear et al. (2021) compared MLST, core genome MLST (cgMLST), core genome single 
nucleotide variant (cgSNP) and whole genome nucleotide variant (wgSNP) analysis on 129 
M. bovis isolates. Although all methods provided highly comparable results, MLST, which 
only compared 7 house-keeping genes had the lowest discriminatory power. The highest 
resolution was obtained with wgSNP (Kinnear et al., 2021). In contrast, another study showed 
lower discriminatory power of wgSNP compared to cgMLST (Tardy et al., 2020). Beside 
technical differences (bioinformatics pipelines are often not standardized), the differences in 
discriminatory power between studies can be explained by the divergence within the studied 
populations. When more variety in genomes is observed, the core genome becomes relatively 
smaller and the accessory genome larger. Also overall genome quality and completeness are 
very important, as when large parts of the genomes are missing, these parts cannot be 
included in the core genome analysis. This is especially the case for the reference genome, 
when included in the SNP analysis (Besser et al., 2018). Long-read sequencing methods (e.g. 
SMRT or nanopore sequencing) can possibly help increase the discriminatory power, as less 
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gaps in the genome are observed compared to short-read sequencing methods (e.g. Illumina) 
(Fig. 10). On the contrary, the lower read accuracy of long-read sequencing methods should 
be kept in mind (Rang et al., 2018). Therefore, short reads can help improve the quality of 
base-reading in each individual position by increasing the coverage. Combining both long-
read sequencing for complete genomes with Illumina reads (‘hybrid-assembly’) can then also 
improve genome assemblies (Goldstein et al., 2019). However, due to the delay in results, this 
is not recommended for routine diagnostic purposes.  
 
 
Figure 10. Short-read sequencing results in multiple short contigs and a genome with gaps (purple), 
whereas with long-read sequencing mostly full genomes are covered for M. bovis (blue) in comparison 
to the reference genome (grey) (figure adapted from Vereecke et al., 2020). 
 
Apart from the sequencing method that is used, optimizing the bioinformatics pipelines is 
very important to obtain reliable high quality and complete genomes. This might be more of a 
technical challenge and a disadvantage of NGS compared to MLST as sequencing method 
(Register et al., 2020; Kinnear et al., 2021). Nevertheless, these difficulties did not discourage 
researchers, as NGS for strain typing M. bovis and obtaining epidemiological information on 
M. bovis strains from different countries, has been widely explored in recent years (Parker et 
al., 2016; Yair et al., 2020; Tardy et al., 2020; Kumar et al., 2020; Kinnear et al., 2021). In 
these studies, short-read sequencing by Illumina was used. However, as previously 
mentioned, where Illumina is highly time-consuming and requires a significant upfront 
investment, long-read nanopore sequencing is known to create faster results and is a highly 
accessible tool for routine diagnostics and surveillance due to its portable form (Theuns et al., 
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2018). Unfortunately, to date their use is limited to research or national surveillance settings, 
and it has not been integrated in bacterial routine diagnostics. 
 
Phenotypic methods 
MALDI-TOF MS, a phenotypic method, has also been described as a strain typing method 
using French isolates. The protein profiles of M. bovis obtained by MALDI-TOF MS showed 
the same topology as MLVA and MLST. However MALDI-TOF MS and MLVA showed a 
higher discriminatory power of individual isolates than MLST, and reflected the loss of 
heterogeneity in the French M. bovis population (Becker et al., 2015). MALDI-TOF MS 
seems like a promising tool for phenotypic strain typing of M. bovis¸ but so far no other 
studies showed the use of MALDI-TOF MS as strain typing method. Therefore, it remains 
unclear whether this is a reproducible method, can be compared between laboratories and if 
its applicable to all M. bovis populations. Most likely, a standardized protocol with extra 
attention to growth phase and culture conditions is necessary (Sauer et al., 2008; Sloan et al., 
2017).   
 
Table. 4 Overview of different strain typing methods for M. bovis showing characteristics, advantages 










AFLP ++ +/- - - 
RAPD + - ++ +/- 
PFGE + +/- +/- + 
MALDI-TOF + ND + +/- 
IS typing + +- + +/- 
PolC typing +- ++ + ++ 
MLVA +++ -- + ++ 
MLST ++ ++ + ++ 
NGS +++ ++ +/- +/- 
AFLP: amplification fragment length polymorphism; RAPD: random amplification of polymorphic DNA; 
PFGE: pulsed-field gel electrophoresis; MALDI-TOF: matrix-assisted laser desorption ionization-time of flight 
mass spectrometry; IS typing: insertion sequence typing;  MLVA: multiple-locus variable-number tandem-repeat 
analysis; MLST: Multi-locus sequence typing; NGS: next-generation sequencing (Illumina, PacBio, ONT); ND: 
not determined. Interpretation of very good (+++), good (++), acceptable (+), dubious (+-) or bad (-) are based 
on a combination of the authors experience, specific M. bovis literature and Sabat et al., 2013.  
 
Molecular diversity of M. bovis  
There are many studies, showing the widespread heterogeneity of M. bovis strains all over the 
world. For example, in Japan already 52 different sequence types (STs) have been identified, 
while in western Canada, 30 STs have been described (Hata et al., 2019; Kinnear et al., 2021). 
Some of the Canadian STs were also identified on other continents, such as ST52 (Europe, 
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Asia and Oceania), and ST21 (Europe and Asia) (Kinnear et al., 2021). Not surprisingly, due 
to the bilateral trade between both countries, isolates from Canada and the USA clustered 
together as well (Kumar et al., 2020; Kinnear et al., 2021). Depending on the subgroup, 
Japanese STs clustered together with American, European, Australian, Israeli and/or Chinese 
isolates, suggesting exchange of M. bovis isolates between these regions (Hata et al., 2019). 
Chinese isolates cluster together with isolates from the USA, Australia, and Israel (Liu et al., 
2020), which is in line with other studies separating most European isolates apart from 
Australian, Chinese and American isolates (Kumar et al., 2020; Yair et al., 2020). 
Nevertheless, some of the American isolates seem to cluster together with European isolates, 
such as the Swiss and Lithuanian isolates (Kumar et al., 2020). Israel purchased animals and 
probably imported M. bovis from Europe, China and Australia, which is also reflected in the 
way Israelian isolates cluster with STs described in these countries (Yair et al., 2020). It is 
however observed that Australian isolates show notable genetic similarities, while isolates 
from the USA and Europe show much more divergence (Parker et al., 2016; Kumar et al., 
2020; Register et al., 2020; Yair et al., 2020). This might be due to strict biosecurity practices 
in Australia, such as quarantine rules for the imported livestock, which possibly helped to 
prevent the introduction of multiple strains over time into the country (Parker et al., 2016).   
 
In Europe and Japan, a shift in homogeneity was observed in the M. bovis population (Becker 
et al., 2015; Bürki et al., 2016; Hata et al., 2019; Tardy et al., 2020). First in Denmark, more 
genetic variation was observed in isolates from 1992 on with AFLP (Kusiluka et al., 2000), 
while a more recent publication identified again homogeneity within isolates obtained after 
2000 with cgMLST and wgSNP (Tardy et al., 2020). Such a shift was also observed in France 
with MLST, and MLVA, around 2000 (Becker et al., 2015), and with PFGE in 2003 
(Arcangioli et al., 2012), suggesting clonal emergence of M. bovis in these countries (Becker 
et al., 2015; Tardy et al., 2020). Although in the Scandinavian countries (Denmark, Sweden, 
Finland) a certain level of homogeneity was observed with wgSNP and cgMLST (Haapala et 
al., 2018; Tardy et al., 2020), more heterogeneity compared to the Scandinavian countries was 
observed between isolates from the Netherlands and France after 2000 (Tardy et al., 2020). 
This is in line with earlier reports from France based on PolC typing, where st2 and st3 were 
the only abundantly present strain types in France, but recently also st5 was isolated for the 
first time (Becker et al., 2015; Becker et al. 2020). Also in Hungary and the United Kingdom, 
high heterogeneity of isolates has been observed (McAuliffe et al., 2004; Sulyok et al., 2014). 
One possible reason could be the intensive (inter)national cattle movements in these countries 
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with relatively more heterogeneity (McAuliffe et al., 2004; Sulyok et al., 2014; Tardy et al., 
2020).   
 
Strain types and disease course   
The question whether certain strain or sequence types can be related to different M. bovis 
associated diseases or severity of clinical signs was raised many times. For example, some 
countries seem to have more problems with M. bovis mastitis (e.g. Israel, Switzerland), where 
others face more respiratory diseases caused by M. bovis (e.g. France). Both in Switzerland 
and Israel, a sudden increase in mastitis cases was observed. Therefore, introduction of a new 
or mutated M. bovis strain with another predilection site preference was suspected (Bürki et 
al., 2016; Lysnyansky et al., 2016). Although ST10 has been isolated frequently from these 
clinical mastitis cases in Israel and China (Lysnyansky et al., 2016; Liu et al., 2020), ST10 
was also frequently isolated from the respiratory tract and joints of Chinese calves 
(Menghwar et al., 2017; Guo et al., 2020). So far, many studies were unsuccessful in 
identifying an association between strain type and anatomical location, no matter what strain 
typing method was used (Kusiluka et al., 2000; Biddle et al., 2005, Rosales et al., 2015; 
Parker et al., 2016; Garciá-Galàn et al., 2020; Tardy et al., 2020).  
 
During M. bovis outbreaks, different strain types can be identified from the same animal or in 
the same herd (Soehnlen et al., 2011; Sulyok et al., 2014; Rosales et al., 2015; Garciá-Galàn 
et al., 2020; Becker et al., 2020). However, whether different M. bovis strains are circulating 
probably depends on the management style, being an open or closed herd (Butler et al., 2001), 
as several studies show one dominant type in an outbreak (Butler et al., 2001; Aebi et al., 
2012; Arcangioli et al., 2012; Becker et al., 2020). In feedlots, clonal spread of a single M. 
bovis strain has been demonstrated mainly in young calves. Later on in the production cycle, 
multiple genotypes are generally isolated (Castillo-Alcala et al., 2012; Timsit et al., 2012; 
Becker et al., 2020). In an Australian dairy herd however, the same M. bovis strain was found 
for seven consecutive years (Parker et al., 2016). Also in the Alpine areas strain typing 
analysis with RAPD and MLVA suggested the re-emergence of the same strain type in 2009 
and outbreaks in 2010-2011, after the first outbreak in 2007 (Spergser et al., 2013).  
 
No direct association between M. bovis strain type and health status has been described up till 
today (Parker et al., 2016; Register et al., 2019; Garciá-Galàn et al., 2020; Yair et al., 2020), 
although it was shown that isolates from dead animals showed more antimicrobial resistance 
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than those obtained from healthy animals (Jelinski et al., 2020). Whether this is associated 
with strain type or antimicrobial therapy is not clear. In China and Japan, certain STs were 
associated with increased antimicrobial resistance (AMR) (Hata et al., 2019; Liu et al., 2020), 
and it has been shown that st3 isolates (PolC typing) acquire resistance against 
fluoroquinolones more easily than st2 isolates under antimicrobial selection pressure. These 
associations can have an influence on the efficacy of the therapy and therefore indirectly on 
health status (Khalil et al., 2015; García-Galán et al., 2020).  
 
1.6 ANTIMICROBIAL SUSCEPTIBILITY OF MYCOPLASMA BOVIS 
As described earlier in this thesis, M. bovis is inherently resistant against beta-lactam 
antibiotics and (potentiated) sulphonamides. It is however more worrisome how easy M. bovis 
can acquire resistance in the presence of an antimicrobial selection pressure (Sulyok et al., 
2017). This can at least partly be explained by the small genome and lack of certain genetic 
information coding for DNA repair mechanisms, resulting in a high mutation rate in this 
species (Rocha et al., 2005). In the last two decades, many studies explored antimicrobial 
susceptibility of M. bovis in different parts of the world. Most of the research is based on 
phenotypic antimicrobial susceptibility testing (AST), but an increase in the determination of 
antimicrobial susceptibility based on molecular genetic methods is seen in the last few years 
(Sulyok et al., 2018; Hata et al., 2019; Kinnear et al., 2020).   
 
Phenotypic antimicrobial susceptibility testing 
Conventional antimicrobial susceptibility testing and pitfalls  
Performing and interpreting phenotypic AST of M. bovis knows many difficulties and pitfalls. 
These can roughly be subdivided into long turnaround time, absence of standard protocols, 
and interpretation of results. 
 
First of all, the long turnaround time of approximately 2 weeks, often prevents the use of AST 
for M. bovis in routine diagnostics (Ben Shabat et al., 2010; Sulyok et al., 2018). Secondly, 
comparing the results of different phenotypic AST studies is often difficult, as there are no 
internationally recognized standardized methods for AST of M. bovis and validated reference 
values for quality control strains aren’t available either (Gautier-Bouchardon, 2018). Usually, 
the minimum inhibitory concentration (MIC) is determined in phenotypic AST methods. The 
MIC is the lowest concentration of an antimicrobial that will inhibit visible growth or 
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metabolism after its optimal incubation period in vitro (Hannan, 2000). To determine the MIC 
for M. bovis, some studies use the agar dilution assay (Uemura et al., 2010; Siugzdaite et al., 
2012; Sato et al., 2013, 2017; Gautier-Bouchardon et al., 2014; Kong et al., 2016; Khalil et 
al., 2017; Hata et al., 2019; Becker et al., 2020; Tardy et al., 2020), the gradient strip test 
(Francoz et al., 2005; Gerchman et al., 2009) or flow cytometry (Soehnlen et al., 2011). 
However, broth microdilution (BMD) is considered the ‘gold standard’ method for most 
bacterial species (Lallemand et al., 2016), and in the last few years, an increasing number of 
studies are reporting the use of BMD as exemplified in Table 5.  
 
Nevertheless, even in these studies no standardized protocol is followed, as different broth 
compositions, inoculum concentrations, pH indicators and incubation periods are described, 
possibly affecting the results and preventing straightforward one on one comparison between 
these studies (Table 3) (Thomas et al., 2003; Lallemand et al., 2016). 
 
The last pitfall, is the subsequent interpretation of obtained MIC values for M. bovis, as there 
are no clinical breakpoints available translating in vitro results into clinical expectations. Even 
though this is probably questionable, several studies interpret M. bovis MIC values with the 
clinical breakpoints provided by CLSI standards for other bovine respiratory pathogens or 
human Mycoplasma species (Heuvelink et al., 2016; Anholt et al., 2017; Becker et al., 2020; 
Tardy et al., 2020) to categorize isolates as ‘resistant’, ‘intermediate’ or ‘susceptible’ to an 
antimicrobial agent (Table 3). In addition, when choosing antimicrobial therapy based on 
antimicrobial susceptibility results, care should be taken with the interpretation of the 
‘intermediate’ result. Intermediate results could reflect three different principles, being (1) the 
uncertain effect of the antimicrobial drug used on therapy outcome (2) increased antimicrobial 
concentration in certain body parts may still result in therapy success or (3) as a buffer zone 
for technical variation. To clarify the meaning of the category ‘intermediate’, the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) recently adjusted this term to 
‘susceptible, increased exposure’ (EUCAST), while the Clinical and Laboratory Standards 
Institute (CLSI) added the category ‘susceptible, dose dependent’, and the addition of ‘^’ to 
the ‘intermediate’ category indicating the possible accumulation of the antimicrobial agent in 
certain body parts, and therefore possible therapy success in those circumstances (Kahlmeter 
et al., 2019). The full definitions of ‘intermediate’ and ‘susceptible, increased exposure’ are 
shown in Table 6.  
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Table 5. Overview of antimicrobial susceptibility publications of M. bovis over 2015-2020. 









A 73 55 
2011-
2014 
BEL, DEU, ITA Dairy cattle NA BMD 104 UCC/ml 18h – growth* Mode; MIC50-MIC90 
B 95 NA 
2008-
2014 
NLD Veal & dairy Diseased or dead BMD 0.5 x 103-105 CCU/ml 48h MIC50-MIC90; CLSI 
C 32 32 
2011-
2013 
CHN Feedlot Symptomatic BMD 103-105 CCU/ml NA CLSI 
D 40 NA 
2012-
2014 
CAN Bison Dead BMD 2 x 103-105 CUU/ml 96h MIC50-MIC90; CLSI 
E 226 NA 
2014-
2015 
CAN Feedlot Diseased BMD 0.5 McFarland 24-96h MIC50; CLSI 
F 58 51 
2010-
2011 
JPN Dairy calves Asymptomatic ADM 104-105 CFU/ml 72h NA 
G 26 NA 
2000-
2014 
FRA NA Diseased ADM 104-105 CFU/ml 5d CLSI; Hannan, 2000 





NA Diseased BMD 5 x 105 CFU/ml 24-48h MIC50-MIC90 






Diseased BMD 103-105 CFU/ml 24-96h MIC50 
J 232 224 
2014-
2016 
FRA, HUN,  ITA, 
ESP, GBR 
NA Diseased BMD 5 x 105 CFU/ml 24-48h MIC50-MIC90 
K 203 52 
1993-
2018 
JPN Unknown Unknown ADM 103-105 CFU/ml NA MIC50-MIC90 
L 211 31 
2006-
2018 
CAN, USA Feedlot All  BMD 103-105 CFU/ml 48-72h CLSI 
M 39 14 
2016-
2018 
FRA Veal Unknown ADM 104-105 CFU/ml 5d CLSI; MIC90 
N 81 NA 
1981-
2017 
DNK, SWE, FRA, 
NLD, EST, FIN 
NA NA ADM 104-105 CFU/ml 5d CLSI 
O 50 23 
2018-
2019 
CHN Dairy Diseased BMD 103-105 CCU/ml 48h MIC50-MIC90 
P 95 22 
2016-
2019 
ESP Beef, dairy Healthy/diseased BMD 103-105 CCU/ml 48h MIC50-MIC90 
A: Barberio et al., 2016; B: Heuvelink et al. 2016; C: Kong et al., 2016; D: Suleman et al., 2016; E: Anholt et al., 2017; F: Sato et al., 2017; G: Khalil et al., 2017; H: Klein et 
al., 2017; I: Cai et al., 2018; J: Klein et al., 2019; K: Hata et al., 2019; L: Jelinksi et al., 2020; M: Becker et al., 2020; N: Tardy et al., 2020; O: Liu et al., 2020: P: Garciá-
Galan et al., 2020. Country name is coded following ISO 3166-1: alpha-3 code; *: positive growth control. MIC = minimum inhibitory concentration, NA = not available; 
BMD = broth microdilution, ADM = agar dilution method, UCC = unit changing color; CCU = colour changing untis, CFU = colony forming units, CLSI = clinical 
breakpoints following CLSI guidelines, MIC50-MIC90 =  the lowest MIC at which at least 50% or 90% of the isolates were inhibited in their growth 
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Table 6. Recent changes in the definitions of ‘intermediate’ isolates by CLSI (Clinical and Laboratory 
Standards Institute) and EUCAST (European Committee on Antimicrobial Susceptibility Testing) as 
cited by Kahlmeter et al. (2019) 
Intermediate (I)  CLSI A category defined by a breakpoint that includes isolates for which MICs or 
zone diameters are within the intermediate range; the drug approaches 
usually-attainable blood and tissue levels, and response rates may be lower 
than for susceptible isolates. The intermediate category implies clinical 
efficacy in body sites where the drugs are physiologically concentrated. The I 
category also includes a buffer zone for inherent variability in test methods, 
which should prevent small, uncontrolled technical factors from causing 
major discrepancies in interpretations, especially for drugs with narrow 
pharmacotoxicity margins. 
Intermediate ^ CLSI An I with a “^” in document M100 Table 2 is used to describe agents that 
have the potential to concentrate at an anatomical site. 
Previous definition 
of  ‘intermediate’ 
EUCAST A microorganism is defined as intermediate by a level of antimicrobial agent 
activity associated with uncertain therapeutic effect. It implies that an 
infection due to the isolate may be appropriately treated in body sites where 
the drugs are physically concentrated or when a high dosage of the drug can 
be used; it also indicates a buffer zone that should prevent small, 






EUCAST A microorganism is categorized as “susceptible, increased exposure” when 
there is a high likelihood of therapeutic success because exposure to the 
agent is increased by adjusting the dosing regimen or by its concentration at 
the site of infection. 
 
Another way of interpreting MIC results is distinguishing the wild type (WT) population from 
strains with acquired antimicrobial resistance, also called the non-wild type population (non-
WT) by means of the epidemiological cut-off (ECOFF) value or wild type cut-off. The 
ECOFF is independent of evolutionary changes, and is therefore believed to remain the same 
for a particular organism and antimicrobial agent throughout time, independent of geographic 
location or host species (Silly, 2012). Unfortunately, the epidemiological criterium is not 
designed to predict in vivo effectiveness of the antimicrobial agent, but it can be used as a 
sensitive threshold to predict antimicrobial resistance emergence in specific bacterial 
populations, including M. bovis. Therefore, the ECOFF is most useful in monitoring and 
surveillance of AMR development (Turnidge et al., 2006; Silley, 2012). 
 
The methodology on how the ECOFF should be determined is currently not harmonized 
(Silly, 2012). The ECOFF can be determined using visual estimation (“eyeball”) or statistical 
methods (e.g. normalized resistance interpretation (NRI) or the iterative statistical method 
(ISM)) (Turnidge et al., 2006; Kronvall, 2010; Callens et al., 2016). The visual estimation 
method distinguishes two populations of bacterial strains based on a bimodal MIC distribution 
in those with (non-WT) and without (WT) acquired resistance (Turnidge and Paterson, 2007; 
Toutain et al., 2017). The statistical methods are based on the assumption that the wild type 
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population is symmetrical round its midpoint. Data are either normalized (NRI) or log-
transformed (ISM), and based on mean and standard deviations, the ECOFF is determined 
(Turnidge et al., 2006; Kronvall and Smith, 2016). 
 
Foremost, M. bovis susceptibility results were reported as MIC50 and MIC90 values as shown 
in Table 3, being the lowest MIC at which at least 50% or 90% of the isolates were inhibited 
in their growth. The MIC50 is expected to show the potency of an antimicrobial against a 
bacterial species, whereas the MIC90 indicates potential and first stages of specific bacteria 
developing resistance (Lysnyansky and Ayling, 2016). However, this assumes that the MIC50 
and MIC90 are always situated in the WT or non-WT population, respectively. Unfortunately, 
these indicators are subject to the tested population, do not hold a lot of clinically relevant 
information and are difficult to interpret related to acquired resistance when MIC distributions 
are not presented as well (Turnidge et al., 2006; Schwarz et al., 2010). Nowadays, most M. 
bovis populations have shifted to increased acquired resistance, showing limited significance 
of the MIC50 and MIC90 as parameters for antimicrobial susceptibility.  
 
Whenever one is using the ECOFF, clinical breakpoints or MIC50/MIC90 for the interpretation 
of AST results, one should be very cautious in the conclusions that are drawn. To support this, 
an example of the different outcomes of ECOFF (visual estimation method), clinical 
breakpoints for bovine respiratory pathogens, and MIC50/MIC90 for a hypothetical 
antimicrobial distribution of MIC values of M. bovis isolates is shown in Fig. 11.     
 
In conclusion, many variables can influence the results and interpretation of AST in M. bovis. 
Therefore there is a clear need for standardization of AST protocols and M. bovis specific 
clinical breakpoints, to be able to compare AST results and draw straightforward conclusions, 
both epidemiologically and clinically.  
 




Figure 11. Hypothetical bimodal distribution of M. bovis MIC-values for an antimicrobial showing 
the determination of the epidemiological cut-off (ECOFF) by the visual estimation dividing the 
population in wild type (WT) and non-wild type (non-WT) isolates. The corresponding interpretation 
of the clinical breakpoints for bovine respiratory pathogens (CLSI, VET01-S3, 2015) is included, 
categorizing the isolates in either susceptible (S  ≤ 4 µg/mL), intermediate (I = 8 µg/mL), or resistant 
(R ≥ 16 µg/mL), and showing a substantial difference between clinical and epidemiological 
interpretation. Also MIC50 (128 µg/mL) and MIC90 (> 128 µg/mL) were calculated. Although a large 
dataset was used, both values might be reflecting the non-WT population instead of WT and non-WT 
for MIC50 and MIC90, respectively.  
 
Antimicrobial susceptibility testing with MALDI- TOF MS  
By the introduction of MALDI-TOF MS into microbiological laboratories, not only bacterial 
identification possibilities of this technique have been explored, but also methods to identify 
AMR. Two methods that are commercially available, are the MBT STAR®-BL and MBT 
STAR®-CEPHA. These methods detect a mass shift when beta-lactamase activity hydrolyzes 
the beta-lactam antibiotic (Bruker Daltonics). These methods are not of value for M. bovis, 
due to its inherent resistance against beta-lactam antibiotics. However, antimicrobial 
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resistance determination can also be based on the detection of specific peaks in mass spectra, 
such as for MRSA, or be based on the ability to grow within the presence of an antimicrobial 
agent (MBT-ASTRA) (Josten et al., 2013; Lange et al., 2014). The latter, showed to be 
applicable to many bacteria and antimicrobials, both in human medicine and veterinary 
medicine (Lange et al., 2014; Ceyssens et al., 2017; Van Driessche et al., 2018), resulting in 
the determination of antimicrobial resistance profiles within 3 hours after obtaining pure 
cultures (Sparbier et al., 2016; Van Driessche et al., 2018). The advantage of this phenotypic 
technique is that knowledge of underlying resistance mechanisms is not necessary, as relative 
growth between the isolate with and without the antimicrobial is determined. Unfortunately, 
to be able to standardize this method for M. bovis, cultivation of an isolate is necessary 
(additional 1-2 days), the start concentration should be easily determinable (which for M. 
bovis usually takes ‘backwards counting’) and clinical breakpoints are necessary to categorize 
isolates as either resistant or susceptible for final cut-off values. Therefore, this method seems 
inappropriate or at least far-fetched for AST of Mycoplasma species, at least until clinical 
breakpoints are available. 
 
Molecular genetic tools for antimicrobial susceptibility testing  
In the quest to find other more rapid and standardized methods for the determination of AMR 
in M. bovis, the popularity of molecular genetic methods seems rising (Sulyok et al., 2018; 
Hata et al., 2019; Kinnear et al., 2020). Hereunder some of these techniques will be explained.  
 
qPCR based methods 
Beside the use of qPCR as identification method for M. bovis (see ‘diagnostics’), it is also 
possible to detect antimicrobial resistance genes and specific mutations with qPCR (Maurin, 
2012). Target DNA will be amplified and simultaneously fluorescence production will be 
detected, which makes this method more rapid than conventional PCR (Maurin, 2012). In 
human medicine, qPCR is already widely implemented in the rapid detection of antimicrobial 
resistance genes, such as for MRSA and vancomycin resistance in Enterococcus species, and 
detection of mutations, such as in Mycoplasma pneumoniae (Peuchant et al., 2009; Bourdon 
et al., 2010; Patel et al., 2011). Also several qPCR assays are commercially available for the 
detection of macrolide resistance by point mutations in Mycoplasma genitalium, which is a 
sexually transmitted organism in humans. The diagnostic accuracy of three of these kits were 
explored, showing high diagnostic accuracy (sensitivity 95-100%, specificity 95-97%) (Le 
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Roy et al., 2020). Unfortunately, such assays are not (yet) commercially available for M. 
bovis.  
 
In 2009, Ben Shabat et al. explored a qPCR method for the differentiation between 
fluoroquinolone resistant and susceptible isolates. Unfortunately, this method was only 
targeting one mutation in the parC quinolone resistance-determining region (QRDR). 
However, most M. bovis isolates are only resistant against fluoroquinolones when an 
additional mutation in the gyrA gene is present as well, although mutations in the gyrA gene 
alone can also increase MIC values (Lysnyansky et al., 2009). More recently, real-time PCR 
based assays, such as melt curve analysis of mismatch amplification mutation assays (Melt-
MAMA) and high resolution melting (HRM) assays, were explored by Sulyok et al. (2018) to 
discriminate between M. bovis isolates with ‘low’ and ‘high’ MIC value from lung and nasal 
swabs. Within one day, results are available from clinical samples for tetracyclines, 
macrolides, lincosamides and fluoroquinolones, while for spectinomycin an initial isolate 
should be obtained before DNA extraction for the MAMA assay, which takes about 3-4 days 
(Sulyok et al., 2018). The latter is necessary because the HRM assay is not able to 
simultaneously detect mutation T1199C (associated with tetracycline resistance) and C1192A 
(associated with spectinomycin resistance), and the MAMA assay directly on the clinical 
sample showed a high false result rate (53.3%) for spectinomycin, due to a lower sensitivity 
of the assay (105 copies/reaction compared to 102-103 for all other antimicrobials). 
Unfortunately, only discrimination between low and high MIC values were possible, which 
can be problematic for the clinical interpretation when isolates with ‘moderate’ MIC values 
are tested, as no clinical breakpoints are available. Melting curve analysis using hybridization 
probes on milk samples, also detects mutations in the target area of the genome within 3 hours 
for several antimicrobials (Hata et al., 2019). However, it was still recommended to perform 
DNA sequencing afterwards for better interpretation, as this methods also identifies silent 
mutations (Hata et al., 2019).  
 
Next-generation sequencing methods  
More recently also NGS has come to the forefront in the determination of AMR in veterinary 
medicine (Owen et al., 2017; Stanford et al., 2019). However, where most pathogens contain 
well known AMR genes (e.g. Pasteurellaceae) (Owen et al., 2017), the challenge for 
Mycoplasma spp. is that resistance is mainly determined by point mutations (Table 7). To 
determine single nucleotide mutation throughout the entire genome, obtaining high quality 
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genomes and high accuracy of the used method are very important. Missing or altered 
nucleotides could easily result in false non-synonymous mutations (nsSNPs), and therefore 
mistakenly be (dis)associated with AMR phenotype. Those nsSNPs can result in amino acid 
sequence changes, resulting in altering the function of proteins. When these nsSNPs are 
associated with AMR phenotype, they can act as markers for AMR (Wondji et al., 2007). 
Very recently, studies have identified specific point mutations associated with phenotypic 
antimicrobial susceptibility of M. bovis in specific regions of three strains of M. bovis through 
Ilumina sequencing (Ledger et al., 2020) and on a large set of isolates for macrolides (Kinnear 
et al., 2020). In Kinnear et al. (2020) 100% concordance was observed between genotype 
(mutations in both domain II and V of the 23S rRNA) and phenotype (macrolide resistant 
isolates based on CLSI clinical breakpoints), showing high potential of this method to predict 
macrolide resistance in M. bovis. In human medicine, targeted sequencing has already been 
implemented in point-of-care settings for M. pneumoniae community-acquired respiratory 
infection outbreaks (Pereyre et al., 2016).  
 
Limitations of present molecular genetic methods  
Genetic-based antibiotic resistance determination is rapid, as in most cases it can be applied to 
the clinical samples, thus avoiding time losses due to isolation and identification steps. 
However, up until now molecular testing cannot replace phenotypic AST. An important 
limitation of these specific methods is the focus on known mutations in a small homogenous 
population. For example, the qPCR method developed by Sulyok et al. (2018) for macrolides 
was based on mutations at position 2059 in the 23S rRNA gene, which indeed is involved in 
macrolide resistance in Hungary, as well as in Japan and Canada (Sulyok et al., 2017; Hata et 
al., 2019; Kinnear et al., 2020 – Table 7). However, in several other countries (e.g. China, 
France, and Spain), a mutation at position 2058 is involved in macrolide resistance (Kong et 
al., 2016; Khalil et al., 2017; García-Galán et al., 2020), and is therefore missed by this real-
time PCR method. In addition, when unknown or new resistance mechanisms, such as 
nsSNPs, efflux mechanisms, target-site modification by methylation, and plasmids are 
present, these will be overlooked (Jaillard et al., 2018). It is also not always clear whether 
multiple mutations or mechanisms collaborate together to obtain resistance, and it can be 
difficult to detect those simultaneously when only one of them is targeted by the used 
molecular method (Maurin, 2012). To circumvent these shortcomings, whole genome 
sequencing and genome-wide association studies can help to reveal both well-known and 
novel associations between genotype and phenotype. Even when the association between 
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whole genome results and phenotype remains inconclusive, it can point into the direction to 
investigate other resistance mechanisms (e.g. methylation) as well (Coll et al., 2018). Finally, 
in order to have clinically relevant molecular genetic assays, a causal link between genotype 
and phenotype should be present. Therefore clinical breakpoints should be obtained for M. 
bovis or randomized clinical trials with M. bovis strains of which the full genome is available.  
 
Antimicrobial resistance mechanisms of M. bovis 
Several AMR mechanisms have been described for different pathogens coming down to (1) 
preventing the antimicrobial from entering the cell (e.g. decreased porin formation in 
Klebsiella species), (2) efflux pumps which drift the antimicrobial out of the cell (e.g. efflux 
of tetracycline in E. coli), (3) inactivation by modification or degradation of the antimicrobial 
agent (e.g. beta-lactamase producing organisms), and (4) modification or blockage of the 
antimicrobial target (e.g. mutations in quinolone resistance-determining regions) (Boerlin and 
White, 2013). The meaning of the first three mechanisms are unclear for M. bovis. However, 
the most frequently described resistance mechanism in M. bovis so far, is the modification of 
the antimicrobial target as a result of point mutations. These mutations are able to change the 
protein sequences (nonsynonymous mutations) in such a way that antimicrobials cannot act 
on the M. bovis target molecule anymore.  
 
Acquiring antimicrobial resistance  
Mutations occur continuously in bacteria, and are often repaired by DNA repair mechanisms. 
However, due to its small genome, M. bovis has only few DNA repair mechanisms, resulting 
in higher numbers of fixed mutations (Rocha et al., 2005). The mutation frequency can 
increase in organisms under stress, such as chemical exposure, ultra violet light, and during 
antimicrobial treatment.  
Other ways of acquiring AMR is through receiving DNA from other organisms (horizontal 
gene transfer) by (1) transformation: the uptake of DNA present in the environment, (2) 
transduction: injection of viral DNA by bacteriophages, and (3) conjugation: transfer of 
mobile genetic elements (Boerlin and White, 2013; Dordet-Frisoni et al., 2019). Well-known 
mobile genetic elements carrying antimicrobial resistance are plasmids, but also integrative 
conjugative elements (ICEs) or chromosomal conjugative transfer can spread antimicrobial 
resistance between bacteria. Plasmids have not yet been described in M. bovis, but they were 
abundantly found in the Mycoplasma mycoides cluster (Breton et al., 2012). Also the presence 
of a prophage, which is a bacteriophage genome integrated in the bacterial DNA, has not (yet) 
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been observed in M. bovis, but was identified in M. agalactiae and M. bovigenitalium, both 
part of the hominis cluster (Tardy et al., 2012). Mycoplasma integrative conjugative elements 
(MICEs; also conjugative transposons) are present in M. bovis and M. agalaciae (Dordet-
Frisoni et al., 2014; Tardy et al., 2015), and transfer of MICE containing the parC and parE 
genes, which can be associated with fluoroquinolone resistance, has been observed (Dordet-
Frison et al., 2014). In addition, under in vitro antibiotic pressure, chromosomal transfer 
showed to be able to transfer parts of the chromosome containing genes with specific 
mutations associated with enrofloxacin resistance between M. agalactiae isolates (Faucher et 
al., 2019).   
 
In the next subchapters, the most frequently used antimicrobials for M. bovis infections and 
the associated mechanisms for acquired resistance in M. bovis are described in more detail.  
 
Florfenicol 
Florfenicol binds irreversibly to the 50S ribosomal subunit and inhibits protein synthesis by 
disturbing transpeptidation and translation of the bacterial mRNA (Dowling, 2013a; 
Lysnyansky and Ayling, 2016). No mutation associated with florfenicol resistance has been 
identified in M. bovis field isolates yet, but in vitro generated resistant mutants showed 
mutations in G2062T and A2063T of the 23S rRNA genes (Sulyok et al., 2017) (Table 7). 
However, also in field M. ovipneumoniae strains with increased MIC values for florfenicol, 
no mutations in the 23S rRNA were shown, therefore suggesting the presence of other 
mechanisms, such as efflux (Jaÿ et al., 2020). The floR gene, located on various plasmids and 
associated with florfenicol resistance by efflux, has been detected in E. coli and 
Pasteurellaceae isolated from calves (White et al., 2000; Kehrenberg and Schwarz, 2005; 
Katsuda et al., 2012). However, until now, no mechanism increasing the florfenicol efflux in 
Mycoplasma species has been described.  
 
Tetracyclines  
Tetracyclines inhibit protein synthesis by binding to the 30S ribosomal subunit and blocking 
tRNA to their docking site (Brodersen et al., 2000; del Castillo, 2013). Usually tetracyclines 
are bacteriostatic for susceptible bacteria, but for doxycycline also a bactericidal time-
dependent effect has been shown (del Castillo, 2013). Doxycycline also seems to be the most 
effective tetracycline (lowest MIC values and non-wild type population) in the recent years 
(Figure 10). Probably due to a small non-wild type population, not much is known about the 
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resistance mechanisms (Gerchman et al., 2009; Barberio et al., 2016; Kong et al., 2016). Point 
mutations in the 16S rRNA-encoding genes (rrs1, rrs2) of the Tet-1 site of the 30S ribosomal 
subunit have been linked with tetracycline resistance in M. bovis (Table 7). Additionally, it 
seems that the more such mutations are present, the more the MIC value of these strains 
increases (Amram et al., 2015; Khalil et al., 2017; Sulyok et al., 2017; Hata et al., 2019).  
 
Macrolides 
Macrolides reversibly bind to the 23S rRNA of the 50S ribosomal subunit and inhibit protein 
synthesis by disturbing transpeptidation and translocation of bacterial mRNA (Giguère, 
2013a; Lysnyansky and Ayling, 2016). They are mostly bacteriostatic, but at very high 
concentrations may be bactericidal (Giguère, 2013a). Resistance is caused by either target site 
modification through methylation or mutation, efflux pumps or enzymatic inactivation 
(Leclercq, 2002; Giguère, 2013a). Mutations in the 23S rRNA and L4/L22 proteins associated 
with macrolide resistance in M. bovis are shown in Table 7. The presence of methylated bases 
and methyltransferases have been described in several Mycoplasma species (Razin and Razin, 
1980; Lluch-Senar et al., 2013; Wojciechowski et al., 2013), but were never associated with 
macrolide resistance. However, it has been shown that efflux pumps (possibly ABC-type) are 
involved in resistance to macrolides in M. pneumoniae (Li et al., 2017), but so far such efflux 
pumps are not identified in M. bovis.  
 
Although high MIC values are reported in several studies, this does not necessarily result in 
therapy failure due to several features of the antimicrobials belonging to the macrolide class. 
Macrolides concentrate in the lung, for example tulathromycin results within 12 hours after 
SC administration of 2.5 mg/kg in approximately 3000 ng/g or higher for 7 days, which is 
much higher than in plasma (Nowakowski et al., 2004; Godinho et al., 2005a). The lung 
concentration was even higher for SC administration of 6 mg/kg gamithromycin, where a 
concentration of 18,500 ng/g was obtained after 24 hours administration, and high lung to 
plasma ratios (265-410) persisted over 15 days (Huang et al., 2010). This does however not 
explain why tulathromycin is still effective on an M. bovis with a MIC value of 64 µg/mL. It 
has also been shown that macrolides can accumulate intracellularly in phagocytic cells 
(Villarino et al., 2014; Lysnyansky and Ayling, 2016), just like M. bovis (Van Der Merwe et 
al., 2010; Bürki et al., 2015), and that macrolides have profitable immunomodulatory effects 
in humans (Zimmermann et al., 2018).  
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Table 7. Overview of mutations associated with antimicrobial resistance identified in M. bovis and for which a minimum level of evidence is available, such 
as presence in multiple independent isolates with increased MIC values for a relevant antimicrobial agent or a statistically significant association with 
phenotypic resistance. Table shows mutations ordered by gene, whenever mutations in specific genes correspond to resistance against multiple antimicrobials, 
this agent is pointed out by its letter between brackets (e.g. macrolides: (M)).      
Study Country Method R/S #   16S rRNA (rrs1 and rrs2) 
23S rRNA (domain 
II/V) 
L4 L22 gyrA parC 
   
Tetracyclines (T), Spectinomycine 
(S) 
Macrolides (M), florfenicol (F), lincosamides (L) Fluoroquinolones 
A ISR CLSI  G748Ab (M)   Ser83Phe Asp84Asn 




D ISR, GBR, DEU MIC  G748Ac (M) 
C752Tc (M) 
A2058Gc (M)  
A2059G/Cc (M) 
T186Pd (M)    
E ISR, GBR, DEU,  
HUN, ESP, AUS, LIT, 
CUB 
ECOFF 
A965Tb + A967T/Cb  
(+ G1058A/Cb) (T) 
     
F CHN CLSI  A2058Gc (M)     
G HUN ECOFF A965Tb + A967T/Cb (T) 
C1192Aa (S) 
G2062Tc (F)*  
G2063Tc (F)* 
G748Ab (M) 
A2059Gc (M)  
A2059Gc (L) 
  Ser83Phe Ser80Ile 
Asp84Asn 




 Q93K/H (M)   
I JPN MIC A965Tc (T) + A967Tb (T)   





  Ser83Phe Ser80 
J ESP PolC type  G458Ab (M) 
A2058Gc (L) 
  Ser83Phe Ser80Ile 
Asp84Asn 
K CAN CLSI 
 
 G748Ac (M) 
G748Ac +A2059Gc (M) 
G748Ac +A2060Gc (M) 
    
A = Lysnyansky et al., 2009; B = Sato et al., 2013; C = Sato et al., 2017; D = Lerner et al., 2014; E = Amram et al., 2015; F = Kong et al., 2016; G = Sulyok et al., 2017; H = Khalil et al., 2017; 
I = Hata et al., 2019; J = García-Galán et al., 2020; K = Kinnear et al., 2020; country of origin is abbreviated following ISO 3166-1; Alpha-3 code; # Method R/S: method used for categorizing 
isolates into resistant/susceptible (CLSI), wild type/non-wild type (ECOFF), strain type (PolC) or high/low MIC (MIC); CLSI = bovine respiratory pathogens or other Mycoplasma species, 
ECOFF = epidemiological cut off based on visual estimation, MIC = minimum inhibitory concentration; a in one alle, bboth alleles, cin one or both alleles, dno clear association with AMR alone, 
* in vitro mutants  




The binding site on the 23S rRNA of the 50S subunit of lincosamides overlaps with the 
binding site of macrolides (Giguère, 2013b). Resistance can occur to lincosamides alone, but 
cross-resistance with macrolides occurs more frequently (Giguère, 2013a). Mutations in the 
23S rRNA associated with lincosamide resistance are located at position 2058 and 2059 
(Table 7). As far as the author is aware, no additional lincosamide resistance mechanisms 
have so far been described in Mycoplasma species.   
 
Aminoglycosides  
Aminoglycosides bind with the 30S ribosomal subunit to disturb protein synthesis (Dowling, 
2013b). Whereas streptomycin only acts at one target site, the other aminoglycosides (e.g. 
neomycin, gentamicin) interfere with more sites (Dowling et al., 2013b). Plasmid-mediated 
enzymes are mostly responsible for resistance against aminoglycosides in many bacterial 
species, but such enzymes are not observed in M. bovis (Dowling et al., 2013b; Lysnyanski 
and Ayling, 2016). Mutations associated with resistance against spectinomycin are problaby 
the results of a single mutation in the rrs1 gene of the 16S rRNA at position 1192 (Sulyok et 
al., 2017; Hata et al., 2019) (Table 7).  
 
Fluoroquinolones  
All fluoroquinolones are antimicrobials of which the mode of operation depends on their 
structure, resulting in a slightly different binding affinity for their targets. These target 
enzymes are DNA-gyrase and topoisomerase IV (Giguère and Dowling, 2013; Redgrave et 
al., 2014), and resistance of M. bovis against fluoroquinolones is caused by alternations in the 
QRDRs of DNA gyrase (gyrA and gyrB genes) and/or topoisomerase IV subunits (parC and 
parE) (Gautier-Bouchardon, 2018). Mutations associated with increased MIC values are 
shown in Table 7. The accumulation of different mutations appears to result in step-wise 
resistance (Lysnyansky et al., 2009, Sato et al., 2013; Hata et al., 2019). Efflux pumps have 
been identified in M. hominis by Raherison et al. (2002), and were also suggested to be 
present in M. mycoides subsp. capri (Antunes et al., 2015), but this has not been investigated 
for M. bovis.   
 
Table 7 shows an overview of mutations identified in M. bovis which were either found in 
multiple isolates with increased MIC values or were associated with AMR supported by 
statistical analysis. Besides those mutations, many more mutations were identified in DNA 
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regions associated with AMR, but not (yet) evidently associated with AMR in M. bovis, and 
are therefore not included in Table 5.  
 
Antimicrobial susceptibility of M. bovis  
An overall decrease in the antimicrobial susceptibility of M. bovis to various antimicrobial 
classes targeting protein synthesis (e.g. phenicols, tetracyclines, lincosamides and macrolides) 
and DNA synthesis (e.g. fluoroquinolones) has been reported in many countries (Gautier-
Bouchardon et al., 2014; Cai et al., 2019; Klein et al., 2019). For example, susceptibility in 
France decreased between 1978-1979 and 2010-2012 for eight antimicrobial agents within the 
classes of the tetracyclines, fluoroquinolones, aminoglycosides and macrolides (Gautier-
Bouchardon et al., 2014). In Canada, an increased MIC50 was seen for tetracyclines, and 
tylosin over two decades, and remained high in the third decade (Cai et al., 2019). Klein et al. 
(2019) demonstrated a slight increase in MIC50 (at most one doubling dilution) between 
isolates obtained in Europe between 2014-2017 and 2010-2012, for almost all antimicrobials. 
Only for oxytetracycline a small reduction was observed (Klein et al., 2019). Especially high 
MIC50 and MIC90 values against tetracyclines and macrolides have been reported, as shown in 
Figure 12. In most countries the major part of M. bovis isolates are still susceptible to 
fluoroquinolones (Cai et al., 2019; Becker et al., 2020; Liu et al., 2020), although high MIC50-
90 have been reported for Italian and Spanish strains (Klein et al., 2019; Garciá-Galan et al., 
2020). Nevertheless, fluoroquinolones are critically important antibiotics for human medicine, 
and therefore recommended to be only used in food-producing animals, when susceptibility 
testing shows resistance against all other antimicrobial classes (WHO, 2017). More recently, 
macrolides were also added to this list, leaving the use of florfenicol and tetracyclines as good 
first choice treatment options in some countries, but problematic for countries with high 
percentages of resistant M. bovis against these drugs, such as France (Becker et al., 2015).  





Figure 12. Maps of Europe (a), Canada (b), China and Japan (c), showing reported MIC50 and MIC90 
(µg/mL) values for different antimicrobials (corresponding to specific legend color) since 2015. MIC50 
and MIC90 for tilmicosin was excluded from this figure, as both MIC50-90 were generally high in all 
studies (>32 µg/mL). Letters are corresponding to the different studies: A: Heuvelink et al., 2016; B: 
Barberio et al., 2016; C: Klein et al., 2019; D: Khalil et al., 2017; E: García-Galán et al., 2020; F: 
Jelinski et al., 2020; G: Anholt et al., 2017; H: Cai et al., 2019; I: Hata et al., 2019, J: Kong et al., 











Figure 12. Maps of Europe (a), Canada (b), China and Japan (c), showing reported MIC50 and MIC90 
(µg/mL) values for different antimicrobials (corresponding to specific legend color) since 2015. MIC50 
and MIC90 for tilmicosin was excluded from this figure, as both MIC50-90 were generally high in all 
studies (>32 µg/mL). Letters are corresponding to the different studies: A: Heuvelink et al., 2016; B: 
Barberio et al., 2016; C: Klein et al., 2019; D: Khalil et al., 2017; E: García-Galán et al., 2020; F: 
Jelinski et al., 2020; G: Anholt et al., 2017; H: Cai et al., 2019; I: Hata et al., 2019, J: Kong et al., 
2016; K: Liu et al., 2020. Maps were created using Piktochart (2020, www.piktochart.com).    
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Differences in MIC values for M. bovis can be observed due to year or site of isolation, type 
of livestock production systems, age or health status of livestock, geographical origin, and 
antimicrobial treatment history (Gerchman et al., 2009; Siugzdaite et al., 2012; Heuvelink et 
al., 2016; Lysnyansky and Ayling, 2016; Gautier-Bouchardon et al., 2018; Cai et al., 2019; 
Jelinski et al., 2020). There are also studies where no significant association between site of 
isolation, geographic location, breed of cattle, antimicrobial use or strain type were evidenced  
(Francoz et al., 2005; Barberio et al., 2016; Khalil et al., 2017; Cai et al., 2019; Becker et al., 
2020).    
 
M. bovis isolates with acquired resistance against certain antimicrobials (e.g. tetracycline, 
valnemulin) have been described to regain susceptibility after a short time in the absence of 
the antimicrobial in vitro (Sulyok et al., 2017). This is in contrast to fluoroquinolones, as 
Sulyok et al. (2017) tested three M. bovis isolates in vitro which remained resistant for several 
passages without fluoroquinolone presence. Also the frequency in which resistance of M. 
bovis against antimicrobials develops seem to differ between antimicrobial agents. For 
example resistance against florfenicol and tiamulin developed more rapid in vitro in three M. 
bovis isolates than resistance against tetracyclines (Sulyok et al., 2017). Cross-resistance may 
also occur between tetracyclines, macrolides (tylosin and tilmicosin), tiamulin and florfenicol, 
among fluoroquinolones (enrofloxacin, danofloxacin, marbofloxacin), and also between 
macrolides, pleuromutilins, and lincosamides (Sulyok et al., 2017; Cai et al., 2019). However, 
again, we should be cautious translating these results to clinical relevance. Most of the AMR 
in these studies developed in vitro, and as AMR mechanisms by mutation can interfere with 
bacterial virulence and fitness (Beceiro et al., 2013), it is not clear whether the observations 
described above are relevant in vivo. 
 
Important drivers associated with antimicrobial resistance  
It is important to understand the drivers behind AMR of M. bovis in order to prevent further 
AMR development, and ideally to reduce AMR of M. bovis and other pathogens. The 
intensive use of antimicrobials is most likely the largest driver for the development of AMR 
(Barbosa and Levy, 2000; Holmes et al., 2016). Administration of antimicrobials can result in 
inhibiting the growth or killing the susceptible population of both the targeted pathogen and 
the commensal microbiota. Subsequently, the resistant population that survives, can multiply 
in the host or can be transmitted to the environment (Barbosa and Levy, 2000).  
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M. bovis is inherently resistant against many agents used as first choice antimicrobials for 
treating BRD, such as penicillin and potentiated sulphonamides. The use of these 
antimicrobials will therefore mainly affect the commensal microbiota or potentially secondary 
pathogens, while leaving M. bovis unharmed. When treated with antimicrobials effective 
against M. bovis (e.g. tetracyclines, macrolides, ..), both M. bovis and the commensal 
microbiota are exposed to an antimicrobial selective pressure.  
 
Next to the choice of antimicrobial drug, the administered dose, treatment duration and 
treatment interval are very important in the development of AMR as these influence the 
course of serum or tissue drug concentration over time (Catry et al., 2003). It has been 
hypothesized, “that for each antimicrobial-pathogen combination and antimicrobial 
concentration a range exists in which selective amplification of single-step, drug-resistant 
mutants occur”. This range is called the ‘mutant selection window’ (MSW) (Drlica and Zhao, 
2007). Every time a drug is administered, this MSW will be passed at least twice, resulting in 
selection pressure on the population. Starting with high concentrations, and repeating the 
treatment before the MSW is reached, will prevent extensive AMR selection (Drlica, 2003). 
This MSW is believed to be located between the MIC and ‘mutant prevention concentration’ 
(MPC) (‘the minimum concentration that inhibits growth of the least-susceptible single-step 
mutant subpopulation’, Huang et al., 2020). The duration of the serum or tissue drug 
concentrations being in the MSW, is for example depending on maximum plasma 
concentrations, time of peak concentration, distribution volume, and half-life of the 
antimicrobial (Catry et al., 2003). For M. hyopneumoniae and M. gallisepticum, the existence 
of a MSW for tetracyclines, macrolides, pleuromutilins and fluoroquinolones was explored 
(Zhang et al., 2017; Huang et al., 2020). The analyses showed that danofloxacin, macrolides 
(tylosin, tilmicosin), and doxycycline are more likely to select resistant mutants than 
pleuromutilins (tiamulin, valnemulin) in both Mycoplasma species. Unfortunately, no such 
studies have been performed for M. bovis so far.  
 
In outbreaks of M. bovis, metaphylactic treatment is often used (as described above). Group 
treatment compared to individual treatment, increases the selection pressure, and is most 
likely associated with increased AMR (Dunlop et al., 1998; Varga et al., 2009; Graveland et 
al., 2010). However, these studies did not take administration route into account, which can 
be a confounder as different routes of administration may lead to different course of serum 
and tissue concentrations, resulting in a variety of duration in the MSW (Wiuff et al., 2002; 
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Catry et al., 2003). However, oral group treatment in veal calves was associated with 
increased AMR in BRD pathogens (M. haemolytica, P. multocida) and E. coli compared to 
individual parenteral treatment (Schönecker et al., 2019). Although antimicrobials in feed as 
growth promoter are prohibited in Europe, and not commonly used for metaphylactic 
treatment in dairy and beef herds, the use of oral group treatment is still widely used in the 
veal calf sector in for example France, Belgium and The Netherlands, when facing M. bovis 
outbreaks (Jarrige et al., 2017; Bokma et al., 2019a; SDa, 2020). This is in contrast to other 
countries, such as Denmark and Switzerland, which already made a switch towards more 
individual treatment (Fertner et al., 2016; Lava et al., 2016). Oral group treatment is a risk for 
AMR in both pathogens as the commensal microbiota, and appropriate individual treatment of 
calves is necessary to reduce AMR (Schönecker et al., 2019).  
 
To be able to start appropriate individual antimicrobial treatment in calves facing M. bovis, 
rapid identification of this pathogen is necessary to prevent the use of ineffective 
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in M. bovis and therapy failure. In addition, strain typing of the isolate can support in control 
and prevention measurements by showing insights in transmission and virulence of the 
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Mycoplasma bovis is the leading primary cause of pneumonia, arthritis and otitis in calves, 
but also causes arthritis and mastitis in adult cattle. M. bovis is highly contagious and affects 
multiple cattle production systems. Despite a growing body of epidemiological studies, little 
is known on molecular epidemiology and persistence within specific sectors. M. bovis 
associated diseases usually respond poorly to antimicrobial therapy, resulting in production 
losses, hampered animal welfare and excessive antimicrobial use. Next to inherent immune-
evasive characteristics of the bacteria, the main reasons for treatment failure are late therapy 
initiation due to late detection and inappropriate antimicrobial treatment. M. bovis is often 
either naturally resistant (beta-lactam antibiotics and sulphonamides) or has acquired 
resistance against first choice antibiotics. For a better control and treatment success both rapid 
identification of M. bovis and antimicrobial susceptibility testing are key. Available 
diagnostic methods, like culturing techniques or PCR have several drawbacks, such as costs, 
diagnostic accuracy, interpretative issues and in particular a long sample-to-result turnaround 
time. To date, no routine antimicrobial susceptibility testing is performed and a reference 
framework for resistance determination is lacking.    
 
Therefore, the general aim of this thesis was to develop new Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) and nanopore 
sequencing based diagnostic methods for rapid identification, strain typing, and antimicrobial 
susceptibility testing of M. bovis, and to apply those methods on Belgian field isolates and 
samples, gaining better insight into the epidemiology of M. bovis. 
 
The specific objectives were: 
• To explore and optimize M. bovis identification with MALDI-TOF MS from solid 
(Chapter 3.1) and liquid media (Chapter 3.2) 
• To develop new methods for the rapid identification of M. bovis from broncho-
alveolar lavage fluid with MALDI-TOF MS (Chapter 3.3) and nanopore sequencing 
(Chapter 3.4) 
• To explore rapid nanopore sequencing as a new method for M. bovis strain typing and 
to map the spread of M. bovis strain types over Belgium and in different sectors 
(Chapter 4) 
• To determine the antimicrobial susceptibility of recent Belgian M. bovis isolates from 
different cattle sectors (Chapter 5.1)  
• To develop a rapid molecular method for antimicrobial susceptibility testing based on 
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MALDI-TOF MS is a fast and accurate tool to identify Mycoplasma species in liquid media. 
However, when trying to identify presumptive Mycoplasma bovis (M. bovis) colonies from 
solid medium (the “direct transfer method”) a surprisingly high occurrence of M. arginini and 
M. alkalescens identification was observed. It was hypothesized that agar medium 
components are associated with false positive identification with Mycoplasma spp., as M. 
bovis colonies are very small and grow into the agar. The objective of this study was to 
determine whether complete modified pleuropneumonia-like organism (PPLO) agar 
(supplemented with horse serum, sodium pyruvate, technical yeast extract, ampicillin sodium 
salt and colistin) and the separate components, result in false identification as Mycoplasma 
spp. by MALDI-TOF MS. A total of 100 samples were examined, of which thirty-three 
percent of the modified PPLO agar spots were identified as M. alkalescens (16%) and M. 
arginini (17%)), albeit with relatively low score values (< 1.85). No false identification of M. 
bovis was obtained. Several medium components (unsupplemented PPLO agar, horse serum 
and colistin) resulted in spectra with peaks showing close matches with peaks present in the 
M. alkalescens and M. arginini database spectra. This study shows that the direct transfer 
method should be interpreted with caution, and one should strive to pick as little as possible 
agar when sampling Mycoplasma-like colonies from solid medium containing PPLO agar, 
horse serum and/or colistin.  
 
Keywords: Colistin, Direct transfer method, Horse serum, PPLO agar 




Cattle are subject to diseases associated with multiple Mycoplasma species of which 
Mycoplasma bovis (M. bovis) is widely accepted as a primary pathogen (Maunsell and 
Donovan, 2009; Maunsell et al., 2011; Haapala et al., 2019; Oliveira et al., 2019). M. bovis is 
causing pneumonia, arthritis and otitis in calves (Maunsell and Donovan 2009), but also 
arthritis and mastitis in adult cattle (Maunsell et al., 2011). For other Mycoplasma spp. 
literature is more contradictory. M. alkalescens has been associated with arthritis in calves 
(Bennett et al., 1978; Whithear et al,. 1983) and mastitis in cattle (Jasper, 1982) in the past, 
whereas M. arginini has been described as an opportunistic pathogen (Shahriar et al., 2002; 
Thomas et al., 2002). M. canadense causes mastitis, and has been isolated from the lung 
(Jasper, 1977; Ball and Mackie, 1986). The pathogenicity of M. bovirhinis is questionable, as 
it is isolated from healthy and pneumonic lungs (Thomas et al., 2002). Also M. dispar was 
long thought to be pathogenic, but seems currently abundant in healthy animals (Timset et al., 
2018). The impact of former Mycoplasma species in respiratory diseases is unknown (Thomas 
et al., 2002; Ayling et al., 2004), and may represent a part of the natural microbiome of the 
bovine respiratory tract (Klima et al., 2019; McMullen et al., 2019).  
Rapid diagnosis and differentiation between Mycoplasma spp. is important, as M. bovis 
spreads easily, can be resistant against a lot of antimicrobials (both intrinsically and acquired) 
and is difficult to eradicate (Gautier-Bouchardon, 2018; Maunsell and Chase, 2019). Isolation 
of M. bovis from clinical samples requires nutrient rich media, often based on 
pleuropneumonia-like organisms (PPLO) agar, supplemented with animal serum, yeast 
extract and various antibiotics to prevent M. bovis of being overgrown by other bacteria. As 
for many other bacterial species, MALDI-TOF MS is a fast and accurate tool to identify 
Mycoplasma species, from a liquid medium (Pereyre et al., 2013; Randall et al., 2015; 
Spergser et al., 2019). However, most commonly, bacteria are cultured on solid medium and 
identified by MALDI-TOF MS by transferring colonies from the agar to the MALDI-TOF 
MS target plate (“direct transfer method”) (Bizzini and Greub, 2010). In contrast to other 
bacteria, this direct transfer method appears to be unreliable for M. bovis identification 
(Pereyre et al., 2013). Culturing in broth and subsequent protein extraction are still necessary 
to achieve consistently high identification scores in M. bovis (Pereyre et al., 2013; Bokma et 
al., 2019). During attempts to identify presumptive Mycoplasma-like colonies obtained from 
broncho-alveolar lavages and pure M. bovis cultures with the direct transfer method, we 
observed a surprisingly high occurrence of M. arginini and M. alkalescens identifications 
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(data not shown). We noticed this especially in cases with very few and/or small colonies, 
suggesting that medium components might play a role. Therefore, the objective of this study 
was to explore whether agar medium components are associated with false positive 
Mycoplasma spp. identification using MALDI-TOF MS.  
Five modified PPLO agar plates were produced in-house and contained PPLO agar (DifcoTM) 
supplemented with 25% inactivated horse serum (GibcoTM), 0.5% sodium pyruvate 
(ReagentPlus, Sigma-Aldrich®), 0.7% technical yeast extract (BactoTM), 520 µg/mL 
ampicillin sodium salt (Sigma-Aldrich®) and 670 I.E./mL colistin (Colistine sulfate, VMD). 
The non-inoculated modified PPLO agar plates were incubated for 4 days (37ºC, 5% CO2) 
and subsequently spotted 20 times per plate on a polished steel BC target plate with a 
toothpick using the direct transfer method. Additionally, we spotted the single components 
(PPLO agar, horse serum, yeast extract, pyruvate, ampicillin, and colistin) in duplicate to 
obtain reference spectra for the respective components. For colistin, both the injectable 
colistin sulfate (VMD) and a colistin sulfate standard (Sigma-Aldrich®) dissolved in distilled 
water to a concentration of 1 MIO I.E./ml, were included. Spotted samples were covered with 
one µl matrix (α-cyano-4-hydroxy-cinnamic acid in 50% acetonitrile - 47.5% water - 2.5% 
trifluoroacetic acid; Bruker Daltonics, Bremen) and processed with an Autoflex III (Bruker 
Daltonics, Bremen). Successful Mycoplasma species identification at species level was 
considered for logarithmic score values ≥ 1.7, as suggested earlier (Pereyre et al., 2013; 
Randall et al., 2015; Spergser et al., 2019). The standard Bruker library (server version 4.1.80 
PYTH) was extended with four main spectrum profiles of recent M. bovis strains as described 
in Bokma et al. (2019). Peaks and spectra were  analyzed with Flex-analysis 3.4 software after 
smoothing and baselining with the MBT_standard method and MALDI Biotyper Compass 
Explorer 4.1 (Bruker Daltonics, Bremen). Bruker Bacterial Test Standard (Bruker Daltonics, 
Bremen) was included in every run as quality control.  
Thirty-three percent of the 100 spots with pure modified PPLO agar were as best match 
identified as M. alkalescens (16%) and M. arginini (17%), albeit with relatively low score 
values (1.70 – 1.82) (Supplement 1). In 7 out of 100 spots, both M. alkalescens and M. 
arginini were identified. We also observed a discrepancy between plates, as 7 out of 20 spots 
from plate 1 were false positive, wheras 7/20, 3/20, 5/20 and 12/20 were false positive from 
plate 2-5, respectively (Supplement 1). This variation might have been caused by slightly 
different concentrations of the agar components after solidifying the agar or the quantity of 
agar that was spotted on the target plate. Nonetheless, the results show that false positive 
identification of M. alkalescens and M. arginini was possible from every plate. No false 
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positive identification of M. bovis was obtained. The latter is in line with a previous study 
where false identification of M. arginini was detected with the direct transfer method from 
CHROMagarTM Orientation agar. However, in the previous study, M. alkalescens was never 
identified with relevant identification scores ≥ 1.7 (Lagacé-Wiens et al., 2019).  
In order to gain information on which medium components might evoke the false positive 
results, the spectra of specific medium components were compared with peaks showing 
similar m/z [Da] values in the M. alkalescens 22B10 VLW and M. arginini 7SR10 VLW 
main spectrum profiles (MSP) in Bruker database records as these strains showed the highest 
matching identification scores with modified PPLO. As described in the metadata of the 
library, both MSPs of these Mycoplasma spp. were based on protein extraction after 
incubation for 3-5 days in Eaton’s broth. Additionally, peaks of the entire modified PPLO 
agar were compared with M. alkalescens 22B10 VLW (Figure 1A) and M. arginini 7SR10 
VLW (Figure 1B) MSPs. 
 
 
Figure 1A. Spectra comparison of modified PPLO agar (containing horse serum, yeast extract, 
pyruvate, ampicillin and colistin) (bars above the x-axis) with Mycoplasma alkalescens 22B10 VLW 
(blue bars) in MALDI Biotyper Compass Explorer 4.1 (Bruker Daltonics, Bremen). Peaks of matched 
spectra are depicted as green (peak match within experimental error range), orange (close peak match, 
but not within experimental error range) or red (no matching peaks). 
 
 




Figure 1B. Spectra comparison of modified PPLO agar (containing horse serum, yeast extract, 
pyruvate, ampicillin and colistin)(bars above the x-axis) with Mycoplasma arginini 7SR10 VLW (blue 
bars) in MALDI Biotyper Compass Explorer 4.1 (Bruker Daltonics, Bremen). Peaks of matched 
spectra are depicted as green (peak match within experimental error range), orange (close peak match, 
but not within experimental error range) or red (no matching peaks). 
 
When analyzing the separate components, only PPLO agar, horse serum and colistin (both 
injectable and pure form) resulted in meaningful MALDI-TOF spectra. The components 
together showed 39 (close) matching peaks with the investigated Mycoplasma spp. (7 for 
PPLO agar, 3 for horse serum and 32 for colistin) based on m/z [Da] values between 3000 – 
15.000 (as used for identification), as shown in Table 1. Using Compass Explorer software, 
peaks of matched spectra are depicted as green (peak match within experimental error range), 
orange (close peak match, but not within experimental error range) or red (no matching 
peaks), as defined by the manufacturer. When comparing modified PPLO agar with M. 
alkalescens 22B10 VLW, 14 peaks matched within experimental error range (green) and 20 
were close peak matches (orange), for M. arginini 7SR10 this was 12 and 21, respectively. 
These overlapping peaks might vary sometimes due to small variations in spectra caused by 
the sample quality or when intensity of a peak is on the borderline of detection.   
No false positive M. bovis identification was observed with the current protocol. 
Nevertheless, false positive Mycoplasma spp. results could lead to unnecessary antimicrobial 
use in animals, risking increased antimicrobial resistance selection (Chantziaras et al., 2014; 
Tang et al., 2017).  
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This study showed that to a large extend, spectrum peaks originating from PPLO agar, horse 
serum and colistin can result in false positive identification of M. alkalescens and M. arginini. 
This is in contrast to an earlier study where it was hypothesized, though not investigated, that 
false positive Mycoplasma identifications were a result of yeast extract or peptone related 
peaks (Lagacé-Wiens et al., 2019). Nevertheless, not all PPLO agar, colistin and horse serum 
related peaks could explain the overlapping peaks between modified PPLO agar and the 
Mycoplasma spp. Therefore, it could be possible that yeast extract or peptones show indeed 
peaks, but intensity might be too low for MALDI-TOF MS to generate a distinguishable 
spectrum when investigating the separate agents.  
 
One of the reasons that M. alkalescens and M. arginini were identified, while other 
Mycoplasma spp. cultivated in the same medium were not, could be the use of an imperfect 
protocol of generating these specific MSPs. For example, the use of Mycoplasma cultures 
with too low bacterial biomass, due to either concentration limits or phase requirements in 
broth culture or inefficient washing steps, may have contributed to low quality protein 
extractions. In addition, it was recently described that ethanol protein precipitation for 
Mycoplasma spp. may lead to unstable quality of spectra (Spergser et al., 2019). It is very 
probable that ethanol was used when obtaining older MSPs, even though it is not clear 
whether this could have contributed to differences between species. Finally, mere chance may 
have resulted in the fact that some M. alkalescens and M. arginini peptides/proteins share 
molecular masses with certain medium components, while this might not be the case for other 
Mycoplasma spp. Replacing the current library MSPs by new ones obtained with another 
protocol (for example including efficient washing steps and without ethanol precipitation) 
might be effective. Alas, the present software does not provide the liberty to replace MSPs.  
As alternative technique to reduce the amount of agar attached to the Mycoplasma colonies, 
the authors explored the use of a plastic loop instead of a toothpick. Unfortunately, it was 
almost impossible to gather enough material for reliable peak recognition with MALDI-TOF 
MS. Currently, the best option to identify Mycoplasma spp. with MALDI-TOF MS seems to 
be from broth cultures (Spergser et al., 2019., Bokma et al., 2019). Misidentifications 
probably do not occur starting from broth cultures, as they are usually washed and therefore 
medium-related proteins are removed prior to protein extraction. This results in clearer 
bacterial peaks and less background noise. Also Mycoplasma spp. concentrations are likely 
higher in liquid medium compared with what can be obtained from picking one colony from 
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an agar plate. Therefore, the balance between bacterial matter and medium components is 
expected to be better starting from broth cultures.  
 
Table 1. Overview of spectra (m/z)[Da] showing peaks of horse serum and colistin (injectable and 
standard form) similar to M. alkalescens 22B10 VLW and M. arginini 7SR10 VLW (within a 

































3024 3031 3028  3024  3028     
    3036 3031      
    3072 3073 3071     
    3087 3091 3090     
    3106 3113 3111     
    3128 3132 3129     
    3148 3151 3148     
    3170 3168      
    3187 3183      
    3195 3200 3195     
    3290 3288      
3319 3326 3324         
3334  3334         
    3412 3416 3416     
    3451 3448 3445     
    3460 3465 3465     
    3488 3489 3487     
    3507  3511     
    3679 3679 3678     
    3717  3717     
    3745 3745      
3979  3979  3980  3979     
    4010 4009      
    4043  4046     
    4065 4061      
    4085 4078 4079     
    4099 4097 4097     
    4114 4118 4115     
    4120 1118      
    4177 4176 4175     
    4178 4176      
    4232 4232 4232     
4300 4304 4305  4304 4304 4305     
    4470 4468 4467     
        4715 4717 4718 
        5542 5544 5545 
        5580 5574  
6804  6805         
6821 6815          
All peaks were extracted from the mass list generated by Flex-analysis 3.4 software after smoothing 
and baselining the initial spectra generated by MALDI-TOF MS (Bruker Daltonics, Bremen)  
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The present study shows that MALDI-TOF identification results using the direct transfer 
method from solid media for Mycoplasma spp., which allows identification of bacteria within 
several minutes and with minimal labor, should be interpreted cautiously in diagnostic 
laboratories. One should strive to pick enough bacterial material with as little as possible agar, 
especially when colonies are small (higher risk for including agar) and when PPLO agar, 
colistin and/or horse serum is added to the medium. This should not only be kept in mind for 
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Fast and accurate identification of Mycoplasma bovis in cattle samples is of great importance 
for rational treatment and control of pneumonia, arthritis and mastitis. However, which 
growth conditions will allow for the fastest identification of M. bovis with MALDI-TOF MS 
remains unclear. Therefore, growth conditions and incubation time were investigated to 
optimize identification of M. bovis with MALDI-TOF MS and an in-house library was 
constructed. Nine different M. bovis strains were inoculated in triplicate in three liquid media 
(B1-3). Basic broth (B1) consisted of pleuropneumonia-like organism broth, enriched with 
25% horse serum and 0.7% yeast extract. B2 and B3 were additionally supplemented with 
0.5% pyruvate or 520 µg/mL ampicillin, respectively. Protein extraction was performed after 
24, 48, 72, 96 and 120 hours of incubation (37°C, 5% CO2) and processed with Autoflex III 
smartbeam. Identification scores ≥1.7 were interpreted as reliable. The present study showed 
reliable identification of M. bovis with MALDI-TOF MS as early as 24h after inoculation, and 
in broth supplemented with pyruvate, up to 120h after inoculation. Serial dilutions showed 
improved survival of M. bovis in broth with pyruvate. The addition of ampicillin to prevent 
contamination, did not impair identification of M. bovis and state-of-the-art in-house libraries 
contributed to higher identification scores for M. bovis with MALDI-TOF MS.  
 
Keywords: ampicillin, incubation time, library, protein extraction, pyruvate   
 




Mycoplasma bovis (M. bovis) is an important pathogen causing primarily pneumonia, otitis 
and arthritis in calves, and pneumonia and mastitis in adult cattle (Maeda et al., 2003; 
Maunsell and Donovan, 2009; Maunsell et al., 2011). Mixed infections of M. bovis with other 
less or apathogenic Mycoplasma or Acholeplasma species, such as Mycoplasma bovirhinis, 
Mycoplasma arginini and Acholeplasma laidlawii can be present in bovine clinical samples 
(Thomas et al., 2002; Ayling et al., 2004; Autio et al., 2007; Szacawa et al., 2018). While 
cultivation is inexpensive and allows further characterization of the isolates, such as 
susceptibility testing and strain typing, definite identification requires other techniques, such 
as PCR methods (Calcutt et al., 2018; Parker et al., 2018). Nevertheless, fast identification of 
M. bovis is highly important in order to rationalize antimicrobial use, since M. bovis is 
inherently resistant against various antimicrobials, such as penicillins, cephalosporins and 
(potentiated) sulphonamides, often used to treat bovine respiratory disease (Gautier-
Bouchardon, 2018; Nicholas and Ayling, 2003). Matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) is a fast and reliable technique for 
identifying bacteria until species level (Bizzini and Greub, 2010; Kuhnert et al., 2012; 
Puchalski et al., 2016). Even though spectra peaks are mainly originating from ribosomal 
proteins (Sauer and Kliem, 2010), quality and reproducibility of obtained spectra can be 
influenced by different circumstances, e.g. growth medium and incubation time (Welker and 
Moore, 2011; Anderson et al., 2012; Martiny et al., 2013). Although the identification of M. 
bovis with MALDI-TOF MS has been described earlier (Pereyre et al., 2013; Becker et al., 
2015; Randall et al., 2015), it remains unclear what the best growth conditions are allowing 
for the fastest and most reliable identification of M. bovis for clinical applications. Therefore, 
the objective of this study was to investigate whether growth media, incubation time and used 
library influence identification of M. bovis with MALDI-TOF MS.  
One to three colonies of nine different clinical bovine M. bovis strains (K6, Mb51, Mb99, 
Mb219, VK1, VK13, VK27, Mb263, Mb274; Table 1) were inoculated in triplicate in 25 mL 
of three liquid media (B1-3). As M. bovis is a fastidious grower, the basic broth (B1) 
consisted of DifcoTM pleuropneumonia-like organism broth, enriched with 25% inactivated 
horse serum (GibcoTM) and 0.7% technical yeast extract (BactoTM). B2 and B3 were 
additionally supplemented with 0.5% sodium pyruvate (ReagentPlus, Sigma-Aldrich®) or 
520 µg/mL ampicillin sodium salt (Sigma-Aldrich®), respectively. Hypothesis was that 
supplementing pyruvate might improve growth rate and protein expression, since adding 
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pyruvate resulted in increased growth yield in non-fermenting Mycoplasma spp. before (Miles 
et al., 1988). Ampicillin was investigated as this antibiotic is often used to prevent 
contamination and bacterial overgrowth (Sachse et al., 1993).  
 
Table 1. Descriptives of the twelve Mycoplasma bovis strains obtained in Belgium and used in this 
study. 
Name Sample Herd Region Year MSP 
K1 Bronchoalveolar lavage Veal Antwerp 2014 Yes 
K3 Bronchoalveolar lavage Veal Limburg 2014 Yes 
K6 Bronchoalveolar lavage Beef East-Flanders 2014 Yes 
K7 Bronchoalveolar lavage Beef East-Flanders 2014 Yes 
Mb51 Bronchoalveolar lavage Beef Antwerp 2016 No 
Mb99 Middle ear Dairy Limburg 2017 No 
Mb219 Bronchoalveolar lavage Dairy East-Flanders 2017 No 
VK1 Deep nasal swab Veal Antwerp 2017 No 
VK13 Deep nasal swab Veal Antwerp 2017 No 
VK27 Deep nasal swab Veal East-Flanders 2017 No 
Mb263 Joint Dairy/Beef West-Flanders 2018 No 
Mb274 Milk Dairy Henegouwen 2018 No 
MSP = main spectrum profiles added to the in-house library  
 
One mL aliquots were derived from the cultures, and protein extraction was performed as 
previously described at 24, 48, 72, 96 and 120 hours of incubation (37°C, 5% CO2) (Pereyre 
et al., 2013). One µL of the protein extract was spotted in triplicate, air dried and covered with 
1 µL alpha-cyano-4-hydroxycinnamic acid matrix (Bruker Daltonics, Bremen, Germany) on a 
MSP 384 target polished steel BC plate. All samples were processed with an Autoflex III 
smartbeam MALDI-TOF MS, using FlexControl and MBT Compass software (Bruker 
Daltonics, Bremen, Germany). External calibration and validation were performed by adding 
Bacterial Test Standard, as described by the manufacturer (Bruker Daltonics). Spectra 
obtained during the experiments were compared to the standard Bruker library (SL; including 
M. bovis 86B96 VLW and M. bovis NCTC 10131T VLW) and the in-house library (IHL). 
The IHL consisted of the SL which was extended with four MSP’s (main spectra profiles) 
from clinical bovine M. bovis isolates by Bruker’s protocol to improve identification scores 
(Rettinger et al., 2012; Schulthess et al., 2016). Strains used to construct MSP’s (K1, K3, K6, 
K7) were obtained from calves with pneumonia and identified using real-time PCR (Clothier 
et al., 2010) (Table 1). At the same time points aliquots were obtained for MALDI-TOF 
analysis, an aliquot was obtained for performing bacterial cell counts for five strains (VK13, 
Mb51, Mb99, Mb263, Mb274) in order to determine the concentration of M. bovis at the 
moment of protein extraction. Fifty µL of the dilution was inoculated on PPLO-agar plates 
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and counted manually after five to seven days of incubation (37°C, 5% CO2) on plates 
showing 20-200 colonies per plate. 
Identification score (ID-score) per spot were obtained and successful identification was 
considered at ID-scores ≥ 1.7, as proposed in previous studies (Pereyre et al., 2013; Randall et 
al., 2015; Schulthess et al., 2016). Spots were excluded as being contaminated, when a non-
M. bovis ID was obtained within the first 10 matches with ID score values ≥ 1.7. All data 
were transferred to SAS 9.4 (SAS Institute Inc., Cary, N.C.). Data was analyzed by both a 
linear mixed regression model with the ID-score as continuous outcome variable and a 
logistic mixed regression models with ID-scores as a binary outcome variable (0 < 1.7; 1 ≥ 
1.7). In both models, time was included as repeated effect to adjust for the repeated 
measurements within an isolate. Also, broth and isolate were in both models included as 
categorical predictor variables. Significance was set at P < 0.05.  
Due to contamination, possibly caused by preserving contaminated samples during the 
experiment and a high number of technical repetitions, 5.2% (103/1980) of the readings (1 
spot at 24h; 13 at 96h; 89 at 120h after incubation) were excluded from the statistical analysis. 
Therefore, cross contamination could be a potential drawback for long incubation. Statistical 
analysis showed significant differences in ID-score between broths (P < 0.001), which is in 
line with previous studies in other bacterial pathogens (Valentine et al., 2005; Anderson et al., 
2012; Martiny et al., 2013). No significant strain effects were identified (P = 0.11). After 24 
and 48h of incubation, the ID-score using the IHL was, although not statistically significant, 
superior in B2, in contrast to B1 (24h: P = 0.15; 48h: P = 0,10), and B3 (P = 0.18; P = 0.27). 
After 72h of incubation, ID-scores reduced drastically for B1 and B3, which has also been 
reported for Campylobacter (Martiny et al., 2013). In contrast, ID-scores for B2 remained 
similar until the end of the experiment (Figure 1). Also the percentage of correct identification 
was consistently higher in B2 after different incubation times (24h: 83%, 48h: 99%, 72h: 
100%, 96h: 100% and 120h: 92%) compared to B1 (68%, 92%, 87%, 67% and 15%) and B3 
(68%, 92%, 86%, 69% and 18%). The possible effects of pyruvate on M. bovis growth and 
protein expression has been described before (Miles et al., 1988; Masukagami et al., 2017), 
nevertheless results of the bacterial cell counts, showed that pyruvate did not improve M. 
bovis growth during the first 48h of incubation, but facilitated the survival of M. bovis. Cell 
counts remained more or less stable in B2, compared with B1 and B3 after 48-120 hours of 
incubation (Figure 1). In addition, even though not statistically significant, the MALDI-TOF 
score values did seem slightly higher and more robust using B2. The statistically significant 
stabilising effect of pyruvate at time points after 48h of incubation, might have contributed to 
Optimizing identification by MALDI-TOF MS  Chapter 3.2 
125 
 
the seemingly more robust results at 24 and 48h of incubation. Lack of statistical significance 
at these earlier time points may be due inter-strain variation, because score values were 
already quite high for B1 and B3, or due to the fact that supplementing pyruvate actually does 
not have an added value at these earlier time points. Masukagami et al. (2017) showed that 
incorporation of pyruvate could not be detected in M. bovis in the very early logarithmic 
growth phase (after 4h of incubation). However, the earliest sampling point in this study is at 





Figure 1. Evolution of MALDI-TOF MS identification scores of 9 Mycoplasma bovis strains (K6, 
Mb51, Mb99, Mb219, VK1, VK13, VK27, Mb263 and Mb274) after protein extraction at different 
incubation times, using the in-house library. Identification scores ≥ 1.7 (horizontal black line) were 
interpreted as reliable. Basic broth 1 (B1: green filled square), broth 2, supplemented with pyruvate 
(B2: blue filled triangle), broth 3, supplemented with ampicillin (B3: red filled circle). Vertical line 
presents standard deviation, based on 132 repetitions minus contaminated samples. Different 
superscripts(a,b) mean significantly different identification scores at one time point (P < 0.001). The 
table below presents M. bovis concentrations (CFU/ml) and standard deviation (SD) based on 5 M. 
bovis strains (Mb51, Mb99, Mb263, Mb274, VK13) in different broths at 24 to 120 hours of 
incubation. 
 
 24h SD 48h SD 72h SD 96h SD 120h SD 
B1 (basic) 2.0x108 2.8x108 1.7x108 7.5x107 1.6x108 1.2x108 3.9x107 5.3x107 1.1x105 1.5x105 
B2 (pyruvate) 2.2x107 2.5x107 2.6x108 2.1x108 2.2x108 1.5x108 2.2x108 7.5x107 3.0x107 3.5x107 
B3 (ampicillin) 1.4x108 1.0x108 1.3x108 8.2x107 1.7x108 9.6x107 3.7x107 2.3x107 1.3x105 1.2x105 
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Reliable identification of M. bovis with MALDI-TOF MS was possible for 83% of the 
samples as early as 24h after inoculation with one to three colonies obtained from an agar 
plate. This is as quick or even faster than other techniques as growth inhibition, 
immunofluorescence or dot immunobinding, used for identification after isolation (Devriese 
and Haesebrouck, 1991; Calcutt et al., 2018). PCR of the initial sample would be faster 
(Sachse et al., 1993), but to a higher cost, and lacks the opportunity for additional research on 
clinical isolates (Parker et al., 2018). Using a pyruvate supplemented broth, successful 
identification of M. bovis can be expected up to 120h after inoculation. This could be useful in 
routine diagnostics and research, when for example weekends and holiday’s need to be 
overcome. Supplementation of ampicillin did not influence the ID-score, as expected, since 
M. bovis is inherently resistant against this antimicrobial drug (Gautier-Bouchardon, 2018). 
Therefore, supplementation of ampicillin could be useful in conditions where contamination 
is considered likely, without affecting MALDI-TOF MS identification efficiency.  
The IHL showed higher ID-scores in broth 1, 2 and 3 after 48h (2.33; 2.51 and 2.33, 
respectively) and 72h (2.36; 2.54 and 2.37, respectively) of inoculation compared to the SL 
(48h: 1.75; 1.64; 1.77/72h: 1.77; 1.67; 1.77). The observed diversity between ID-scores for 
SL and IHL could be due to the genetic variation of M. bovis (McAuliffe et al., 2004; Amram 
et al., 2013; Becker et al., 2015). 
 
In conclusion, this study showed that adding pyruvate to the medium ensured reliable 
identification with MALDI-TOF MS after 24 hours of incubation, persisting up to five days 
after inoculation. Additionally, adding ampicillin to the medium may be useful in avoiding 
contamination, as it does not undermine accurate identification with MALDI-TOF MS. Also 
expanding the MSP library could contribute to better identification of M. bovis, as the use of a 
state-of-the-art in-house library can contribute to higher score values. This information can be 
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Mycoplasma bovis is a leading cause of pneumonia in modern calf rearing. Fast identification 
is essential to ensure appropriate antimicrobial therapy. Therefore, the objective of this study 
was to develop a protocol to identify M. bovis from bronchoalveolar lavage fluid (BALf) with 
MALDI-TOF MS and to determine diagnostic accuracy in comparison with other techniques. 
BALf was obtained from 104 cattle and presence of M. bovis was determined in three ways: 
(1) BALf was enriched and after 24, 48 and 72 hours of incubation analyzed by MALDI-TOF 
MS (RIMM), (2) triplex real-time PCR for M. bovis, M. bovirhinis and M. dispar and (3) ten 
day incubation on a selective-indicative agar. Diagnostic accuracy of the three tests was 
determined with Bayesian latent class modelling (BLCM). After 24h of enrichment, M. bovis 
was identified by MALDI-TOF MS in 3 out of 104 BALf samples. After, 48 and 72h of 
enrichment, 32/104 and 38/100 samples were M. bovis positive, respectively. Lipase positive 
Mycoplasma-like colonies were seen in 28 of 104 samples. Real-time PCR resulted in 28/104 
positive and 12/104 doubtful results for M. bovis. The BLCM showed a sensitivity (Se) and 
specificity (Sp) of 86.6% (Confidence Interval: 69.4%-97.6%) and 86.4% (CI: 76.1-93.8) for 
RIMM. For real-time PCR Se was 94.8% (89.9-97.9) and Sp 88.9% (78.0-97.4). For 
selective-indicative agar, Se and Sp were 70.5% (52.1-87.1) and 93.9% (85.9-98.4), 
respectively. These results implicate that rapid identification of M. bovis with MALDI-TOF 
MS after an enrichment procedure is a promising test for routine diagnostics in veterinary 
laboratories.  
 
Key words: Bayesian latent class model, lipase activity, Mycoplasma bovis, Mycoplasma 
bovirhinis, Mycoplasma dispar




Mycoplasma bovis is one of the primary pathogens causing severe pneumonia in cattle, and is 
also associated with arthritis, otitis, mastitis and reproductive disorders (Maunsell and 
Donovan, 2009; Maunsell et al., 2001). Bovine respiratory disease (BRD) is the leading cause 
of antimicrobial use in calves (Pardon et al., 2012; Lava et al., 2016), and M. bovis is involved 
in approximately 20-30% of pneumonia outbreaks in conventional dairy or beef calves, and 
almost 100% of the veal calf herds have been in contact with this bacterium (Pardon et al., 
2011; Francoz et al., 2015; Pardon et al., 2020). Rapid diagnosis of M. bovis is of great 
importance to rationally use antimicrobials and limit economic losses, since M. bovis is 
inherently resistant against widely used antimicrobial agents and difficult to eradicate once 
chronically present (Maunsell and Donovan, 2009; Gautier-Bouchardon, 2018). In contrast to 
other Mycoplasma species, M. bovis can be cultured quite well, although it easily takes 5-10 
days before culture results become available. Also, to obtain definite Mycoplasma spp. 
identification, other techniques, such as biochemical characterisation or PCR are needed 
(Calcutt et al., 2018; Parker et al., 2018). This is of great importance, as M. bovis is generally 
recognised as a primary pathogen. However, pathogenic significance of other species such as 
M. arginini, M. bovirhinis, M. dispar are more controversial as they are both isolated from 
healthy and pneumonic lungs (Thomas et al., 2002; Bottinelli et al., 2017; Nicola et al., 2017; 
Timsit et al., 2018), and wrong identification could lead to unnecessary antimicrobial use. 
Selective-indicative agar using lipase activity as M. bovis-specific feature has been described 
to distinguish M. bovis from other bovine Mycoplasma spp. (Shimizu et al., 1983; Devriese 
and Haesebrouck, 1991). Unfortunately, its diagnostic performance is currently not known. 
PCR is the preferred method for final identification of Mycoplasma species. We currently 
observe a shift towards PCR identification directly on the specimen, such as bronchoalveolar 
lavage fluid (BALf) in case of pneumonia. Even though this is more rapid, due to logistic 
reasons laboratories usually collect samples to perform on a (two)-weekly analysis, 
whereupon diagnostic results still take several days.  
MALDI-TOF MS (Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass 
Spectrometry) is widely used as a rapid, low cost, culture-based diagnostic tool for 
identification of bacteria, including Mycoplasma spp. (Spergser et al., 2019). Nevertheless, 
prior isolation of M. bovis on specific solid media is still necessary and final identification can 
take up to ten days (Pereyre et al., 2013; Parker et al., 2018; Bokma et al., 2019). To reduce 
sample turnaround time, at present there is great interest in identification of bacteria by 
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MALDI-TOF MS directly from the sample or after a short enrichment period in liquid broth, 
as already done for urine, blood, milk or BALf specimens (Ferreira et al., 2011; Lallemand et 
al., 2017; Barreiro et al., 2018). However, such a technique is currently not available for 
Mycoplasma spp., presumably because of difficulties like their fastidious growth and 
overgrowth by other bacteria.  
Therefore, the objective of this study was to develop a protocol to identify M. bovis directly 
from BALf after an enrichment procedure with MALDI-TOF MS. The accuracy of this 
diagnostic test was compared with real-time PCR and biochemical characterisation (lipase 
activity) on solid media in a Bayesian Latent Class Model (BLCM).  
 
MATERIALS AND METHODS 
Development of a protocol for fast MALDI-TOF detection of M. bovis in BALf 
Determination of an enrichment procedure and antimicrobial concentrations  
M. bovis concentration in BALf usually ranges from 1.8x103 to 1.03x108 CFU/ml (Castillo-
Alcala et al., 2012), whereas a minimum concentration of 1.0x108 CFU/ml is necessary to 
obtain interpretable spectra with MALDI-TOF MS starting from mycoplasma grown in broth 
(Pereyre et al., 2013; Bokma et al., 2019). Therefore, an enrichment procedure seemed 
necessary to identify M. bovis directly from BALf. We explored different broths as described 
earlier (Bokma et al., 2019) and experimented additionally with different antimicrobials, since 
overgrowth of M. bovis by other bacteria, such as (faecal) contaminants (eg. 
Enterobacteriacae), commensals (eg. Streptococcus, Staphylococcus, Enterococcus) or 
pathogenic bacteria (eg. Pasteurellaceae) in liquid media is very likely (Nicola et al., 2017; 
Sung et al., 2018).  
Starting from a fresh culture, three M. bovis strains obtained from clinical field samples 
(Mb144, K6, K7; passaged 3-5 times) were cultured in modified basic PPLO-broth (#255420 
BD DifcoTM, Berkshire, United Kingdom) with inactivated horse serum (25%, GibcoTM, 
Ireland) and technical yeast extract (0.7%, BactoTM, Belgium), supplemented with sodium 
pyruvate (0.5%, Sigma-Aldrich, Germany), ampicillin sodium salt (520µg/mL, Sigma-
Aldrich, Germany) (Bokma et al., 2019), and with colistin sulfate (VMD, Belgium), at a 
concentration of 967 IU/ml, similar as described previously (Angulo et al., 2003; Yassin et 
al., 2012). One mL of the M. bovis cultures with either meropenem (USP Reference Standard, 
Sigma-Aldrich, Germany) or vancomycin (Vancomycin hydrochloride from Streptomyces 
orientalis, Sigma-Aldrich, Germany) in final concentrations of 32, 16, 8, 4, 2, 1, 0.5 and 0 
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µg/mL were prepared in Eppendorf tubes at a final M. bovis concentration of 1-3x104 CFU/ml 
(Kanci et al., 2017). After 48 hours of incubation (37°C, 5% CO2) protein extraction was 
performed as described before (Pereyre et al., 2013). Antimicrobial concentrations where the 
MALDI-TOF MS identification score (ID-score) for M. bovis was ≥1.7 were considered to 
not inhibit successful identification (Pereyre et al., 2013; Randall et al., 2015). The highest 
antimicrobial concentration that did not inhibit successful M. bovis identification with 
MALDI-TOF MS was chosen for the rapid identification protocol.       
 
Identification and enrichment protocol with MALDI-TOF MS from BALf  
The final protocol is presented in the next paragraphs as part of the diagnostic test study, and 
will be referred to as “Rapid identification of M. bovis with MALDI-TOF MS” (RIMM). 
 
Diagnostic test study 
Study population and sampling method  
A prospective diagnostic test accuracy assay was performed. To detect a difference in 
sensitivity of 0.90-0.70 with 80% power, a minimum of 103 samples was needed (Bujang and 
Adnan, 2016). Therefore, a convenience sample of 104 BALf was collected for diagnostic 
purposes as described before (Van Driessche et al., 2017). Samples were taken from 3 week 
to 4 year old cows originating from 10 different farms (5 beef (A-D, F), 3 dairy (E, G, H) and 
2 veal (I, J)) in Flanders, Belgium, between January 2019 and May 2019. Subsequently, 
samples were stored at 4°C for three to twenty hours before culture-based methods (index-
tests: RIMM and selective-indicative agar) were performed. All samples were stored (-20°C) 
before the reference test (real-time PCR) was performed blindly. All procedures were 
approved by the local ethical committee under approval number EC2019-1.  
 
Rapid identification of M. bovis with MALDI-TOF MS (RIMM)  
BALf was vigorously vortexed and 4 mL was inoculated in 8 mL modified basic PPLO-broth 
as described above, supplemented with 32 µg/ml vancomycin and 32 µg/ml meropenem. 
After 24, 48 and 72 hours of incubation (37°C, 5% CO2), protein extraction was performed on 
1 mL of the enriched BALf culture as described before and 1 µL of lysate was spotted in 
triplicate on target polished steel BC plates (Pereyre et al., 2013; Bokma et al., 2019). Spotted 
samples were air dried and covered with 1 µL alpha-cyano-4-hydroxycinnamic acid matrix 
(Bruker Daltonics, Bremen, Germany). All samples were processed with an Autoflex III 
smartbeam MALDI-TOF MS, using FlexControl and MBT Compass software (Bruker 
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Daltonics, Bremen, Germany). External calibration and validation were performed by adding 
Bacterial Test Standard, as described by the manufacturer (Bruker Daltonics, Bremen, 
Germany). Negative controls were performed by adding 1 µL of the matrix only. The standard 
library (server version 4.1.90 PYTH) was extended with four in-house main spectra profiles 
(MSPs) for M. bovis as outlined before (Bokma et al., 2019) and extra MSPs of M. bovirhinis 
(NCTC 10118), M. ovipneumoniae (NCTC 10151) and M. dispar (NCTC 10125). 
Identification of Mycoplasma spp. was considered as reliable at species level when 
logarithmic score values were ≥1.7 as proposed in previous studies (Pereyre et al., 2013; 
Randall et al., 2015), whereas non-mycoplasmal bacteria were considered reliable at species 




100 µL of tenfold dilutions of BALf was inoculated on an in-house modified PPLO-agar, 
containing DifcoTM PPLO-agar (#241210), enriched with 25% inactivated horse serum 
(GibcoTM), 0.7% technical yeast extract (BactoTM), 0.5% D-(+)-glucose monohydrate (Sigma-
Aldrich), 520 µg/mL ampicillin sodium salt (Sigma-Aldrich), 967 IU/ml colistin sulfate 
(VMD) and 0.1% Tween-80 (Polysorbate 80, Sigma-Aldrich). Tween-80 was added to 
observe lipase activity as indicator for M. bovis (Shimizu et al., 1983; Devriese et al., 1991). 
After 1-10 days of incubation (37°C, 5% CO2), presumptive mycoplasma colonies (fried egg 
morphology) were identified as M. bovis based on the presence of lipase activity, observed as 
an “oil-like” film surrounding the colonies, and were counted.  
 
Triplex real-time PCR 
A previously described triplex real-time PCR was chosen as reference test as this method 
showed comparable results with other PCR methods used for routine diagnostics to identify 
M. bovis from BALf (Cornelissen et al., 2017; Wisselink et al., 2019). The limit of detection 
was determined at 30 CFU/ml for M. bovis and M. bovirhinis, and 300 CFU/ml for M. dispar 
as described previously (Cornelissen et al., 2017). BALf samples were thawed before DNA 
extraction. After vortexing, 200 µL sample was used for DNA extraction with the MagNA 
Pure 96 Instrument (Roche) using the MagNA Pure 96 DNA and Viral NA Small Volume Kit  
(Roche) for DNA extraction. Five µL extracted DNA was used for the triplex real-time PCR 
detecting M. bovis, M. dispar and M. bovirhinis as described before (Cornelissen et al., 2017). 
Fresh M. bovis, M. dispar and M. bovirhinis cultures from in-house reference strains were 
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used as internal control to monitor DNA extraction, as well as inhibition of the PCR reactions. 
Ct values were interpreted as positive (< 35), doubtful (35-40) or negative (> 40), as 
previously described (Wisselink et al., 2019).  
 
Conventional bacterial culture for non-mycoplasmal bacteria 
An essential part of the protocol was to avoid overgrowth of M. bovis by other pathogens. 
Therefore to quantify other fast growing non-mycoplasmal pathogens and contamination 
present in the BALf samples, 100 µl of tenfold dilutions of BALf was cultured on Columbia 
agar, supplemented with 5% sheep blood (blood agar; Oxoid, UK). Non-mycoplasmal 
bacteria were identified with MALDI-TOF MS after one day of incubation (37°C, 5% CO2). 
Additionally, after 72 hours of enrichment in the BALf in modified PPLO medium, 50 µl was 
cultured on blood agar for 24 hours (37°C, 5% CO2) to check for residual presence of non-




First, the diagnostic accuracy (sensitivity and specificity) of both the RIMM and the selective-
indicative agar (index tests) were determined with real-time PCR as reference test (WinEpi, 
Zaragoza, Spain). BALf was considered positive for M. bovis when ID-score of MALDI-TOF 
MS was ≥ 1.7 (direct identification) after 72 hours of incubation, Ct score < 40 (real-time 
PCR) or when Mycoplasma-like colonies showed lipase activity (bacterial culture). For 4 
BALs, no results for 72h of incubation were obtained (due to a practical problem), for these 
samples results of 48h were used to compare with real-time PCR and the selective-indicative 
agar.   
 
Bayesian latent class modelling 
Definition of outcome tested 
Sensitivity and specificity of the real-time PCR are not 100% (Cornelissen et al., 2017; 
Wisselink et al., 2019). Therefore, and also because of issues with clinical interpretation 
(detection of small amount of non-viable pathogens), this test cannot truly be considered a 
gold standard. To account for this issue, a second statistical analysis was performed to 
determine the diagnostic accuracy of the three methods. Bayesian latent class models create 
their own probabilistic definition of the outcome studied, depending on what the tests actually 
detect. In this study PCR detects DNA, either from living or death bacteria. The selective-
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indicative agar detects culturable bacteria with lipase activity. Culture enrichment combined 
with MALDI-TOF MS detects protein spectra from culturable bacteria. Therefore, in our 
judgement the three tests detect three distinguished parameters, and a model for three 
independent tests was built. In addition, the model for dependent tests (with both culture-
based methods being dependent of each other), was built to compare independent and 
dependent outcomes.  
 
Model development 
In order to access the accuracy of the three tests: (1) real-time PCR (detection of DNA), (2) 
RIMM (detection of proteins) and (3) selective-indicative agar (detection of lipase activity) to 
detect the presence of M. bovis, a latent class model (1 population, 3 tests) was considered, 
with each test regarded independent from the others. The unknown parameters of interest 
were sensitivity and specificity of the three diagnostic tests and the prevalence of M. bovis in 
the study population. Once the likelihood of the process generating the data observation is 
described, which is in this case a multinomial probability distribution, the estimation of 
posterior densities can be obtained using the Bayes theorem which links the likelihood with 
the posterior distribution (inference). At this stage, prior information on any parameter in the 
likelihood can be added to obtain posterior densities of the different parameters using a 
Markov Chain Monte-Carlo algorithm (Gibbs sampling). The prior information is a way to 
narrow parameter uncertainty when previous scientific information is available. In terms of 
prevalence and Se/Sp of tests, the priors are modelled using beta distributions that are 
naturally bound from 0 to 1. Priors can be uninformative (any value same probability of 
happening) or informative (some values are more or less probable) (Branscum et al., 2005).   
 
Prior distribution determination process 
Prior information was derived from available literature and expert opinion. Both for RIMM as 
for the selective-indicative agar, no literature information was available. Previous work on M. 
bovis real-time PCR, estimated a Se of 95.2% (CI95: 76.1%-99.9%) and Sp of 73.9% (51.6%-
89.8%) (Cornelissen et al., 2017). Also for the prevalence of M. bovis in the population, prior 
information was available (Pardon et al., 2020; Gille et al., 2018). This literature information 
was combined with the best guesses of experts in the field (first author and senior authors). 
The 5th percentiles were guessed at 90%, 95% and 50% for Se, Sp and prevalence, 
respectively. These values were used to determine the beta distribution parameters of the 
corresponding prior distribution using a free online beta distribution calculator (Epitools, 
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Sergeant, ESG, Ausvet Animal Health Services and Australian Biosecurity calculator, 
available at http://epitools.eu/content.php?page=home, Ausvet) resulting in beta (99.7, 6.19), 
beta (1, 1) and beta (6.28, 13.32) for Se, Sp and prevalence, respectively.   
In total three models were run. A first model with all prior information on all parameters set at 
uninformative (Beta 1,1). A second model included informative priors on Se and Sp of real-
time PCR. The third model included informative priors on M. bovis prevalence and of real-
time PCR.  
The parameters of interest were determined based on a sample from the posterior distribution 
using Gibbs sampling with the WinBUGS statistical freeware (version 1.4.3., MRC 
Biostastics unit, Cambridge, UK). Estimation of posterior densities and model assessment was 
done using recommended techniques (Kostoulas et al., 2017). A total number of 100,000 
iterations were used for each model, after a burn in of 5000 iterations. Three chains were run, 
with different initial values. Posterior median and 2.5-97.5 credibility intervals (95% CI) were 
extracted for each parameter. Model convergence was checked by visual inspection of density 
and Gelman-Rubin plots. Plots of chain autocorrelation were inspected to investigate the need 
of thinning of chains.    
For smaller datasets, informative prior elicitation can be a process that could potentially have 
an impact on posterior density. Therefore, a sensitivity analysis was performed, running 
alternative models with highly different prior specifications to the main model. It was 
inspected whether posterior estimates of these alternatives models were included in the 95% 
credibility intervals of the main model (Branscum et al., 2005).  
 
RESULTS  
Development of a protocol for fast MALDI-TOF detection of M. bovis in BALf 
Determination of an enrichment procedure and antimicrobial concentrations 
After 48 hours of incubation, M. bovis strains were identified by MALDI-TOF MS as M. 
bovis (ID-score ≥2.0) after protein extraction for all tested antimicrobial concentrations. 
Therefore, a concentration of 32 µg/mL for both meropenem and vancomycin was selected 
for further testing.  
 
Diagnostic test study 
Triplex real-time PCR resulted in 26.9% (28/104) positive BALf samples (Ct ≤ 35), 11.5% 
(12/104) were doubtful (35 < Ct < 40) and 61.5% (64/104) were negative (Ct ≥ 40 or no 
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detection) for M. bovis. For M. bovirhinis 79.8% (83/104) were positive, 11.5% (12/104) 
doubtful, and 8.7% (9/104) negative, for M. dispar this was 92.3% (96/104), 3.8% (4/104), 
and 3.8% (4/104), respectively (Supplementary Table 1).   
After 24h of enrichment with the RIMM method, 2.9% (3/104) of the BALf samples were 
positive for M. bovis, and after 48 and 72 hours, 30.7% (32/104) and 38.0% (38/100), 
respectively. For 4 samples no results were obtained after 72 hours of incubation, because of a 
practical problem. ID-scores for M. bovis ranged between 1.74 and 2.65 and are shown in 
Supplementary Table 1. M. bovirhinis was identified after 24h (BALf no. 18, 23, 28, 60 and 
95), 48h (BALf 26, 28, 29, 32, 35, 38, 43, 60, 64, 102) and 72h (BALf 60, 63, 66 and 88) with 
ID-scores between 1.70 and 1.88. In BALf no. 24, M. ovipneumoniae was identified after 48 
and 72h of incubation (ID-score: 1.78 and 1.72). M. dispar was not detected with the RIMM 
method in any sample throughout the entire experiment. 
Out of 104 samples, 28 (26.9%) showed lipase positive Mycoplasma-like colonies on the 
selective-indicative agar (Supplementary Table 1) ranging from 1.0x101 to 4.6x104 CFU/mL 
BALf (mean: 3.8x103; median 3.3x102). 18% (19/104) of the BALf samples did not show 
additional bacterial growth on blood agar plates, whereas 81.7% (85/104) did, among which 
were multiple pathogens and commensals (Supplementary Table 1). Despite the presence of 
these non-mycoplasmal bacteria in the original BALf samples, the selective enrichment phase 
did not allow non-mycoplasmal bacterial growth to an extent that was able to be detected by 
MALDI-TOF MS.   
Residual contamination was checked after 72 hours of enrichment. There was no microbial 
growth on blood agar in 70% of the BALf samples after 24 hours of incubation (70/100). For 
the samples with microbial growth on blood agar MALDI-TOF MS identified Candida spp. 
(4/30), Aspergillus fumigatus (2/30), Stenotrophomonas maltophilia (1/30) and 
Staphylococcus spp. (1/30). In 23 out of 30 blood agars showing microbial growth, no 
identification was possible with MALDI-TOF MS, but macroscopic appearance suggested 
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Table 1. 2x2 Contingency table for direct MALDI-TOF MS identification as index test compared to 
real-time PCR as reference test for identification of Mycoplasma bovis from BALf samples (n=104).  
Test  Reference test (real-time PCR) 
  Positive Negative Total 
 
MALDI-TOF MS 
Positive 75% (30/40) 14% (9/64) 39 
Negative 25% (10/40) 86% (55/64) 65 
Total 40 64 104 
     
 
Selective-indicative agar 
Positive 60% (24/40) 6% (4/64) 28 
Negative 40% (16/40) 94% (60/64) 76 
Total 40 64 104 
 
The 2x2 contingency tables of the RIMM method and the selective-indicative agar compared 
with real-time PCR as reference test are shown in Table 1. The sensitivity (Se) and specificity 
(Sp) for the RIMM compared to real-time PCR were 75.0% (Confidence Interval 95%: 61.6-
88.4%) and 85.9% (CI95: 77.4%-94.5%), respectively. The selective-indicative agar showed a 
60.0% (CI95: 44.8%-75.2%) Se and 93.8% (CI95: 87.8%-99.7%) Sp, compared to the real-
time PCR test. 
 
All latent class models converged and prior distributions and posterior summary statistics of 
each model are shown in Table 2. Parameters were particularly stabile between models, and 
the results obtained from the sensitivity analysis were highly robust to changes in the prior 
distributions. Model three included the most prior information and is therefore expected to be 
the most accurate one. Prevalence of M. bovis was 32.6% (23.5%-42.6%), which was 
comparable to the prior information added to the third model. In independent model 3, RIMM 
showed a Se and Sp of 86.6% (69.4%-97.6%) and 86.4% (76.1%-93.8%). Real-time PCR had 
a Se of 94.8% (89.9%-97.9%) and Sp of 88.9% (78.0%-97.4%). The selective-indicative agar 
had a Se and Sp of 70.5% (52.1%-87.1%) and 93.9% (85.9%-98.4%), respectively. No 
significant difference between the independent and dependent model were observed.     
 
  




Table 2. Posterior median and 95% credible interval of three independent Bayesian latent class models for the prevalence of M. bovis (Prev), sensitivity (Se) 
and specificity (Sp) of the Rapid identification of M. bovis with MALDI-TOF MS method (RIMM), triplex real-time PCR (PCR) and selective-indicative agar 
(SIA) used to diagnose M. bovis from bronchoalveolar lavage fluid samples.  
 Model 1 Model 2 Model 3 
 Prior densities Posterior densities Prior densities Posterior densities Prior densities Posterior densities 
Sepcr Beta (1,1) 93.5 (77.2-99.7) Beta (99.7,6.19) 94.8 (89.8-97.8) Beta (99.7,6.19) 94.8 (89.9-97.9) 
Sppcr Beta (1,1) 89.2 (78.1-97.8) Beta (1,1) 89.1 (78.1-97.7) Beta (1,1) 88.9 (78.0-97.4) 
Serimm Beta (1,1) 86.0 (68.3-97.5) Beta (1,1) 86.3 (68.8-97.5) Beta (1,1) 86.6 (69.4-97.6) 
Sprimm Beta (1,1) 86.8 (76.3-94.9) Beta (1,1) 86.5 (76.2-93.9) Beta (1,1) 86.4 (76.1-93.8) 
Sesia Beta (1,1) 69.5 (50.8-86.7) Beta (1,1) 70.2 (51.8-86.9) Beta (1,1) 70.5 (52.1-87.1) 
Spsia Beta (1,1) 94.1 (86.0-98.8) Beta (1,1) 94.0 (86.0-98.5) Beta (1,1) 93.9 (85.9-98.4) 
Prev Beta (1,1) 33.7 (23.2-45.9) Beta (1,1) 33.3 (23.1-44.6) Beta (6.28,13.32) 32.6 (23.5-42.6) 
Model 1: No informative priors 
Model 2: Informative priors on prevalence and Sepcr (mode 95%; 5th percentile = 90%) and Sppcr (mode 74%; 5th percentile = 95%)(30) 
Model 3: Informative prior on Sepcr, Sppcr and prevalence of M. bovis in BALf (mode 30%; 5th percentile = 50%)(33) 




The objective of the present study was to achieve a proof of concept for rapid identification of 
M. bovis from bovine BALf samples after enrichment with MALDI-TOF MS and to compare 
these with another culture-based method (selective-indicative agar) and a DNA-based 
reference test (real-time PCR). In this study we were able to identify M. bovis from the 
majority of BALf with RIMM within two days after incubation, and even more after three 
days. The current protocol was able to reduce relevant growth of non-mycoplasmal bacteria 
and non-pathogenic Mycoplasma spp. present in BALf, resulting in high sensitivity (86.6%; 
CI95: 69.4-97.6) and specificity (86.4%; 76.1-93.8) of this diagnostic test as determined by 
BLCM. Prior information of the BLCM was extracted from peer-reviewed journals and 
sensitivity analysis for robustness of all models were verified. These together, make the 
possibility of bias due to the best guesses of the experts in the field less likely.   
False negatives of the RIMM method compared to real-time PCR can be explained by the 
livability of M. bovis. PCR detects DNA, while for culture-based methods, like the MALDI-
TOF MS, bacteria need to be alive. Some of the sampled calves might have been treated with 
antimicrobials before obtaining BALf resulting in non-viable M. bovis in the lung, so only 
DNA could be detected. This would suggest that no active M. bovis infection is currently 
present and the clinical relevance of positive results from the real-time PCR might be argued, 
in contrast to culture-based methods (RIMM and selective-indicative agar). In addition, cross 
reaction with M. agalactiae has been described for the currently used real-time PCR 
(Cornelissen et al., 2017), while MALDI-TOF MS has been described to accurately 
distinguish M. bovis and M. agalactiae (Pereyre et al., 2013; Spergser et al., 2019). Both 
previous arguments are therefore more likely resulting in a false positive PCR result, rather 
than a false negative culture-based result and therefore current specificity of the RIMM might 
be underestimated.  
Incoherence between a negative result for M. bovis with real-time PCR, but positive with the 
RIMM method, might be explained by the fact that the BALf volume used for RIMM was 4 
mL, while this was only 200 µL for the real-time PCR reference test and 100 µL for 
biochemical identification (lipase activity) on agar. BALf contains mucus clumps and cells, 
which could lead to a heterogenic suspension of M. bovis. Although samples were vortexed 
vigorously, it is possible that certain parts of the BALf did not end up in the aliquot for real-
time PCR. This could have caused a higher chance for isolation using the RIMM method 
compared with detection using real-time PCR or selective-indicative agar. The ability to 
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process larger volumes with the RIMM method from BALf without extra labor, is an 
advantage over both other tests (real-time PCR and selective-indicative agar) and might even 
increase sensitivity of culture-based methods. Considering that most clinical samples in this 
study contained 102-103 CFU/mL, the generation time of M. bovis (two hours in exponential 
phase) (Bürgi et al., 2018), and that the detection limit of the MALDI-TOF MS is 108 
CFU/mL (Pereyre et al., 2013), detection of M. bovis from BALf after 48 hours of incubation 
can be expected and is in line with the observations. For samples in which M. bovis was 
detected after 72 hours of incubation at earliest, for example the presence of other pathogens, 
mucus composition, number of inflammatory cells or other antimicrobial substances might 
have influenced the M. bovis growth rate or MALDI-TOF MS identification efficacy. 
Various antimicrobials were added to the modified PPLO broth, as high antimicrobial 
resistance levels against different antimicrobials were observed in bacteria isolated from cattle 
(Graveland et al., 2010; Catry et al., 2016; Hordijk et al., 2019). Meropenem was considered 
due to its broad spectrum and strong activity against Gram-negative bacteria, although this 
would probably not suppress all bacterial growth in BALf as for example methicillin-resistant 
Staphylococcus aureus (MRSA) show resistance against meropenem in humans, but is also a 
common pathogen in calves (Watanabe et al., 2001). Therefore, vancomycin was used as 
well. Until now only very low levels to no resistance is detected against this antibiotic in 
MRSA and Enterococcus strains obtained from cattle (Barlow et al., 2017; de Jong et al., 
2019). It should be kept in mind that critically important antibiotics, even though used under 
laboratory circumstances, should be properly disposed of after use.   
Even though the current method was able to suppress non-mycoplasmal bacterial growth, 
there is still room for improvement for the reduction of yeast and fungi growth. In five of the 
BALf samples with a false negative MALDI-TOF MS result compared to real-time PCR, 
fungal growth was observed and this might have caused interference with identification of M. 
bovis as fungal pigments can suppress the desorption process (Buskirk et al., 2011), or may 
lead to the presence of interfering peaks. Adding an antimycotic drug such as Amphotericin 
B, might help increase sensitivity of the rapid MALDI-TOF MS identification method (Arai 
et al., 1966).  
The real-time PCR cannot be seen as ‘gold standard’ technique for several reasons. First, 
sensitivity and specificity are not 100% (Cornelissen et al., 2017). Secondly, studies 
concluded that sensitivity of culture was sometimes higher than real-time PCR assays 
(Castillo-Alcala et al., 2012; Wisselink et al., 2019), and in this study 11.5% of the real-time 
PCR results were doubtful, and therefore difficult to compare to the culture-based methods 
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where culture was either positive or negative. Therefore, a third test was included in this study 
to perform a BLCM, as is recommended when no gold standard is available (Kostoulas et al., 
2017).     
The selective-indicative agar using lipase activity to identify M. bovis is not widely used, and 
therefore somewhat controversial. Though national laboratories in Belgium already use this 
method for years, this study is the first to show its diagnostic accuracy. This method resulted 
in a moderate sensitivity (70.5%) on the one hand, but on the other hand a specificity (93.8%) 
that was even higher than real-time PCR (88.9%). It has been described that not all M. bovis 
strains show lipase activity, which could explain false negatives, whereas some other 
Mycoplasma spp. do possess this characteristic, which could result in false positives (Rottem 
and Razin, 1964). Nevertheless, current results show that this medium might be helpful in M. 
bovis screenings where low cost is necessary and less experienced staff is located. It could 
also be helpful in choosing relevant colonies on agar plates for subsequent identification 
methods, such as real-time PCR. In addition, it cannot be ruled out that the use of other 
selective/indicative agar media, commercially available or not, could have resulted in 
different sensitivity or specificity  data. 
Other Mycoplasma spp. were identified as well in the BALf. Real-time PCR showed that at 
least 79.8% of the BALf samples were positive for M. bovirhinis and 92.3% for M. dispar. 
However, only 15.4% were positive for M. bovirhinis using the RIMM method with MALDI-
TOF MS after 72 hours of enrichment. Mixture of M. bovis, M. bovirhinis and M. dispar in 
BALf of cattle are common (Thomas et al., 2002). Real-time PCR might have overestimated 
the prevalence of M. bovirhinis and M. dispar, because M. bovirhinis PCR cross-reacts with 
M. canis, and M. dispar PCR cross-reacts with Acholeplasma axanthum and M. alkalescens 
(Cornelissen et al., 2017). However, cross reaction can probably not explain the large 
difference observed between the RIMM method and the real-time PCR. The enrichment 
medium used in this study seemed to preselect for M. bovis growth. M. bovirhinis and M. 
dispar are glucose fermenting while in the current medium only pyruvate was added as 
carbon source (Tully and Whitcomb, 1979). The latter is a great advantage in the diagnosis of 
M. bovis, as M. bovirhinis and M. bovis can both be identified with MALDI-TOF MS after 
two days of incubation (Spergser et al., 2019). We did however observe a shift in 
identification of M. bovirhinis where two samples were positive after 24h and negative after 
48h. As the medium was not optimal for M. bovirhinis, one reason could be that the 
concentration of (viable) M. bovirhinis balanced around the detection limit of the MALDI-
TOF MS. Another reason might be that after 24h the concentration of M. bovis became higher 
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than the concentration of M. bovirhinis, as Pereyre et al. (2013) confirmed that M. bovis was 
the only pathogen recognized by MALDI-TOF MS, when samples contained 2-3 Mycoplasma 
species. Irrelevant M. dispar growth is less of a concern in culture-based methods, as this is a 
fastidious grower and more difficult to isolate (Tully and Whitcomb, 1979). Identification of 
M. ovipneumoniae from bovine BALf was unexpected. However, a recent study showed this 
species to be abundantly present in bovine BALf as well (Klima et al., 2019). Clinical 
relevance in cattle is unknown, although M. ovipneumoniae infections can have serious 
consequences in small ruminants, such as pneumonia, decreases in lamb production and 
average daily gain (Lindström et al., 2018; Manlove et al., 2019). Even though the MALDI-
TOF MS specificity for accurate M. ovipneumoniae detection is not described, Spergser et al. 
(2019) tested 19 M. ovipneumoniae clinical isolates against their own in-house library, which 
resulted in 100% identification with a score value ≥ 1.7 (Spergser et al., 2019). 
MALDI-TOF MS already proved to be of assistance for the identification of human and 
veterinary mycoplasmas from culture (Pereyre et al., 2013; Randall et al., 2015; Spergser et 
al., 2019). In the future it might be a great opportunity to develop a rapid and specific 
diagnostic tool to identify other pathogenic Mycoplasma spp. from BALf as well (for example 
M. ovipneumoniae from small ruminants or M. pneumoniae from humans) and accelerate 
turnover time in pneumonia diagnostics.  
The current study shows that identification of M. bovis from BALf with the RIMM method is 
possible within 48-72 hours after sampling. Compared to real-time PCR, RIMM is probably 
cheaper, the clinical relevance might be higher, and when desired, it holds the opportunity to 
perform additional susceptibility testing and strain typing (Van Driessche et al., 2018; Hata et 
al., 2019). Therefore, rapid identification of M. bovis with MALDI-TOF MS is a promising 
method for diagnosis of M. bovis in veterinary laboratories. Yet, it is necessary for 
laboratories using this approach for the detection of M. bovis from clinical samples, to fully 
validate or comprehensively qualify this method. The validation parameters should include 
accuracy, precision, linearity and range of measurement, specificity, limit of detection, limit 
of quantitation, and robustness.   
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SUPPLEMENTARY DATA. Table 1. Overview of identification scores (ID) after 72 hours of 
incubation with MALDI-TOF MS after enrichment method for Mycoplasma bovis (Mb), Ct scores (Ct) 
of triplex real-time PCR for Mb, M. bovirhinis (Mbr), M. dispar (Md), selective-indicative agar of M. 
bovis (SIA) obtained from 104 BALf originating from cattle in Flanders, Belgium (2019). Also results 
of blood agar plates are shown (after 24 hours of incubation).  
No. 
 










Blood agar (24 hours) 
Identification with MALDI-TOF 
 
1 A -* - 25,30 23,47 - Mannheimia haemolytica, Moraxella branhamella ovis 
2 A 
-* - 27,19 23,15 - 
M. haemolytica, Staphylococcus cohnii, Bacillus species, 
Corynebacterium spp., Streptococcus suis 
3 A 
2,08* 21,66 24,98 23,00 + 
M. haemolytica, Aeromonas veronii, Bacillus spp., Staphylococccus 
sciuri, Bibersteinia trehalosi 
4 A -* 36,46 31,56 26,66 - M. haemolytica, S. sciuri, Staphylococcus lentus, Neisseria perflava 
5 A - - 27,74 23,16 - Histophilus somni  
6 A - - 29,45 23,57 - B. trehalosi, Streptococcus hyovaginalis 
7 A - - 25,26 23,06 - M. haemolytica, B. trehalosi, H. somni, Escherichia coli 
8 A - - 26,87 22,59 - M. haemolytica, H. somni, M. ovis 
9 A - - 26,39 21,73 - M. haemolytica, B. trehalosi, Bacillus subtilis 
10 A - - 33,90 26,58 - M. haemolytica 
11 A - - 30,20 23,96 - B. trehalosi 
12 A - - 28,08 21,48 - H. somni 
13 A - - 33,17 32,11 - H. somni 
14 A - - 30,01 24,17 - M. haemolytica, B. trehalosi, H. somni 
15 A - - 27,38 26,21 - H. somni, Staphylococcus equorum 
16 A - - 22,99 22,53 + M. haemolytica, H. somni, M. ovis  
17 A 1,74 - 26,93 24,23 + M. haemolytica, Pasteurella multocida 
18 A 2,08 37,00 30,18 25,80 - 
M. haemolytica, B. trehalosi, Streptococcus hyovaginalis, N. subflava, 
Staphylococcus xylosus 
19 A 1,81 24,26 29,56 21,40 + 
Gallibacterium anatis, Bacillus pumilus, Lactobacillus salivarius, 
Pelistega europaea 
20 A 1,75 29,09 28,55 23,28 + M. haemolytica, Staphylococcus aureus 
21 A - - 30,46 23,74 - M. haemolytica, H. somni, S. equorum 
22 B - - 36,08 40,29 - - 
23 C - - 30,39 28,06 - - 
24 C - - 27,09 23,72 - - 
25 C - - - 23,26 - S. suis,, B. subtilis 
26 D - - 33,12 24,53 - Acinetobacter towneri, Serratia liquefaciens, Aerococcus viridans 
27 D - - 26,43 20,73 - P. multocida, M. ovis 
28 D - - 29,08 29,22 - E. coli, N. subflava, S. suis 
29 D - - 26,41 27,27 - M. ovis, S. sciuri 
30 D - - 26,66 25,10 - S. xylosus, Neisseria flavescens, S. suis 
31 D - - 26,61 26,41 - P. multocida 
32 D - - - - - - 
33 D - - 29,37 26,83 - M. haemolytica, P. multocida, M. ovis, S. suis 
34 D - - 29,79 25,43 - P. multocida, M. ovis 
35 D - - 35,07 33,39 - S. sciuri 
36 D - - 27,62 20,61 - M. ovis, Staphylococcus haemolyticus 
37 D - - 29,33 26,39 - G. anatis, S. suis 
38 D - - 28,47 28,38 - M. ovis, Staphylococcus spp. 
39 D - - 22,28 21,95 - M. ovis, Staphylococcus chromogenes 
40 E 2,33 - 34,44 32,70 - E. coli 
41 E - 32,24 38,18 27,26 - Morganella morganii, Lysinibacillus fusiformis 
42 E 2,42 - 30,23 28,94 - L. fusifromis, Providencia rettgeri 
43 E - 39,55 - 29,61 - - 
44 E 2,24 27,71 29,22 28,58 + M. haemolytica, E. coli 
45 E 2,41 31,53 36,07 36,08 + Pantoea agglomerans, Staphylococcus felurettii, B. subtilis 
46 E 1,96 36,51 31,85 23,17 + H. somni 
47 E 2,41 31,80 27,15 26,06 + M. haemolytica, H. somni, S. suis 
48 E 2,36 36,13 28,31 24,71 - M. haemolytica 
49 E 2,11 32,39 27,29 21,50 + P. multocida, B. pumilus, Streptococcus dysgalactiae 
50 E 2,46 38,98 38,46 31,94 - -  















Blood agar (24 hours) 
Identification with MALDI-TOF 
 
51 F - - - 23,54 - M. haemolytica, S. suis 
52 F - - - 37,32 - - 
53 F - - 29,89 30,13 - 
Mannheimia varigena, bacillus licheniformis, B. pumilus, 
Streptococcus pluranimalium 
54 F - - 31,47 30,11 - B.licheniformis, B. pumilus, S. pluranimalium, E. coli 
55 F - - 35,47 28,30 - B. trehalosi, B. pumilus 
56 F - - 34,53 38,17 - B. licheniformis, B. pumilus, S. pluranimalium, S. chromogenes 
57 G - - 36,06 - - - 
58 H - - 25,58 23,06 - Moraxella bovoculi 
59 H - - 26,31 21,07 - P. multocida, M. bovoculi 
60 H - - 28,55 27,10 - M. bovoculi, Streptococcus spp. Trueperella pyogenes 
61 H - - 26,71 24,68 - P. multocida, M. bovoculi S. suis 
62 H - - 27,21 21,85 - P. multocida, M. ovis, Streptococcus  
63 H - - 37,00 27,10 - S. equorum  
64 H - - 31,03 23,80 - Moraxella spp., Streptococcus spp. 
65 H - - 31,53 23,31 - M. ovis, Neisseria meningitidis 
66 H - - - 28,72 - - 
67 H - - - 27,32 - Acinetobacter wolfii 
68 I 2,65 27,93 29,52 28,82 + - 
69 I - 32,42 25,72 24,63 + M. haemolytica, B. licheniformis 
70 I 2,26 33,65 29,13 22,80 + M. haemolytica 
71 I - 28,14 27,04 23,10 + M. haemolytica, Neisseria spp. 
72 I 2,16 31,65 28,00 22,75 + M. haemolytica 
73 I 2,08 40,87 36,66 24,30 - - 
74 I 2,35 34,14 28,79 22,47 - M. haemolytica 
75 I - 31,28 25,69 21,06 + M. haemolytica, P. multocida,Streptococcus spp. 
76 I 1,93 30,51 27,18 20,81 + M. haemolytica, Stenotrophomonas spp., Bacillus spp.  
77 I 2,06 40,13 29,82 24,29 - M. haemolytica  
78 I 2,44 34,91 32,04 25,57 - P. multocida 
79 I 2,28 29,90 28,96 25,38 + M. haemolytica 
80 I 1,93 - 27,91 23,65 - P. multocida 
81 I 2,04 31,83 27,29 23,41 + M. haemolytica, P. multocida 
82 I 2,29 30,81 29,32 26,20 + P. multocida 
83 I 2,48 23,29 28,19 25,99 + P. multocida 
84 I - - 39,01 28,54 - P. multocida 
85 J 1,92 38,87 25,54 22,48 - M. haemolytica, S. suis 
86 J - - 32,45 23,39 - M. haemolytica 
87 J - - 38,95 35,40 - - 
88 J - 35,92 - 32,20 - M. varigena 
89 J 2,01 34,15 26,03 25,00 + 
M. haemolytica, Staphylococcus cohnii, E. coli, S. suis, Streptococcus 
ferus 
90 J - 37,67 - 41,68 - - 
91 J 1,84 38,30 28,92 23,03 - P. multocida, Staphylococcus saprophyticus  
92 J 2,05 40,24 27,68 26,31 - B. trehalosi 
93 J 2,2 34,39 29,04 23,81 - M. haemolytica, T. pyogenes 
94 J 1,96 28,00 24,61 26,42 + M. haemolytica, Serratia rubidaea, Citrobacter amalonaticus 
95 J 2,24 31,56 24,71 27,02 + S. chromogenes 
96 J 1,89 31,52 27,73 22,01 + - 
97 J - - 28,73 23,09 - - 
98 J - 34,76 33,59 31,76 - M. haemolytica, P. multocida 
99 J - 41,34 26,02 23,16 + M. haemolytica 
100 J - - 28,55 21,59 + - 
101 J 2,51 - 35,07 31,20 - M. haemolytica, E. coli 
102 J 1,92 35,03 27,88 27,25 - Staphylococcus haemolyticus  
103 J - 39,30 34,68 30,39 - P. multocida 
104 J 1,84 31,61 24,81 22,02 + M. haemolytica, Moraxella branhamella ovis 
* = result based on ID after 48h of incubation; Ct values were interpreted as positive (< 35), doubtful (35-40) or 
negative (>40)(Wisselink et al., 2019). 
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Rapid identification of Mycoplasma bovis infections in cattle is a key factor to guide 
antimicrobial therapy and biosecurity measures. Recently, nanopore sequencing became an 
affordable diagnostic tool for both clinically relevant viruses and bacteria, including 
Mycoplasma, but the diagnostic accuracy for M. bovis identification is currently 
undocumented. Therefore, in this study nanopore sequencing was compared to rapid 
identification of M. bovis with MALDI-TOF MS (RIMM), and triplex real-time PCR in a 
Bayesian latent class model (BLCM) for M. bovis infection. Bronchoalveolar lavage fluid 
(BALf) was obtained from individual calves and analyzed with the three above mentioned 
methods. In practice, pooling of samples is often recommended. Therefore, a convenience 
sample of 17 pooled samples containing 5 individual BALf samples per farm was analyzed as 
well. The results of the pooled samples were compared to the individual samples, to 
determine sensitivity (Se) and specificity (Sp). The BLCM showed a good Se (77.4%; 95% 
Credible Interval: 58.6%-92.3%) and high Sp (97.3%; 91.1%-99.7%) for nanopore 
sequencing compared to RIMM (Se: 93.3%; 77.6%-99.5%, Sp: 92.7; 84.0%-98.0%) and real-
time PCR (Se: 93.9%; 88.8%-97.3%, Sp: 86.0%; 76.0-93.6%). Se and Sp of pooled analysis 
for M. bovis were 68.8% (95% confidence interval: 52.7-84.8%) and 97.1% (93.0%-101.1%) 
for nanopore sequencing and 81.3% (67.7%-94.8%) and 85.3% (76.9%-93.7%) for RIMM, 
respectively. In conclusion, nanopore sequencing is a rapid and reliable tool for the 
identification of M. bovis. To reduce costs and increase chance of pathogen identification, 
pooling of 5 samples for nanopore sequencing and RIMM is possible.  
 
Key words: Bayesian latent class model, bronchoalveolar lavage, MALDI-TOF MS, 
Mycoplasma species, selective indicative agar 




Many bovine Mycoplasma species can be isolated from cattle, but only few of them are 
considered pathogenic, in particular Mycoplasma bovis (Maunsell and Donovan, 2009; 
Caswell et al., 2010; Oliveira et al., 2020). Worldwide, M. bovis is associated with a long list 
of diseases, predominantly pneumonia and otitis in calves and mastitis and arthritis in adult 
cattle (Maunsell and Donovan, 2009; Maunsell et al., 2011). Early recognition of an M. bovis 
infection is crucial for different reasons. First, M. bovis is highly contagious and any delay in 
therapy increases the number of infected animals in a herd. Second, M. bovis is inherently 
resistant against many antimicrobials recommended in antimicrobial guidelines as empiric 
first intention treatment in several European countries, like beta-lactam antibiotics and 
sulphonamides (Lysnyansky and Ayling, 2016; Gautier-Bouchardon, 2018). Third, M. bovis 
has several virulence factors facilitating chronic infections, making antimicrobial therapy less 
successful when initiated later in the course of disease (Razin and Hayflick, 2010; Perez-
Casal, 2020). Fourth, given its highly contagious nature, antimicrobial group treatment with 
an appropriate antimicrobial is a preferred control mechanism for M. bovis infections in both 
feedlot and veal calf industry. Therefore, rapid identification is important in the framework of 
antimicrobial use, antimicrobial resistance, and animal welfare. However, currently available 
routine diagnostic tests either take over a week before results are available (e.g. culture 
techniques) or are expensive and have interpretative issues regarding infectious load and 
clinical relevance (e.g. PCR) (Parker et al., 2018). Recently, a new culture-based method to 
identify M. bovis with MALDI-TOF MS from bronchoalveolar lavage fluid (BALf) was 
developed, with a significant lower sampling-to-diagnostic-result turnaround time (TAT) of 
2-3 days (Bokma et al., 2020a). An alternative method for rapid identification may be whole 
genome sequencing, with the advantage that also strain typing and antimicrobial resistance 
determination may be possible (Bokma et al., 2020b; Kinnear et al., 2020; Ledger et al., 2020; 
Yair et al., 2020). Thus far next- and third generation sequencing technologies were highly 
time consuming, expensive, and therefore mainly applied in research settings or specific areas 
in human medicine (e.g. cancer identification). Newer real-time sequencing approaches (e.g. 
Oxford Nanopore Technologies) revolutionized the sequencing field, becoming affordable, 
and having sequencing data readily available. This makes it a new tool that is now available 
in veterinary medicine for quick metagenomics routine diagnostics (Theuns et al., 2018). One 
of the advantages of nanopore sequencing over culture-based methods, is the possibility of 
simultaneously identifying different Mycoplasma species, viruses and bacteria (McCabe et al., 
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2018; Theuns et al., 2018). However, there is no information available concerning the 
diagnostic accuracy of nanopore sequencing used for the identification of Mycoplasma 
species directly from BALf. Despite the fact that knowledge on viral involvement when 
facing a respiratory disease outbreak is very informative (e.g. for vaccination), knowing 
whether M. bovis is involved is most crucial for antimicrobial decision making, including the 
decision for group therapy. For this purpose, an accurate, but also affordable test is preferred. 
In the field, to reduce costs and enhance the probability for pathogen detection, pools of 
samples from 5 animals are often made (Pardon and Buczinski, 2020). Nevertheless, whether 
pooling influences the sensitivity (Se) and specificity (Sp) of our previously described 
MALDI-TOF MS protocol (Rapid Identification of M. bovis by MALDI-TOF MS, RIMM; 
Bokma et al., 2020a) or nanopore sequencing protocols was not explored yet.  
Therefore, the first aim of this study was to determine the Se and Sp of M. bovis identification 
with nanopore sequencing compared to real-time PCR and RIMM on individual samples in a 
Bayesian Latent Class Model (BLCM). The second aim was to determine diagnostic accuracy 
of pooled samples compared to individual samples for RIMM and nanopore sequencing.  
 
MATERIALS AND METHODS 
Diagnostic test study 
Study population and sampling method  
A prospective diagnostic test accuracy assay was performed. In our previous diagnostic test 
accuracy experiment, executed under the same circumstance, it was shown that 100 BALf 
were sufficient for the determination of Se and Sp of diagnostic methods for the identification 
of M. bovis (Bokma et al., 2020a). Therefore, a convenience sample of 100 BALf was 
collected for diagnostic purposes as described before (Van Driessche et al., 2017) and as 
approved by the local ethical committee (EC2020-068). Samples were taken between 
November 2020 and December 2020 from 3-week to 8-month-old calves originating from 14 
different farms located in Belgium, and one in the Netherlands. BALf was stored at 4°C for 
maximum 20 hours until separating the samples for the different diagnostic methods, 
reflecting the routine diagnostic workflow. Whenever possible, a pool of samples from 1 farm 
was made from 5 BALf samples by taking 800 µL from each sample resulting in 4 mL 
aliquots. Both index-tests (nanopore sequencing and RIMM) were performed immediately 
after splitting the sample up, while samples for the M. bovis reference test (real-time PCR) 
were first stored at -20°C, prior to blind testing.  
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Nanopore sequencing for Mycoplasma species 
Four mL of BALf and BALf pool (even ratio) was purified by aspirating the fluid through a 
newly developed swab in connection to a 0.8 µm surfactant-free cellulose acetate filter and a 
syringe. This sampler facilitates on-site purification of diagnostic samples and purifies viruses 
and bacteria for rapid sequencing. For nanopore sequencing, an innovative platform at 
PathoSense was used, which relies on an in-house developed sampling-to-diagnostics-
interpretation workflow (Theuns et al., 2018). In short, samples were spiked with an internal 
control (semi-quantification purpose) prior to pathogen pre-enrichment using a nuclease 
treatment in order to remove free nucleic acids and only diagnose clinically relevant species 
and not free non-infectious pathogen nucleic acids. Subsequently nucleic acids were extracted 
and used for sequencing library preparation, multiplexing 12 samples at a time. Next, the 
samples were subjected to third-generation sequencing using an R.9.4.1 Flow Cell and 
MinION sequencer. Final sequencing data was processed using an in-house bioinformatics 
pipeline to profile the metagenomic context of the samples,  highlighting both viral and 
bacterial (incl. Mycoplasma species) agents. Samples were interpreted as positive, when ≥ 5 
reads for Mycoplasma species were detected. 
 
Rapid identification of M. bovis with MALDI-TOF MS (RIMM)  
Four mL of BALf was vigorously vortexed and processed as described before (Bokma et al., 
2020a). Briefly, BALf was added to modified PPLO broth including vancomyin (32 µg/ml) 
and meropenem (32 µg/ml). After 48 and 72 hours of incubation (37°C, 5% CO2), protein 
extraction was performed on 1 mL of the enriched BALf culture. The protein extraction was 
slightly adjusted in comparison to our previous study, as we now omitted the ethanol step for 
quicker identification and clearer peak spectra (Spergser et al., 2019). Eventually, lysates 
were spotted, covered with matrix, and analyzed with Autoflex III smartbeam MALDI-TOF 
MS, using FlexControl and MBT Compass software (Bruker Daltonics, Bremen, Germany). 
The standard library (server version 4.1.100 PYTH) was extended with four M. bovis strains, 
M. bovirhinis (NCTC 10118), M. ovipneumoniae (NCTC 10151) and M. dispar (NCTC 
10125) (Bokma et al., 2020a). Identification of Mycoplasma spp. was considered reliable at 
species level when logarithmic score values were ≥1.7 as proposed in previous studies 
(Pereyre et al., 2013; Randall et al., 2015), whereas non-mycoplasmal bacteria were 
considered reliable at species level when score values were ≥ 2.0 and at genus level between ≥ 
1.7 and < 2.0 (Ferreira et al., 2011). 
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Triplex real-time PCR for M. bovis, M. bovirhinis, and M. dispar 
A previously described triplex real-time PCR targeting the 16S rRNA gene was chosen as 
reference test as this method showed comparable results with other PCR methods used for 
routine diagnostics to identify M. bovis from BALf (Cornelissen et al., 2017; Wisselink et al., 
2019). Compared to DGGE a Se/Sp of 95.2% (95%CI: 76.2-99.9)/73.9% (51.5-0.90), 87.5% 
(47.4-100.0)/38.9% (23.1-56.5), and 100% (100.0-100.0)/19.4% (8.19-36.0) for M. bovis, M. 
bovirhinis, and M. dispar were obtained, respectively. The limit of detection (LOD) was 
determined at 30 CFU/ml for M. bovis and M. bovirhinis, and 300 CFU/ml for M. dispar as 
described previously (Cornelissen et al., 2017). The workflow was described in our previous 
diagnostic accuracy study (Bokma et al., 2020a), but briefly, BALf samples were thawed and 
200 µL sample was used for DNA extraction with the MagNA Pure 96 Instrument (Roche) 
using the MagNA Pure 96 DNA and Viral NA Small Volume Kit (Roche) for DNA 
extraction. Five µL extracted DNA was used for the triplex real-time PCR detecting M. bovis, 
M. dispar and M. bovirhinis (Cornelissen et al., 2017). Fresh M. bovis, M. dispar and M. 
bovirhinis cultures from in-house reference strains were used as internal control to monitor 
DNA extraction, as well as inhibition of the PCR reactions. Samples were processed in two 
separate runs. Cq values were interpreted as positive (< 35) or negative (≥ 35).  
 
Bacterial culture for M. bovis, non-mycoplasmal bacteria, and fungal growth  
For M. bovis isolation, 100 µL of BALf was inoculated on a selective-indicative agar, an in-
house modified PPLO-agar (Bokma et al., 2020a). After 1-7 days of incubation (37°C, 5% 
CO2), presumptive Mycoplasma colonies were identified as M. bovis based on the presence of 
lipase activity, observed as an “oil-like” film surrounding the colonies. For non-mycoplasmal 
bacteria 50 µl of BALf was cultured on Columbia agar, supplemented with 5% sheep blood 
(blood agar; Oxoid, UK), and incubated for 1-2 days (37°C, 5% CO2). After 48-72 hours of 
incubation of the RIMM method, 50 µl was deposed on Columbia agar or Sabouraud dextrose 
agar with penicillin and streptomycin, and evaluated after 24-72 hours of incubation to 
determine fungal growth (37°C, 5% CO2), as this was suggested as a potential inhibitor of M. 
bovis identification before (Bokma et al., 2020a). Identification of all pathogens was 










First, the diagnostic accuracy (Se and Sp) of M. bovis identification with both nanopore 
sequencing and the RIMM method (index tests) were determined with real-time PCR as 
reference test (WinEpi, Zaragoza, Spain) for individual samples. This was also done for M. 
bovirhinis and M. dispar identification with nanopore sequencing. Subsequently, also 
nanopore sequencing and real-time PCR were compared to RIMM as reference test for the 
identification of M. bovis, as no ‘gold standard’ is available for M. bovis. BALf was 
considered positive for M. bovis when ≥5 reads were observed (nanopore sequencing), the ID-
score of MALDI-TOF MS was ≥1.7 after 48 and/or 72 hours of incubation (RIMM) or the Cq 
score < 35 (real-time PCR). The diagnostic accuracy was also determined for the 
identification of M. bovis from individual and pooled samples with nanopore sequencing and 
RIMM (WinEpi, Zaragoza, Spain). In this case individual samples were the reference test 
(positive when at least one sample contained M. bovis), while the pooled samples (5 
individuals) were the index test.  
  
Bayesian latent class modelling 
Definition of outcome tested 
The Se and Sp of the triplex real-time PCR and RIMM method are not 100% (Cornelissen et 
al., 2017; Bokma et al., 2020a). Therefore, none of them can be used as ‘gold standard’ for 
the determination of the diagnostic test accuracy of nanopore sequencing. To circumvent this 
problem, a Bayesian latent class model was built. The BLCM is based on a common latent 
class between the diagnostic tests, and does not provide prior ‘superiority’ of one method over 
another. Nevertheless, it is possible to give the prior information whether two methods are 
more comparable to each other than the third method by including covariates (conditional 
dependent model). In this study, nanopore sequencing detects DNA from intact M. bovis, 
RIMM detects proteins from viable M. bovis, and real-time PCR detects DNA, both from 
living and dead M. bovis. Based on the detection component, one can argue whether a 
conditional dependent (nanopore sequencing and real-time PCR) or independent model is 
more appropriate. Both models were worked out, and compared to each other by visual 
comparison of Se and Sp. In addition, the deviance information criterion (DIC) was inspected 
as parameter for model fit.    
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Model development and prior distribution determination 
The model was developed similarly to the model as described before (Bokma et al., 2020a; 
Rijckaert et al., 2020), using a code derived from S. Buczinski (University of Montreal, 
Canada). In short, a latent class model was considered to assess the accuracy of the three tests 
(Se and Sp) for M. bovis identification, being: (1) nanopore sequencing (detection of DNA 
from intact organisms), (2) RIMM (detection of proteins), and (3) real-time PCR (detection of 
DNA, both living and dead), and prevalence of M. bovis in the study population. Prior 
information was derived from available literature and expert opinion as described before 
(Bokma et al., 2020a). We decided to use the same prior information (Se 95%, Sp 74% of 
real-time PCR and 30% prevalence) as these were in line with our findings in the previous 
analysis (Cornelissen et al., 2017; Gille et al., 2018; Pardon et al., 2020). Nevertheless, we 
increased the 5th percentile from 50% to 80% for prevalence of M. bovis, as this prevalence 
was confirmed in our previous study on a similar study population (Bokma et al., 2020a). 
Priors for the RIMM method obtained by our previous study were not included, as the 
protocol was changed. The priors were modelled using beta distribution parameters of the 
corresponding prior distributions (Epitools, Sergeant, ESG, Ausvet Animal Health Services 
and Australian Biosecurity calculator, available at 
https://epitools.ausvet.com.au/betaparamsone, Ausvet), resulting in Beta (99.7, 6.19), Beta 
(1,1) and Beta (1.54, 2.26) for Se, Sp and prevalence, respectively.   
 
Model analysis  
In total three models were run for the conditional dependent and independent test in 
WinBUGS statistical freeware (version 1.4.3., MRC Biostastics unit, Cambridge, UK) using 
Gibbs sampling. In the first model prior information on all parameters was set at 
uninformative (Beta 1,1). The second model included informative priors on prevalence of M. 
bovis, and the third model included informative priors on prevalence of M. bovis, Se and Sp 
of real-time PCR. For each model, three chains with varying initial values were run for 
100,000 iterations, after a burn in of 5,000 iterations. Model convergence was checked by 
visual inspection of density and Gelman-Rubin plots. Plots of chain autocorrelation were 
inspected to investigate the need of thinning of chains. The posterior median and 95% 
credibility intervals (CI) were extracted for each parameter. An additional sensitivity analysis 
was performed, running alternative models with highly different prior specifications to the 
main model. It was inspected whether posterior estimates of these alternatives models were 
included in the 95% credible interval of the main model (Branscum et al., 2005). 
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Quantification of M. bovis infection by qPCR and nanopore sequencing  
To be able to quantify the concentration of M. bovis in the BALf with qPCR and potentially 
with nanopore sequencing, a ten-fold dilution series of M. bovis was made in distilled water. 
Concentration of the different dilutions was checked before freezing by counting colonies on 
solid PPLO medium as described earlier (Bokma et al., 2019). Subsequently, the aliquots 
were frozen at -20°C until triplex real-time PCR was performed as described above. Then, 
obtained Cq values were compared with the ten-fold dilution series for correlation, and with 
the logarithmic scale of the number of reads obtained by nanopore sequencing. Correlations 
were inspected visually and gave a general impression whether (semi)quantification of M. 
bovis with nanopore sequencing would be possible or not. In order to confirm the quantitative 
aspect of qPCR and nanopore sequencing, raw nanopore reads were first normalized to the 
internal control of the test, after which the logarithm was plotted against raw Cq values. 
 
RESULTS  
With nanopore sequencing 24% (24/100) of the BALf samples were positive for M. bovis (≥ 5 
reads), and 76% (76/100) were negative (none or < 5 reads) (Supplementary file 1). Next to 
M. bovis, other Mycoplasma species were identified with nanopore sequencing, such as M. 
bovirhinis (49% of the samples), M. dispar (91%), Ureaplasma species (11%), M. arginini 
(7%), M. penetrans (4%), and M. wenyonii (4%). Triplex real-time PCR resulted in 36% 
(36/100) positive BALf samples (Cq < 35), and 64% (64/100) were negative (Cq > 35 or no 
detection) for M. bovis. For M. bovirhinis 67% (67/100) were positive, and 33% (33/100) 
negative, for M. dispar this was 88% (88/100) and 12% (12/100), respectively 
(Supplementary file 1). After 48-72h of enrichment with the RIMM method, 32% (32/100) of 
the BALf samples were positive for M. bovis. ID-scores for M. bovis ranged between 1.79 and 
2.38 (Supplementary file 1). M. bovirhinis was identified in 5% (5/100) of the samples with 
ID-scores ranging from 1.70 to 1.85. M. dispar was not detected with the RIMM method in 
any sample throughout the entire experiment. 
Out of 100 samples, 29 (29%) showed lipase positive Mycoplasma-like colonies on the 
selective-indicative agar. In addition, 15% (15/100) of the BALf samples did not show 
additional bacterial growth on blood agar plates, whereas 85% (85/100) did, but none of the 
identified bacteria on blood agar were detected with the RIMM method. This supports the 
expectation that all bacteria were killed or suppressed by the supplementation of the different 
antimicrobials. Residual contamination of fungal growth was checked after 72 hours of 
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enrichment. Out of the sabouraud or blood agar plates checked for fungal growth, 19% 
(19/100) showed fungal growth, which was not further identified. In two BALf (AB8, AB13) 
Aspergillus species were identified with the RIMM method after 72u of incubation. No M. 
bovis was detected in these samples by nanopore sequencing, real-time PCR or the selective-
indicative agar.     
 
Diagnostic test study of M. bovis  
The 2x2 contingency tables of nanopore sequencing and RIMM compared with real-time PCR 
as reference test are shown in Table 1. The Se and Sp for the identification of M. bovis with 
nanopore sequencing compared to real-time PCR were 58.3% (Confidence Interval 95%: 
42.2-74.4%) and 95.3% (CI95: 90.1%-100.5%), respectively. The RIMM showed a 72.2% 
(CI95: 57.6%-86.9%) Se and 90.6% (CI95: 83.5%-97.8%) Sp, compared to the real-time PCR 
test. When comparing the identification of M. bovis with nanopore sequencing and real-time 
PCR to the RIMM (Table 2), the Se and Sp for nanopore sequencing were 68.8% (CI95: 52.7-
84.8%) and 97.1% (CI95: 93.0%-101.1%), respectively. Real-time PCR showed a 81.3% 
(CI95: 67.7%-94.8%) Se and 85.3% (CI95: 76.9%-93.7%) Sp, compared to the RIMM. 
 
Table 1. 2x2 Contingency table for nanopore sequencing and RIMM as index test compared to real-
time PCR as reference test for identification of Mycoplasma bovis from BALf samples (n=100). 
Test  Reference test (real-time PCR) 
  Positive Negative Total 
 
Nanopore sequencing 
Positive 58% (21/36) 5% (3/64) 24 
Negative 42% (15/36) 95% (61/64) 76 
Total 36 64 100 
     
 
RIMM 
Positive 72% (26/36) 9% (6/64) 32 
Negative 28% (10/36) 91% (58/64) 68 
Total 36 64 100 
 
The Se of nanopore sequencing for M. bovirhinis identification compared to real-time PCR 
was 73.1% (95CI: 62.5-83.7) and Sp 93.9% (85.8-102.1). For M. dispar this was 100% 
(100.0-100.0) and 66.7% (40-93.3), respectively. The 2x2 contingency tables are shown in 
Table 3.   
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Table 2. 2x2 Contingency table for nanopore sequencing and real-time PCR as index test compared to 
RIMM as reference test for identification of Mycoplasma bovis from BALf samples (n=100).  
Test  Reference test (RIMM) 
  Positive Negative Total 
 
Nanopore sequencing 
Positive 69% (22/32) 3% (2/68) 24 
Negative 31% (10/32) 97% (66/68) 76 
Total 32 68 100 
     
 
Real-time PCR 
Positive 81% (26/32) 15% (10/68) 36 
Negative 19% (6/32) 85% (58/68) 64 
Total 32 68 100 
 
Table 3. 2x2 Contingency table for nanopore sequencing as index test compared to real-time PCR as 
reference test for identification of Mycoplasma bovirhinis and Mycoplasma dispar from BALf samples 
(n=100).  
Test  Reference test (Real-time PCR) 




Positive 73% (49/67) 6% (2/33) 51 
Negative 27% (18/67) 94% (31/33) 49 
Total 67 33 100 
     
Nanopore sequencing 
M. dispar 
Positive 100% (88/88) 33% (4/12) 92 
Negative 0% (0/88) 67% (8/12) 8 
Total 88 12 100 
 
Bayesian latent class modelling 
All models converged and the prior and posterior densities of model 1 to 3 are shown in Table 
3. Parameters were very stable between models, although adding Se of triplex real-time PCR 
to model 3, had some influence on the posterior distributions. However, adding informative 
priors is a way to narrow parameter uncertainty when previous scientific information is 
available, therefore model 3 is expected to be the most accurate one. The results obtained 
from the sensitivity analysis were highly robust to changes in the prior distribution, only with 
extreme unrealistic low Se values (20%) or high prevalence (90%) the prior distributions were 
subject to small deviations from the 95% credible interval of model 3.  
The differences between the outcomes of the conditional independent and dependent model 
were insignificant for most parameters, but in the dependent model, the Se of nanopore 
sequencing and real-time PCR decreased notably (Table 4). The DIC values of both the 
models differed minimally (< 2), with the lowest DIC for the conditional independent model. 
Based on these findings, we decided that the covariate term of the dependent model did not 





Table 4. Posterior median and 95% credible interval (CI) of three conditional independent and one dependent Bayesian latent class models for the prevalence 
of M. bovis (Prev), sensitivity (Se) and specificity (Sp) of the identification with nanopore sequencing (np), rapid identification of M. bovis with MALDI-TOF 
MS method (rimm), and triplex real-time PCR (pcr) used to diagnose M. bovis from bronchoalveolar lavage fluid samples.  
 Model 1 (independent) Model 2 (independent) Model 3   (independent) (dependent) 














Sepcr Beta (1,1) 88.5 (72.1-97.8) Beta (1,1) 88.5 (72.1-97.8) Beta (99.7, 6.19) 93.9 (88.8-97.3) 86.9 (69.7-97.4) 
Sppcr Beta (1,1) 86.0 (76.0-93.6) Beta (1,1) 86.0 (76.0-93.5) Beta (1,1) 86.0 (76.0-93.6) 84.8 (74.9-92.2) 
Serimm Beta (1,1) 93.0 (77.0-99.5) Beta (1,1) 93.0 (77.2-99.5) Beta (1,1) 93.3 (77.6-99.5) 94.8 (89.8-97.8) 
Sprimm Beta (1,1) 93.5 (84.6-99.0) Beta (1,1) 93.5 (84.6-99.0) Beta (1,1) 92.7 (84.0-98.0) 94.4 (85.1-99.6) 
Senp Beta (1,1) 76.2 (56.8-91.8) Beta (1,1) 76.2 (57.0-91.8) Beta (1,1) 77.4 (58.6-92.3) 74.1 (55.7-90.6) 
Spnp Beta (1,1) 97.5 (91.3-99.8) Beta (1,1) 97.5 (91.4-99.8) Beta (1,1) 97.3 (91.1-99.7) 97.2 (91.0-99.8) 
Prev Beta (1,1) 29.8 (20.5-40.5) Beta (1.54, 2.26) 29.8 (20.6-40.3) Beta (1.54, 2.26) 29.1 (20.1-39.3) 30.0 (20.7-40.4) 
Model 1: No informative priors 
Model 2: Informative prior on prevalence of M. bovis in BALf (mode 30%, 5th percentile = 80%) (Bokma et al., 2020a; Pardon et al., 2020) 
Model 3: Informative priors on and Sepcr (mode 95%; 5th percentile = 90%), Sppcr (mode 74%; 5th percentile = 95%), and prevalence (Cornelissen et al., 2017) 
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improve the fit of the model, and we continued the analysis with the conditional independent 
model. Therefore, prevalence of M. bovis was 29.1% (95% Credible Interval: 20.1%-39.3%), 
nanopore sequencing had a Se and Sp of 77.4% (CI: 58.6%-92.3%) and 97.3% (CI: 91.1%-
99.7%), respectively. RIMM showed a Se and Sp of 93.3% (CI: 77.6%-99.5%) and 92.7 (CI: 
84.0%-98.0%). The Se and Sp of real-time PCR were 93.9% (CI: 88.8%-97.3%) and 86.0% 
(CI: 76.0-93.6%), respectively.  
 
Pooling of BALf for nanopore sequencing and RIMM 
In total, 17 pools were analyzed for both nanopore sequencing and RIMM as described above. 
In Supplementary file 2, an overview is shown of the M. bovis identified in the individual and 
pooled samples by both nanopore sequencing and the RIMM method. In Table 5, the 
contingency table of both individual and pooled samples with nanopore sequencing and 
RIMM are shown. Se and Sp for the identification of M. bovis in pooled samples with 
nanopore sequencing are 85.7% (CI95: 59.8-111.6%) and 90.0% (CI95: 71.4-108.6%), 
respectively. While for the RIMM method a 100% (CI95: 100-100%) Se and 88.9% (CI95: 
68.4-109.4%) Sp were obtained. 
 
Table 5. 2x2 Contingency table for nanopore sequencing and RIMM comparing pooled samples with 
individual samples for identification of Mycoplasma bovis from BALf samples (n=17). 
Test  Individual sample 




Positive 86% (6/7) 10% (1/10) 7 
Negative 14% (1/7) 90% (9/10) 10 
Total 7 10 17 




Positive 100% (8/8) 11% (1/9) 9 
Negative 0% (0/8) 89% (8/9) 8 
Total 8 9 17 
     
Pooled samples were categorized as positive, when at least one out of the five individual sample was 
positive  
 
Quantification of M. bovis infection by qPCR and nanopore sequencing  
The tenfold dilution series showed a concentration range of approximately 8.0 x 107 to 8.0 x 
101 CFU/mL. Between tenfold concentrations, the Cq scores differed with a mean of 3.80 
(standard deviation: 0.78; range: 2.67-5.42). The calibration line is shown in Figure 1 
(determination coefficient R2 = 0.995). In Figure 2, the number of M. bovis reads obtained by 
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nanopore sequencing are outlined on a logarithmic scale in respect to the Cq-values obtained 
by real-time PCR for M. bovis, showing a good agreement (R2 = 0.87) between both values.  
 
 
Figure 1. Calibration line of Cq values and logarithmic concentration of M. bovis in 
CFU/mL (R2 = 0.995), showing the correlation between Cq value and M. bovis 




Figure 2. The logaritmic number of nanopore sequencing M. bovis reads and the 
Cq-values obtained by real-time PCR for M. bovis on 100 BALf from calves (R2 = 








In this study, it was shown that nanopore sequencing can readily (24-36 hours turnaround 
time) identify M. bovis from BALf with reasonable Se (77.4%; CI 58.6-92.3) and high Sp 
(97.3%; CI 91.1-99.7) compared to identification with RIMM and real-time PCR. The 
disagreement between methods on individual samples can be addressed into different 
categories, being differences caused by (1) the protocol, (2) the component of interest and 
limit of detection, and (3) the interpretation of results.  
Differences in start volumes and differences in sample preparation can explain the first 
category of disagreement. BALf can contain mucus clumps and cells, which could have led to 
a heterogenic suspension of M. bovis. However, as volumes between protocols were not equal 
(4 mL for nanopore sequencing/RIMM, 200 µL for real-time PCR), this could have been 
advantageous for methods using larger volumes. More detail on this subject is available 
elsewhere (Bokma et al., 2020a). Here, the preparation protocol of nanopore sequencing  
included an additional filter step to discard sample impurities. Potential biofilm and 
microcolony formation or clumping with other bacteria and mucus could have resulted in 
(partial) loss of M. bovis (McAuliffe et al., 2006; Hoelzle et al., 2020) during the filter step for 
nanopore sequencing or during splitting of the samples for real-time PCR.   
The second category of disagreement (component of interest and limit of detection) also has 
its repercussions on the third category (interpretation). All three methods in the BLCM focus 
on the detection of different biological components of M. bovis. Current real-time PCR will 
detect DNA from culturable, viable but not culturable (those who can multiply) and dead M. 
bovis. Nanopore sequencing targets nucleic acids of clinically relevant intact (viable, both 
culturable and non-culturable) M. bovis and other pathogens due to the nuclease treatment, 
while RIMM can only detect culturable M. bovis as an enrichment procedure is necessary to 
exceed the detection limit of the MALDI-TOF MS. Therefore, real-time PCR is more 
sensitive to detect causative agents than culture-based methods when diseased animals 
already received antimicrobial therapy (Maurin, 2012). In farm ‘AB’, where disagreement 
between methods was observed, a previous M. bovis outbreak had been extensively treated 
with antimicrobials 4 to 6 weeks before sampling. Possibly only residual M. bovis DNA was 
left, which may explain the relatively high Cq values (>30) with real-time PCR and no 
identification of M. bovis with nanopore sequencing or RIMM (Supplementary file 1). In 
addition, this raises the question of clinical relevance of detecting elevated Cq values (>30). 
Another possibility of not detecting M. bovis with RIMM, could be the interference of fungal 
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growth at this farm (possibly induced by the intensive antimicrobial use), as 53% (8/15) of the 
samples showed fungal growth after incubation (in contrast to an overall percentage of only 
19%), and interference has been described (Buskirk et al., 2011). In farm ‘AI’ the same 
incongruence was observed. In this farm M. bovis was previously diagnosed, calves were 
frequently treated with antimicrobials, and pregnant cows received an autogenous vaccine 
containing M. bovis intramuscularly twice (halfway gestation, and three weeks before partus). 
It has been described that autogenous vaccine can reduce colonization and spread of M. bovis 
(Nicholas et al., 2002; Dudek et al., 2016), but the role of passive immunity of the calves, 
coming from the mother is not clear (Maunsell et al., 2011). Therefore, in this farm it may be 
that no clinical infection was present anymore, or that very low numbers of M. bovis were 
present, not exceeding the LOD of nanopore sequencing and RIMM. The LOD of the real-
time PCR (30 CFU/ml; Cornelissen et al., 2017) could have been lower than nanopore 
sequencing. Unfortunately, we did not define the LOD of nanopore sequencing, as we were 
not able to include the M. bovis ten-fold dilution series in the nanopore sequencing protocol at 
the time of preparing the dilutions. Freezing and thawing, as was done with real-time PCR, is 
not possible, as we observed that this can result in unreliable results for M. bovis 
identification with nanopore sequencing (unpublished results). We did however show, that 
(semi)quantification with nanopore sequencing is possible. To get better insights in the extent 
of this quantification, differentiation between culturable, viable, but not culturable, and dead 
M. bovis should be made in future studies.  
The third category of disagreement related to the interpretation of different outcome values 
and relevance for clinical interpretation, is especially based on cut off values for positive M. 
bovis identification with nanopore sequencing (≥ 5 reads) and real-time PCR (Cq < 35). In 
BALf with Cq-values > 30 for M. bovis, no or very low reads were obtained by nanopore 
sequencing. This is not surprising, as the aim of the technology is only diagnosing viable  
pathogens (Theuns et al., 2018). Due to the use of a nuclease treatment in the nanopore 
protocol, non-infectious pathogen nucleic acids are discarded, whereas this is being detected 
in the real-time PCR flow. The latter should be taken carefully into account when interpreting 
real-time PCR results. This was also seen for the RIMM method, where in 6 out of 8 negative 
BALf, real-time PCR results showed a Cq-value of 32 to 35, while only 3 of the negative 
RIMM BALf for M. bovis had a Cq value < 32. This could be related to a lower Se of the 
latter methods or the presence or absence of a clinical infection versus residue of M. bovis 
DNA, contamination of the sample or aspecific hits in the real-time PCR test. In a previous 
study it was shown that in veal calves, four weeks after antimicrobial treatment, 49% of the 
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nasal swab samples were still positive for M. bovis with real-time PCR (mean Cq = 30.4), 
while only 19% of the samples were positive with culture (Becker et al., 2020). At the 
moment of the outbreak, 51% of the samples were positive for M. bovis with real-time PCR 
(mean Cq = 25.7) and 52% with culture. It was suggested that animals that were positive on 
real-time PCR, but negative on culture were in the recovery phase (Becker et al., 2020). 
(Re)starting antimicrobial treatment in this phase would not be recommended. However, 
optimizing cut off values of real-time PCR taking into account clinical relevance should be 
considered carefully, as small adjustments can result in different outcomes, resulting in 
different treatment of animals with potentially great consequences for antimicrobial use, 
antimicrobial resistance, and animal welfare. Therefore, more research is necessary to 
determine the association between test outcomes and the clinical status of the calf. 
Nevertheless, even though clinical examination and thoracic ultrasound can aid in 
determining the clinical status of the animal, the degree of self-cure in M. bovis infections is 
not clear. Next to this, the combination of multiple pathogens in a respiratory outbreak may 
hamper clear associations between detected pathogens and results. Once these associations are 
more established, Cq values and nanopore sequencing output may be used to support the 
evaluation of antimicrobial treatment efficacy and prognosis in acute or chronic bacterial 
infections, which has already been proposed in human medicine for Mycobacterium 
tuberculosis infections (Broccolo et al., 2003; Takahashi et al., 2007). Also, in Mycoplasma 
pneumonia patients, higher bacterial concentrations detected by real-time PCR were 
associated with severe respiratory disease, showing its potential as follow up tool (Nilsson et 
al., 2010).  
Pooling five BALf for the identification of M. bovis showed high Se and Sp for nanopore 
sequencing and RIMM compared to individual sample processing. Pooling of samples can 
reduce diagnostic costs and can result in a more efficient diagnostic workflow when a high 
turnaround of samples is required, for example when the complete herd needs to be screened 
for eradication programs (Murai et al., 2014; Lohse et al., 2020). Pooling can also increase the 
possibility of detecting the causative pathogen of the disease (Pardon and Buczinski, 2020). In 
this study, we had a convenience sample of 17 pooled BALf samples. Pooled RIMM analysis 
showed very high Se (100%; CI95: 100-100) and Sp (88.9%; CI95: 68.4-109.4) for the 
identification of M. bovis. The loss in Sp of the RIMM method, was probably caused by a 
‘false negative’ in the reference test (the individual samples, AI8), as all other methods, 
including selective-indicative agar, were positive for this sample. It is likely that the Sp of 
pooled RIMM was even underestimated in this study. Pooling of five BALf for nanopore 
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sequencing, also showed good Se (85.7%; CI95: 59.8-111.6) and Sp (90.0%; CI95: 71.4-
108.6%) for the identification of M. bovis. Dilution of samples resulting in concentrations 
below the LOD, interference of high numbers of other pathogens present in the samples or 
different volumes/parts of the sample, are the most likely reasons for the slight loss in Se and 
Sp by pooling. Nevertheless, pooling of samples for nanopore sequencing and RIMM seems 
very reliable, although research on a larger sample size and different populations is still 
recommended for further confirmation.  
Besides the identification of M. bovis, also other Mycoplasma species were identified with 
nanopore sequencing and triplex real-time PCR. Nanopore sequencing showed good Se and 
Sp for M. bovirhinis and M. dispar compared to the triplex real-time PCR, although these 
results should be interpreted with caution, as this triplex real-time PCR test is far from being 
‘the gold standard’ for these species. M. bovirhinis and M. dispar are frequently isolated from 
BALf (Thomas et al., 2002; Timsit et al., 2018; Bokma et al., 2020a), and also in the present 
study this was the case. In our previous study, we speculated that the high prevalence could be 
partly attributed to the cross-reactivity of the real-time PCR with Acholeplasma axanthum, M. 
alkalescens and M. canis, but none of these Mycoplasma species were detected with nanopore 
sequencing, making this hypothesis less likely. Nonetheless, cross-reactivity with M. 
penetrans, M. arginini, Ureaplasma species and M. wenyonii, which were detected with 
nanopore sequencing, were not included in the study of Cornelissen et al. (2017), and could 
still result in cross-reactivity issues. The detection of M. penetrans in calves, detected by 
nanopore sequencing is an extraordinary finding, as this bacterium is usually detected in the 
urogenital or respiratory tract of humans with the human immunodeficiency virus (HIV) 
(Grau et al., 1995; Preiswerk et al., 2020). M. penetrans has only been associated with 
respiratory disease in a non-HIV patient once (Yáñez et al., 1999), and together with the 
relatively low number of reads detected in bovine BALf, more research is necessary to clarify 
whether this identification was a false positive potentially caused by cross-reactivity (e.g. with 
other Mycoplasma species) or whether calves can truly carry M. penetrans. Another 
unexpected finding was the identification of M. wenyonii in BALf, as this pathogen is a 
hemoplasma mostly diagnosed from whole blood (Tagawa et al., 2008). M. wenyonii is 
usually subclinical, but can cause several clinical signs, such as limb edema, swollen teats, 
anemia and milk drop, but so far pneumonia was not described (Smith et al., 1990; Genova et 
al., 2011; Nouvel et al., 2019). During BALf sampling, sometimes small blood vessels are 
damaged, and indeed some of the BALf where M. wenyonii was identified from, contained 
visible traces of blood.  
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In conclusion, the current study showed nanopore sequencing as a reliable cost-efficient 
method for the rapid identification of M. bovis and certain other Mycoplasma species in BAL 
fluid of calves. To reduce the cost and increase the chance of identifying M. bovis, BALf can 
be pooled and analyzed with both nanopore sequencing or RIMM. The advantage of nanopore 
sequencing, is the simultaneous rapid detection of viruses (1-2 days), while the advantage of 
the RIMM is that an M. bovis isolate is rapidly obtained (2-3 days), and fast additional strain 
typing (Chapter 4; Bokma et al., 2020b) or antimicrobial susceptibility testing with nanopore 
sequencing can be performed (Chapter 5.2).  
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Supplementary Table 1. Overview of identification scores for M. bovis (ID Mb) after 48-72 hours of 
incubation with RIMM, Cq scores (Cq) of triplex real-time PCR for Mb, M. bovirhinis (Mbr), M. 
dispar (Md), reads with nanopore sequencing, and selective-indicative agar of M. bovis (SIA) obtained 
from 100 BALf originating from calves.  
No Farm + 
Nº 
Reads Mb ID Mb Cq Mb Reads 
Mbr 
Cq Mbr Reads Md Cq Md SIA 
Mb 
1 AA1 - - - 72 29.40 18640 25.11 - 
2 AA2 - - 33.92 9 30.20 1978 25.72 - 
3 AA3 - - - 24 28.04 552 26.27 - 
4 AA4 - - - 73 27.34 2806 25.03 - 
5 AA5 - - - 36 27.31 12535 22.89 - 
6 AB1 - - - - 37.64 3380 25.15 - 
7 AB2 - - 32.85 18 28.41 10359 22.50 - 
8 AB3 - - - - 33.07 141 26.29 - 
9 AB4 - - - - 36.03 681 30.06 - 
10 AB5 - - - 6 26.18 717 24.01 - 
11 AB6 - - - - - 823 27.05 - 
12 AB7 - - - 1 - 1130 24.32 - 
13 AB8 - - - - - 373 24.12 - 
14 AB9 - - - 1418 22.71 1078 24.11 - 
15 AB10 - - 33.42 - 39.12 592 26.32 - 
16 AB11 - - - - - 375 26.47 - 
17 AB12 - - - - - 396 28.50 - 
18 AB13 - - 36.67 - - 121 31.14 - 
19 AB14 - - - - - 1115 24.48 - 
20 AB15 - - - 3 25.81 315 22.22 - 
21 AC1 - - - 9 28.33 365 26.29 - 
22 AC2 - - - 1 32.98 5 34.90 - 
23 AC3 - - 39.65 7 27.18 503 25.71 - 
24 AD1 1 - 36.62 432 25.66 1937 25.48 - 
25 AD2 1540 1.96 20.57 1016 23.22 40098 19.12 + 
26 AD3 1 1.91 35.72 110 26.57 1567 24.70 - 
27 AD4 1 - 32.97 3 28.79 66 30.34 - 
28 AD5 41 1.81 24.57 709 23.37 1522 23.90 + 
29 AD6 272 2.09 23.30 1054 21.01 35617 19.47 + 
30 AE1 - - - - - 1374 25.44 - 
31 AE2 - - 34.48 21 31.33 10 46.45 - 
32 AE3 - 2.19 24.26 - 37.44 4 - + 
33 AE4 - - - - 37.97 4 - - 
34 AE5 1 - - 84 26.36 3 40.56 - 
35 AE6 3 - - 7 28.35 - - - 
36 AE7 4 - - 1 - 1 43.34 - 
37 AE8 3 - - 1 - 2 - - 
38 AF1 28414 1.88 19.03 769 25.28 2756 25.22 + 
39 AF2 3146 2.07 21.89 277 24.37 270 28.16 + 
40 AF3 2046 1.97 21.49 145 25.55 254 26.67 + 
41 AF4 6 - - 56 29.20 1660 25.68 - 
42 AF5 1 2.33 - - 39.66 2 41.28 - 
43 AF6 8 2.30 37.60 30 34.48 82 35.01 - 
44 AG1 1 - - - 26.03 201 24.91 - 
45 AG2 - - 22.42 50 27.32 735 20.14 - 
46 AH1 - - - 6 26.33 5001 20.89 - 
47 AI1 - - - 187 26.34 111 28.37 - 
48 AI2 - - - 177 26.11 1182 23.82 - 
49 AI3 - - 37.71 26 28.89 3791 24.29 - 
50 AI4 - - - 138 23.78 3041 22.67 - 
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No Farm Reads Mb ID Mb Cq Mb Reads Mbr Cq Mbr Reads Md Cq Md SIA Mb 
51 AI5 - - - 18 32.99 2324 26.82 - 
52 AI6 - - 33.96 1 30.31 482 26.51 - 
53 AI7 - - - 23 31.11 4319 24.73 - 
54 AI8 12 - 22.00 37 24.05 569 23.48 + 
55 AI9 - - - 74 24.30 207 26.04 - 
56 AI10 - - - 88 24.10 167 26.73 - 
57 AI11 1 - - - 36.65 9 33.96 - 
58 AI12 1 - - 42 27.31 2551 24.35 - 
59 AI13 - - - - - 132 30.29 - 
60 AJ1 2 - - 74 - 863 33.27 - 
61 AJ2 - - - - 24.91 297 23.57 - 
62 AK1 92 2.17 25.30 - 32.01 50 31.93 + 
63 AK2 7312 2.20 22.80 70 31.27 67 39.18 + 
64 AK3 2038 2.20 19.08 - 31.91 2467 20.94 + 
65 AK4 260 2.34 28.54 111 29.17 19 35.42 + 
66 AK5 7277 1.97 20.12 488 23.17 5035 22.00 + 
67 AK6 21 2.30 29.83 - 35.44 28 31.73 + 
68 AK7 3 2.23 28.72 - 34.35 93 27.56 + 
69 AK8 186 1.91 27.12 - 37.46 281 27.32 + 
70 AK9 103 2.28 23.43 1 30.28 18 27.53 + 
71 AK10 5830 1.72 19.52 - 29.11 996 25.17 + 
72 AK11 2102 2.18 21.63 - 34.90 55 35.53 + 
73 AK12 677 1.96 21.85 2 31.04 1488 26.99 + 
74 AK13 5 2.01 27.32 - 30.88 9 29.35 + 
75 AK14 3 - 28.48 - - 10 26.04 + 
76 AK15 - 2.34 39.60 10 28.43 5 30.25 - 
77 AK16 1467 1.79 20.63 - 38.38 546 24.25 + 
78 AK17 14 2.24 25.38 - 34.67 14 30.87 + 
79 AK18 - 1.95 37.39 - 37.27 6 30.61 - 
80 AK19 - 2.10 30.39 - 38.57 1 31.75 + 
81 AK20 - 1.95 37.41 - 35.04 1 32.71 + 
82 AL1 - 2.22 33.58 18 31.36 37 31.24 + 
83 AL2 - 2.38 33.00 20 32.38 1068 26.96 - 
84 AL3 - - - - 28.20 24 28.08 - 
85 AL4 3 2.27 30.36 99 27.79 10 31.83 + 
86 AL5 - - - 32 25.25 1115 24.07 - 
87 AL6 - - - 257 21.09 905 22.63 - 
88 AL7 - - 38.70 534 23.25 6964 21.90 + 
89 AM1 - - 37.81 - - 1461 27.66 - 
90 AM2 - - - - - 232 31.62 - 
91 AM3 - - - - - 857 22.79 - 
92 AM4 - - - - - 34 32.07 - 
93 AM5 - - - 5 28.57 83 28.52 - 
94 AM6 - - - - - 1629 21.32 - 
95 AN1 2 - - 733 23.46 2633 23.18 - 
96 AN2 - - - - 39.68 14 29.33 - 
97 AN3 - - - - - 107 27.04 - 
98 AN4 - - - 15 24.21 262 22.75 - 
99 AN5 - - 34.09 4 33.20 1 35.00 - 
100 AN6 - - 41.15 - 30.26 174 23.98 - 
Interpretation as follows: positive result when  ≥ 5 reads, ID ≥ 1.7, Cq < 35 or when “oil-like” film surrounding 
colony is observed   
 






Supplementary Table 2. Overview of the identification of Mycoplasma bovis in individual BALf 
(n=85) and pooled samples (n=17) by nanopore sequencing and the RIMM method.  
No. Farm Number of samples positive for M. bovis 
  Nanopore sequencing RIMM 
  Individual Pooled Individual Pooled 
1 AB 0/5 Negative  0/5 Negative  
2 AB 0/5 Negative 0/5 Negative 
3 AB 0/5 Negative 0/5 Negative 
4 AB/AC 0/5 Negative 0/5 Negative 
5 AD 3/5 Positive 4/5 Positive 
6 AE 0/5 Positive 2/5 Positive 
7 AF 4/5 Positive 4/5 Positive 
8 AI 0/5 Negative 0/5 Negative 
9 AI 1/5 Positive 0/5 Positive 
10 AI 0/5 Negative 0/5 Negative 
11 AK 5/5 Positive 5/5 Positive 
12 AK 4/5 Positive 5/5 Positive 
13 AK 3/5 Positive 4/5 Positive 
14 AK 2/5 Negative 5/5 Positive 
15 AL 0/5 Negative 2/5 Positive 
16 AM 0/5 Negative 0/5 Negative 
17 AN 0/5 Negative 0/5 Negative 
Pooled samples were categorized as positive, when at least one out of the five individual sample was 
positive  
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M. bovis is one of the leading causes of respiratory disease and antimicrobial use in cattle. 
The pathogen is widespread in different cattle industries worldwide, but highest prevalence is 
found in the veal industry. Knowledge on M. bovis strain distribution over the dairy, beef and 
veal industries is crucial for the design of effective control and prevention programs, but 
currently undocumented. Therefore, the present study evaluated the molecular epidemiology 
and genetic relatedness of M. bovis isolates obtained from Belgian beef, dairy and veal farms, 
and how these relate to M. bovis strains obtained worldwide. Full genomes of one hundred 
Belgian M. bovis isolates collected over a 5-year period (2014-2019), obtained from 27 dairy, 
38 beef and 29 veal farms, were sequenced by long-read nanopore sequencing. Consensus 
sequences were used to generate a phylogenetic tree in order to associate genetic clusters with 
cattle sector, geographical area and year of isolation. The phylogenetic analysis of the Belgian 
M. bovis isolates resulted in 5 major clusters and 1 outlier. No sector-specific M. bovis 
clustering was identified. On a world scale, Belgian isolates clustered with Israeli, European 
and American strains. Different M. bovis clusters circulated for at least 1.5 consecutive years 
throughout the country, affecting all observed industries. Therefore, the high prevalence in the 
veal industry is more likely the consequence of frequent purchase from the dairy and beef 
industry, than that a reservoir of veal specific strains on farm would exist. These results 
emphasize the importance of biosecurity in M. bovis control and prevention.   
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Mycoplasma bovis (M. bovis) causes mostly pneumonia, arthritis, otitis in calves and mastitis 
in adult cattle (Maunsell and Donovan, 2009; Maunsell et al., 2011) resulting in high 
antimicrobial use (AMU) and enormous economic losses in cattle farming sectors worldwide 
(Nicholas and Ayling, 2003; Fox et al., 2005; Maunsell and Donovan, 2009). In Belgium, 
100% of the veal farms are seropositive for M. bovis (Pardon et al., 2011; Pardon, 2012), 
whereas M. bovis is involved in 33% of acute pneumonia outbreaks in beef and dairy farms 
(Pardon et al., 2020). Treatment of M. bovis is frequently unsatisfactory, probably due to a 
combination of intrinsic and acquired antimicrobial resistance, immuno-evasive properties of 
the pathogen and failure of the animal to generate an effective immune response (Gautier-
Bouchardon, 2018; Maunsell and Chase, 2019). Together with the absence of an effective 
commercially available vaccine, the control of M. bovis is particularly challenging.  
A contemporary fear is that the veal sector, currently combining a high AMU and a farm level 
M. bovis prevalence of 100%, is a reservoir for multi-resistant sector-specific M. bovis strains 
(Arcangioli et al., 2008; Pardon, 2012; Bokma et al., 2019). Currently, there is insufficient 
knowledge about the epidemiology of circulating M. bovis strains to answer this question. 
Several epidemiological studies observed clonal emergence and identified dominant lineages 
of the M. bovis bacterium, based on antimicrobial resistance patterns and different strain 
typing methods (Gautier-Bouchardon et al., 2014; Becker et al., 2015; Rosales et al., 2015; 
Bürki et al., 2016). In the past, different approaches were used to subtype M. bovis strains, 
including random amplification of polymorphic DNA (RAPD), arbitrarily primed PCR (AP-
PCR), amplification fragment length polymorphism (AFLP), pulsed-field gel electrophoresis 
(PFGE), multiple-locus variable-number tandem repeat (MLVA), and multi-locus sequence 
typing (MLST) (Butler et al., 2001; McAuliffe et al., 2004; Spergser et al., 2013; Becker et 
al., 2015; Rosales et al., 2015). Unfortunately, results from these typing methods are difficult 
to compare and only focus on a small fraction of the genomic information, resulting in a 
limited insight in the genetics and incongruence among studies (Maiden et al., 1998; 
McAuliffe et al., 2014; Register et al., 2020). Therefore, whole genome sequencing (WGS) 
could be a great opportunity, considering its highly discriminative capacity and 
reproducibility compared to older typing methods (Leekitcharoenphon et al., 2014; Deng et 
al., 2016).  
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Several studies already investigated whether specific M. bovis strains were associated with 
affected organs, such as udder, respiratory tract or joints (Register et al., 2015; Rosales et al., 
2015; Parker et al., 2016), geographical location (Register et al., 2015; Parker et al., 2016) or 
health status (Register et al., 2015; Yair et al., 2020). Only one study determined 
epidemiology based on AP-PCR in three farms from three different husbandry conditions 
(dairy calf ranch, feedlot and closed beef herd), presuming that management factors could 
influence the distribution of M. bovis (Butler et al., 2001). These husbandry conditions are not 
comparable with the three main sectors in Europe. In Europe, a lot of short-distance 
movements of cattle between farms is seen, and the veal industry is an important side market 
of the dairy and beef industry (Ensoy et al., 2014; Pardon et al., 2014). It is currently not clear 
whether sector-specific M. bovis strains are present and what their genetic relation is to 
previously sequenced M. bovis isolates. Therefore, the present study first evaluated the 
molecular epidemiology and genetic relatedness of M. bovis isolates obtained from Belgian 
beef, dairy and veal farms. Furthermore, it studied the relationship of these isolates to M. 
bovis strains from other countries.  
 
MATERIALS AND METHODS 
Mycoplasma bovis collection and identification 
One hundred M. bovis isolates were obtained from 94 Belgian farms (27 dairy, 38 beef and 29 
veal) over a 5-year period (2014-2019). All isolates were obtained from diagnostic samples 
collected by field veterinarians from clinical cases, in compliance with EU legislation on 
ethics in animal experimentation [2010/63/EU]. Isolates were collected in 2014 (n = 1), 2016 
(11), 2017 (63), 2018 (19) and 2019 (6), originating from the provinces East-Flanders (n = 
10), West-Flanders (25), Antwerp (38), Limburg (6), Flemish Brabant (10), Heynowes (6), 
Namen (2) and Liege (1). The origin of two isolates was unclear. The samples were retrieved 
from the respiratory tract (89), middle ear (3), milk (4), joint (2) and other fluids (3) of calves 
and adult cattle, as shown in Supplement 1. The samples were cultured on selective indicative 
agar (Bokma et al., 2020), and identification was verified with MALDI-TOF MS (score value 
≥ 1.7), as described earlier (Bokma et al., 2019) and Kraken2 analysis (v2.0.8; Wood et al., 
2019). Isolates had a passage history of maximum 3-5 times and all isolates were stored at 
maximum -20°C until further analysis.  
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Preparation and DNA extraction  
In ten separate runs, all M. bovis isolates were thawed and cultured in 10 mL modified PPLO 
broth (pH 7.8) (DifcoTM, BD Diagnostic Systems, Sparks, Md.), supplemented with 25% 
inactivated horse serum (GibcoTM), 0.7% technical yeast extract, 0.5% sodium pyruvate 
(ReagentPlus, Sigma-Aldrich®), 0.5% D-(+)-glucose monohydrate (Sigma-Aldrich) and 
0.005% phenol red. After 4 days of incubation (37ºC, 5% CO2) a bacterial suspension of 
approximately 108 CFU/mL was obtained. Bacterial DNA was obtained using the 
ZymoBIOMICS DNA Miniprep kit (Zymo Research) according to the manufacturer’s 
instructions. Quantity and quality were verified using NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific). Low quality samples were further cleaned using CleanNGS (CleanNa) 
beads. All runs included the M. bovis PG45 type strain (ATCC 25523) and modified PPLO 
broth as the positive and negative control, respectively.    
 
Library preparation and MinION long-read sequencing  
Quality-checked native M. bovis DNA was immediately used for library preparation using the 
Rapid Barcoding Sequencing Kit (SQK-RBK004; Oxford Nanopore Technologies (ONT)), 
following manufacturers’ instructions. For each run, ten field strains, one positive control 
(PG45) and one negative control (sterile broth) were multiplexed (400 ng DNA per sample). 
A new R9.4.1 Flow cell (ONT) was used for a 48h sequencing run on MinION device (ONT). 
Raw fast5 read files were collected using MinKnow v.3.6.5. 
  
Bioinformatics pipeline 
All data were analyzed on an Ubuntu 18.04.3 LTS system. In order to speed up bioinformatics 
analyses, GPU resources (GeForce RTX 2080 Ti/PCIe/SSE2) were exploited where possible. 
Raw fast5 files were basecalled using Guppy basecaller (GPU v.3.3.0; ONT), followed by 
demultiplexing, adapter trimming, and quality filtering (Q-score ≥ 7) of fastq files with qcat 
(v.1.1.0; ONT) and NanoFilt (v. 2.5.0; De Coster et al., 2018), respectively. Reference-based 
assemblies were generated using the M. bovis PG45 type strain sequence (NC_014760.1) by 
mapping filtered reads onto the reference using GraphMap (v.0.5.2; Sović et al., 2016). Final 
consensus sequences were generated using Medaka (GPU v.0.10.0; ONT). All strains were 
identified as M. bovis using Kraken2 (v2.0.8; Wood et al., 2019) by aligning the reads against 
the minikraken_v1_8GB database with standard settings. Overall consensus assembly 
accuracies were verified by comparing total Single Nucleotide Polymorphisms (SNPs) using 
the CSI phylogeny package (v1.4, Center for Genomic Epidemiology, Denmark; Kaas et al., 
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2014) as compared to the M. bovis PG45 type strain (NC_014760.1) reference sequences. To 
validate the use of long-read sequencing, SNPs of ten independent M. bovis PG45 assemblies 
were compared to those in a single MiSeq experimental dataset. All M. bovis consensus 
genomes are available for download on the NCBI GenBank database under the BioProject 
PRJNA639688 and accession numbers (SAMN15246515-SAMN1524662). Sequencing 
summaries can be found in Supplement file 1. 
 
Phylogenetic analysis 
Phylogenetic analysis was performed on all newly generated consensus sequences alone or in 
combination with 250 previously published M. bovis sequences using the FastTree-based CSI 
Phylogeny v1.4 (see Supplement 2). All analyses included the M. bovis PG45 type strain 
(NC_014760.1) as reference and M. agalactiae PG2 (NC_009497.1) as outgroup. Resulting 
Newick files were visualized with MEGA-X software (Kumar et al., 2018).  
 
Cluster and strain determination 
Due to the lack of relatedness criteria for SNP typing schemes of M. bovis and the need to 
establish these per organism and experimental design (Schürch et al., 2018), clusters were 
defined by visual inspection of the phylogenetic tree and by taking into account bootstrap 
support. In addition, the matrix of pairwise SNP counts was extracted from CSI Phylogeny for 
further inspection. Mean SNP differences were calculated between within-cluster isolates, and 




Esri®ArcMapTM (version 10.7.1) software was used to visualize the geographical distribution 
and density of M. bovis isolates over Belgium. Herd size was based on the national 
Identification and Registration system, containing, on the first of January 2017, a total of 
23,995 cattle herds in Belgium (23,733 conventional herds; 262 veal), and a total of 2,517,850 
cattle. The spatial distribution of the Belgian cattle (both cattle and veal calves) was displayed 
using kernel smoothing. Coordinates of Belgian cattle herds were converted into a continuous 
raster using the kernel density estimation function weighted by number of cattle (Spatial 
Analyst, ArcMAP X, ESRI, Redlands, CA, USA). 
 
 




Phylogenetic analysis of Belgian isolates 
A median sequencing depth of 618X (range: 32X-2689X) was obtained from long reads with 
an average N50 read length of 5,706 ± 1,514 bp for all Belgian M. bovis isolates. First, 
implementation of long-read sequencing of M. bovis genomes was validated by comparing 
total SNPs from ten independently sequenced M. bovis PG45 sequences and a single M. bovis 
PG45 MiSeq dataset, showing 53 ± 3 SNPs and 27 SNPs difference, respectively, compared 
with the 1,003,404 bp of the M. bovis PG45 reference genome (NC_014760.1). The observed 
average SNP difference of 0.005% for the long-read sequencing approach was considered 
acceptable to allow meaningful phylogenetic analyses. In addition, control strain M. bovis 
PG45 results were mutually compared over all ten runs, showing a mean SNP difference of 20 
(range 8-30, standard deviation 4.6), which was also demonstrated an acceptable inter-
experimental variation. Taking into account all Belgian M. bovis strains, and also including 
the outgroup M. agalactiae, 51.4% of the M. bovis genome or 515,324 nucleotide positions 
were used for phylogeny. The minimum and maximum SNP differences among Belgian M. 
bovis isolates were 33 and 3,775, respectively.  
Table 1. Pairwise SNP differences between M. bovis isolates within Belgian cluster I to V and VK30. 
Cluster Min SNP Max SNP ΔSNP Mean SD 
I 292 1126 834 843 427 
VK30a 3221 3775 3436 3457 95 
II 78 165 87 135 22 
III 60 376 316 198 71 
IV 76 1103 1027 245 251 
V 77 1512 1435 445 267 
Δ: difference between minimum (min) and maximum (max) pairwise SNPs; SD: standard deviation; a VK30 was 
compared to cluster I to V.   
Visual inspection of the phylogenetic analysis of 100 M. bovis isolates resulted in 5 clusters 
(I-V): 3 large clusters (n ≥ 10 isolates), 2 smaller clusters (n < 10), and 1 distinct strain 
(VK30) as shown in Figure 1. Cluster I to V contained 3, 7, 16, 33, and 40 M. bovis isolates, 
respectively. Inspection of pairwise SNP differences per cluster, showed more homogeny 
within clusters II and III (mean ΔSNPs of 87 and 316, respectively), compared with cluster I, 
IV and V (mean ΔSNPs of 834, 1027, and 1435) (Table 1). Mean SNP differences among 
within-cluster isolates and outlier calculations showed outliers within cluster III (Mb222, 
Mb231), IV (Mb201, Mb240, Mb175, TOVK) and V (Mb116, Mb166, VK11, VK23).   





Figure 1. SNP-based phylogenetic tree of 100 M. bovis isolates from Belgian dairy, beef and veal 
farms. The figure was created using MEGA-X software with M. bovis isolates obtained over 2014-
2019. The tree was rerooted to M. agalactiae PG2, which was included as an outgroup. Clusters (I-V), 
and VK30 are represented by different colors. The designation of the isolates features the sector (■ 
dairy; ● beef; ♦ veal), year of isolation (2014-2019), affected organ (R: respiratory tract; M: milk; E: 
ear, J: joint and O: other) and sequence identification (see Supplement file 1). The scale bar indicates 
the number of substitutions per site, and bootstrap values are represented on nodes.  
 




Figure 2. Geographical distribution of different M. bovis clusters over 2014-2019 and cattle density in 
Belgium (2017). The map was created using Esri®ArcMapTM (version 10.7.1) software. Clusters (I-V) 
are represented by different colors and the radius of the circle represents the number of isolates from 
one village. Mixed colors within one circle represent the presence of different clusters within one 
village.  
 
Between and within clusters, no association could be observed for the different cattle sectors 
or year of isolation (Fig. 1). Two different isolates from the same herd (veal) and same 
sampling period (Mb49 and Mb50) did not cluster together (II and V). All clusters persisted in 
Belgium for at least 1.5 consecutive years throughout the country. M. bovis strains isolated 
from the middle ear (n = 3) were clustered within cluster IV, while those obtained from milk, 
joint and other samples were scattered over different clusters (Fig. 1). Finally, no clear 
association between geographic location of sampled farms and M. bovis clusters was 
observed, as shown in Figure 2.  





Figure 3. SNP-based topology of 350 M. bovis isolates in MEGA-X. The tree was rerooted to M. 
agalactiae PG2 (EPS 1952 PG2), which was included as outgroup. Belgian clusters (I-V) were 
collapsed as far as possible and represented by different colors (I: yellow; II: purple; III: brown; IV: 
blue, V: red; VK30: green). The designation of the isolates contains the coded name of country of 
origin (ISO 3166-1; Alpha-3 code), continent of origin (● Europe; o Non-Europe), year of isolation 
(1952-2019), affected organ (R: respiratory tract; M: milk; E: ear, J: joint and O: other or unknown) 
and sequence identification (see Supplement 2) or the number of collapsed Belgian isolates between 
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Phylogenetic analysis of M. bovis worldwide 
All 100 Belgian isolates were added to the worldwide phylogenetic tree. The percentage of 
the reference genome covered by all isolates, including the PG45 standard strain and the M. 
agalactiae outgroup strain PG2 was 39.3%, therefore 394,303 positions were found in all 
analyzed genomes. The minimum and maximum SNP differences among all M. bovis isolates 
including the reference strain, were 0 and 4,871, respectively. Belgian clusters are situated in 
different parts of the phylogenetic tree worldwide (Fig. 3). Cluster I is related to strains 
isolated in the USA (2007; mean ΔSNPs of 636) and Israel (2016; mean ΔSNPs of 1369). 
Cluster II is closely related to one recent French strain (2016; mean ΔSNPs of 171) and is 
situated in a larger cluster related to older strains from Israel and Eastern Europe (2001-2009; 
ΔSNPs < 200), and other more recently isolated strains from Israel and Eastern Europe (2011-
2017; ΔSNPs < 500). Belgian cluster III and V do not cluster together with non-Belgian 
isolates, while cluster IV is closely related (ΔSNPs < 300 without cluster IV outliers) to M. 
bovis strains obtained in Israel (2012-2017) and Eastern Europe (2013-2016). VK11 remains 
an outlier that does not collate with the rest of cluster V. Consistent with Figure 1, VK30 is 
well separated from the other Belgian isolates and is very closely related (mean ΔSNPs of 
171) to strains obtained from milk in the USA (2017).  
 
DISCUSSION 
In this study, one-hundred M. bovis isolates from different Belgian cattle sectors (beef, dairy 
or veal) were phylogenetically compared to investigate whether sector-specific strains exist 
and whether such strains are related to M. bovis strains previously isolated and sequenced 
worldwide.  
In this study, we chose to apply the ONT long-read sequencing approach (Goodwin et al., 
2016), because no default WGS approaches are defined for Mycoplasma spp. and short-read 
sequencing biases have been described for genomes with highly repetitive regions. 
WGS approaches have become more attractive over the last years, as the cost for next-
generation sequencing has significantly reduced. Single Nucleotide Polymorphism (SNP) 
analysis using Illumina short read data from M. bovis isolates already showed to be an 
effective way for M. bovis genotyping (Parker et al., 2016; Yair et al., 2020). Long-read 
nanopore sequencing (Oxford Nanopore Technologies) is known to create much faster results, 
and was recently applied in veterinary medicine as well (Quick et al., 2015; Theuns et al., 
2018). Yet, lower single read accuracies are currently obtained with ONT in comparison to 
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Illumina (Rang et al., 2018). Therefore, the implementation of long-read sequencing to 
generate M. bovis genome assemblies was verified, showing only on average 53 SNPs 
difference of the long-read approach with the publically available M. bovis PG45 genome, 
representing an acceptable error rate of 0.005%. As a result, the authors believe that nanopore 
sequencing is a highly accessible tool, allowing practical use outside academia in routine 
diagnostics and real time surveillance. 
From the study results, several interesting observations were made. First of all, the obtained 
M. bovis isolates belonged to at least five different M. bovis clusters, of which three dominant 
clusters were identified. This is in agreement with an Israeli study based on WGS-SNP, where 
six clusters were observed of which three were dominant. Remarkably, one cluster contained 
more than 50% of the isolates in that study (Yair et al., 2020). Several other studies also 
showed one or two dominant lineages, although different typing methods were used (Spergser 
et al., 2013; Becker et al., 2015; Bürki et al., 2016; Parker et al., 2016; Menghwar et al., 
2017). In contrast to Aebi et al. (2012), where mostly herd-specific M. bovis isolates were 
seen in Switzerland, we observed close relatedness of M. bovis isolates over the different 
herds. This might be a result of more frequent purchasing cattle from different origins and 
transportation in Belgium, because 40% of cattle is transported at least once (and up to eight 
times) over a 5-year lifespan in Belgium (McAuliffe et al., 2004; Soehnlen et al., 2011; 
Spergser et al., 2013; Ensoy et al., 2014; Pardon et al., 2020). As such, the higher 
heterogeneity observed in cluster I, IV and V compared with clusters II and III, may be 
caused by different rates of genetic drift between clonal lines (McAuliffe et al., 2004).  
Secondly, no sector-specific strains or clusters were identified in the present study, which 
does not entirely come as a surprise. In Belgium, veal calves are purchased from both dairy 
and beef farms, and fattened and slaughtered in specialized veal farms and slaughterhouses, 
respectively (Pardon et al., 2014). Also, approximately 15-20% of the farms in Belgium are 
mixed farms. Therefore, contact among different cattle sectors is intense. In addition, herd 
visitors and artificial insemination might play a role in spreading of M. bovis or introducing 
new strains on farms (Gonzalez et al., 1992; Gille et al., 2016; Haapala et al., 2018). 
Thirdly, when we take a closer look on how the different clusters have spread over Belgium, 
no clear association with location was observed. This was also concluded in studies 
performed in the UK and USA (McAuliffe et al., 2004; Soehnlen et al., 2011; Register et al., 
2015). Nevertheless, in the provinces of Antwerp and Western Flanders seem to be hotspots 
for M. bovis outbreaks. Besides a high number of local transports, Antwerp and the Flanders 
area are also the main gates for cattle import, which makes these areas predisposed for the 
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introduction of new M. bovis strains (Ensoy et al., 2014). Unfortunately, M. bovis genomes 
were not available for isolates obtained from the top import countries for Belgium, which are 
Germany and the Netherlands.  
Although this study was not designed to draw definitive conclusions about year of isolation 
and affected organs, some preliminary observations can be made. For example, no association 
between M. bovis strain and year of isolation was observed. On the other hand, we saw that 
representatives of all clusters persisted for at least 1.5 consecutive years on Belgian territory. 
The persistence of strains within a country or herd has been described before (Butler et al., 
2001; Aebi et al., 2012; Parker et al., 2016). Furthermore, shifts between dominant lineages 
from older to new strains have been reported before as well (Arcangioli et al., 2012; Becker et 
al., 2015; Bürki et al., 2016; Hata et al., 2019). Also, we did not observe an association 
between cluster and affected organ, which is in line with previous studies (Register et al., 
2015; Rosales et al., 2015; Parker et al., 2016). Yet, it was remarkable that all isolates 
obtained from the middle ear were clustered, which could suggest the middle ear as possible 
predilection site for certain M. bovis strains. However, no definitive conclusions can be drawn 
as there were only few isolates obtained from this isolation site in the present study. In 
addition, we isolated different M. bovis strains (Mb49, Mb50) from two veal calves on the 
same farm at the same time. The observation of two different strains in one herd or even one 
animal has been described before (Butler et al., 2001; Soehnlen et al., 2011; Sulyok et al., 
2014; Rosales et al., 2015), in contrast to Arcangioli et al. (2012), who isolated only one 
identical dominant profile in the same feedlot.   
Finally, it was evident that Belgian isolates were mostly related to European and Israeli M. 
bovis isolates, even though only a few genomes of European M. bovis isolates have been 
published in the NCBI database. This seems plausible, as Belgian farmers mostly purchase 
cattle from European farms, while Israel also partly imports cattle from Eastern-Europe. The 
fact that Israeli isolates are often related to Chinese and Australian strains, is also due to 
import of cattle, as outlined in detail elsewhere (Menghwar et al., 2017; Yair et al., 2020). 
Some of the Belgian outlier strains were related to American isolates, which might be 
explained by the fact that M. bovis was first isolated in the USA and outbreaks in Europe were 
only seen years later. So, we can only speculate whether these outlier strains could have been 
imported or evolved geographically distinct from each other. Clusters of the Belgian isolates 
were not clustered exactly in the same way in the Belgian vs. the worldwide phylogenetic 
tree. A possible explanation could be the loss of overall coverage between the construction of 
both phylogenetic trees (51% for the Belgian to 40% worldwide). This might be due to (1) 
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heterogeneity among isolates worldwide and/or (2) the use of genomes obtained by different 
laboratories, using different sequencing protocols, as the quality can be influenced by strain 
maintenance, DNA extraction, library preparation, sequencing, and the bioinformatics 
analysis (Portmann et al., 2018).  
In conclusion, multiple M. bovis clusters were circulating in Belgium in 2014-2019, and were 
persisting for several years. Neither the veal industry, nor any other cattle industry could be 
identified as source of strain persistence. Connections between dairy, beef and veal industry 
are intense and M. bovis appears to easily spread among these sectors. The M. bovis issues in 
the veal industry seem more likely the consequences of strain import from dairy and beef, 
rather than persistence of a limited number of veal specific strains. This information can 
contribute to better control and prevention of M. bovis infections by improved biosecurity. 
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Mycoplasma bovis is an important pathogen causing mostly pneumonia in calves and mastitis 
in dairy cattle. In absence of an effective vaccine, antimicrobial therapy remains the main 
control measure. Antimicrobial use in veal calves is substantially higher than in conventional 
herds, but whether veal calves also harbour more resistant M. bovis strains, is currently 
unknown. Therefore, we compared antimicrobial susceptibility test results of M. bovis isolates 
from different cattle sectors and genomic clusters. The minimum inhibitory concentration of 9 
antimicrobials was determined for 141 Belgian M. bovis isolates (29 dairy, 69 beef, 12 mixed, 
31 veal farms), and used to estimate the epidemiological cut-off. Acquired resistance was 
frequently observed for the macrolides, while no acquired resistance to oxytetracycline and 
doxycycline, minimal acquired resistance to florfenicol and tiamulin, and a limited acquired 
resistance to enrofloxacin was seen. M. bovis isolates from beef cattle or genomic cluster III 
had higher odds to be gamithromycin resistant than those from dairy cattle or genomic 
clusters IV and V. In this study, no cattle industry could be identified as source of resistant M. 
bovis strains. A single guideline irrespective of cattle sector for antimicrobial use for M. bovis 
infections, with a small remark for gamithromycine, is likely sufficient.  
 
Keywords: epidemiological cut-off methods; gamithromycin; genomic clusters; iterative 
statistical method; normalized resistance interpretation; visual estimation  
 




In the last decade, Mycoplasma bovis (M. bovis) has come to the forefront as an economically 
important bacterium with a large impact on health, welfare and antimicrobial use (AMU) in 
cattle operations worldwide (Calcutt et al., 2018). The bacterium is mainly feared as the cause 
of pneumonia, arthritis and otitis in calves, and pneumonia and mastitis in adult cattle 
(Maunsell and Donovan, 2009; Maunsell et al., 2011). In the absence of an effective vaccine, 
antimicrobial therapy remains a crucial factor to control an outbreak. 
In recent years, a decrease in antimicrobial susceptibility of M. bovis to various antimicrobial 
classes targeting protein synthesis (e.g. phenicols, tetracyclines, lincosamides and macrolides) 
and DNA synthesis (e.g. fluoroquinolones) has been reported in different countries (Gautier-
Bouchardon et al., 2014; Cai et al., 2019; Klein et al., 2019; García-Galán et al., Jelinski et al., 
2020; Liu et al., 2020). Especially for macrolides high percentages of resistant M. bovis 
isolates are reported, while fluoroquinolones remain the most effective antimicrobial in vitro 
in most countries (Heuvelink et al., 2016; Cai et al., 2019; Becker et al., 2020; Liu et al., 
2020), except for Spain and Italy (Klein et al., 2019; García-Galán et al., 2020). Geographical 
differences in antimicrobial susceptibility of M. bovis, as well as differences between strains 
isolated from various predilection sites, such as the joint, udder and lung have been described 
(Gerchman et al., 2009; Heuvelink et al., 2016; Cai et al., 2019). Also more antimicrobial 
resistance was observed in Canadian M. bovis strains obtained from dead animals compared 
to those isolated from healthy animals (Jelinski et al., 2020). Despite that antimicrobial 
susceptibility differences between production systems have been shown for other respiratory 
pathogens, such as Pasteurella and Mannheimia isolates (Catry et al., 2005), this was not 
previously explored for M. bovis. Quantity and quality of AMU can differ greatly between 
production systems, with veal calf operations showing much higher AMU compared to 
conventional herds (Dorado-García et al., 2016). Varying AMU may result in a different 
resistance selection pressure, subsequently changing antimicrobial susceptibility patterns or 
supporting clonal emergence of specific M. bovis strains in outbreaks (Becker et al., 2015; 
García-Galán et al., 2020; Liu et al., 2020). If production-specific antimicrobial susceptibility 
exists for M. bovis, it might be necessary to adjust M. bovis treatment guidelines to specific 
production systems. Also, whether antimicrobial resistance is associated with specific genetic 
strains is not clear, as some studies observed no association between genetic subtypes based 
on the polC subtyping scheme (Becker et al., 2020), while others did for lincosamides and 
macrolides (Liu et al., 2020). With whole genome sequencing (WGS) becoming more popular 
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and commercially available for identification and strain typing (Parker et al., 2016; Yair et al., 
2020; Bokma et al., 2020a), it might be helpful to determine whether phenotypic 
antimicrobial susceptibility patterns are associated with genomic clusters of M. bovis. 
Therefore, the objective of the present study was to compare antimicrobial susceptibility 
results of M. bovis isolates obtained from veal calf, conventional dairy and beef herds, and to 
explore the association of AMR with specific M. bovis genomic clusters.  
 
MATERIAL AND METHODS 
Mycoplasma bovis collection 
One hundred forty-one epidemiologically independent M. bovis isolates, originating from 29 
dairy, 69 beef, 12 mixed (both dairy and beef) and 31 veal farms were included in this study. 
Isolates were obtained from the respiratory tract (128), middle ear (4), milk (5), joint (2), 
abscess (1) and seroma (1), collected in Belgium between 2016 and 2019, with the exception 
of one isolate which was obtained in 2014. One hundred of these isolates have been strain 
typed previously [18]. All isolates were obtained from diagnostic samples collected by field 
veterinarians from clinical cases, in compliance with EU legislation on ethics in animal 
experimentation [2010/63/EU]. All samples were cultured on a modified pleuropneumonia-
like organism (PPLO) agar plate and incubated for 7-10 days (37°C, 5% CO2). Presumptive 
M. bovis identification was based on the typical fried-egg colony appearance on modified 
PPLO agar and the presence of lipase activity as tested on medium containing Tween-80 
(Bokma et al., 2020b). Final identification was performed with MALDI-TOF MS as described 
before (Bokma et al., 2019). All samples were stored at -80°C until further analysis. 
 
Antimicrobial susceptibility testing 
Minimum inhibitory concentrations (MIC) were obtained following the guidelines for MIC 
testing of veterinary Mycoplasma spp. described by Hannan (2000). M. bovis isolates were 
thawed and cultured on modified PPLO agar. After 7 days of incubation at 37°C in a 5% CO2 
enriched atmosphere, colonies were inoculated in modified PPLO broth (pH 7.8) (DifcoTM, 
BD Diagnostic Systems, Sparks, Md.) supplemented with 25% inactivated horse serum 
(GibcoTM), 0.7% technical yeast extract, 0.5% sodium pyruvate (ReagentPlus, Sigma-
Aldrich®), 0.5% D-(+)-glucose monohydrate (Sigma-Aldrich) and 0.005% phenol red as 
growth indicator. After 3 days of incubation (37°C; 5% CO2) a bacterial suspension of 
approximately 108 CFU/ml was obtained. Ten-fold serial dilutions were made using the same 
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broth, and 200 µl of the diluted suspension with approximately 105 CFU/ml was transferred to 
each well of a custom-made 96-U-bottom well Sensititre microplate (Thermofisher) 
containing doubling florfenicol concentrations between 0.25 and 128 µg/ml, oxytetracycline 
(0.12-128 µg/ml), doxycycline (0.06-32 µg/ml), tilmicosin (0.06-128 µg/ml), tylosin (0.06-32 
µg/ml), gamithromycin (0.06-256 µg/ml), tiamulin (0.03-1 µg/ml), gentamicin (0.06-32 
µg/ml) and enrofloxacin (0.06-32 µg/ml). Additionally, two growth control wells (no 
antimicrobial, with inoculum), a sterility control well (200 µL uninoculated broth, pH 7.8) 
and a pH control well (200 µL uninoculated broth, pH 6.8) were added to each plate. Hundred 
µL from one growth control well was used to perform ten-fold dilutions and subsequent 
inoculation on a modified PPLO agar plate. Colonies were counted after 7 days of incubation 
at 37°C in a 5% CO2 enriched atmosphere, to confirm inoculum concentrations were within a 
103-105 CFU/ml range. 
Plates were sealed with adhesive foil and incubated at 37°C. Interpretation of color change 
from red to orange/yellow was done after 48 and 72 hours of incubation. The lowest 
antimicrobial concentration without color change was recorded as the MIC at the earliest time 
point the growth control well had the same color as the pH control well. When for a certain 
isolate, more than one skipped well was observed, results for these isolates were excluded. 
When only one well was skipped, the highest MIC value was listed (EUCAST, 2020). Quality 
control was performed in every run (six in total) by determining the MIC values of M. bovis 
strain PG45 (ATCC 25523) and comparing these to previously published values (Ter Laak et 
al., 1993; Gerchman et al., 2009; Sulyok et al., 2014; García-Galán et al., 2020). Reference 
strains Staphylococcus aureus (ATCC®29213TM) and Escherichia coli (ATCC®25922TM) 
were included as extra quality control strains in the same broth as M. bovis, but observed after 
24 hours of incubation. 
 
Interpretation of MIC values 
Due to the lack of clinical breakpoints (CBPs), the interpretation of MIC values of M. bovis is 
not straightforward (Rosenbusch et al., 2005; Maunsell et al., 2001; Toutain et al., 2017). The 
best option to interpret M. bovis MIC data is probably to determine the epidemiological cutoff 
value (ECOFF). With this method, wild-type bacterial populations are distinguished from 
those with acquired resistance (non-wild type) by observing the MIC distribution. Three 
methods to estimate the ECOFF were compared in this study: the visual estimation 
(“eyeball”) method based on the uni-, bi- or multimodal MIC distribution and/or tailing, as 
described previously (Turndige et al., 2007; Toutain et al., 2017) and two statistical methods: 
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“Normalized Resistance Interpretation (NRI)” (http://www.bioscand.se/nri/, Bioscand AB, 
Täby, Sweden; Callens et al., 2016) and the “Iterative Statistical Method” processed in 
ECOFFinder (version 2.1; https://www.eucast.org/mic_distributions_and_ecoffs/, EUCAST) 
(Turnidge et al., 2006; Kronvall et al., 2010). Instructions provided by the founders were 
followed. When using the NRI method, standard deviations of the normal distribution of wild 
type MIC values exceeding 1.2 log2, result in a tentative estimate of the ECOFF and one can 
only speak of the “putative wild type group”. With ECOFFinder plots for residuals were 
checked and categorized, corresponding to whether the residuals scattered on either side of 
the horizontal axis in the center (well fit, selected subset values are considered reliable), only 
partly (poor fit) or not (no fit). As users can choose the cut-off value (95% to 99.9%) with 
ECOFFinder, depending on the intended use and influencing the sensitivity and specificity of 
the (non-)wild type population, both the 95% and 99% cut-off were determined. In addition, 
the MIC50 and MIC90 were calculated as the lowest MIC at which at least 50% and 90% of the 
isolates in a test population are inhibited in their growth, respectively. Since no ECOFF 
within the testing range of our study could be obtained by any of the three methods for 
tilmicosin, also previously published data and cross-resistance with tylosin were taken into 
account to make the decision that the isolates with MIC ≥ 32 µg/ml belonged to the non-wild 
type population (see discussion section). The latter tilmicosin ECOFF, together with the 
ECOFFs obtained with the visual estimation method, were used in further analysis to compare 
AMR in M. bovis isolates obtained from different cattle sectors or belonging to specific 
genomic clusters.    
 
Statistical analysis 
To determine whether there are significant differences between conventional herds (dairy, 
beef) and veal calves, a logistic regression was performed on binary variables, representing 
acquired resistance (1) and wild type (0) isolates. A P-value smaller than 0.05 was considered 
statistically significant. The Hosmer-Lemeshow test was included to determine the goodness 
of fit of the model (SPSS Statistics 26). To allow a meaningful statistical analysis, only for 
antimicrobials for which 5 to 95% acquired resistance was observed, statistical analysis was 
done. 
In a former study, a subset of 100 isolates of the currently used M. bovis database has been 
strain typed, as described earlier [18]. These isolates have been categorized in 5 phylogenetic 
clusters, based on single nucleotide polymorphism (SNP) analysis (Bokma et al., 2020a). In 
the present study, the association between the presence of acquired resistance according to the 
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visual estimation method and the phylogenetic clusters of this subset of strains was 
investigated for antimicrobials for which 5 to 95% acquired resistance was observed, and 
further visualized in MEGA-X (Kumar et al., 2018). Logistic regression on binary variables 
(1: acquired resistance; 0: wild type) was only performed for cluster III to V, as cluster I and 
II did not contain enough M. bovis isolates for the model to run.  
 
RESULTS 
Antimicrobial susceptibility of Belgian M. bovis  
MIC results of 141 epidemiologically unrelated M. bovis isolates are shown in Table 1. All 
obtained isolates were identified as M. bovis with MALDI-TOF MS (score value ≥ 1.7). MIC 
values for the M. bovis PG45 reference strain were within a small range of dilutions between 
runs for gamithromycin (8-16 µg/ml), tilmicosin (0.12-0.5 µg/ml), florfenicol (1-2 µg/ml), 
doxycycline (≤ 0.06-0.12 µg/ml), enrofloxacin (≤ 0.06-0.12 µg/ml), tylosin (≤ 0.06-0.12 
µg/ml), tiamulin (≤ 0.03 µg/ml), and oxytetracycline (≤ 0.12 µg/ml) and were similar to 
previously described results (Ter Laak et al., 1993; Rosenbusch et al., 2005; Gerchman et al., 
2009; Sulyok et al., 2017; Heuvelink et al., 2016; García-Galán et al., 2020). The quality 
control (QC) MIC-values for Staphylococcus aureus subsp. aureus (ATCC®29213TM) and 
Escherichia coli (ATCC®25922TM) were within the acceptable quality control ranges as 
provided by the Sensititre manufacturer. Results for gentamicin were excluded from this 
study, as the quality control was not passed, and MIC values for type strain M. bovis PG45 
deviated from previous studies (Gerchman et al., 2009; Sulyok et al., 2014). However, no 
quality control strains were included in previous studies, therefore the results are included in 
Supplementary file 1.   
 
Interpretation of MIC values 
The ECOFF as determined using the different methods and percentage of isolates belonging 
to the wild type and non-wild type population are shown in Table 2. For all three ECOFF 
methods, acquired resistance was frequently observed for macrolides (gamithromycin, 
tylosin), while only a few isolates showed acquired resistance against florfenicol, 
enrofloxacin and tiamulin. Following the visual estimation method, no acquired resistance 
against oxytetracycline and doxycycline was observed. Although, the statistical methods 
categorized part of the population (3.6%-13.0%) as non-wild type for doxycycline. 
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Table 1. Distribution of MIC-values (µg/ml) of 141 M. bovis isolates obtained from cattle in Belgium 
over 2016 - 2019  




≤ 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 Total 
Phenicol Florfenicol ND ND ND 1 5 27 44 43 13 3 4   ND 140 
Tetracycline Oxytetracycline ND ND 5 2 15 49 46 17 5     ND 139 
 Doxycycline ND 3 4 43 47 23 13 5    ND ND ND 138 
Macrolide Tilmicosin ND        1   3 23 114 141 
 Tylosin ND     1 3 11 16 22 7 77a ND ND 137 
 Gamithromycin ND 1    3 2 8 19 26 9 1 4 66 139 
Pleuromutilin Tiamulin 46 43c 29 15 5   1b ND ND ND ND ND ND 139 
Fluoroquinolone Enrofloxacin ND 1 17 51 37 20 2 3 2 2 1 1a ND ND 137 
ND: not determined, a MIC ≥ 32, b MIC ≥ 2, c MIC 0.06; ECOFFs based on the visual estimation method are shown as black 
vertical lines   
 
We were able to determine the ECOFF for 7 out of the 8 antimicrobials with the visual 
estimation method, whereas normalized resistance interpretation (NRI) and ECOFFinder 
determined a reliable ECOFF in 8/8 and 3/8 of the antimicrobials, respectively. The NRI 
method was able to determine an ECOFF for every antimicrobial tested, even when this 
needed extrapolation from the tested MIC range, such as for tilmicosin. However, when the 
standard deviation of the normal distribution of the wild type MIC value is > 1.2 log2, the 
program provides only the “putative wild type population”, as was the case for the 
macrolides. The ECOFFinder method was only able to determine reliable results (good fit 
plots for residuals), for florfenicol and the two tetracyclines. Truncated distributions influence 
the reliability or possibility to interpret some of the results, such as those for the macrolides. 
All three methods determined ECOFF values for corresponding antimicrobials within one 
dilution, except for doxycycline and tiamulin. This results in substantial differences in the 
(non)wild-type population. When ECOFFinder 95% was used for doxycycline, 13% was 
categorized as non-wild type in comparison to 0% when using the visual estimation method. 
For tiamulin the visual method indicated 0.7% non-wild type, whereas NRI indicated 15.1%. 
This might be due to the combination of “tailing” and the lack of a normal distribution, which 
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Table 2. Epidemiological cut-offs for M. bovis from Belgian cattle (n = 141) based on the visual 
estimation method, NRI and with ECOFFinder, resulting in different percentages of wild type (WT) 
and non-wild type (n-WT) 















WT (%) n-WT 
(%) 
Phenicol Florfenicol > 16 97.1 2.9 > 16 97.1 2.9 > 8/16 (+) 95.0/97.1 5.0/2.9 
Tetracycline Oxytetracycline > 8 100.0 0.0 > 8 100.0 0.0 > 4/8 (+) 96.4/100.0 3.6/0.0 
 Doxycycline > 4 100.0 0.0 > 2 96.4 3.6 > 1/2 (+) 87.0/96.4 13.0/3.6 
Macrolide Tilmicosin ND - - > 1024 - - ND - - 
 Tylosin > 32 43.8 56.2 > 128 # - - ND - - 
 Gamithromycin > 64 49.6 50.4 > 128 # 52.5 47.5 ND - - 
Pleuromutilin Tiamulin > 0.5 99.3 0.7 > 0.125 84.9 15.1 > 0.06/0.06 (-) - - 
Fluoroquinolone Enrofloxacin > 2 93.4 6.6 > 1 92.0 8.0 > 1/2 (±) 92.0/93.4 8.0/6.6 
# = tentative estimate, as standard deviation > 1.2 log2 
* plots for residuals were checked and categorized in either well fit (+), poor fit (±) or no fit (-) 
corresponding to whether the subset values are reliable or not. ND: not possible to determine 
 
Variability of antimicrobial susceptiblity per production system 
The distribution of M. bovis MIC values for the different antimicrobials and per production 
system are available in Supplementary file 2. Logistic regression did not show significant 
differences in antimicrobial resistance between production systems, except for gamithromycin 
(Table 3). Beef M. bovis isolates (58.21% acquired resistance) had a three times higher odds 
(CI 95%: 1.23-7.69) for gamithromycin resistance than dairy isolates (31.03%; P = 0.02).  
 
The MIC50 and MIC90 values are shown per sector in Table 4. No differences in MIC50 were 
observed between sectors for tilmicosin, doxycycline, and tiamulin. A single two-fold dilution 
difference in MIC50 between herd types was observed for florfenicol (highest in veal), 
oxytetracycline (lowest in dairy) and enrofloxacin (lowest in beef). A difference between 
herds was seen for gamithromycin and to a lesser extend for tylosin. MIC50 of gamithromycin 
was higher in beef cattle (> 128 µg/ml) than in dairy (16 µg/ml) or veal calf isolates (32 
µg/ml). No difference was observed in MIC90 for florfenicol, tilmicosin, and gamithromycin. 
While a single two-fold dilution was observed in MIC90 for oxytetracycline (lowest in dairy), 
doxycycline (highest in beef), tylosin (lowest in dairy), tiamulin (lowest in veal) and 
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Table 3. Results of logistic regression of antimicrobial resistant M. bovis isolates obtained from beef, 
dairy and veal calves over 2016-2019 in Belgium 
  ECOFF WT (%) nWT (%) OR  CI95% P - value 
Florfenicol Beef > 16 95.59 4.41    
 Dairy > 16 96.55 3.45    
 Veal > 16 100.00 0.00    
Oxytetracycline Beef > 8 100.00 0.00    
 Dairy > 8 100.00 0.00    
 Veal > 8 100.00 0.00    
Doxycycline Beef > 4 100.00 0.00    
 Dairy > 4 100.00 0.00    
 Veal > 4 100.00 0.00    
Tylosin Beef > 32 42.42 57.58 Ref  0.48 
 Dairy > 32 51.62 48.38 0.60 (0.25-1.44) 0.25 
 Veal > 32 41.94 58.06 1.02 (0.43-2.42) 0.96 
Tilmicosin Beef > 32 1.45 98.55    
 Dairy > 32 0.00 100.00    
 Veal > 32 0.00 100.00    
Gamithromycin Beef > 64 41.79 58.21 Ref  0.06 
 Dairy > 64 68.97 31.03 0.32 (0.13-0.81) 0.02 
 Veal > 64 51.61 48.39 0.67 (0.29-1.58) 0.36 
Tiamulin Beef > 0.5 98.53 1.47    
 Dairy > 0.5 100.00 0.00    
 Veal > 0.5 100.00 0.00    
Enrofloxacin Beef > 2 92.54 7.46 Ref  0.98 
 Dairy > 2 92.59 7.41 0.99 (0.18-5.45) 0.99 
 Veal > 2 93.55 6.45 0.86 (0.16-4.67) 0.86 
OR = odds ratio; CI95%: 95% confidence interval   
 
 
Table 4. MIC50 and MIC90 (µg/ml) of all M. bovis isolates and per sector, obtained from cattle in 
Belgium over 2016-2019 
  Total (n = 144) Beef (n = 70) Dairy (n = 31) Veal (n = 32) 
Class Antimicrobial MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 
Phenicol Florfenicol 2 8 2 8 2 8 4 8 
Tetracycline Oxytetracycline 1 4 2 4 1 2 2 4 
 Doxycycline 0.5 2 0.5 2 0.5 1 0.5 1 
Macrolide Tilmicosin > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 
 Tylosin > 32 > 32 > 32 > 32 16 32 > 32 > 32 
 Gamithromycin 128 > 128 > 128 > 128 16 > 128 32 > 128 
Pleuromutilin Tiamulin 0.06 0.25 0.06 0.25 0.06 0.25 0.06 0.12 
Fluoroquinolone Enrofloxacin 0.5 1 0.25 1 0.5 2 0.5 1 
MIC50: the lowest MIC at which at least 50% of the isolates were inhibited in their growth MIC90: the 




Antimicrobial susceptibility  Chapter 5.1 
220 
 
Association between AMR and genomic cluster  
In Figure 1, the distribution of the wild type and non-wild type M. bovis isolates for 
gamithromycin, tylosin, and enrofloxacin are shown over the five clusters obtained by whole 
genome sequencing. Most of the macrolide resistant isolates were located in cluster II and III, 
whereas cluster I contained isolates susceptible to all antimicrobials. Statistical analysis 
showed that M. bovis isolates from cluster III (85% acquired resistance) had a 22.7 (CI95%: 
4.0-125.0, P < 0.01) and 7.9 (CI95%: 1.5-40.0, P = 0.01) higher odds for gamithromycin 
resistance compared to cluster IV (19%) and V (41%), respectively. No significant association 
was found for tylosin or enrofloxacin.    
   
(a) (b) (c) 
Figure 1. Phylogenetic tree with the distribution of Belgian M. bovis isolates being susceptible (○) or 
resistant (●) for gamithromycin (a), tylosin (b), and enrofloxacin (c) based on the visual estimation 
method. These isolates were classified in five genomic clusters by a SNP-analysis of 100 Belgian M. 
bovis isolates (Bokma et al., 2020a). The figure was created using MEGA-X software with M. bovis 
isolates obtained over 2014-2019. 
 
DISCUSSION 
In this study, susceptibility of 141 M. bovis isolates obtained from beef, dairy and veal calves, 
was tested against 9 antimicrobial agents covering the 6 antimicrobial classes most frequently 
used to control M. bovis in Belgium, though results of gentamicin (covering the 
aminoglycosides) were excluded. Since neither clinical breakpoints (CBPs) nor guidelines to 
interpret ECOFFs for M. bovis are available, three methods (visual, NRI and ECOFFinder) to 
determine ECOFF and interpret antimicrobial susceptibility of M. bovis were explored.  
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Although one should be cautious in comparing results of different studies, because of the lack 
of internationally recognized standard protocols, the observed MIC values and distributions in 
this study were similar to previous publications from Western-Europe (Thomas et al., 2003; 
Barberio et al., 2014; Heuvelink et al., 2016; Klein et al., 2019). A large number of isolates 
had high MIC values for macrolides, resulting in more than half of the isolates being non-wild 
type for gamithromycin or tylosin. Cross-resistance between tylosin and tilmicosin has been 
described for M. bovis (Lerner et al., 2014; Sulyok et al., 2017), but determination of ECOFF 
based on the MIC values for tilmicosin was not possible as no normal distribution was 
obtained due to the very high MIC values.  
Surprisingly, there were no indications for acquired resistance against tetracyclines. Current 
study showed decreased MIC50-90 values (1-4 µg/ml) of M. bovis for oxytetracycline 
compared with a 20-year old Belgian study reporting MIC50-90 values of 2 and 32 µg/ml 
respectively (Thomas et al., 2003). In other European countries as well, a similar trend has 
been observed in recent years (Heuvelink et al., 2016; Klein et al., 2019). For doxycycline, 
percentages of acquired resistance depended on the ECOFF method used (0% to 13%). When 
using the 95% rule with ECOFFinder, 13% acquired resistance was obtained, while using the 
99% rule only 3.6% resistant isolates were observed. One should be aware that the decision 
using 95% or 99% can influence the outcome by either increasing the sensitivity for nWT 
(95%) or specificity for the WT population (99%). The distribution and MIC50-90 for 
florfenicol were similar (2-8 µg/ml) to previously published data (Gautier-Bouchardon et al., 
2014; Heuvelink et al., 2016; Klein et al., 2019), and only four isolates showed acquired 
resistance (MIC 32 µg/ml). In general, a small non-wild type population was observed for 
tiamulin. In Europe, pleuromutilins are not registered for use in cattle, while this class of 
antimicrobials is registered for treatment of Mycoplasma infections in pigs and poultry. In 
addition, valnemulin appears to be very effective against M. bovis in vivo (Stipkovits et al., 
2005) and low numbers of acquired resistance have been reported in M. bovis isolates in 
France, Spain, and Hungary as well (Gautier-Bouchardon et al., 2014; Sulyok et al., 2017; 
García-Galán et al., 2020). One possible non-wild type isolate for tiamulin was identified in 
this study. In a previous study, all tiamulin-resistant mutant strains showed cross-resistance 
against florfenicol (Sulyok et al., 2017), which was not observed in the current study. 
Distribution and MIC50-90 values for enrofloxacin (0.5-1 µg/ml) were comparable with 
previous studies (Thomas et al., 2003; Gautier-Bouchardon et al., 2014; Heuvelink et al., 
2016), except for Klein et al. (2019), who found higher MIC90 values (8 µg/ml).  
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Gentamicin did not pass the quality control with S. aureus (ATCC 29213) and E. coli (ATCC 
25922), also MIC for M. bovis PG45 deviated from previous studies (Gerchman et al., 2009; 
Sulyok et al., 2014), based on these observations the results were excluded. Previous studies 
did not include these quality control strains, and therefore we are not aware whether this is a 
reoccurring problem (Thomas et al., 2003; Gerchman et al., 2009; Sulyok et al., 2014). It is 
likely that specific medium components, resulting in an adjusted pH, have altered the results 
of the quality control strains (Gudmundsson et al., 1991), but as there is no standard protocol 
or quality control standard for M. bovis PG45, more research is necessary. Notwithstanding 
this, we included the results in the supplementary data to contribute to this research 
(Supplementary file 1). 
We did not observe significant sector-specific antimicrobial resistance, except for 
gamithromycin. M. bovis isolates from beef cattle had higher odds to be non-wild type than 
those from dairy cattle. Dairy cattle isolates also had the lowest MIC50 for tylosin. This could 
possibly be explained by the low number of macrolides registrated for use in lactating 
animals, and the high use of macrolides to combat bovine respiratory disease in beef cattle 
and veal calves. Also other factors, such as age, housing conditions and milk diet could play a 
part in the evolution of antimicrobial resistance in different production systems (Catry et al., 
2003). Considering the small difference in AMR over sectors, together with previously 
obtained knowledge about the lack of sector-specific M. bovis strains in Belgium (Bokma et 
al., 2020a), a single guideline for antimicrobial use for M. bovis infections covering all 
different cattle sectors in Belgium, with a small remark for gamithromycine, is likely 
sufficient.  
All used methods to determine the ECOFF are in some way based on a normal distribution. 
As a consequence, problems occurred with truncated MIC distributions (e.g. tilmicosin, 
tiamulin). Although the NRI method was able to determine more ECOFFs than the 
ECOFFinder (only florfenicol and tetracyclines) in an objective manner, the visual estimation 
method was mostly in agreement with these methods. Even though more subjective, the visual 
estimation method has the advantage that expert opinion and additional information from 
MIC data obtained from other class representatives or previous reports can be taken into 
account. For instance, even though a bimodal distribution was observed for tylosin, the 
population showing the lower MIC values might not represent the true wild type population. 
This is supported by a previous MIC study showing a much lower ECOFF (2 µg/ml), while 
similar QC values were obtained (Klein et al., 2017). In addition, it has been previously 
shown that specific mutations associated with macrolide resistance were absent in isolates 
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with MIC values between <0.5 and 4 µg/ml (Lerner et al., 2014). Therefore, an overall shift 
from M. bovis wild type to non-wild type for tylosin is suspected. The same line of reasoning 
is applicable to tilmicosin. Lerner et al. (2014) did not find any mutations associated with 
macrolide resistance in isolates with tilmicosin MIC values between < 0.5 and 32 µg/ml. 
Therefore it seems that all the isolates in this study acquired resistance to tilmicosin to some 
extent, except for one isolate with a MIC of 1 µg/ml for tylosin and 8 µg/ml for tilmicosin 
probably representing the wild type population for 16-ring macrolides. Indeed, a recent study 
showed very high MIC values (≥ 256 µg/ml) for >80% of the M. bovis population against 
tilmicosin (Heuvelink et al., 2016), whereas an older study showed a large population with 
lower MIC values between 0.5 and 32 µg/ml (Rosenbusch et al., 2005).  
Finally, we observed an association between gamithromycin susceptibility patterns and 
previously published genomic clusters. M. bovis isolates in cluster II and III were more 
frequently belonging to the non-wild type population, than those in cluster IV and V. This 
might be due to the higher heterogeneity in cluster IV and V caused by genetic drift (Bokma 
et al., 2020a). Yet, we should be careful in our conclusions, as we are not aware of the 
influence of genetic drift within any of the cluster on antimicrobial susceptibility data. We 
believe to this point that even when strain typing can be done very fast and easily, this should 
always be supplemented with phenotypically antimicrobial susceptibility testing (AST) to 
detect acquired resistance in M. bovis outbreaks. Nevertheless, strain typing could support in 
the surveillance of AMR by pointing out whether isolates are clonally spread or (closely) 
related to each other.  
 
CONCLUSIONS 
High acquired resistance percentages of M. bovis in Belgium were observed for macrolides, 
with almost all isolates having acquired resistance to 16-ring macrolides and a large 
proportion to 15-ring macrolides. In addition, minimal acquired resistance to florfenicol and 
tiamulin was observed, a limited acquired resistance to enrofloxacin, and almost none to the 
tetracyclines. Higher AMR for gamithromycin was observed in beef cattle compared to dairy, 
but the veal industry could not be identified as a reservoir of resistant M. bovis strains. A 
single guideline for antimicrobial use for M. bovis infections covering all different cattle 
sectors in Belgium, with a small remark for gamithromycine, is likely sufficient. In addition, 
only M. bovis strains belonging to cluster II and III had more isolates with acquired resistance 
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for gamithromycin compared to IV and V. Therefore, this study shows that strain typing 
cannot replace phenotypically AST of M. bovis in surveillance programs. 
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Mycoplasma bovis causes many health and welfare problems in cattle. Due to the absence of 
clear insights in transmission dynamics and the lack of a registered vaccine in Europe, control 
mainly depends on antimicrobial therapy. Unfortunately, antimicrobial susceptibility testing is 
usually not performed, because it is time consuming and no standard protocol or clinical 
breakpoints are available. Fast identification of genetic markers associated with acquired 
resistance may at least partly resolve former issues. Therefore, the aim of this study was to 
implement a first genome-wide association study (GWAS) approach to identify genetic 
markers linked to antimicrobial resistance in M. bovis using rapid long-read sequencing. High 
quality genomes of hundred M. bovis isolates were generated by nanopore sequencing and 
categorized into wild type and non-wild type isolates. Subsequently, a k-mer based GWAS 
was performed to link genotypes with phenotypes based on different epidemiological cutoff 
(ECOFF) thresholds. This resulted in potential genetic markers for macrolides 
(gamithromycin, tylosin; A2058G+/+ in the 23S rRNA gene and Gln93His in the L22 protein 
of the 50S ribosomal unit) and enrofloxacin (Ser83Phe or Glu87Gly/Val in gyrA and 
Ser80Ile, Ser81Pro or Asp84Asn/Tyr/Val/Gly in parC). Also, for tilmicosin and the 
tetracyclines, previously described mutations in both 23S rRNA alleles (G748A+/+) and one or 
both 16S rRNA alleles (A965T, A967T, T1199C, C1992A) were observed. In addition to two 
new 16S rRNA mutations (A1408G+/- and G1488A+/-) associated with gentamicin resistance. 
In conclusion, this study shows the potential of quick high quality nanopore whole genome 
sequencing and GWAS in the evaluation of phenotypic ECOFF thresholds and the rapid 
identification of M. bovis strains with acquired resistance.  
 
Key words: epidemiological cutoff, fluoroquinolones, gamithromycin, gentamicin, 
macrolides, nanopore sequencing




Mycoplasma bovis (M. bovis) is an important veterinary pathogen causing various diseases in 
cattle, such as pneumonia, mastitis and arthritis (Maunsell and Donovan, 2009; Maunsell et 
al., 2011). Transmission pathways and pathophysiology are not fully understood, hampering 
development of effective prevention and control (Calcutt et al., 2018; Parker et al., 2018). 
Also, no effective, commercial vaccine is available. Therefore, the most important way to 
control an outbreak of M. bovis associated diseases remains the adequate use of antimicrobials 
(Calcutt et al., 2018). M. bovis is naturally resistant against beta-lactam antibiotics and 
(potentiated) sulphonamides (Gautier-Bouchardon, 2018). Given that the use of critically 
important fluoroquinolones as first intention treatment in animals is strongly discouraged 
(Aidara-Kane et al., 2018), empiric therapy is mainly limited to florfenicol, tetracyclines and 
macrolides (Gautier-Bouchardon et al., 2014; Lysnyansky and Ayling, 2016).   
Worldwide, an overall increase in acquired resistance in M. bovis for mostly macrolides and 
tetracyclines, but also for florfenicol, lincosamides and fluoroquinolones is reported (Gautier-
Bouchardon et al., 2014; Cai et al., 2019; Klein et al., 2019; Bokma et al., 2020a; García-
Galán et al., 2020; Liu et al., 2020). To rationalize antimicrobial use for M. bovis, there is an 
urgent need for a rapid and meaningful antibiogram. Unfortunately, phenotypical AST of M. 
bovis is time consuming (up to two weeks), difficult to compare between studies as no 
standard protocol is available, and almost impossible to translate into in vivo results, 
considering the absence of M. bovis-specific clinical breakpoints (CBPs). Therefore, 
phenotypical AST is not routinely used in practice.  
A genetic approach may at least partly resolve former issues, since it is faster and more 
standardized for AST in M. bovis (Ellington et al., 2017; Kinnear et al., 2020). Molecular 
detection of antimicrobial resistance determinants with methods based on targeted PCR were 
explored in the past for M. bovis (Kong et al., 2016; Sulyok et al., 2018), and targeted gene 
sequencing for macrolide resistance has already been implemented in research and 
development settings for human Mycoplasma pneumoniae community-acquired infections 
(Pereyre et al., 2016). Recently, the association between point mutations identified with whole 
genome sequencing and phenotypic antimicrobial resistance (AMR) have been explored in 
specific regions of three M. bovis strains (Ledger et al., 2020) and on a large set of isolates for 
macrolides (Kinnear et al., 2020). However, these targeted approaches may result in a 
narrowed view and potential new genomic alterations within genes, operons, or even 
promotor, enhancer and/or inhibitory regions might be overlooked (Jaillard et al., 2018; 
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Kinnear et al., 2020). One way to overcome this shortcoming, is the use of a genome-wide 
association study (GWAS) to reveal both previously described and novel associations 
between genotype and phenotype (Coll et al., 2018). In addition, this approach can shed new 
lights to investigate other resistance mechanisms (e.g. methylation and transcription) if a 
whole genome versus phenotype association remains inconclusive. Key to this kind of 
analysis, is the generation of complete and highly accurate bacterial genomes. While short-
read sequencing approaches have been typically considered as gold standard for sequence 
accuracy, they result in highly contiguous genome assemblies for M. bovis due to its distinct 
genomic architecture. This is mainly due to a low GC content (29.3%), many highly repetitive 
regions and the use of a distinct genetic code (Translation table 4) (Razin et al., 1998). 
Nowadays, high quality (complete and accurate) long-read sequencing approaches have 
shown to be promising for all-in-one diagnostic workflows (including identification, strain 
typing, and possibly AMR detection), enormously reducing costs and turnaround time 
(Bokma et al., 2020c; Vereecke et al., 2020). The aim of this study was to identify known and 
potential new genetic markers linked with AMR phenotypes in a collection of 100 M. bovis 
isolates, exploiting the power of a genome-wide association approach on high quality and 
complete nanopore sequenced M. bovis genomes. 
 
MATERIALS AND METHODS 
Mycoplasma bovis collection and identification 
One hundred M. bovis isolates obtained from Belgian cattle between 2014-2019 were 
collected and described in a previous study (Bokma et al., 2020a). Briefly, the M. bovis strains 
were isolated from diagnostic samples (nasal and ear swabs, bronchoalveolar lavage fluid, 
milk, joint fluid and abdominal fluid). All samples were cultured on a selective-indicative 
agar plate as described before (Bokma et al., 2020b), and identified with MALDI-TOF MS 
(Bokma et al., 2019). The isolates were stored at -80°C until phenotypic AST, then aliquots 
were stored at -20°C until nanopore sequencing was performed on freshly grown cultures. 
 
Phenotypic antimicrobial susceptibility testing and interpretation 
The EUCAST Subcommittee recommends the epidemiological cutoff value (ECOFF) as the 
primary comparator for identifying an association between genotype from whole genome 
sequence data and phenotype (Ellington et al., 2017). The ECOFF distinguishes M. bovis 
isolates in wild-type (WT) bacterial populations and those with acquired resistance (non-wild 
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type; non-WT) based on the minimum inhibitory concentration (MIC). In a previous study, 
MICs of M. bovis isolates and M. bovis PG45 were obtained with microbroth dilution for 
tetracyclines (oxytetracycline; OXY, doxycycline; DOXY), macrolides (tilmicosin; TIL, 
tylosin; TYL, and gamithromycin; GAM), florfenicol (FLOR), gentamicin (GEN), 
enrofloxacin (ENRO) and tiamulin (TIA), using custom-made 96-U-bottom well Sensititre 
microplates (Thermofisher), resulting in different ECOFF values depending on the method 
used (Bokma et al., 2020a). In the present study, these different ECOFF values obtained by 
the visual estimation and two statistical methods (Normalized Resistance Interpretation (NRI) 
and the Iterative Statistical Method (95/99%)) were explored to determine the best ECOFF for 
the GWAS on M. bovis. As no ECOFF could be determined for TIL, isolates with MIC ≥ 32 
µg/mL were categorized as non-WT population, as previously suggested by Lerner et al. 
(2014). 
 
Generation of high quality and complete M. bovis genome assemblies with nanopore 
sequencing 
Total DNA of 100 M. bovis recent field isolates was extracted and subjected to whole-genome 
long-read nanopore sequencing as described previously (Bokma et al., 2020c). Sequencing 
was performed using native DNA sequencing with the Rapid Barcoding Sequencing Kit 
(SQK-RBK004; Oxford Nanopore Technologies (ONT)). A total of 12 strains were 
sequenced per run on an R9.4.1 flow cell (ONT) using a MinION device. In each sequencing 
run, the M. bovis PG45 type strain (ATCC®25523TM) was included as a positive quality 
control and mock inoculated broth was used as negative control. Raw data (fast5 files) were 
collected in the MinKnow software (v.3.6.5; ONT) and used in downstream bioinformatics 
analyses. M. bovis genomes were assembled as described before. Raw read files were 
basecalled using a M. bovis-specific trained Bonito basecalling model on Bonito (v.0.2.2; 
ONT) to generate high quality and reliable M. bovis sequences (Vereecke et al., 2020). 
Resulting reads were assembled into genomes using canu (v.1.9; Koren et al., 2016) and 
Medaka (v.1.0.0; ONT). Final genome assemblies were annotated using the Prokka rapid 
prokaryotic genome annotation pipeline (v.1.14.6; Seemann, 2014) and absence of plasmids 
was verified by contig evaluation and abricate (v.1.0.1; https://github.com/tseemann/abricate; 
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Genome-wide association study  
Firstly, we assessed the quality of all M. bovis genomes to ensure only high quality and 
complete genomes were included in downstream GWAS. Only genomes with sufficient 
median depth (>30X) and genome completeness (at least 224/226 marker genes; >99%) were 
used. Genome quality control was done using QUAST (v.5.0.2; Gurevich et al., 2013) and 
CheckM (v.1.1.0; Parks et al., 2015) using the Mycoplasma spp. (n = 226 markers from 83 
genomes) gene marker set. When all gene markers were present, a genome was considered 
100% complete. Contamination was assessed using Kraken2 classification (v2.0.9-beta; 
Wood et al., 2019) of contigs against the k2_pluspf_20200919 database. Contaminating 
contigs were removed along with duplicated contigs based on their size and effect on 
completeness. 
A k-mer based GWAS was performed to link phenotypes to genotypes. To this end the 
DBGWAS software (v.0.5.4; Jaillard et al., 2018) was used at default settings. The DBGWAS 
algorithm relies on extended k-mer searches based on compacted De Bruijn graphs to 
associate genetic variants with clear phenotypes. Firstly, a list was generated to link 
genotypes to phenotypes by categorizing the genomes as WT (designated 0), non-WT 
(designated 1) or undefined (designated as NA) if no phenotypic data was available. This was 
done for each antimicrobial drug tested and using the four ECOFF methods as mentioned 
above. This was given as input along with a phylogenetic tree of all genomes, generated 
through CSI phylogeny using the M. bovis PG45 type strain genome (NC_014760) as 
reference. Final DBGWAS visualization output was evaluated by significance (p- and q-
values), annotation, and allele frequencies of each phenotypic category. Final DBGWAS 
analysis output links are available upon request. Subsequently, designated “suspicious” gene 
targets were extracted from the annotated genomes, aligned using mafft (v.4.471; Katoh and 
Standley, 2013), manually curated, and analyzed for non-synonymous protein or nucleotide 
mutations in protein-coding sequence or ribosomal RNAs (rRNAs), respectively. A similar 
strategy was used for previously published genetic markers if insufficient phenotypic data 
(tilmicosin, tetracyclines and gentamicin) were available. Results were visualized using 









Phenotypic AST and the evaluation of high-quality M. bovis genomes  
Results of the phenotypic AST resulting in the determination of the ECOFFs were published 
elsewhere (Bokma et al., 2020a). All M. bovis PG45 tests showed comparable MIC values, 
classifying them to the WT population for each antimicrobial tested. Only high quality and 
complete (n=95 of 100) genomes were included in the GWAS, therefore a total of 5 genomes 
were excluded from subsequent GWAS analyses. Classification of M. bovis strains into (non-) 
WT or susceptible/resistant isolates was based on the ECOFFs as previously determined by 
Bokma and colleagues (2020a). Results for the 95 isolates and M. bovis PG45 in this study are 
shown in Table 1.  
 
Table 1. Distribution of antimicrobial susceptibility (WT: wild-type; n-WT: non wild-type) of 95 
nanopore sequenced M. bovis isolates and M. bovis PG45 per epidemiological cut-off (ECOFF) 
method (Visual estimation, Normalized Resistance Interpretation (NRI), and Iterative Statistical 
Method; ISM). Determination of ECOFFs were previously published (Bokma et al., 2020a). 
 Visual estimation NRI ISM (95/99%) 
Antimicrobial EC WT n-WT EC WT n-WT EC WT n-WT 
Florfenicol >16 91 4 >16 91 4 >8/16 (+) 89/91 6/4 
Oxytetracycline >8 94 0 >8 94 0 >4/8 (+) 92/94 2/0 
Doxycycline >4 94 0 >2 91 3 >1/2 (+) 82/91 12/3 
Tilmicosin ND - - >1024 - - ND - - 
Tylosin >32 46 50 >128 # 46 50 ND - - 
Gamithromycin >64 53 43 >128 # 56 40 ND - - 
Gentamicin >16 95 1 > 8 94 2 >4/4 (-) 91/91 5/5 
Tiamulin >0.5 95 1 >0.125 80 13 >0.06/0.06 (-) 59/59 34 
Enrofloxacin >2 85 8 > 1 83 10 >1/2 (±) 83/85 10/8 
# = tentative estimate, as standard deviation >1.2 log2. * plots for residuals were checked and categorized in 
either well fit (+), poor fit (±) or no fit (−) corresponding to whether the subset values are reliable or not. 
ND: not possible to determine. NA: not available 
 
GWAS analysis based on different ECOFF methods 
First, the GWAS analysis was applied to the different distributions of WT and non-WT based 
on ECOFFs determined by visual estimation, NRI, and ISM95/99% approaches (Table 1). 
The most significant (p and q values) results for ENRO and TYL were seen when ECOFF 
was based on the visual estimation method. For GAM a negligible difference between the 
visual estimation and NRI was observed (Supplement 1). Unfortunately, for FLOR, OXY, 
DOXY, TIL, GEN and TIA, the GWAS analysis was not successful as either (i) no, (ii) too 
little (n<5) strains were addressed to the (non-)WT group or (iii) no clear association could be 
made between the classified genotypes and observed phenotypes. As not all methods could be 
applied to all macrolides, and results of the visual estimation were for the most part more 
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significant than the other methods, from here on GWAS results are shown based on ECOFFs 
determined by the visual estimation method as described in Bokma et al. (2020a).  
 
Mutations in the M. bovis gyrA and parC encoding genes are associated with 
enrofloxacin resistance 
A successful GWAS analysis for fluoroquinolone ENRO could be performed as the non-WT 
population contained 8 isolates out of 96 (95 field isolates + PG45) total high-quality 
genomes. Two significant components were identified covering the gyrA (Fig. 1A) and parC 
(Fig. 1B) gene targets for the ENRO phenotype. These genes encode for the DNA gyrase 
subunit A and DNA topoisomerase 4 subunit A protein, respectively. Other components were 
analysed but did not show an association with the ENRO resistant phenotype. In-depth 
analysis of these “suspected” target genes from each genome showed the existence of two 
non-synonymous mutations (Ser83Phe or Glu87Gly/Val) located in the Quinolone Resistant 
Determining Region (QRDR). In addition, four possible mutations (Asp79Asn, Ser80Ile, 
Ser81Pro and Asp84Asn/Tyr/Val/Gly) were identified in the ParC protein (Fig. 2; orange). 
The MIC values for the M. bovis isolates and their associated mutations in GyrA and ParC are 














Figure 1. DBGWAS analysis for enrofloxacin resistance in 95 Belgian M. bovis isolates and M. bovis 
PG45. Two significant associations between the enrofloxacin non-wild type (non-WT) phenotype 
(n=8) and genotype could be found for two known fluoroquinolone gene targets, including the gyrA 
(a) and parC (b) genes. Further in-depth analysis showed the identification of 2 and 4 non-
synonymous mutations in the GyrA and ParC protein, respectively. Amino acid positions are labelled 
according to classical E. coli numbering. 
 
 




Figure 2. Distribution of phylogenetic tree, MIC values and (non-synonymous) mutations of 95 
Belgian M. bovis field isolates and M. bovis PG45. Colour lapse shows gradient of MIC values for 
enrofloxacin (orange), macrolides (gamithromycin, tylosin, tilmicosin; green) and gentamicin (blue), 
while coloured blocks show the presence/absence of (non-synonymous) mutations. Nucleotide and 
amino acid positions are labelled according to classical E. coli numbering. 
 
 




Figure 3. Distribution of MIC values for 100 Belgian M. bovis isolates and M. bovis PG45 and their 
associated mutations in gyrA and parC. All strains, except Mb184, with a double mutation in gyrA and 
parC show MIC values above the ECOFF (n=10).  
 
Macrolide resistance in M. bovis is associated with genetic markers in the 23S ribosomal 
subunit 
TIL had only one isolate belonging to the WT (PG45) population, therefore a GWAS could 
not be performed. However, the determined ECOFF allowed us to identify a known mutation 
by investigating previously reported resistance target genes. The G748A mutation in domain 
II of both 23S rRNA alleles could be linked to the non-WT population (n = 95) and was not 
present in PG45 (Fig. 2; green). For the two macrolides, GAM and TYL, 52 and 45 out of 96 
isolates (95 field isolates + PG45) belonged to the non-WT population. The DBGWAS 
analysis highlighted the association of both 23S rRNA gene and the ribosomal operon in the 
resistance phenotypes of both TYL and GAM. Hence, both 23S rRNA alleles and all 50S 
accessory ribosomal proteins were extracted and screened for mutations in association to TYL 
and GAM.   
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As shown in Figure 5A, comparable significant associations of point mutations at position 
A2058 and A2062 within domain V of the 23S rRNA gene were shown. The A2058 mutation 
was found in both alleles, whereas the A2062 mutation was only found in one allele of the 
23S rRNA gene (Fig. 5B). 23S rRNA mutations C2062A, G2506A, and C2611G were present 
in allele 1 of 6, 4, and 12 isolates, respectively, but it was not possible to link them with 
observed macrolide phenotypes. In addition, both TYL and GAM phenotypes were associated 
with an operon as suggested by the thread-like structure in the DBGWAS analyses output 
(Fig. 5C) (Jaillard et al., 2018). DBGWAS k-mer annotation and further analyses of the 
resulting operon, suggested the association of the ribosomal operon with the GAM and TYL 
phenotype (Fig. 5D). Further analyses of the ribosomal genes revealed GAM/TYL resistance-
associated mutations in the rplD and rplV gene, encoding for 50S ribosomal protein 4 (L4) 
and 22 (L22). While no clear association of the non-synonymous Gly185Val/Arg mutation in 
the L4 protein with the n-WT of TYL/GAM was identified, the Gln93His mutation in L22 
suggested an association with (combined) GAM and TYL non-WT type phenotypes. The 
latter was observed in all isolates (n=35) harboring the transition at the A2058 position in 
domain V of one or both alleles of the 23S rRNA, of which 27 strains lacked the Gln93His 
mutation in the L22 ribosomal protein. Still 6 out of 41 double TYL and GAM resistant 
isolates showed distinct mutation patterns which could not be linked to a specific resistance 
phenotype (Fig. 2; green), and 15% (6/41) of isolates showing a double TYL and GAM 
resistance phenotype could not be linked to a specific non-WT phenotype (Fig. 2; green). This 
was also the case for 7 and 13 strains which belonged to only one of GAM or TYL non-WT 
populations, respectively.  
 
Mutations in the 16S rRNA possibly associated with tetracycline resistance  
Depending on the ECOFF used, no to limited (13%) phenotypic tetracycline resistance was 
observed in this study. Nevertheless, previously reported 16S rRNA mutations possibly 
associated with resistance were observed. In all isolates one or more mutatations were 
identified, except for M. bovis PG45 (MIC ≤ 0.12 µg/mL), where no mutations was observed 
on residue 965, 967, 1058, 1192 or 1199 of the 16S rRNA. In all 95 field isolates A965T and 
A967T mutations are present, with additional mutations C1192A (8 in one allel, 23 in both 
alleles) and T1199C (26 in one allel, 3 in both alleles). No clear association with increased 
MIC values was observed, although an increase in number of mutations resulted in increased 
MIC values (Fig. 4).   
 





Figure 4. Distribution of MIC values for 95 M. bovis isolates and M. bovis PG45 and the number of 
mutations at position 1192 and 1199 in the 16S rRNA (0: blue, 1: orange, 2: grey, 3: yellow, 4: green) 
for doxycycline (above) and oxytetracycline (down).  
 
Marker mutation in 16S rRNA observed in gentamicin resistant M. bovis isolate 
For GEN the GWAS could not be performed. Nevertheless, one of the M. bovis isolates 
(Mb218) showed a significantly higher MIC (64 g/mL) as compared to the WT population 
(< 32 g/mL). Since GEN is known to act on the 16S ribosomal subunit, all small ribosomal 
proteins and both 16S rRNA alleles were manually checked for mutations. Two transversions 
(A1408G and G1488A) in either one of both 16S rRNA alleles were observed in the Mb218 
strain. Since none of the WT isolates harbored these mutations and both A1408 and G1488 
transversions were located at or near the GEN binding site of domain II of the 16S rRNA, 
these mutations are possibly marker mutations for GEN resistance in M. bovis (Fig. 2, blue). 
 





Figure 5. DBGWAS analysis for gamithromycin (GAM) and tylosin (TYL) resistance in 95 Belgian 
M. bovis isolates and M. bovis PG45. (A) Association of GAM (non-WT=43) and TYL (non-WT=50) 
genotypes with phenotypes, resulted in a shared 23S rRNA target association. (B) Secondary structure 
of Domain V of both 23S rRNA alleles, showing the observed mutations (A2058 and A2062). 23S 
rRNA positions are labelled according to classical E. coli numbering. (C) DBGWAS analysis output 
highlights a complex k-mer web, including continuous k-mer strands, suggesting the association of a 
genetic operon with the phenotype. (D) Genetic context of the M. bovis ribosomal operon, indicating 
known GAM and TYL drug target genes (23S rRNA, rplD, and rplV).  
 




In this study, we exploited a GWAS approach to associate the M. bovis genotype to 
phenotypic antimicrobial susceptibility test results. High quality complete and accurate whole 
genomes were generated using nanopore sequencing and an optimized taxon-specific base 
calling model and assembly as previously described (Vereecke et al., 2020). In addition, 
different methods to determine ECOFFs and therefore the delineation of the M. bovis WT 
population and strains with acquired resistance (non-WT) were explored. The GWAS analysis 
showed significant and clear results for the critically important antibiotics ENRO, GAM, and 
TYL, as enough strains were available belonging to the WT or non-WT populations. These 
antimicrobials require top concern, according to the World Health Organization and the 
World Organization for Animal Health (WHO, 2017; OIE, 2019).   
In this study we identified several previously reported mutations for ENRO resistance in M. 
bovis (gyrA: Ser83Phe, Glu87Gly/Val; parC: Ser80Ile, Ser81Pro, and 
Asp84Asn/Tyr/Gly/Val), supporting the relevance of the obtained output. In addition, a new 
genetic marker in parC (Asp79Asn) was identified and associated with acquired ENRO 
resistance. This mutation was previously described in clinical M. synoviae isolates and in 
vitro mutated M. agalactiae isolates (Lysnyansky et al., 2013; Tatay-Dualde et al., 2017). No 
mutations in the GyrB protein could be associated with the phenotypes (data not shown), 
which was expected because such mutations are described to be associated with evolutionary 
mutations for which we corrected by implementing the phylogenetic tree (Lysnyansky et al., 
2009; García-Galán et al., 2020). Any single gyrA mutation (Ser83Phe or Glu87Gly/Val) was 
observed in strains with MIC-value of 0.5 and 1 μg/ml, as was previously described for 
Ser83Phe in Israeli M. bovis isolates (Lysnyansky et al., 2009). Even though these strains still 
belonged to the WT population according to an ECOFF of >1 µg/mL, the isolates were all on 
the right-hand side of the normal distribution and therefore close to the ECOFF. In Israeli 
isolates, an additional mutation in Asp84Asn (parC) was necessary to obtain resistance (MIC 
>2 μg/ml) (Lysnyansky et al., 2009), which supports our findings. Mutations in Glu87 (gyrA) 
were previously only demonstrated after in vitro selection and were believed to have no 
impact on resistance (Khalil et al., 2015; Sulyok et al., 2017). However, in our study the 
Glu87Gly/Val mutation was associated with elevated MIC values (Mb225: 2 µg/ml and 
Mb134: 4 µg/ml) when co-occurring with a parC gene (Aps84) mutation. It was previously 
described that a mutation on the same position (Asp84Asn) results in a 2-fold increase of the 
MIC-value (Lysnyansky et al., 2009; Khalil et al., 2015; Sulyok et al., 2017), which possibly 
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explains the increased MIC-value of the Glu87 mutation. Influence on MIC values of other 
mutations on this location (Asp84Tyr/Gly) have not yet been determined (Khalil et al., 2015). 
Therefore, further research is necessary whether mutations on this location could result in 
resistance on its own. Hata and coworkers (2019) concluded that single mutations in parC do 
not result in lower susceptibility. However, in our study one isolate (Mb184) contained a 
single mutation Asp84 in parC with a non-WT phenotype (MIC = 2 µg/ml). Other resistance 
mechanisms might have been involved, as efflux pumps were identified in M. hominis 
resulting in resistance for fluoroquinolones (Raherison et al., 2002), which cannot be 
evaluated with the current approach.  
In one isolate, highest MIC-values (≥ 32 μg/ml) were obtained for the combination of 
Ser83Phe and Ser80Ile, which is in line with mutations identified in French, Japanese and 
Spanish M. bovis isolates (Sato et al., 2013; Khalil et al., 2015; Hata et al., 2019; García-
Galán et al., 2020).  
The GWAS suggested the visual estimated ECOFF of > 2 µg/ml should be lowered to > 1 
µg/ml. However, isolates containing only a mutation in Ser83 were still not identified as non-
WT by the phenotypical AST but were close to the ECOFF. Therefore, using molecular 
methods may be superior to the phenotypical AST as an early warning tool for the emerging 
of AMR in surveillance programs. In addition, on the individual animal or herd level, it would 
be recommended to avoid the use of ENRO when at least one mutation is found, even though 
phenotypical susceptibility testing shows susceptibility, as more selection pressure would 
result in additional mutations, and therefore increased MIC values.  
All non-WT isolates for the 16-membered-ring macrolide TIL contained the G748A mutation 
in domain II of both 23S rRNA alleles, which was also observed in previous studies (Sato et 
al., 2017; Hata et al., 2019; Kinnear et al., 2020; Ledger et al., 2020). An additional mutation 
at position 2058, was associated with GAM (15-membered-ring) and TYL (16-membered-
ring) resistance in our GWAS. This combination of mutations was also observed in previous 
TYL and TIL resistant isolates (Lerner et al., 2014; Kong et al., 2016; Khalil et al., 2017). The 
mutation at A2058 has also been associated with macrolide and lincosamide resistance in M. 
bovis before, although in clinical Spanish isolates, there was only an association with 
lincosamide resistance (Sato et al., 2017; García-Galán et al., 2020). In our study the 
Gln93His mutation in the L22 protein was observed in 73% of isolates. This is in the same 
range as reported by Lerner et al. (2014) and is below the 100% incidence in Kinnear et al. 
(2020). The C2611G mutation was identified in our study, but was not associated with 
increased resistance phenotypes, which is in line with observations in M. pneumoniae 
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(Pereyre et al., 2016). The A2062 and G2506A mutations have been suggested to be linked to 
florfenicol and pleuromutilin (e.g. tiamulin) resistance before in M. bovis (Sulyok et al., 2017; 
Hata et al., 2019). Even though these mutations were identified in some of the currently 
investigated M. bovis isolates, no clear association was identified with the phenotypical 
resistance against any of the tested antimicrobials. The associations between other mutations 
and macrolide resistance of M. bovis were non-conclusive (data not shown). This could be 
due to a less black-and-white division between WT and non-WT populations, representing an 
overlapping grey area, or insufficient distribution of the isolates in this study. Together, this 
will result in errors in current used methodology. However, it is more likely that we are not 
fully understanding the genotypic basis of the phenotypic resistance yet (Ellington et al., 
2017; Ledger et al., 2020). For example, other resistance mechanisms, such as target-site 
modification by methylation has been described for macrolides in Streptomyces fradiae (Liu 
and Douthwaite, 2002). Analogous mutations have been identified in M. bovis but have not 
yet been associated with AMR (Ledger et al., 2020). Another macrolide AMR mechanism 
that was not fully investigated in current research, is the efflux of the drug by ABC-
transporters. While (ABC-type) efflux pumps were identified in the M. bovis genome (data 
not shown), their causal link with macrolide resistance still has to be confirmed using targeted 
mutagenesis, efflux pump inhibitors or gene expression analyses using RNA-sequencing. 
However, for M. pneumoniae it has been shown that efflux pumps (possibly ABC-type) are 
involved in resistance to macrolides (Li et al., 2017). Cross-resistance with other 
antimicrobials not included in this study, such as lincosamides, may also be a likely 
explanation. Cross-resistance between the macrolides and lincosamides is frequently 
described for Mycoplasma species, as both classes of molecules bind to domain V of the 23S 
rRNA and the L22 ribosomal protein (Sulyok et al., 2017; Prats-van der Ham et al., 2018). 
Mutation of A2059G in both 23S rRNA alleles was also seen in lincomycin resistant M. bovis 
isolates (Sulyok et al., 2017; Hata et al., 2019) and in M. pneumoniae strains, where mutations 
in L4 and L22 ribosomal proteins were associated with both macrolide and lincosamide 
resistance (Pereyre et al., 2004).   
When insufficient strains belong to the (non-)WT population (e.g. OXY, DOXY, FLOR, TIL, 
GEN, TIA) a GWAS analysis is not successful or renders inconclusive outputs. Hence the 
genetic profiling of AMR is limited to the detection of previously described mutations 
available in literature. For OXY and DOXY, several mutations previously associated with 
tetracycline resistance were observed, although the mutation at site 1058, previously 
described in France and Japan was not observed in this study (Amram et al., 2015, Khalil et 
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al., 2017; Hata et al., 2019). For a part of the isolates, the data suggests an increase in MIC 
value when more alterations are observed, in the remaining part another unknown mechanism 
(e.g. efflux mechanisms) may be involved in increasing the MIC values (Chopra and Roberts, 
2001). Alterations at 1192 in one or two alleles were also associated with spectinomycin 
resistance (Sulyok et al., 2017; Hata et al., 2019), but could not be confirmed in this study as 
spectinomycin was not included in the phenotypic AST. In the case of GEN, only one strain 
was classified as non-WT and was the only strain showing mutations (A1408G and G1488A) 
in either one of both 16S rRNA alleles. Due to their approximate localization to the known 
gentamicin-binding region of the 16S rRNA, both mutations are suggested to contribute to 
GEN acquired resistance. Even though RNA methyltransferases were extensively investigated 
in aminoglycoside resistance, mutations were shown to confer aminoglycoside resistance in 
Mycobacterium abcessus (Nessar et al., 2011; Doi et al., 2016). Whether these mutations are 
really resulting in higher GEN MIC values and if so, whether both mutations are required or 
only one is sufficient to show a GEN resistance phenotype, should be addressed in further 
research.  
Investigating the genome by GWAS for nonsynonymous mutations associated with resistance 
can clarify whether ECOFFs have been rightfully chosen. The present study showed that 
determination of the ECOFF with the visual estimation method resulted in best agreement 
between antimicrobial resistant phenotype and genotype for the antimicrobials which had a 
clear bimodal distribution. Nonetheless, it also showed that statistical methods can be of great 
help in case of truncated distributions (‘tailing’), which are frequently observed for step-by-
step resistance mechanisms, such as the fluoroquinolones (ECOFF visual estimation: >2; 
statistical methods: >1). The determination of ECOFF is very suitable for surveillance and to 
rapidly recognise development of resistance in a population, as it shows small changes 
compared to the WT population (Bywater et al., 2006). Although the ECOFF is a good 
indicator for the determination of acquired resistance, it should be kept in mind that 
translating ECOFFs to clinical outcomes is discouraged (Bywater et al., 2006). To clinically 
interpret MIC values and associate these with mutations in the genome, clinical breakpoints 
for M. bovis should be available first. Only then, the concordance between WGS and clinical 
breakpoints can be assessed.  
This study showed nanopore sequencing as rapid new tool to readily determine acquired 
antimicrobial resistance and support evaluation of ECOFF values in M. bovis. Since 
conventional identification and AST for Mycoplasma spp. are highly time-consuming (up to 2 
weeks). This approach allows to significantly shorten current sampling-to-result workflow. 
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Even though here pre-enriched samples were used, implementing nanopore-based approaches 
immediately on field samples should be a reachable future goal to make identification and 
AST data of various species readily available. Using GWAS, we were able to reveal genetic 
markers associated with acquired antimicrobial resistance of M. bovis for critically important 
antibiotics of the fluoroquinolone and macrolide family, were revealed. By using data 
generated in this kind of analyses, M. bovis field strains can be classified as WT or non-WT in 
a rapid and easy way, which is not possible with current growth-dependent methods and the 
lack of widely used ECOFFs or CBPs. Therefore, rapid nanopore sequencing may help in 
antimicrobial decision making, while facing an M. bovis outbreak. The applicability can be 
even more broad by expanding the input of the GWAS analysis with additional phenotypical 
and genome information of (non-)WT M. bovis isolates from different populations.  
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Supplement 1. Results of GWAS on 96 M. bovis isolates based on different ECOFF methods 
Antimicrobial Gene p-value q-value Significance WT vs nWT 
 Visual estimation 
Enrofloxacin ParC 2,07E-50 2,06E-46 40 unitigs (14 significants) 85/8 
 GyrA 4,11E-19 8,19E-16 23 unitigs (4 significants) 85/8 
Tylosin 23S rRNA 6,90E-13 6,87E-09 24 unitigs (4 significants) 46/50 
 rOperon 1,28E-06 4,24E-03 2452 unitigs (139 significants) 46/50 
Gamithromycin 23S rRNA 6,85E-11 6,83E-07 24 unitigs (3 significants) 53/43 
 rOperon 4,12E-06 1,37E-02 4929 unitigs (226 significants) 53/43 
 Normalized resistance interpretation 
Enrofloxacin ParC 7,38E-43 7,35E-39 40 unitigs (12 significants) 83/10 
 GyrA 5,59E-18 1,11E-14 23 unitigs (4 significants) 83/10 
Tylosin 23S rRNA 6,90E-13 6,87E-09 24 unitigs (4 significants) 46/50 
 rOperon 1,28E-06 4,24E-03 2452 unitigs (139 significants) 46/50 
Gamithromycin 23S rRNA 2,70E-12 2,69E-08 24 unitigs (3 significants) 56/40 
 rOperon 6,70E-07 1,33E-03 4833 unitigs (183 significants) 56/40 
 ECOFFinder 95% 
Enrofloxacin ParC 7,38E-43 7,35E-39 40 unitigs (12 significants) 83/10 
 GyrA 5,59E-18 1,11E-14 23 unitigs (4 significants) 83/10 
 ECOFFinder 99% 
Enrofloxacin ParC 2,07E-50 2,06E-46 40 unitigs (14 significants) 85/8 
 GyrA 4,11E-19 8,19E-16 23 unitigs (4 significants) 85/8 
WT = wild type, nWT = non-wild type 
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Worldwide, in all cattle production systems, Mycoplasma bovis remains a huge cause of high 
antimicrobial use, hampering animal welfare and economic losses. To combat this highly 
infectious pathogen, identification, antimicrobial susceptibility testing (AST), and knowledge 
about its epidemiology are of great importance. In this thesis, new MALDI-TOF MS and 
whole genome sequencing protocols for the identification of M. bovis from BALf and 
additional AST were developed and validated. These methods and the information that came 
to light while using these methods can help in better understanding and controlling M. bovis 
infections.  
In this general discussion, first the improvements made on M. bovis diagnostics with the 
present available techniques and their (dis)advantages will be outlined. This overview will be 
followed by recommendations on the diagnostic approach in (1) outbreak management of M. 
bovis, (2) purchase policies, and (3) M. bovis herd status. These recommendations can help 
veterinarians in their decision making, and other authorities in implementing (inter)national 
surveillance and monitoring systems for M. bovis.   
 
6.1 INNOVATIONS IN MYCOPLASMA BOVIS DIAGNOSTICS 
For a long time, the three commercially available methods to diagnose a present or recent M. 
bovis infection were culture, PCR, and antibody ELISA (Parker et al., 2018). These methods 
all have their potential, but also several drawbacks, like higher costs, low diagnostic accuracy, 
interpretative issues and a long sample-to-result turnaround time, as was extensively 
described in the general introduction. Although unfounded, it is mostly assumed that PCR is 
the best method for M. bovis identification, reaching almost 100% sensitivity and 100% 
specificity. In contrast, the selective-indicative agar, which is widely used in Belgium for the 
identification of M. bovis, is frequently criticized by international experts, because no studies 
showed its diagnostic potential. In this thesis, qPCR appeared less perfect as previously 
assumed, and the selective-indicative agar, although having a moderate sensitivity (70.5%), 
even showed a greater specificity (93.9%) than the triplex qPCR (88.9%). An advantage of 
PCR over the selective-indicative agar is that multiplex PCR can also include identification of 
other pathogens (Mycoplasma species, bacteria, viruses), and turnaround time is faster. In Fig. 
1, the currently available methods for the identification of M. bovis from BALf are shown, 
including the two new techniques developed in this thesis. MALDI-TOF MS can be applied 
in three different ways. When the sample is cultured on conventional agar for Mycoplasma 
species (5-10 days), subsequent identification with the ‘direct transfer method’ is sometimes 
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possible when enough M. bovis material can be gathered (Pereyre et al., 2013) . However, it 
should be kept in mind, that sometimes false positive results (Mycoplasma alkalescens and 
Mycoplasma arginini) can be obtained due to interference of medium-related (e.g. horse 
serum, colistin) peaks (Chapter 3.1). When the ‘direct transfer method’ fails, probably due to 
insufficient bacterial mass, an M. bovis colony from the agar plate can be added to a specific 
liquid culture (Pereyre et al., 2013; Randall et al., 2015). After incubation of 24-120 hours in 
liquid culture with pyruvate, a protein extraction and MALDI-TOF MS analysis results in 
reliable identification of M. bovis (Chapter 3.2). However, these methods still require a 
culture step on agar taking 5-10 days before result. Therefore the method ‘rapid identification 
of M. bovis with MALDI-TOF MS’ (RIMM), using an enrichment procedure of 2-3 days in 
liquid medium, is more likely to be used in routine diagnostics when rapid identification is 
necessary (Chapter 3.3). In contrast to the first two methods, the latter method has only been 
tested on BALf. However, preliminary tests show promising results in milk as well, after only 
minor adjustments to the RIMM protocol. It can be expected that similar protocols will 
probably also work for nasal swabs or samples from other body fluids. As final method, direct 
identification of M. bovis from respiratory tract samples with nanopore sequencing (ONT) 
was shown to be possible (Chapter 3.4). Although ONT is less sensitive and more expensive 
than RIMM, this method should be able to simultaneously identify all Mycoplasma species, 
bacteria and viruses. This is in contrast to qPCR, where the target for specific Mycoplasma 
species or other micro-organisms are previously defined.   
 
To date, no routine AST is performed in Belgium, and a reference framework for resistance 
determination is lacking worldwide. In this thesis a new method to determine antimicrobial 
susceptibility of M. bovis for macrolides and fluoroquinolones with nanopore sequencing was 
developed. In addition, this method also provides the possibility of strain typing. An 
important remark to make is that AST and strain typing with nanopore sequencing, currently 
still require the purification of high M. bovis DNA concentrations. These can only be obtained 
following culture-based methods for the moment, such as the selective-indicative agar or 
RIMM (Fig. 1), but this can of course change in the future with increasing technological 
possibilities.  




Figure 1. Currently available diagnostic methods for the identification of M. bovis and its cost, turnaround time and diagnostic accuracy. Cost and turnaround 
time are estimated, and can vary between laboratories. The dashed line represents the direct transfer method, which is not optimized (yet). ONT: nanopore 
sequencing, RIMM: rapid identification of Mycoplasma bovis with MALDI-TOF MS.  
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Therefore, to rapidly identify M. bovis we recommend the RIMM method as the most cost-
effective identification method (2-3 days). Afterwards, AST (for macrolides and 
fluoroquinolones) and strain typing can be done with nanopore sequencing (2 days). In the 
next chapters, more specific recommendations and clarification will be given for specific 
events, such as outbreak management, purchase, and herd status determination.  
 
 
Figure 2. Recommended cost-efficient workflow for M. bovis identification and antimicrobial 
susceptibility testing. Cost and turnaround time are estimated, and can vary between laboratories 
 
6.2 MYCOPLASMA BOVIS OUTBREAK MANAGEMENT   
While facing a disease outbreak, both a diagnostic decision and an antimicrobial treatment 
decision need to be made. Preferably, before the antimicrobial treatment decision is made in a 
BRD or mastitis outbreak, one should diagnose whether M. bovis is involved or not because 
this has major implications for treatment and general control measures. Different diagnostic 
approaches are possible, and among other factors the urgency of the situation and financial 
limitations of the farm will drive the veterinarian to a tailored approach for the particular 
farm. The information from the laboratory results can aid to make a better informed choice of 
an antimicrobial for first intention treatment. This is especially important when considering 
metaphylactic treatment, as large amounts of antimicrobials will be used. Both diagnostic 
decision making and antimicrobial treatment decision making will be outlined beneath. In 
addition, the use of strain typing in outbreak management will be discussed on the basis of an 
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Diagnostic decision making  
Many factors influence the veterinarian in his/her decision to sample a particular outbreak, 
including the management and history of the farm, the farmers expectations and financial 
restrictions and the suspected involved pathogen(s). A whole range of diagnostic tests is 
available, with advantages and disadvantages, varying accuracy and associated cost, resulting 
in the fact that there is no one size fits all diagnostic test. Hence, several questions arise in this 
diagnostic decision making helping the veterinarian to decide which test(s) to request. These 
questions are: (1) Which pathogens should be looked for in the laboratory for this particular 
outbreak? (2) Is it necessary to obtain an isolate for additional testing (e.g. AST, strain 
typing)? (3) Which samples can be obtained and are necessary for the desired analysis? (4) Is 
it possible to pool the samples to reduce analytic costs without losing accuracy? For each of 
these questions the possibilities and diagnostic methods are shown in Table 1.  
  
As mentioned before, some qPCR and NGS methods can offer, in function of need and 
sometimes at higher cost, simultaneous identification of other Mycoplasma species, bacteria 
or viruses. The sample choice depends mainly on the disease form present (respiratory, 
mastitis, arthritis). Also, even though a good agreement between deep nasopharyngeal swabs, 
BAL, and TTA for M. bovis has been observed (Doyle et al., 2017), it should be considered 
that for example deep nasopharyngeal swabs may be easy to obtain, but compared to 
BALf/TTA/TTW have an increased risk of overgrowth of other pathogens and/or 
contamination (Van Driessche et al., 2017). In addition, not all methods are already optimized 
for all possible samples (Table 1). Pooling of samples can seriously reduce cost, especially for 
costly methods such as qPCR or nanopore sequencing. Taking five samples for pooling 
appeared the most cost-effective number of analyzing samples with a diagnostic test 
(sensitivity: 70%; specificity: 100%) (Pardon and Buczinski, 2020). In this case the risk of not 
finding the pathogen causing the outbreak is almost zero, if the test would be 100% specific 
(Pardon and Buczinski, 2020). We showed that pooling five BALf samples is indeed a 
reliable M. bovis identification method when applied with the RIMM and nanopore 
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Table 1. Questions to be asked in the diagnostic decision process during a potential M. bovis outbreak. 
 Culture RIMM qPCR 
Nanopore  
sequencing 
1. Which pathogens do I want to detect? 
M. bovis ✓ ✓ ✓ ✓ 
M. bovis + bacteria ✓a - ✓ ± 
M. bovis + viruses  - - ✓ ✓ 
2. Do I want to perform additional antimicrobial susceptibility testing or strain typing? 
Isolate obtained ✓ ✓ - - 
3. What sample do I want to analyze to detect M. bovis? 
BALf/TTA ✓ ✓ ✓ ✓ 
Deep nasal swab ✓ ND ✓ ✓ 
Milk ✓ ± ✓ ND 
Body fluids* ✓ ND ✓ ✓ 
4. Do I want to pool five samples for M. bovis identification? 
BALf/TTA ND ✓ ✓ ✓ 
Deep nasal swab ND ND ✓ ✓ 
Milk ND ND ✓ ND 
Body fluids* ND ND ND ND 
a additional cost for bacteria * e.g. joint, pleural, abdominal or cerebrospinal fluid; ± probably after small 
adjustments to the protocol; ND: not determined 
 
Next to the above mentioned considerations, turnaround time and cost-effectiveness of the 
different tests are very important in the selection of a diagnostic method (Fig 1.). However, 
interpretation of ‘accuracy’ of a test is sometimes a difficult concept to comprehend. 
Therefore, Fagan nomograms can help to visualize what the sensitivity and specificity of a 
test actually mean in the field and how they contribute to the relevance of the test outcome 
(Caraguel and Vanderstichel, 2013). First sensitivity and specificity are translated to positive 
and negative likelihood ratios (LR) per diagnostic test (LR+ = Se/(1-Sp); LR- = (1-Se)/Sp) 
(Caraguel and Vanderstichel, 2013). These values support and give direction to the translation 
from pre-test probability (possibility that an animal is infected, mostly based on prevalence) 
to the post-test probability (possibility that indeed the animal is infected when the test is either 
positive or negative). When LR is smaller than 1, the test result supports the absence of the 
condition. When the LR is 1, the test has no diagnostic value, and when the LR is higher than 
1, the presence of the condition is supported by the test. This may sound too complicated to 
bring into practice, but available online calculators (http://araw.mede.uic.edu/cgi-
bin/testcalc.pl) or the two-step Fagan’s nomogram can be used on paper without additional 
calculations (Caraguel and Vanderstichel, 2013) for the visualization of these outcomes.    
 
For example, in an acute outbreak of BRD on a beef farm in Belgium, the prevalence of M. 
bovis is approximately 30% (Pardon et al., 2020). Therefore, a reasonable estimate of our pre-
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test probability, the possibility that an animal is infected with M. bovis, would be 0.3. Using 
different diagnostic methods, with different sensitivity and specificity for M. bovis 
identification, will eventually lead to different post-test probabilities, as shown in Fig. 3a. 
When the test result in the lab is positive, the chance an animal is truly infected with M. bovis, 
depending on the used method, is 75-92% (post-test probability/positive predictive value) 
when a prevalence of 30% is expected. A negative lab test means that the chance the animal is 
infected with M. bovis is still 3-12% (post-test probability; 1-negative predictive value), 
depending on the used test. Probably, while facing an acute BRD outbreak, this is an 
acceptable risk, especially when as recommended at least five animals are tested to obtain a 
farm-level result (Pardon and Buczinski, 2020). Both false positive and false negative results 
have their consequences. On the one hand, animal welfare will be hampered when an animal 
is not properly treated although enduring a bacterial infection (false negative). On the other 
hand, the risk of antimicrobial resistance will increase when animals not infected are treated 
with antimicrobials (false positive). Figure 2a shows that when comparing these tests, the 
lowest probability for a false positive test is the use of nanopore sequencing (orange), while 
the lowest probability of false negatives can be obtained by RIMM (red) or qPCR (green). 
When prevalence of M. bovis is believed to be lower in another country or when eradication 
programs are implemented (a lower prevalence would be expected then, e.g. 10%), this can 
influence the post-test probability as shown in Fig 3b.  
 
Nevertheless, for a reliable analysis and interpretation of the test results in a disease outbreak, 
several basic rules in sample-taking should be considered. First, the sampled animal should: 
(1) reflect the (herd) problem, (2) be in the acute phase of the disease, and (3) not previously 
be treated with antimicrobials. Next, the sample should be taken as clean as possible 
(especially for culture-based methods) from the site of interest, and finally the samples should 
be stored and transported at low temperatures. For M. bovis and Pasteurellaceae from BALf, 
the recommended temperature is 0-8ºC (Boonyayatra et al., 2010; Parker et al., 2016; Van 
Driessche et al., 2020). Freezing of samples is possible and recommended for culture when 
arrival in the laboratory takes more than 24 hours after sampling, however a decrease in 
sensitivity can be expected (Biddle et al., 2004; Boonyayatra et al., 2010; Vyletělová, 2010; 
Gille et al., 2018). Freezing is discouraged for identification of M. bovis from BALf with 
nanopore sequencing, as non-viable M. bovis are not detected, due to the nuclease step in the 
protocol, resulting in a lower sensitivity. 





Figure 3. Example of Fagan nomograms showing the pre- and post-test probability of culture (blue), 
RIMM (red), qPCR (green), and nanopore sequencing (orange) on BALf, facing an acute outbreak of 
bovine respiratory disease while prevalence is expected to be 30% (a) or 10% (b). Sensitivity, 
specificity, and corresponding positive and negative likelihood ratios (LR) per diagnostic test are 
shown in the table.  
 
Antimicrobial treatment decision making 
Once diagnostic samples are taken, the decision to either start or wait with antimicrobial 
therapy before the results of the diagnostic tests get back, needs to be made. Rapid 
identification of M. bovis, can already direct towards a more appropriate first choice 
antimicrobial use, as its inherent resistance can be circumvented. A combination of 
experience on farm therapy success and local antimicrobial susceptibility data, can then help 
in the antimicrobial choice. For example, in Belgium we did not observe acquired in vitro 
antimicrobial resistance against tetracyclines in M. bovis, and only very limited acquired 
resistance against florfenicol (Chapter 5.1). In addition, it was also shown in an M. bovis field 
ba
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trial that parenteral use with these antimicrobials resulted in a rapid cure of almost all 
clinically affected animals (De Cremer, 2019). Nevertheless, it is still possible that resistance 
against these antimicrobials in M. bovis occurs and may result in therapy failure. In this case, 
a second antimicrobial should be administered. In the authors opinion, it is important to 
already have an antibiogram before initiation of a second therapy, because in Belgium, a fair 
level of acquired resistance against macrolides and fluoroquinolones has been observed 
(Chapter 5.1). Therefore, blind usage of gamithromycin, for which 50% of the Belgian M. 
bovis isolates demonstrated acquired resistance, and with even greater odds of acquired 
resistance in beef cattle, would signify an unnecessary delay in treatment. The longer the 
period before appropriate treatment is implemented for M. bovis, the higher the risk that an 
animal becomes chronically diseased as a result of immune evasion, virulence factors or 
biofilm formation of M. bovis (Buchenau et al. 2010; Razin and Hayflick, 2010; Perez-Casal, 
2020). Hence, determining antimicrobial susceptibility of M. bovis for macrolides and 
fluoroquinolones with nanopore sequencing can be of great help (Chapter 5.2). The 
identification of specific mutations associated with the step-wise fluoroquinolone resistance is 
of great importance. Using fluoroquinolones on a farm with animals harbouring M. bovis 
strains with only a slight increase in fluoroquinolone MIC value, increases the risk of an 
additional mutation, resulting in clinically relevant resistance of M. bovis. Logically, when 
these specific step-wise mutations are observed, the use of fluoroquinolones should definitely 
be discouraged.  
Therefore, the authors recommend in BRD outbreaks with suspected M. bovis involvement, to 
obtain BALf, process with RIMM (2-3 days), and when positive for M. bovis, perform 
additional AST with nanopore sequencing (2 days) (Fig 2). Also, we would recommend 
systematic sampling and laboratory testing in every situation that may need a group 
antimicrobial therapy.  
 
For mastitis cases, antimicrobial therapy is not recommended, and therefore the above 
suggested workflow may seem less attractive (Jasper, 1981; Bushnell, 1984). However, it is 
really important to remember that in mastitis outbreaks where M. bovis is involved, calves and 
young stock are frequently affected as well, and may need antimicrobial treatment. For 
example, in 15 of 17 Finnish outbreaks starting with a mastitis index case, M. bovis could be 
isolated from nasal swabs in the calves (Vähänikkilä et al., 2019). In addition, a high 
prevalence of M. bovis was seen in calves in herds with previous M. bovis outbreaks 
(Maunsell and Donovan, 2009). But also when no clinical mastitis is detected in the last few 
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months, isolation of M. bovis in calves is possible, as half a year later in 10 out of these 17 
previous herds, calves were still positive. One and 1.5 year after the index case, M. bovis was 
still present in the calves on 3 of these herds (Vähänikkilä et al., 2019).  
 
MIC determination can also be applied after an isolate is obtained, as commercially offered in 
the Netherlands. Alternatively, qPCR based methods (Melt-MAMA, HRM) are offered to 
motivated Hungarian cattle-breeders in a research setting. These qPCR methods can also be 
applied directly to clinical samples for most antimicrobials. However, resistance genes can 
easily be overlooked, as only most common (in a certain region) SNPs are targeted. When 
communicating AST results to veterinarians and farmers, it is of huge importance to warn 
them about the limitations of the used tests. Especially, the lack of specific clinical 
breakpoints for M. bovis can result in unintentional, but inappropriate antimicrobial use.  
 
Use of strain typing in M. bovis outbreak management   
In 2020, our veterinary teaching hospital was confronted with an acute outbreak of respiratory 
disease and otitis in a large beef herd (~100 calves). M. bovis was isolated from BALf, nasal 
swabs, and the middle ear. The same herd also faced respiratory disease in 2017 caused by M. 
bovis as well. Following AST protocols and ECOFFs as determined in Chapter 5.1, four 
isolates (2 from 2017; 2 from 2020) were wild type for florfenicol, tetracyclines, 
gamithromycin and enrofloxacin. Indeed, in the first outbreak, immediate treatment with 
either florfenicol or oxytetracycline resulted in cure of almost all animals after 8 and 14 days 
as evidenced by thoracic ultrasonography, respectively (De Cremer, 2019). Animals that did 
not cure (7/161), were isolated from the herd and eventually culled. However, in the second 
outbreak (2020), the cure rate to antimicrobial treatment (florfenicol, oxytetracycline, 
gamithromycin, enrofloxacin) was much lower, and after 21 days of treatment, still 30% 
(28/94) of the animals showed lung lesions on thoracic ultrasonography. The question was 
raised whether this was a relapse of a persisting strain or a new outbreak resulting from a 
breach in external biosecurity of this farm. To answer this question, the two isolates obtained 
in 2017 and 2020 were cultured, sequenced, and strain typed as described in Chapter 4. 
  





Figure 4. Phylogenomic analysis of 4 M. bovis strains (bold, red) obtained from two M. bovis 
outbreaks on a Belgian beef farm. The first outbreak (2017) was represented by a M. bovis strain from 
Belgian genomic cluster IV, while those from the second outbreak (2020) were closely related to 
strains from the genomic cluster I (Chapter 4).  
 
The phylogenomic analysis showed that both acute outbreaks were caused by M. bovis strains 
belonging to different Belgian genomic clusters (Fig 4; bold red). Therefore, it seems very 
likely that a new M. bovis strain was introduced in the herd, caused by a security breach. The 
breach in biosecurity was not immediately detected, however when in the future more M. 
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bovis strains are systematically collected and sequenced, tracing back the source might be 
more feasible. The poor therapy response in 2020 of the M. bovis strain belonging to the first 
Belgian genomic cluster, may be due to a late detection of the involvement of M. bovis in the 
BRD outbreak, which emphasizes the importance of rapid diagnosis. In addition, poor 
treatment success could also have been due to a more virulent M. bovis strain or undetected 
other pathogens. Potentially, this strain improved its characteristics to evade antimicrobials or 
produced biofilms better than others. More research is necessary to identify associations 
between strain type and virulence.  
 
In conclusion, the diagnostic decision of using culture-based methods followed by nanopore 
sequencing in M. bovis outbreaks, can help at different moments in the antimicrobial 
treatment decision making process (first intention treatment, and when therapy failure 
occurs). In addition, the confirmation that a new strain has been introduced into the herd by 
strain typing, can help the veterinarian and farmer to discover possible biosecurity breaches, 
such as purchase, artificial insemination of infected semen, or transmission by fomites 
(Gonzalez et al., 1992; Haapala et al., 2018; Pardon et al., 2020). In the future, strain typing 
can also help to determine whether a certain strain is originally from a specific herd. An 
outbreak after purchase, which can be tracked back to one farm, can result in targeted 
protocols, tracing animals at risk and test these animals for potential follow up measurements.   
 
6.3 USE OF MYCOPLASMA BOVIS DIAGNOSTICS IN PURCHASE POLICY 
With purchase being the most frequently observed risk factor for the introduction of M. bovis 
into the herd, the identification of M. bovis carrier animals at purchase is very important. As 
shown with the Fagan’s monogram (Figure 3), the risk that an animal is infected with M. 
bovis during an outbreak with current diagnostic methods would still be ~10% when negative 
test results are obtained. This may be acceptable for M. bovis outbreak management, as more 
than one animal will be tested and the pathogen is already circulating in the herd. However, to 
prevent M. bovis from entering a negative herd, a risk of 10% with every purchase the farmer 
makes is obviously too high. To reduce false negative outcomes, the sensitivity of a test is 
very important. However, when one test cannot reach the desired sensitivity (as shown 
above), parallel testing can help to increase sensitivity. Therefore, parallel testing may be a 
solution in purchase protocols, while keeping the animal in quarantine awaiting the results. 
Examples of different parallel testing options for the identification of M. bovis on BALf are 
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given in Fig 5. In general, when testing two methods in parallel, the Fagan nomogram shows 
that the chance for a false negative result is now smaller than 1%. Parallel use of RIMM and 




Figure 5. Fagan nomogram showing the pre- and post-test probability of parallel testing of culture, 
RIMM, qPCR, and nanopore sequencing on BALf, when prevalence of M. bovis is 30%. Sensitivity 
(Se), specificity (Sp), and corresponding positive and negative likelihood ratios (LR) per diagnostic 
test are shown in the table. Se and Sp determined by Winepsicope (multiple diagnostic tests: 
http://www.winepi.net/uk/index.htm). Population size was set at 100.  
 
One of the downfalls at the moment is that the diagnostic accuracy of most of these methods, 
is only validated on BALf so far. In the context of purchase, testing on deep nasal swabs 
and/or milk samples may be more appropriate. This is an easier way to test animals, and it 
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was also shown by Hazelton et al. (2020) that colonization of the nose is most prevalent. 
Another sample site that can be considered, although tougher to swab, are the pharyngeal and 
palatine tonsils (Maunsell et al., 20212). Buckle et al. (2020) showed that sensitivity of 
mucosal swabs from the palatine tonsillar crypt was seven times higher than those from the 
bronchial main stem after slaughter of 51 asymptomatic calves. However, this kind of sample 
is less evident and more research (e.g. comparison between nasal and tonsil swabs) is 
necessary before implementation in purchase policies can be recommended. When the best 
sampling method is determined, also the diagnostic test accuracy for the different methods 
can be further explored.  
A second downfall is the potential intermittent shedding of M. bovis (Caswell and 
Archambault, 2007; Byrne et al., 2005). A diagnostic test can be perfect, but if the animal is 
not shedding the pathogen, the test cannot detect it. Nevertheless, as it is suspected that 
animals usually start shedding after stress (e.g. calving, disease, transport, introduction in new 
herd), they probably will start shedding after purchase. Therefore, quarantine of purchased 
animals is of great importance, and multiple testing seems appropriate.   
To counteract the absence of shedding, antibody ELISA testing could be used as an additional 
test. Unfortunately, these tests cannot distinguish between present, active infection (acute or 
chronic) or cured infection and therefore cannot distinguish between carrier animals or those 
that cleared the infection. It does however inform on previous contact with M. bovis in the 
herd. Possibly paired sera can give more insight, as Vähänikkilä et al. (2019) observed a 
downward line in serum antibody concentrations in young stock where infection seemed 
under control and no more M. bovis was detected in the second year. In contrast, 60-80% of 
the young stock animals in herds where M. bovis kept circulating remained seropositive with 
MilA ELISA (Vähänikkilä et al., 2019). This was in contrast to BioX ELISA, which did not 
follow similar patterns as culture or PCR, possibly on the one hand due to lower sensitivity of 
BioX ELISA compared to MilA, and on the other hand due to the low prevalence of positive 
animals in the BioX ELISA category. The same actually applies to qPCR, as qPCR can detect 
non-viable M. bovis as well. It is not clear how long after clearance of the infection, an animal 
stays positive for M. bovis on qPCR. In a study on veal calves 49% of the calves were still 
positive with qPCR four weeks after treatment with mostly macrolides or tetracyclines, while 
only 19% of them were still positive with culture (Becker et al., 2020). Another possibility 
could be a lower detection limit of qPCR compared to culture (Hazelton et al., 2018) or the 
inhibition of growth with culture. Although nanopore sequencing has a lower sensitivity for 
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M. bovis identification, it can distinguish better between presence of viable and non-viable M. 
bovis. To be entirely sure, culture remains the ‘gold standard’ to detect viable M. bovis.  
 
6.4 ERADICATION OR HERD STATUS CERTIFICATES 
Although this thesis did not focus on the diagnosis of M. bovis on herd level and methods 
were only validated on the individual animal level, the herd level status of M. bovis is very 
important. In New Zealand for example, the most recent country where M. bovis was 
introduced, started an eradication program in 2018 based on positive and negative M. bovis 
herds. Complete culling of positive herds is an internationally closely followed (and 
criticized) part of the program.  
In this situation of obliged culling, a false positive result can have disastrous consequences on 
economy, animal welfare, and the farmers wellbeing. Therefore, the specificity of the used 
diagnostic method should approach 100% to minimize the risk of false positives. Next to false 
positive results, a false negative result can have enormous consequences as well. When 
eradicating and missing a single case, this can set the whole country back to where it started. 
As there are no tests available approaching 100% sensitivity and specificity, serial testing is 
recommended to increase in the first place specificity. In theory, first the most sensitive 
technique should be applied as a screening test to maximize sensitivity. In New Zealand, this 
would be qPCR. Also, screening all animals with qPCR will be a costly event. Therefore, 
antibody ELISA is often used as a cheap screening method. Unfortunately, sensitivity and 
specificity of ELISA tests have a very broad range, depending both on the commercial or in-
house kit and samples used (Nielsen et al., 2015; Wawegama et al., 2016; Andersson et al., 
2019). Therefore, combination of antibody ELISA with another method for optimal 
monitoring and surveillance is recommended (Vähänikkila et al., 2019). In New Zealand, this 
approach was also first chosen for the eradication program, namely the use of antibody 
ELISA (first Bio-X, for a short while Biovet and eventually the IDvet kit), and subsequent 
PCR (Ministry of Primary Industries, 2019). At least 100 animals were tested with ELISA on 
blood, and additionally PCR testing was performed to confirm an infected herd. When only 
one animal was positive in two consecutive ELISA tests and/or PCR, the herd was culled 
(Jordan et al., 2021). More recently, the strategy was modified. Now also herds are culled 
only based on IDvet ELISA test results. The reason is the believed high sensitivity (93.5%) 
and specificity (98.6%) of this antibody ELISA test (Andersson et al., 2019; Ministry of 
Primary Industries, 2019). It seems that a herd is categorized as infected when ≥ 30% of the 
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animals are seropositive, and negative as <5% is positive with antibody ELISA, due to cross-
reaction with other Mycoplasma species. At the moment (1st of April, 2021), 262 herds in 
New Zealand were confirmed to be infected with M. bovis (67 dairy, 139 beef, 56 other) 
(number of total herds: ~30.000; Stats, 2019), 170,486 animals were culled, 2,030,762 tests 
were executed, and an investment of approximately 200 million New Zealand Dollar was 
made so far (Ministry for Primary Industries, 2021). Although eradication of M. bovis is not 
yet accomplished, progress towards eradication has been made. Since eradication was started 
in 2018, the reproduction number (R value) was always beneath 1, and only few new cases 
were identified in 2019 (Jordan et al., 2021). Nevertheless, M. bovis is still present, and small 
breaches in the track an tracing systems, suboptimal detection systems or a mutation resulting 
in increased virulence, can result in new outbreaks. 
 
Such eradication programs are probably not applicable in Belgium or even in Europe. The 
prevalence of M. bovis is already high and in many areas already endemic (Maunsell et al., 
2011; Timonen et al., 2020). In addition, the control on import and export of animals is more 
difficult in the European mainland than on an island, like New Zealand. Investments to pay 
off farmers, would be incredibly high. However, what could be an opportunity for the future 
in endemic regions is the implementation of M. bovis herd status certificates. Farmers can 
decide for themselves whether to invest in measurements to keep or reach a negative herd 
status. To free a herd of M. bovis, frequent testing and isolating carrier animals will be key. 
Return on investment will depend on the previous status of the herd, but will probably show 
in increased marked value of the animals, reduced antimicrobial use, and less economic 
losses.  
 
How to obtain a negative herd after an outbreak, is outside the scope of this thesis. 
Nevertheless, metaphylactic treatment after the diagnosis of M. bovis and subsequent isolating 
or culling of chronically infected animals may be recommended. Also management changes 
such as termination of raw milk feeding, and individual housing until 8 weeks old could be 
recommended in calves. When facing severe M. bovis mastitis, culling is an easy decision 
given the poor prognosis, but the decision becomes a lot harder for subclinical mastitis. How 
cattle eliminate M. bovis is unclear, but an observational study showed that culling did not 
result in a faster clearance of M. bovis from the herd (Punyapornwithaya et al., 2012). There 
was however no information available on clinical status of the animals or reason for culling 
on the farms. Some of the farmers might have culled M. bovis positive animals 
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unintentionally, because of other reasons (e.g. age, non-mycoplasmal diseases). On the other 
hand, there are studies showing continuing presence of the same M. bovis strain in herds for 
years (Spergser et al., 2013; Parker et al., 2016). Therefore, whether animals should be culled 
or isolated is not clear. For dairy herds, milking suspected animals last or using a separate 
milking machine are logical measures, but actually putting clinically affected animals 
immediately in complete quarantine, avoiding contact with animals with non-M. bovis related 
diseases in the hospital pen, is likely more efficient, but not always easy to implement in 
practice (Punyapornwithaya et al., 2011). Further research on how to identify and isolate 
carrier animals is necessary to obtain a negative herd status. The new methods developed in 
this thesis may be used as supportive tools, but testing on herd level (e.g. BTM in lactating 
cows, nasal swabs in non-lactating cattle), next to the individual level, and frequently testing 
compared to single testing, should be first validated. It has already been shown that PCR on 
BTM can be negative, while there were still individual animals positive for M. bovis mastitis 
in the herd (Vähänikkila et al., 2019). Murai et al. (2014) showed the cost-effectiveness of 
eleven diagnostic strategies based on qPCR and bacterial culture to identify M. bovis mastitis 
cases. The most cost-effective method was pooling of 5 samples for culture, followed by 
culture on individual samples. Including qPCR on 50 or 100 pooled samples as first step, was 
the second most cost-effective alternative compared to the reference strategy (individual 
culture on all animals).  
 
Antibody ELISA can be useful for monitoring programs, but when a farm is suspected to be 
positive for M. bovis based on antibody ELISA, it is necessary to demonstrate the presence of 
the pathogen by culture-based methods, before culling. Strain typing could be helpful both in 
M. bovis outbreak management, as in surveillance programs. Also M. bovis introduction from 
other countries can be traced, when more whole genomes become available (Chapter 4).   
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6.5 FUTURE PROSPECTS 
This thesis added important information on M. bovis diagnostics and epidemiology, but 
unfortunately there are still many knowledge gaps. One of the most important research 
question is probably still: “How do we identify carrier animals to prevent M. bovis from 
entering the herd?”. To answer this question and to establish safe protocols, more research on 
which samples to collect and how frequently animals should be sampled to counter 
intermittent shedding is necessary. 
To what extend the identification and AST methods developed in this thesis can be 
extrapolated or adjusted to other Mycoplasma species, such as M. ovipneumoniae, M. 
hyopneumoniae, and M. pneumoniae, should be explored in further research. On AST, 
consensus on standard protocols and the determination of clinical breakpoints is important. 
Genetic molecular methods are showing potential, but are still only based on in vitro results. 
When clinical breakpoints cannot be realized, randomized clinical trials with known M. bovis 
strains and potential resistance genes may be an option. Until then, phenotypic and genetic 
molecular methods should be used in parallel to avoid missing new antimicrobial resistant 
mechanisms. There is minimal discussion whether antimicrobial treatment is necessary when 
culture shows positive results for M. bovis. However, interpretation of borderline qPCR and 
deep sequencing outcomes in association with clinical status and/or recovery phase of the calf 
is unclear and can have serious consequences on antimicrobial treatment, purchase, and 
culling. When the association between quantification of diagnostic methods and clinical status 
of the animal is clarified, these methods may even support the evaluation of antimicrobial 
treatment efficacy or prognosis in acute or chronic bacterial infections in the future.  
The general public is also getting more and more concerned with animal welfare. For 
example, many people experienced the unpleasant or sometimes painful feeling while they 
were sampled for COVID-19 testing, which might result in strong opinions on performing 
deep nasal swabs, TTA and BAL in calves. Therefore, future research may include parameters 
on stress and pain levels of animals while undergoing different sampling methods, showing 
the combination of the most animal friendly and efficient sampling method. Also, together 
with antimicrobial therapy, it would be helpful to determine whether NSAIDs relieve pain 
when facing disease or whether these substances interfere with the cure rate of cattle infected 
with M. bovis, possibly reducing animal welfare on the long term, as was shown in 
preliminary research (Dudek et al., 2019).   
 




The developed MALDI-TOF MS and ONT methods for rapid identification, antimicrobial 
susceptibility testing and strain typing of M. bovis from BALf are complementary and 
immediately applicable in peripheral laboratories. They can contribute to more efficient 
treatment of acute outbreaks and plans for M. bovis control or eradication. The RIMM is a 
cost-efficient rapid method to identify M. bovis and simultaneously obtaining an isolate for 
further (ONT) testing. NGS shows great potential for a (rapid) detection of M. bovis 
mutations associated with acquired antibiotic resistance, but further development is needed 
for broader use, given that not all resistance phenotypes were present in our dataset. The 
development of standard protocols, clinical breakpoints, and the in vivo validation of these in 
vitro results will still be necessary. Complementing the available whole genome sequences of 
more M. bovis isolates worldwide can support this, but can also give more insights in the 
epidemiology of M. bovis and support in track and tracing of M. bovis introductions and 
outbreaks.  
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Mycoplasma bovis is a leading, primary cause of pneumonia, arthritis, otitis and mastitis in 
cattle, resulting in impaired animal welfare and huge economic losses in all cattle sectors 
worldwide. This small bacterium lost its cell wall and several physiological mechanisms 
through evolution, whereupon it acquired inherent resistance against many conventional 
antimicrobials (e.g. penicillines, cephalosporines, sulfonamides, ..). Next to this natural 
resistance, M. bovis may acquire resistance against other antimicrobials as well. Currently, 
isolation and identification of M. bovis by culture takes 1-2 weeks, and subsequent 
antimicrobial susceptibility testing is currently not performed in routine diagnostics. No 
standard protocol is available and the lack of clinical breakpoints limits the translation of in 
vitro results to clinical outcome predictions of antimicrobial treatment. At a higher price, 
faster identification is possible with PCR (2 days). Although diagnostic accuracy of PCR is 
expected to be higher than culture, scientific information on this matter is limited.  
To be able to control M. bovis and start appropriate antimicrobial treatment immediately, 
there is a great need for rapid and reliable diagnostic tools for this pathogen. However, next to 
control, prevention of M. bovis spreading into/within the herd is also very important. How M. 
bovis is exactly transmitted, and whether there are specific M. bovis strains associated with 
antimicrobial resistance or sectors, has not been elucidated yet. Key factors for successful 
control and prevention are the formulation of specific biosecurity protocols and guidelines 
targeted to M. bovis. To achieve this, a rapid diagnosis of infected or carrier animals and 
better insights into the spread of M. bovis between herds, sectors, and countries are needed. 
 
Therefore, the general aim of this thesis was to develop new Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) and nanopore 
sequencing based diagnostic methods for rapid identification, strain typing, and antimicrobial 
susceptibility testing of M. bovis, and to apply those methods on Belgian field samples, 
gaining better insight into the epidemiology of M. bovis.  
 
In the general introduction (Chapter 1) a literature overview is provided, presenting current 
state-of-the-art on disease course, risk factors and treatment of M. bovis. Subsequently, the 
many different diagnostic techniques available for identification, strain typing, and 
susceptibility testing are described. Next to the existing techniques, more innovative 
techniques, such as MALDI-TOF MS and nanopore sequencing and their potential as rapid 
diagnostic methods are explained.  
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In the first experimental study different methods were explored to identify M. bovis cultures 
grown on solid medium with MALDI-TOF MS (Chapter 3.1). The most straight-forward 
method, being the direct transfer method, is broadly applied for most bacteria, but faced 
several problems for M. bovis identification. In this study, these problems were better 
identified and it was shown that medium-related peaks (mostly obtained from horse serum 
and colistin) can result in false positive Mycoplasma alkalescens and Mycoplasma arginini 
identification. Unfortunately, it was not possible to obtain a more reliable direct transfer 
protocol. Therefore, in Chapter 3.2 the identification of M. bovis with MALDI-TOF MS from 
liquid medium was further explored and optimized. Here it was shown that identification was 
possible within 24 hours after inoculation of one colony from a solid medium into liquid 
medium. Supplementing pleuropneumonia-like organism broth (PPLO-broth) with pyruvate 
prolonged the possibility of M. bovis identification to at least 120 hours after inoculation. 
Also, supplementation with antimicrobials prevented overgrowth with other bacteria, and did 
not influence the identification score.  
 
Although with the previous two methods, a step towards more rapid identification of M. bovis 
was set, prior isolation of M. bovis from any sample is still necessary and could easily take 5-
10 days. Therefore, methods to identify M. bovis directly from bronchoalveolar lavage fluid 
(BALf) with MALDI-TOF MS (Chapter 3.3) and nanopore sequencing (Chapter 3.4) were 
developed and validated in a Bayesian latent class model on 104 and 100 BALf from calves, 
respectively. It was possible to identify M. bovis with MALDI-TOF MS within 2-3 days with 
a sensitivity and specificity of 86.6% (CI95%: 69.4-97.6%) and 86.4% (76.1-93.8%), 
respectively. While sensitivity and specificity of nanopore sequencing were 77.4% (58.6-
92.3%) and 97.3% (91.1-99.7%), respectively. Also when 5 BALf were pooled, both methods 
were still reliable, and therefore very cost-effective possibilities. In addition, the in Belgium 
widely used selective-indicative agar method based on lipase-activity, which was never 
validated before using a large number of field samples, showed a sensitivity of 70.5% (52.1-
87.1%) and specificity of 93.9% (85.9-98.4). All three methods are useful in routine 
laboratories, depending on the diagnostic needs of the applicant.   
 
Currently the prevalence of M. bovis in the Belgian dairy and beef sector is estimated at 30%, 
whereas 100% of the veal calf herds tested positive. Together with the high antimicrobial use 
in the veal sector, the question has been raised whether there is a possible reservoir of multi-
resistant and sector-specific M. bovis strains in this sector, as previously shown for other 
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respiratory bacteria. To better understand the molecular epidemiology and genetic relatedness 
of different M. bovis isolates, the full genome of 100 Belgian M. bovis isolates collected from 
dairy, beef and veal herds was obtained using nanopore sequencing (Chapter 4). A single 
nucleotide polymorphism (SNP) analysis was performed and the phylogenetic tree showed 
five separate genomic clusters of M. bovis isolates and one outlier circulating in Belgium 
between 2014 and 2019. No sector-specific isolates and no association with spatial location in 
Belgium were identified. At world-scale, the Belgian M. bovis isolates clustered together with 
European, American and Israeli strains. These results contribute to emphasizing the 
importance of purchase protocols and biosecurity to prevent M. bovis from entering the 
country or herd.  
 
In Chapter 5.1, antimicrobial susceptibility testing of 141 M. bovis isolates retrieved from 
Belgian dairy, beef and veal calf herds was performed with broth microdilution. Minimum 
inhibitory concentration values were used to establish the epidemiological cut-off (ECOFF) 
with visual and statistical methods to distinguish the population in wild type M. bovis and 
those with acquired antimicrobial resistance (non-wild type). The results showed high 
percentages of acquired resistance for macrolides (tilmicosin, tylosin, and gamithromycin), 
but no acquired resistance for tetracyclines (oxytetracycline, doxycycline). Only little 
acquired resistance was observed for florfenicol, gentamicin, and tiamulin, while there was 
limited acquired resistance to enrofloxacin. Only M. bovis isolates from beef cattle or the third 
genomic cluster had a significantly higher change to have acquired resistance against 
gamithromycin than those collected from other sectors or genomic clusters. These results 
support the current national formulary for respiratory disease associated with M. bovis, 
recommending florfenicol as first choice, and oxytetracycline and macrolides as second 
choice. Possibly, a small remark for gamithromycin is needed, as higher risk for acquired 
resistance for this antimicrobial was seen in beef cattle. In vitro susceptibility testing results 
should be interpreted carefully, as the association with in vivo efficacy has not confirmed yet, 
due to the lack of clinical breakpoints.    
 
Finally, in Chapter 5.2, upgraded genomes derived from Chapter 4 and the susceptibility data 
from Chapter 5.1 were combined to compare genotype and phenotype antimicrobial 
susceptibility of M. bovis isolates. A genome wide association study to reveal genetic markers 
for antimicrobial resistance in M. bovis and verifying the ECOFF values obtained by the 
previously used different methods was executed. Many point mutations were associated with 
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antimicrobial resistance against the critically important antibiotics of the macrolide (A2058G 
in the 23S rRNA gene, Gln83His in the L22 protein) and fluoroquinolone classes. For 
enrofloxacin the combination of different mutations in the GyrA and ParC gene showed the 
step-wise acquired resistance. Also previously described mutations for tilmicosin (G478A 
mutation in 23S rRNA alleles), and new markers for gentamicin (A1408G and G1488A in 
16S rRNA) were identified. The visual estimation of de ECOFF showed to be a reliable 
method, although statistical methods can help when step-wise resistance results in difficult to 
interpret “tailing”. Even when phenotypical resistance is not yet obtained, in case of first-step 
mutations it should be discouraged to use fluoroquinolones as antimicrobial therapy, as 
selection pressure will eventually result in phenotypical resistance as well.    
 
In the general discussion (Chapter 6), the innovations in M. bovis diagnostics achieved with 
this thesis are discussed. In the second part, practical recommendations for diagnostics in M. 
bovis outbreak management, purchase policy, and eradication or herd status certificates are 
proposed.     
 
In this thesis new methods to identify, strain type, and access the antimicrobial susceptibility 
of M. bovis were developed. When rapid identification of M. bovis with MALDI-TOF MS 
(Chapter 3.3) is followed by the determination of antimicrobial resistance with nanopore 
sequencing (Chapter 5.2) it is now possible to obtain identification, strain typing and an 
antibiogram for critically important antibiotics within 3-5 days. This is a major step towards 
better control of M. bovis in clinical outbreaks and prevent herd infection when purchasing 
animals. Together with these new methods, also substantial epidemiological information came 
to light, showing the importance of a more national approach for the prevention of 
introducing M. bovis into the herd and country.  
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Mycoplasma bovis is een primaire oorzaak van pneumonie, artritis, otitis en mastitis bij 
runderen. Deze ziekte resulteert in verminderd dierenwelzijn en leidt wereldwijd tot grote 
economische verliezen. Door evolutie is deze kleine bacterie zijn celwand en verschillende 
fysiologische mechanismes verloren. Hierdoor werd het resistent tegen vele conventionele 
antibiotica (bijv. penicillines, cefalosporinen en sulfonamiden). Naast deze natuurlijke 
resistentie, heeft M. bovis ook resistentie verworven tegen andere antibiotica. 
Momenteel duurt het isoleren en identificeren van M. bovis met cultuur 1 à 2 weken en 
antimicrobiële resistentiebepalingen worden niet routinematig gedaan. Er is namelijk geen 
standaard protocol beschikbaar. Daarnaast zijn er ook geen klinische breekpunten 
beschikbaar, waardoor het voorspellen van de klinische uitkomst aan de hand van in vitro 
resultaten niet mogelijk is. Tegen een hogere prijs is snellere identificatie mogelijk met PCR 
(2 dagen). Echter, ondanks dat men verwacht dat de diagnostische accuraatheid van PCR 
hoger is dan deze van cultuur, is er maar weinig wetenschappelijke informatie over 
beschikbaar.  
Om M. bovis onder controle te krijgen en direct te starten met de juiste antimicrobiële 
therapie, is het van groot belang een snelle en betrouwbare diagnostische test te hebben. Naast 
de controle is het ook van groot belang zowel de introductie van M. bovis in de kudde, als de 
spreiding binnen de kudde tegen te gaan. Hoe M. bovis precies wordt overgedragen en of er 
specifieke M. bovis stammen bestaan die geassocieerd zijn met antimicrobiële resistentie of 
bepaalde sectoren is nog niet duidelijk. Sleutelfactoren voor het succes van controle en 
preventie zijn het formuleren van specifieke bioveiligheidsprotocollen en richtlijnen voor M. 
bovis. Hiervoor is snelle diagnostiek van geïnfecteerde dieren of dragers en een beter inzicht 
in de spreiding van M. bovis in kuddes, sectoren en landen nodig. 
 
Daarom was het algemene doel van deze thesis om snelle diagnostische methoden te 
ontwikkelen met behulp van MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization 
Time-of-Flight Mass Spectrometry) en nanopore sequencing voor identificatie, stamtypering 
en antimicrobiële gevoeligheidstesten voor M. bovis en deze toe te passen op Belgische 
veldstalen voor een beter inzicht in de epidemiologie van M. bovis. 
 
In de algemene introductie (Hoofdstuk 1) is een overzicht gegeven van de literatuur over de 
meest recente inzichten in ziekteverloop, risicofactoren en de behandeling van M. bovis. 
Vervolgens worden de verschillende diagnostische technieken beschikbaar voor identificatie, 
stamtypering en antimicrobiële gevoeligheidstesten beschreven. Naast de bestaande 
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methoden, worden ook de meer innovatieve methoden, zoals MALDI-TOF MS en nanopore 
sequencing en hun potentieel als snelle diagnostische methoden uitgelegd. 
 
In de eerste experimentele studie werden verschillende methoden onderzocht om M. bovis van 
agarcultuur te kunnen identificeren met MALDI-TOF MS (Hoofdstuk 3.1). De meest voor de 
hand liggende methode, de ‘direct transfer method’, wordt grootschalig toegepast voor de 
meeste bacteriën, maar kan problematisch zijn voor M. bovis-identificatie. In deze studie 
werden de problemen beter in kaart gebracht en het werd aangetoond dat mediumgerelateerde 
pieken (vooral afkomstig van paardenserum en colistine) resulteerde in vals-positieve 
Mycoplasma alkalescens en Mycoplasma arginini identificatie. Helaas was het niet mogelijk 
om een betrouwbaarder ‘direct transfer protocol’ te realiseren. Daarom werd in Hoofdstuk 3.2 
de identificatie van M. bovis met MALDI-TOF MS vanuit vloeibaar medium verder 
onderzocht en geoptimaliseerd. Hier werd aangetoond dat identificatie mogelijk is 24 uur na 
inoculeren van één kolonie afkomstig van agar in vloeibaar medium. Supplementeren van 
pleuropneumonia-like organism broth (PPLO-broth) met pyruvaat verlengde de mogelijkheid 
om M. bovis te identificeren tot minstens 120 uur na inoculatie. Daarnaast bleek dat de 
supplementatie met antibiotica de contaminatie met andere bacteriën voorkwam en de 
identificatiescore niet beïnvloedde.  
 
Hoewel er in de twee voorgaande studies stappen in de richting van een snellere identificatie 
van M. bovis werden gezet, is isolatie vanuit een staal, wat 5 tot 10 dagen duurt, nog altijd 
nodig. Daarom werden er methoden voor identificatie van M. bovis rechtstreeks uit 
bronchoalveolaire lavages (BAL) ontwikkeld met MALDI-TOF MS (Hoofdstuk 3.3) en 
nanopore sequencing (Hoofdstuk 3.4). Deze methoden werden gevalideerd op respectievelijk 
100 en 104 BAL-stalen met een Bayesiaanse analyse. Het was mogelijk om M. bovis met een 
sensitiviteit van 86.6% (CI95%: 69.4-97.6%) en specificiteit van 86.4% (76.1-93.8%) binnen 
2 tot 3 dagen te identificeren met MALDI-TOF MS, terwijl de sensitiviteit en specificiteit van 
nanopore sequencing respectievelijk 77.4% (58.6-92.3%) en 97.3% (91.1-99.7%) waren. Ook 
wanneer 5 BAL-stalen werden gepoold, bleken deze methoden betrouwbaar en dus zeer 
kostenefficiënt. Daarnaast werd een nog niet eerder gevalideerde, maar veel in België 
toegepaste, selectief-indicatieve agarmethode gebaseerd op lipase-activiteit, onderzocht. Deze 
methode toonde een sensitiviteit van 70.5% (52.1-87.1%) en specificiteit van 93.9% (85.9-
98.4).  
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Momenteel is de prevalentie van M. bovis in de melkvee- en vleesveesector geschat op 30%, 
terwijl in de vleeskalversector 100% van de bedrijven positief test. Samen met het hoge 
antibioticagebruik in de vleeskalversector werd de vraag gesteld of deze sector een mogelijk 
reservoir is voor multiresistente of sectorspecifieke M. bovis-stammen, zoals aangetoond werd 
voor andere respiratoire bacteriën. Om de moleculaire epidemiologie en het genetisch 
verwantschap van verschillende M. bovis-isolaten beter te begrijpen, werd het volledige 
genoom van 100 Belgische M. bovis isolaten afkomstig van melkvee, vleesvee en 
vleeskalveren verkregen met nanopore sequencing (Hoofdstuk 4). Een single nucleotide 
polymorfisme (SNP) analyse werd uitgevoerd en de fylogenetische boom toonde dat vijf 
aparte genetische clusters van M. bovis-isolaten en een uitschieter circuleerden in België 
tussen 2014 en 2019. Er werden geen sectorspecifieke isolaten of een associatie met de locatie 
in België geïdentificeerd. Op wereldschaal werd wel gezien dat de Belgische M. bovis-
isolaten samen clusterden met Europese, Amerikaanse en Israëlische isolaten. De resultaten 
van dit onderzoek onderstrepen het belang van aankoopprotocollen en bioveiligheid om het 
binnenkomen van M. bovis op een bedrijf en in het land te voorkomen.  
 
In Hoofdstuk 5.1 werden er antimicrobiële gevoeligheidsbepalingen uitgevoerd door middel 
van broth microdilutie op 141 M. bovis-isolaten afkomstig van Belgische melkvee-, vleesvee- 
en vleeskalverbedrijven. Met behulp van visuele en statistische methoden werd de 
epidemiologische cut-off (ECOFF) waarde bepaald op basis van de minimum inhibitoire 
concentraties van de isolaten. De ECOFF verdeelt de M. bovis populatie in ‘wild type’ 
(zonder verworven resistentie) en ‘niet-wild type’ (met verworven antimicrobiële resistentie). 
De resultaten toonden een hoog percentage verworven resistentie voor macroliden 
(tilmicosine, tylosine en gamithromycine), maar geen verworven resistentie tegen 
tetracyclines (oxytetracycline, doxycycline). Er werd minimale resistentie gezien tegen 
florfenicol, gentamicine en tiamuline, terwijl er beperkte resistentie werd gezien voor 
enrofloxacine. Alleen M. bovis-isolaten afkomstig van vleesvee of het derde genetische 
cluster hadden een significant hogere kans op verworven resistentie tegen gamithromycine 
dan deze afkomstig van andere sectoren of genetische clusters. De resultaten steunen de 
huidige nationale formularia voor respiratoire ziekten geassocieerd met M. bovis, waar 
florfenicol als eerste keuze en oxytetracycline en macroliden als tweede keuze worden 
aangeraden. Een kleine kanttekening voor gamithromycine kan worden gemaakt, gezien de 
hogere kans op verworven resistentie van M. bovis tegen dit antibioticum bij vleesvee. 
Resultaten van in vitro gevoeligheidstesten moeten echter wel voorzichtig worden 
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geïnterpreteerd omdat de associatie met in vivo efficaciteit niet is bevestigd, gezien het gebrek 
aan klinische breekpunten. 
 
Ten slotte werden in Hoofdstuk 5.2 de geüpgradede genomen van Hoofdstuk 4 en de 
gevoeligheidstesten uit Hoofdstuk 5.1 gecombineerd om het antimicrobiële resistentie-
fenotype met het genotype te associëren. Een ‘genome wide association study’ om genetische 
markers voor antimicrobiële resistentie in M. bovis te identificeren en eerder gebruikte 
ECOFF waarden te evalueren, werd uitgevoerd. Verschillende puntmutaties werden 
geassocieerd met antimicrobiële resistentie tegen kritisch belangrijke antibiotica van de 
klassen der macroliden (A2058G in het 23S rRNA gen, Gln83His in het L22 eiwit) en 
fluoroquinolonen. Verschillende combinaties van mutaties in de genen GyrA en ParC toonden 
de stapsgewijze resistentieverwerving voor enrofloxacine. Ook eerder beschreven mutaties 
voor tilmicosine (G478A mutaties in de 23S rRNA allelen) en nieuwe markers voor 
gentamicine (A1408G en G1488A in het 16S rRNA) werden geïdentificeerd. De visuele 
schatting van de ECOFF waarde bleek een betrouwbare methode, al kunnen statistische 
methoden bijdragen bij moeilijk te interpreteren resultaten, zoals bij stapsgewijze resistentie 
(‘tailing’). Zelfs wanneer fenotypische resistentie nog niet is bereikt, zou in gevallen van 
eerste-stapmutaties het gebruik van fluoroquinolonen als antimicrobiële therapie moeten 
worden afgeraden, omdat de selectiedruk uiteindelijk toch zal resulteren in fenotypische 
resistentie.  
 
In de algemene discussie (Hoofdstuk 6) worden eerst de innovaties in M. bovis-diagnostiek 
besproken die behaald zijn in deze thesis. Vervolgens worden praktische aanbevelingen 
voorgesteld omtrent diagnostiek van M. bovis in uitbraakmanagement, aankoopprotocollen, 
eradicatie en potentiële certificaten op kuddeniveau.   
 
In deze thesis werden nieuwe methoden ontwikkeld voor de identificatie en stamtypering van 
M. bovis, alsook voor het verkrijgen van inzicht in zijn antimicrobiële gevoeligheid. Wanneer 
snelle identificatie van M. bovis met MALDI-TOF MS (Hoofdstuk 3.3) wordt opgevolgd door 
antimicrobiële resistentiebepaling via nanopore sequencing (Hoofdstuk 5.2), is het nu 
mogelijk om identificatie, stamtypering en een antibiogram van kritisch belangrijke 
antibiotica te realiseren binnen 3 tot 5 dagen. Dit is een grote stap richting betere controle van 
M. bovis in klinische uitbraken en preventie van infecties in de kudde ten gevolge van 
aankoop. Samen met deze nieuwe methoden is ook substantiële epidemiologische informatie 
aan het licht gekomen die het belang van een meer nationale aanpak voor de 
introductiepreventie van M. bovis in kuddes en het land aantoont.  
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nemen en mogen we je binnenkort verwelkomen als onze nieuwe doctorandi. Wouter, fijn om 
weer een Nederlander in het team te hebben en om met iemand over Formule 1 te babbelen! 
Die voetbalwedstrijden zullen er hopelijk ook nog eens van komen. I feel you met de laatste 
loodjes van je doctoraat, nog even doorbijten, maar ik beloof het je: de opluchting nadien gaat 
groot zijn!   
 
Laura, mijn MALDI-maatje, bedankt om mij wegwijs te maken in het bacteriologie labo, er 
op te vertrouwen dat ik kon bijdrage aan je experimenten en me daarbij te drillen tot ik 
droomde over eiwitextracties en kramp in m’n vingers had. ;-) Daarmee was de toon gezet 
voor de komende jaren, en ondanks dat we er op zijn vastgelopen, vond ik onze lysomucil-
cytospin experimenten zalig! Naast werk hebben we ook veel andere dingen meegemaakt 
samen en ik kon altijd op je rekenen. Het mooiste was denk ik wel ons tripje naar Rome: heel 
veel wijn, onszelf doelen stellen om tenminste met enkele onbekenden te praten op het 
congres, zware gesprekken, dansen in onze pyjama, strategisch gesprekken en praktijk 
training door Wout bij het Vaticaan. Onvergetelijk! Wout, jij ook bedankt voor alle leuke 
gesprekken en de lessen over cryptocurrencies. Of het nu in Portugal is of dat jullie nog 
ergens anders gaan belanden, met jullie doorzettingsvermogen ligt de wereld aan jullie 
voeten.  
 
Linde, het is heel fijn om iemand te hebben die weet hoe frustrerend en onvoorspelbaar het 
werken met Mycoplasma soms kan zijn. Daarnaast heb ik je altijd bewonderd voor je 
vastberadenheid, zowel in de kliniek als carrière technisch, en ben je een meerwaarde voor 
iedereen. Ik heb genoten van ons Mycoplasma congres in Londen en de nachtelijke dansjes in 
’s Hertogenbosch, maar ik baal natuurlijk dat we afgelopen jaar niet naar Tel Aviv hebben 
kunnen gaan en dat die housewarming er nog altijd niet van is gekomen! Hopelijk halen we 
dat allemaal nog eens in!  
 
Katharina, recht door zee, zoals een echte Nederlander betaamd en ik ze graag heb. ;-) Bij jou 
stond ik al op de stoep de eerste nacht voordat mijn contract in ging, bedankt om me toen een 
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slaapplek te geven, de gezellige etentjes nadien en de leuke dag op de kerstmarkt in Aken. Nu 
zit je lekker op de boerderie met je vent en heb je volgens mij een baan die je op het lijf 
geschreven is! Christien, het was vaak kort, maar zeer krachtig op alle vlakken. ;-) Respect 
hoe jij al dat onderzoek deed, nachten op de faculteit sliep en kilometers reed. Daarnaast was 
het altijd dolle boel met je, tenzij er even wat tegenslagen waren, die er bij horen en waar je je 
altijd moedig doorheen sloeg. Je hebt dat maar mooi gedaan, een doctoraat. Gelukkig ben je 
nu weer lekker samen met je beestenbende!  
 
Stan, Thomas en Florian, onze nieuwe doctorandi, onze jonge honden. Voor jullie lijkt elke 
werkdag wel een feest en moet ik (bijna) altijd lachen als ik jullie geouwehoer weer over het 
hele verdiep hoor galmen, maar gelukkig werken jullie ook keihard en werpt dat zijn vruchten 
af. Florian, jouw eerste proef laat misschien iets langer op zich wachten dan je had gehoopt, 
maar de data die daar uit gaan komen zal baanbrekend zijn en ik kan niet wachten! Thomas en 
Stan ook bedankt voor alle buitenschoolse activiteiten, corona was maar saai geweest zonder 
jullie. ;-) Stan, alle credits voor de kaft gaan naar jou: dikke merci! 
 
Mathilde, jij verdient natuurlijk je eigen boek, maar ik zal het proberen te houden bij een 
alinea. Het was liefde op het eerste gezicht.. of ja, voor jou toch. ;-) Bij mij duurde dat net wat 
langer, maar inmiddels weet je dat áls ik iemand in m’n hart sluit je al heel hard je best moet 
doen wil ik dit terugdraaien. Van losbandige (vrijdag)avonden in de Peerdestal, de Maecht 
van Ghent of gewoon met Aperol op het terras van de buurman of bij jou thuis, vakantie in 
Frankrijk met tot twee keer toe een kapotte auto en chocola om het goed te maken, tot elkaar 
helpen met vervelende collega’s (ja hooii ;-)), artikels, cases of gewoon keihard huilen, het 
kon en kan allemaal. Mathilde, je bent een keiharde werker, reteslim (veren in je reet!) en 
mooi zo als je bent, vergeet dat alsjeblieft nooit. <3 
 
Aansluitend mijn bureau genootjes, Pia, Ingrid en opnieuw Mathilde, ook wel gekend als 
bewoners  van het ‘liefste bureau’, ‘warmste bureau van het verdiep’, ‘bureau keuken links’, 
of om de spreuk op de deur “You don’t have to be crazy to work here, we will train you”. 
Door covid zien en spreken we elkaar veel te weinig, en waar we in het begin nog wekelijkse 
Teams-meetings deden omdat we elkaar zo misten, wende de stoelendans om wie er in het 
bureau mocht zitten ook wel een beetje. Hopelijk gaat alles snel terug naar normaal en kunnen 
we weer keihard samen werken om af te wisselen met thee, chocola, cava, goede babbels en 
etentjes. Pia, ik hoop dat het goed gaat met jou en Lotta, we missen je enorm. Ingrid, ik 
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verbaas me nog elke keer over je intelligentie, gevoel voor onderzoek en professionaliteit als 
het aankomt op vragen stellen en feedback geven. Bedankt om altijd te luisteren naar mijn 
gezeur en me op te vrolijken als ik het even niet meer zag zitten. Heel veel succes met de 
bouw van jullie droomhuis en de trouw!  
 
Glenn en Lisse, jullie leerde ik eigenlijk veel te laat beter kennen, namelijk pas toen we de 
PhD-meetings in leven hebben geroepen, maar die verloren tijd hebben we snel ingehaald. 
Cava tijdens de meeting of bij aanvaarde papers mocht al snel niet meer, maar daar stond wel 
maandelijks taart, veel snacks en een groepsgevoel tegenover! Lisse, ik kan alleen maar hopen 
dat ik voor de helft zo straal tijdens mijn verdediging als jij tijdens jouw verdediging deed. 
Glenn, jij bent gewoon geniaal, en ondanks dat je zelf misschien vind dat je niet altijd even 
sociaal bent, vind ik het super leuk dat je vaak een babbeltje komt maken en heb ik het gevoel 
dat ik altijd op je kan rekenen! Merci voor alle hulp als er weer iets mis is met mijn computer 
en voor de technische ondersteuning tijdens m’n verdediging. Daarnaast.. het is volgens mij 
hoog tijd om weer eens wat dansjes te wagen! Speciaal voor jullie de ‘tick in the box’ 
toegevoegd in m’n presentatie. ;-)  
 
Sabrina, bedankt om altijd mee te gaan in de gekte van mijn experimenten, mee te denken om 
ze te optimaliseren, de grenzen van ons kunnen op te zoeken, de gezellige babbels en altijd 
flexibel te zijn als er ineens weer ladingen bloed- en BAL-stalen binnen kwamen! Sylvie, 
zonder jou zou ik nergens zijn qua financiën, maar dat is maar één van de weinige dingen die 
jij doet. Als er iemand onze vakgroep samenhoudt ben jij het wel, bedankt voor de leuke 
babbels en het vragen hoe het gaat, maar ook om het labo over te nemen zodat Sabrina mij 
kon helpen! Saar en Elvin, jullie ook bedankt voor het last minute autoclaveren van BAL-
katheters, bestellingen plaatsen en opvangen van allerhande taken als Sabrina mij hielp in het 
labo. Hans, ook jij kan natuurlijk niet ontbreken. Ik word altijd blij als ik je zie zitten in het 
secretariaat, als je ’s ochtends voorzichtig om ’t hoekje van m’n bureau kijkt om over de 
vorderingen van de Fraterbrug, planten, vogels of je laatste training te babbelen en favoriet 
natuurlijk: om te melden dat er iets lekkers in het secretariaat ligt. Bij computer- of 
printerproblemen of eigenlijk bij eender welk probleem: jij bent er.  
 
Team paard en Team cardio, inmiddels lopen deze dusdanig door elkaar dat ik het niet meer 
exact bij kan houden, maar bedankt allemaal voor de samenwerkingen en leuke feestjes! 
Laurence, je leidt daar een topteam in de kliniek! Bedankt ook aan alle interns en residents 
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paard die er de laatste jaren gepasseerd zijn en mij hielpen in de kliniek of bij het vertalen 
wanneer er weer eens Franstalige eigenaren waren. Alex, Ellen, Eva, Zoë en Lize-Maria: 
welkom in de wondere wereld van het onderzoek, ik kijk al uit naar jullie eerste/volgende 
resultaten! Lisa, bedankt voor de gezellige babbels, en heel veel succes met je examen en in 
Frankrijk! Caroline en Pauline, ook jullie zijn natuurlijk onmisbaar in de kliniek, tot op het 
volgende feestje! 
 
Gunther, u werd vakgroepvoorzitter in een ingewikkelde periode en met de lopende fusies zal 
het niet altijd een cadeau zijn geweest, maar ik wilde toch even laten weten dat ik vind dat u 
het heel erg goed doet en bedankt dat ik nog een jaartje extra mocht blijven. Daarnaast, dat u 
en Annelies het ene naar het andere succes hebben, bewijst ook maar weer hoe goed het 
cardio team is! Annelies, jouw opmerking in de schrijfperiode van mijn doctoraat zijnde “je 
kunt schrijven naar wat je wilt of schrijven naar de tijd die je hebt”, kwam op het perfecte 
moment, merci! Ik vind het enorm jammer dat ik nooit skills lab heb gehad tijdens mijn 
opleiding, maar dames van het skills lab team (Annelies, Valentine, An, Alix, Pia en Lotte): 
volgens mij doen jullie daar een fanatische job en hebben de studenten hier enorm veel aan. 
Franky, Tony, Julien, Balder en Carlos, bedankt om de beestjes altijd goed te verzorgen, de 
gezellige praatjes tijdens mijn pauzes en om altijd te helpen met het verslepen/verzetten van 
zowel levende als dode dieren. ;-)  
 
Aangezien ik altijd een beetje tussen twee vakgroepen in hing, wil ik ook iedereen van 
bacteriologie bedanken. Het labo was voor mij, zeker in de eerste jaren, een welkome oase 
van rust tussen de hectiek van de kliniek door. De ontspannen sfeer die bij jullie heerst, de 
leuke babbels, en de bereidbaarheid van iedereen om elkaar te helpen: het was nooit te veel. 
In het speciaal wil ik toch Arlette en Serge bedanken voor het maken van de honderden PAM-
platen en tientallen liters PPLO en alle nodige bestellingen, maar ook voor het last minute 
meenemen van MALDI-analyses en het zorgen dat er altijd matrix en schone targets waren! 
Dat heeft mij enorm veel geholpen. Marleen, ik denk dat er maar weinig zulke lieve en 
zorgzame mensen bestaan zoals jij, bedankt voor alle lieve woorden en berichtjes, maar ook 
voor het in goede banen leiden van de DNA- en eiwitextracties, PCRs en alle pakketjes die 
verzonden moesten worden. Ik had je er heel graag bij gehad vandaag en hoop dat je je heel 
snel weer beter voelt en we allemaal weer kunnen genieten van je aanwezigheid op 
bacteriologie.  
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Bas en Nick, het duurde misschien even voordat ik het concept van “barcodes aan 
verschillende stalen hangen begreep” en het mij ook een goed idee leek om het laatste jaar 
van m’n doctoraat nog even over een compleet andere boeg te gooien, maar wát heb ik 
genoten van onze meetings en jullie enthousiasme. Elke keer als er een probleem zich 
voordeed, werd er niet alleen een oplossing gevonden, maar werd het resultaat meestal nog 
eens overtroffen. Bedankt voor jullie geduld met mij en het wegwijs maken in de wereld van 
het sequencen. Marthe en Gautier, bedankt voor het verwerken van al die stalen die wij maar 
binnen brachten alsof het niets was. Heel veel succes allemaal met PathoSense, jullie hebben 
een mooi team! 
 
Naast samenwerkingen met bacteriologie en virologie, wil ik ook zeker de andere vakgroepen 
bedanken waarmee ik meer op klinisch vlak heb samengewerkt. Bedankt Heelkunde, 
Medische Beeldvorming, Buitenpraktijk, Verloskunde en Pathologie voor allerhande 
(nachtelijke) operaties, beeldvorming, lijkschouwingen en consultaties! Stijn H., aangezien jij 
vaak bij meerdere van deze vakgroepen te vinden was, plak ik je er hier maar tussen. Bedankt 
dat ik bij je mocht komen wonen en zo’n toffe huisgenoot te zijn! Heel veel succes met je 
examen en hopelijke drinken we er binnenkort eens op!  
  
Jill, Vief, Daph en Nicole: we zijn samen aan diergeneeskunde begonnen, woonden in 
hetzelfde huis (ja, Nico, je was onderdeel van het meubilair), en ondanks dat we allemaal 
ergens anders zijn beland, zijn we elkaar daarna nooit uit het oog verloren. Er zijn denk maar 
weinig vriendengroepen met zúlke verschillende karakters, maar meiden, wat zie ik jullie 
graag (ja, deze keer bewust Vlaams ;-))! Jill, we hebben vaak in hetzelfde schuitje gezeten 
(Amsterdam, Psychobiologie, relatie, geen relatie, PhD, ..) en wat is het fijn om iemand om de 
hoek te hebben wonen die er elk moment kon zijn met wijn en chocola, of het nu was om iets 
te vieren of om iets te vergeten. Ik kijk enorm uit naar jouw verdediging! Vief, ik ben zo trots 
op je hoe je ondanks dat diergeneeskunde het niet helemaal was, je de mega nerd van onze 
groep bent geworden en je werk met zo veel passie doet. Daph, aan jou valt niet te tippen, de 
energie en jouw doorzettingsvermogen, dat brengt je óveral. Geniet maar goed van 
Brammetje, Johan en de hele beestenbende, maar zorg ook goed voor jezelf. Nico, je heerlijke 
no-nonsense houding doet me altijd lachen, en door jou (en je moeder) zijn we denk ik kílo’s 
aangekomen over de jaren heen, maar eten hoort nu eenmaal bij ons. Ik hoop dat als ik ooit 
kinderen krijg, ik net zo’n chille moeder zal zijn zoals jij! Ook alle mannen die het door de 
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jaren heen met onze vriendinnengroep hebben moeten volhouden (we weten wel dat jullie 
stiekem genieten van onze gesprekken en hysterie), Steven, René en Johan, bedankt!  
 
Lieve Leo, Miek, Mirth en Wyp, ik ben heel blij dat jullie er vandaag bij zijn. We gaan zo ver 
terug, maar of we nu in verschillende provincies, in Zweden, Slovenië, Zwitserland of België 
wonen en we elkaar misschien maar 2 keer per jaar zien, we weten elkaar altijd te vinden als 
het nodig is. Kijk hoe volwassen iedereen is geworden.. ik zie ons nog als jonge broekies in 
Londen of ons op het vliegveld in Bremen om naar Milaan/Blanes te vertrekken.. en kijk 
jullie nu: huizen verbouwen, een baby, verloofd, gehuwd of geregistreerd partnerschap.. ik 
ben enorm trots op jullie en de laatste puzzelstukjes zullen binnenkort ook wel op zijn plek 
vallen. <3 Bob, Jonas, Arvind en Ward, jullie kwamen er allemaal wat later bij, en ik kan me 
nog goed het eerste weekend herinneren dat we met z’n allen doorbrachten in ons 
appartement in Gent waar we als meiden toch een beetje onze vraagtekens bij hadden, maar 
het was de eerste van een heerlijke traditie!  
 
Lisa, Marien en Tom: Eerst mijn stukje Nederland in Gent, nu mijn stukje Gent in het hoge 
noorden. Lisa, we konden het altijd al wel vinden, maar na onze Slovenië avonturen was het 
pas echt dikke mik. Marien en Tom kreeg ik er gewoon bij. ;-) Lisa, die Vršič Pass met de 
mini vergeet ik nooit weer (“you girls have balls”) en de roadtrip tijdens de zomervakantie 
was fantastisch.. maar het weekendje weg deze zomer was natuurlijk ook heerlijk! Lisa en 
Marien, knap hoe jullie het allemaal doen daar in Veendam en omstreken! Binnenkort weer 
eens borrelen in Spiekerboar? Tom, de Gentse feesten, dagje Giethoorn, veel te eerlijke 
gesprekken, ritjes naar Lisa en Marien of door Denemarken met jou zijn allemaal 
onvergetelijk, maar ik neem je dat stomme spel met oudjaar nog altijd kwalijk. ;-)  
 
Aan al mijn tennismaatjes: zonder alle momenten met jullie om wat te kunnen ontspannen 
tussen het harde werken door, gaande van frustraties eruit mogen kloppen, tot samen op 
vakantie gaan (Jeroen, Yannick en Marijke: het was de moeite!), veel te lang blijven borrelen 
na het tennissen (als we al getennist hadden..), wandelingen, spelletjesavond (zelfs online in 
tijden van COVID), feestjes op de Krijte en dé party crew van de Gentse Feesten, had ik het 
hier nooit gered. Charlie, bedankt om me vanaf dag één op sleeptouw te nemen, aan iedereen 
voor te stellen en me thuis te doen voelen op de Krijte. Jasper, het is heel fijn als iemand 
begrijpt waar je doorheen gaat in deze laatste weken vooraf aan dit moment, merci voor de 
babbels en de heerlijke taarten! Marijke, we zitten een beetje in hetzelfde schuitje en we 
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kunnen dan ook naast het tennissen uren praten en wandelen. Bedankt om altijd bereid te zijn 
me van eten te voorzien, mee te gaan naar het ziekenhuis, of tijd te maken voor een goed 
gesprek! Amber, je tennist niet maar toch een beetje onderdeel geworden van deze groep. De 
picknicks, samen met Marijke, in het Liedemeerspark blijven toch het beste. Binnenkort 
weer? Heel veel geluk met het kleine wondertje in je buik. <3 Wouter, fijn om iemand te 
hebben die wil tennissen ookal ben je van wacht en kun je last minute afzeggen, maar ook 
bedankt voor alle wandelingen, loopjes en drankjes op jouw terras. Heel veel succes met je 
examen! Charlie, Stefan en Stefaan bedankt voor de onvergetelijke interclub in ‘het jaar dat 
het nog mocht’ en Stefan om er altijd voor me te zijn en te helpen met de organisatie van de 
receptie. Delphine, ik denk dat jij de grootste tennisfanaat bent van ons allemaal en dat is te 
zien in hoe je gegroeid bent in je spel het laatste jaar (en hoe vaak je op het terras zit ;-))! 
Stefan, Stevie en Delphine, zonder de padel-avonden afgelopen winter weet ik niet hoe ik die 
donkere dagen had overleefd. Ookal was het áltijd in de regen, sneeuw, vrieskou of keiharde 
wind, het gezelschap, de drank en de babbels maakten dat ik er altijd naar uit keek! Gert, jij 
ook bedankt om stiekem met mij in Merelbeke te kloppen toen het daar alweer kon en Tim 
bedankt om altijd te willen helpen, babbelen, of tennissen en me aan het lachen te maken met 
Stamper. Deze lijst kan nog een heel eind doorgaan, maar ik kan moeilijk iedereen persoonlijk 
bedanken, maar nogmaals, lieve mensen van TC de Krijte, jullie zijn mijn tweede thuis hier in 
België en zonder jullie was dit doctoraat niet geweest wat het nu is.  
 
Zoals altijd.. de belangrijkste mensen worden als laatste vernoemd. Broer/Auryn, we zien en 
spreken elkaar misschien niet zo veel, maar je hebt al meerdere keren laten zien dat wanneer 
het er op aankomt, je er altijd bent en dat is wat telt. <3 Josephine, jij hoort er nu ook een 
beetje bij en ik kijk uit naar meer van zulke Kerstdagen, wintersport en loopsessies! Pap en 
mam, wat zou ik zonder jullie moeten? Bedankt dat jullie er altijd voor me zijn, dat jullie zo 
gek zijn om mij “even op te komen halen”, toen ik zo ziek was en niet mocht rijden. Dat als ik 
het even niet meer zie zitten, ik altijd thuis in hotel Bokma, mag komen opladen. Bedankt 
voor alle fijne gesprekken over teamwerking, management, psychologie en het voorhouden 
van een spiegel als ik dat nodig had. Bedankt voor het oneindige vertrouwen, de knuffels en 
de hulp bij de receptie.  
 
Lieve mensen, ik heb na deze lap tekst nog altijd het gevoel dat ik iedereen te kort doe en 
mocht ik je toch niet genoemd hebben, neem dit dan alsjeblieft niet al te persoonlijk op en bij 
deze nog een welgemeende dankjewel! 





België, ik zie u graag 
 
Ik woon niet waar ik ben geboren 
Ergens tussen Antwerpen en Gent 
In een land waar ik na al die jaren 
Soms nog steeds een vreemde ben 
Land van lang vervlogen tijden 
Land van leven achter luiken 
Land van mensen die iets zeggen 
Met de kunst van het ontwijken 
 
Ik zie u graag, ik zie u graag 
Met al je chaos en je schoonheid 
Al je bier en troosteloosheid 
Ik zie u nog altijd graag 
 
Land van ingehouden woede 
Land van uitgesproken stilte 
Land van lelijkheid die mooi is 
Land van talen die verschillen 
Land van kroegen, kathedralen 
Land van weergaloze vrouwen 
Land van grijze dorpen, zotte morgen 
Ik zal altijd van u houden 
 
Ik zie u graag, ik zie u graag 
Land van chaos en schoonheid 
Bier en achterbaksheid 
Ik zie u nog altijd graag 
 
Dit liefdeslied is ongenaakbaar 
Want ik hou van jou zoals je bent 
Met al je voors en al je tegens 
Niemand heeft jou ooit getemd 
Land dat kan omarmen 
Land dat kan verstoten 
Land om te verlaten 
Land om terug te komen 
Land waar ik altijd een vreemde zal blijven 
Land dat ik nooit echt zal begrijpen 
maar ik zie u graag 
Ik zie u nog altijd graag 
 
Stef Bos 
 
